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Abstract 
 
Airway microvascular leak (MVL) is the extravasation of plasma and plasma proteins 
from post-capillary venules into surrounding tissue.  MVL is thought of as a cardinal 
sign of inflammation and is an important aspect in the pathogenesis of airway 
inflammatory diseases, including allergic asthma.  Prostaglandin E2 (PGE2) is a 
product of cyclooxygenase mediated metabolism of arachidonic acid and acts via the 
activation of 4 different receptor subtypes, termed EP1-4. PGE2 has demonstrated a 
wide variety of effects within the airway, such as on inflammation, sensory nerve 
activation and airway tone.  However, its effects on airway MVL have not been 
extensively studied.  This formed the basis of the thesis hypothesis; PGE2 acts 
through specific EP receptor(s) to induce microvascular leak within the airways. 
Using Evans Blue dye as a marker of leak, PGE2 significantly induced airway MVL in 
mice. I have shown, for the first time that this response is mediated via the activation 
of the EP2 and the EP4 receptors.  This was confirmed using selective EP receptor 
agonists and antagonists, as well as EP receptor deficient mice.  Importantly, this 
airway MVL was not just exclusive to the mouse; PGE2 significantly increased airway 
MVL in guinea pigs.  To investigate MVL in a disease setting, the ovalbumin model 
of allergic asthma was employed to study the role of EP receptors in mediating OVA 
induced MVL. OVA-induced Evans Blue leak was almost completely absent in the 
airways of EP2 and EP4 receptor knock-out mice.  Finally, preliminary work 
investigating four other prostanoid ligands (PGD2, PGF2α, U46619 and Iloprost) 
indicates that they too cause airway MVL to some extent and appear to do so via 
activation of their own receptor subtype (DP1, FP, TP and IP, respectively). 
Therefore, the findings outlined in this thesis suggest that PGE2 activates the EP2 
and EP4 receptors to induce airway microvascular leak and may also be responsible 
for the MVL observed in the OVA model. 
 
  
3 
 
Acknowledgements 
 
First I would like to thank my supervisors Professor Maria Belvisi and Dr Mark Birrell 
for all their help, expertise, encouragement and support throughout my PhD.  I will 
always be grateful for the time they have given me during this project and for making 
my experience here truly enjoyable.  Special thanks must also go to Dr Sarah Maher 
who has always been so generous with her time, support and friendship over the last 
4 years.  
 
My thanks go to the entire Respiratory Pharmacology Group, past and present, 
whose expertise and help I would have been lost without. They really have made this 
a wonderful experience.  In no particular order, thanks to Liang Yew-Booth, Sara 
Bonvini, Katie Baker, Michael Wortley, Matt Baxter, James Buckley, Joe Rastrick, 
Kristof Raemdonck, Eric Dubuis, Megan Grace, Nicole Dale, Suffwan Eltom, Abdel 
Dekkak and Bilel Dekkak.  Special thanks must also go to John Adcock and Meirion 
Davies for their help and expertise with the blood pressure measurements. I must 
also thank ONO Pharmaceuticals for the prostanoid receptor knock-outs and EP 
agonists. 
 
I would especially like to thank my “Les Mills” crew (Sarah, Sara and Liang) for their 
support and friendship over the years; I don’t know what I would have done without 
you. I must also thank Georgie, who started this adventure with me. I am so 
fortunate to have had her with me along the way, as a course mate, a flat mate and 
of course a fantastic friend.  
 
Finally I would like to express my thanks to my family, Mum, Dad, Emily and Laura 
(and Bentley).  Their kindness, support and unconditional love mean so much to me 
and I wouldn’t be where I am without them.  I can’t thank my family without 
mentioning Lucy, whose love and friendship means more to me than she will ever 
know.  She is a true inspiration.  Last, but certainly not least, my love and thanks go 
to Adam for his encouragement, patience and love during my PhD and for never 
failing to make me smile.   
  
4 
 
Statement 
 
This thesis is the product of my own work, except where appropriately referenced. 
Carotid artery cannulation and blood pressure measurements were performed by Dr 
John Adcock and Meirion Davies, with my assistance (Chapters 3 and 6). 
  
5 
 
Copyright Declaration 
 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence.  
Researchers are free to copy, distribute or transmit the thesis on the condition that 
they attribute it, that they do not use it for commercial purposes and that they do not 
alter, transform or build upon it.  For any reuse or redistribution, researchers must 
make clear to others the licence terms of this work. 
  
6 
 
Table of Contents 
 
Abstract .................................................................................................................................................. 2 
Acknowledgements .............................................................................................................................. 3 
Statement ............................................................................................................................................... 4 
Copyright Declaration ........................................................................................................................... 5 
Table of Contents .................................................................................................................................. 6 
List of Figures ..................................................................................................................................... 11 
List of Tables ....................................................................................................................................... 14 
List of Abbreviations .......................................................................................................................... 15 
Chapter One ......................................................................................................................................... 18 
1. Introduction .................................................................................................................................... 19 
1.1. Airway Inflammatory Diseases .............................................................................................. 19 
1.1.1. Asthma ................................................................................................................................ 20 
1.1.1.1. Allergic Sensitisation and Responses ......................................................................... 20 
1.1.1.1.1. EAR and LAR ........................................................................................................... 21 
1.1.1.1.2. Airway Hyperresponsiveness ................................................................................... 22 
1.1.1.2. Treatments .................................................................................................................. 22 
1.1.1.3. In vivo models of Asthma ............................................................................................ 23 
1.1.1.3.1. Ovalbumin Model ..................................................................................................... 24 
1.1.1.3.2. House Dust Mite Model ............................................................................................ 25 
1.1.2. Chronic Obstructive Pulmonary Disease ............................................................................ 26 
1.1.2.1. Treatments .................................................................................................................. 27 
1.1.2.2. In vivo models of COPD .............................................................................................. 28 
1.1.2.2.1. Lipopolysaccharide Model ....................................................................................... 28 
1.1.2.2.2. Cigarette Smoke Model ........................................................................................... 29 
1.2. Prostanoids and Prostanoid Receptors ................................................................................ 30 
1.2.1. Synthesis ............................................................................................................................. 30 
1.2.2. Prostanoid Receptors .......................................................................................................... 31 
1.2.2.1. Prostaglandin E2 and EP receptors ....................................................................... 33 
1.2.2.1.1. EP1 Receptors ....................................................................................................... 33 
1.2.2.1.2. EP2 Receptors ....................................................................................................... 34 
1.2.2.1.3. EP3 Receptors ....................................................................................................... 35 
1.2.2.1.4. EP4 Receptors ....................................................................................................... 37 
1.2.2.2. Prostaglandin D2 and DP receptors ...................................................................... 38 
1.2.2.2.1. DP1 Receptors ...................................................................................................... 38 
1.2.2.2.2. DP2 Receptors ...................................................................................................... 39 
1.2.2.3. Prostaglandin F2α and the FP receptor.................................................................. 40 
7 
 
1.2.2.4. Prostacyclin and the IP receptor ........................................................................... 41 
1.2.2.5. Thromboxane A2 and the TP receptor .................................................................. 42 
1.2.3. Prostanoids in Airway Disease ........................................................................................... 43 
1.2.3.1. Airway Tone .......................................................................................................... 44 
1.2.3.2. Immune and Inflammatory Responses ................................................................. 45 
1.2.3.3. Sensory Nerve Activation ...................................................................................... 47 
1.3. Microvascular Leak ............................................................................................................... 48 
1.3.1. Introduction ......................................................................................................................... 48 
1.3.2. Regulation of Endothelial Permeability ............................................................................... 50 
1.3.2.1. Myosin Light Chain Kinase-Dependent Hyperpermeability ................................... 50 
1.3.2.2. Endothelial Cell-Cell Junctions and Hyperpermeability ........................................ 51 
1.3.3. Intracellular Signalling Pathways Modulating Endothelial Permeability .............................. 53 
1.3.3.1. Calcium ................................................................................................................. 54 
1.3.3.2. RhoA/Rho Kinase .................................................................................................. 54 
1.3.3.3. Cyclic AMP ............................................................................................................ 55 
1.3.4. Airway Microvascular Leak ................................................................................................. 57 
1.3.4.1. Asthma .................................................................................................................. 57 
1.3.4.2. COPD .................................................................................................................... 59 
1.3.5. Methods for Investigating Microvascular Leak .................................................................... 60 
1.3.5.1. In vitro .................................................................................................................... 60 
1.3.5.1.1. Cell Culture ........................................................................................................... 60 
1.3.5.1.2. Whole Vessel Preparations ................................................................................... 62 
1.3.5.2. In vivo .................................................................................................................... 63 
1.3.5.2.1. Intact Microvessels ............................................................................................... 63 
1.3.5.2.2. Miles Assay ........................................................................................................... 63 
1.3.5.2.3. Intravital Fluorescence Microscopy....................................................................... 64 
1.3.5.2.4. Magnetic Resonance Imaging .............................................................................. 65 
1.3.6. Prostanoids in airway microvascular leak ........................................................................... 65 
1.4. Thesis Plan ............................................................................................................................ 67 
Chapter Two ........................................................................................................................................ 68 
2. Methodology .................................................................................................................................. 69 
2.1.  Breeding of Knock-Out Mice ................................................................................................. 69 
2.2 Genotyping of KO Mice ............................................................................................................... 70 
2.2.1 DNA Extraction and Quantification ...................................................................................... 70 
2.2.2 Polymerase Chain Reaction................................................................................................. 70 
2.2.3 Visualisation of PCR Products ............................................................................................. 71 
2.3 Microvascular Leak ..................................................................................................................... 73 
2.3.1 Compound Administration .................................................................................................... 73 
8 
 
2.3.2 Measurement of Plasma Extravasation ............................................................................... 73 
2.3.3 Analysis ................................................................................................................................ 75 
2.4 Blood Pressure Measurements ................................................................................................... 76 
2.4.1 Cannulation of Carotid Artery ............................................................................................... 76 
2.4.2 Measuring Blood Pressure ................................................................................................... 77 
2.5 Ovalbumin Model of Allergic Asthma .......................................................................................... 78 
2.5.1 Assessing airway Microvascular Leak ................................................................................. 79 
2.6 In vitro Organ Bath Experiments ................................................................................................. 80 
2.6.1. Physiological salt solutions ................................................................................................. 80 
2.6.2. Isolated airway preparation ................................................................................................. 80 
2.6.3. Isolated airway organ bath protocols .................................................................................. 81 
2.6.3.1. General protocol.......................................................................................................... 81 
2.6.3.2. Induced tone protocol ................................................................................................. 81 
2.6.4. Data Analysis ...................................................................................................................... 82 
2.7 Human Cell Based Assay of Microvascular Leak ....................................................................... 83 
2.7.1 Cell Culture .......................................................................................................................... 83 
2.7.2 Measuring Endothelial Barrier Permeability ......................................................................... 83 
2.7.3 MTT Assay ........................................................................................................................... 85 
2.8 Measurement of Gene Expression ............................................................................................. 86 
2.8.1 RNA Extraction ..................................................................................................................... 86 
2.8.2 Reverse Transcription .......................................................................................................... 87 
2.8.3 Real Time Polymerase Chain Reaction (PCR) .................................................................... 87 
2.8.4 Analysis of Real Time PCR Results ..................................................................................... 88 
2.9 Statistical Analysis ...................................................................................................................... 89 
Chapter Three ...................................................................................................................................... 90 
3. Characterisation of an in vivo preparation to measure airway MVL and the effect of Prostaglandin 
E2 91 
3.1. Rationale .................................................................................................................................... 91 
3.2. Methods ..................................................................................................................................... 93 
3.2.1. Characterisation of airway MVL in mice using 5-HT ........................................................... 93 
3.2.2. Dose Response of PGE2 - induced airway MVL in Mice ..................................................... 93 
3.2.3. Time Course of PGE2 - induced airway MVL in Mice .......................................................... 94 
3.2.4. Effect of Diclofenac on PGE2-induced airway MVL in Mice ................................................ 94 
3.2.5. Effect of intranasal dosing of PGE2 on airway MVL in Mice ............................................... 94 
3.2.6. PGE2-induced airway MVL in Guinea Pigs ......................................................................... 94 
3.2.7. Effect of PGE2 on Systemic Blood Pressure in Mice .......................................................... 95 
3.2.8. Statistical Analysis .............................................................................................................. 95 
3.3. Results ....................................................................................................................................... 96 
9 
 
3.3.1. Characterisation of airway MVL in mice using 5-HT ........................................................... 96 
3.3.2. Dose Response of PGE2 - induced airway MVL in Mice ..................................................... 98 
3.3.3. Time Course of PGE2 - induced airway MVL in Mice .......................................................... 99 
3.3.4. Effect of Diclofenac on PGE2-induced airway MVL in Mice .............................................. 101 
3.3.5. Effect of intranasal dosing of PGE2 on airway MVL in Mice ............................................. 102 
3.3.6. PGE2-induced airway MVL in Guinea Pigs ....................................................................... 104 
3.3.7. Effect of PGE2 on Systemic Blood Pressure in Mice ........................................................ 105 
3.4. Discussion ................................................................................................................................ 106 
Chapter Four ...................................................................................................................................... 110 
4. Identifying the EP Receptor Mediating PGE2-induced MVL in mouse airways .............................. 111 
4.1. Rationale ...................................................................................................................................... 111 
4.2. Methods ................................................................................................................................... 112 
4.2.1. The Effect of PGE2-induced MVL in EP Receptor Knock-Out Mice ................................. 112 
4.2.2. Effect of ONO-D1-004, ONO-AE1-259, ONO-AE-248 and ONO-AE1-329 on MVL ........ 112 
4.2.3. Investigating the EP2 receptor in airway MVL ................................................................... 112 
4.2.4. Investigating the EP4 receptor in airway MVL ................................................................... 113 
4.2.4.1. Rat Tracheal Organ Bath Preparation ...................................................................... 113 
4.2.4.2. In Vivo Characterisation ............................................................................................ 114 
4.2.5. Effect of the EP2 and EP4 receptor antagonists against PGE2-induced MVL in mice ...... 114 
4.2.7. Genotyping of KO Mice ..................................................................................................... 115 
4.2.8. Statistical Analysis ............................................................................................................ 116 
4.3. Results ..................................................................................................................................... 117 
4.3.1. The Effect of PGE2-induced MVL in EP Receptor Knock-Out Mice ................................. 117 
4.3.2. Effect of ONO-D1-004, ONO-AE1-259, ONO-AE-248 and ONO-AE1-329 on MVL ........ 121 
4.3.3. Investigating the EP2 receptor in airway MVL ................................................................... 122 
4.3.4. Investigating the EP4 receptor in airway MVL ................................................................... 125 
4.3.5. Effect of the EP2 and EP4 receptor antagonists against PGE2-induced MVL in mice ...... 130 
4.4. Discussion ................................................................................................................................ 132 
Chapter Five ...................................................................................................................................... 140 
5. Identifying the Role of EP Receptors in Ovalbumin-Induced MVL in Mouse Airways .................... 141 
5.1 Rationale ................................................................................................................................... 141 
5.2. Methods ................................................................................................................................... 143 
5.2.1. Characterisation of Ovalbumin-induced Microvascular Leak in Mouse Airways .............. 143 
5.2.2. Effect of Diclofenac on Ovalbumin-induced MVL ............................................................. 143 
5.2.3. The role of EP receptors in Ovalbumin-induced MVL ....................................................... 144 
5.2.4. Statistical Analysis ............................................................................................................ 144 
5.3. Results ..................................................................................................................................... 145 
5.3.1. Characterisation of Ovalbumin-induced Microvascular Leak in Mouse Airways .............. 145 
10 
 
5.3.2. Effect of Diclofenac on Ovalbumin-induced MVL ............................................................. 147 
5.3.3. The Role of EP2 and EP4 Receptor Knock-outs in Ovalbumin-Induced Airway MVL ....... 148 
5.3.4. The Role of EP2 and EP4 Receptor Antagonists in Ovalbumin-Induced Airway MVL ...... 150 
5.4. Discussion ................................................................................................................................ 151 
Chapter Six ........................................................................................................................................ 154 
6. The role of additional prostanoids in mediating airway MVL in the mouse ..................................... 155 
6.1. Rationale .................................................................................................................................. 155 
6.2. Methods ................................................................................................................................... 156 
6.2.1. Effect of PGD2, PGF2α, U46619 and Iloprost on airway MVL in mice ............................... 156 
6.2.2. Effect of PGD2, PGF2α, U46619 and Iloprost in individual prostanoid receptor knock-out 
mice ............................................................................................................................................. 156 
6.2.3. Effect of PGD2, PGF2α, U46619 and Iloprost on systemic blood pressure ....................... 156 
6.2.4. Genotyping of Prostanoid Receptor Knockouts ................................................................ 157 
6.2.5. Statistical Analysis ............................................................................................................ 158 
6.3. Results ..................................................................................................................................... 159 
6.3.1. Effect of PGD2, PGF2α, U46619 and Iloprost on airway MVL in mice ............................... 159 
6.3.2. Effect of PGD2, PGF2α, U46619 and Iloprost in individual prostanoid receptor knock-out 
mice ............................................................................................................................................. 160 
6.3.3. Effect of PGD2, PGF2α, U46619 and Iloprost on systemic blood pressure ....................... 164 
6.4. Discussion ................................................................................................................................ 166 
Chapter Seven ................................................................................................................................... 172 
7. Summary and Future Studies ......................................................................................................... 173 
7.1. Summary and discussion ......................................................................................................... 173 
7.1.1. Limitations of the thesis..................................................................................................... 176 
7.2. Future Studies .......................................................................................................................... 178 
7.2.1. Effect of EP agonists on systemic blood pressure ............................................................ 178 
7.2.2. The role of PGE2 and the EP receptors in the guinea pig ................................................ 178 
7.2.3. Investigating the prostanoid receptors mediating airway microvascular leak ................... 179 
7.2.4. Modelling OVA-induced airway MVL in prostanoid receptor knock-out mice ................... 179 
7.2.5 Modelling airway MVL in other airway disease models ..................................................... 179 
7.2.6. Modelling MVL in Human Lung Microvascular Endothelial Cells ..................................... 181 
7.2.7. Modelling MVL in Mouse Lung Microvascular Endothelial Cells ...................................... 182 
7.3. Concluding Remarks ................................................................................................................ 183 
Reference List ................................................................................................................................... 184 
Appendix ............................................................................................................................................ 227 
  
11 
 
List of Figures 
 
Figure 1.1. Schematic representation of the inflammatory cascade in allergic asthma………… 21 
Figure 1.2. Schematic representation of the biosynthesis of prostanoids……………………….. 31 
Figure 1.3. Signalling cascade of prostanoid receptors……………………………………………. 32 
Figure 1.4. Schematic representation of microvascular leakage in the airways………………… 49 
Figure 1.5.  Schematic representation of the mechanisms involved in endothelial barrier 
disruption………………………………………………………………………………………………... 53 
Figure 2.1. Schematic of injection site used for intra venous administration and anatomy of 
the mouse heart illustrating where incisions were made for saline perfusion…………………… 74 
Figure 2.2.  Diagram of right carotid artery cannulation……………………………………………. 76 
Figure 2.3.  Timeline demonstrating the protocol used for the ovalbumin model………………..  78 
Figure 2.4. Diagram illustrating method used for measuring endothelial barrier permeability in 
human lung microvascular endothelial cells (HLMVECs)………………………………………….. 84 
Figure 3.1. Photograph of mouse airway tissue illustrating the effects of intravenous 5-HT on 
microvascular leak.…………………………………………………………………………………….. 96 
Figure 3.2. Effect of 5-HT on MVL into the trachea and the bronchi and intra-pulmonary 
airways of mice.………………………………………………………………………………………… 97 
Figure 3.3. Effect of methysergide on 5-HT-induced MVL into the trachea and the bronchi 
and intra-pulmonary airways of mice.………………………………………………………………... 98 
Figure 3.4. Effect of PGE2 or 5-HT on MVL into the trachea and the bronchi and intra-
pulmonary airways of mice……………………………………………………………………………. 99 
Figure 3.5.  Effect of PGE2 on MVL after 30 minutes or 5 minutes into the trachea and the 
bronchi and intra-pulmonary airways of mice............................................................................. 100 
Figure 3.6. Effect of PGE2 on MVL after 30 minutes into the trachea and the bronchi and 
intra-pulmonary airways of mice……………………………………………………………………… 101 
Figure 3.7. Effect of diclofenac on MVL in vehicle and PGE2 treated mice………………………  102 
Figure 3.8.  Effect of an intranasal dose of PGE2 on MVL after 30 minutes into the trachea 
and the bronchi and intra-pulmonary airways of mice……………………………………………… 103 
Figure 3.9.  Effect of PGE2 after 30 minutes or 5-HT after 5 minutes (respectively) into the 
upper trachea, lower trachea and bronchi and intra-pulmonary airways of Dunkin Hartley 
Guinea Pigs…………………………………………………………………………………………….. 104 
Figure 3.10.  Effect of PGE2, Iloprost and U46619 on the mean arterial blood pressure of 
C57BL/6 mice…………………………………………………………………………………………...  105 
Figure 4.1. Effect of PGE2 on MVL after 30 minutes into the trachea and the bronchi and 
intra-pulmonary airways of wild-type (WT) and EP1-4 receptor deficient mice…………………...  118 
Figure 4.2. Effect of 5-HT on MVL into the trachea and the bronchi and intra-pulmonary 
airways of wild-type (WT) and EP2 and EP4 receptor deficient mice……………………………... 119 
Figure 4.3. Example gel of genotyping for the Ptger3
-/-
 mice……………………………………… 120 
12 
 
Figure 4.4. Effect of PGE2, ONO-D1-004 (EP1), ONO-AE1-259 (EP2), ONO-AE-248 (EP3) 
and ONO-AE1-329 (EP4) on MVL into the trachea and the bronchi and intra-pulmonary 
airways of mice…………………………………………………………………………………………. 121 
Figure 4.5. Effect of ONO-AE1-259 (EP2) on MVL into the trachea and the bronchi and intra-
pulmonary airways of mice……………………………………………………………………………. 122 
Figure 4.6. Effect of PF-04418948 on ONO-AE1-259-induced MVL into the trachea and the 
bronchi and intra-pulmonary airways of mice………………………………………………………..  123 
Figure 4.7. Effect of PF-04418948 on ONO-AE1-259-induced MVL into the trachea and the 
bronchi and intra-pulmonary airways of mice………………………………………………………..  124 
Figure 4.8.  Relaxation of rat isolated rat tracheal tissue…………………………………………..  125 
Figure 4.9. Schild plot analysis of the antagonism of ONO-AE1-329 with ER-819762………… 126 
Figure 4.10. Effect of ONO-AE1-329 (EP4) on MVL into the trachea and the bronchi and 
intra-pulmonary airways of mice……………………………………………………………………… 127 
Figure 4.11. Effect of ER-819762 on ONO-AE1-329-induced MVL into the trachea and the 
bronchi and intra-pulmonary airways of mice……………………………………………………….. 128 
Figure 4.12. Effect of ER-819762 on ONO-AE1-329-induced MVL into the trachea and the 
bronchi and intra-pulmonary airways of mice……………………………………………………….. 129 
Figure 4.13. Effect of PF-04418948 and ER-819762 on PGE2-induced MVL into the trachea 
and the bronchi and intra-pulmonary airways of mice……………………………………………… 130 
Figure 4.14. Effect of simultaneous dosing of PF-04418948 and ER-819762 on PGE2-
induced MVL into the trachea and the bronchi and intra-pulmonary airways of mice…………. 131 
Figure 4.15. Schematic of possible EP2/4 heterodimer and how this interaction influences 
PGE2-induced airway microvascular leak……………………………………………………………  138 
Figure 5.1. Effect of Ovalbumin-challenge on airway MVL in C57BL/6 mice into the trachea 
and the bronchi and intra-pulmonary airways of mice, 2 and 24 hours after final intra nasal 
OVA challenge………………………………………………………………………………………….  145 
Figure 5.2. Effect of Ovalbumin-challenge on wet weight of the bronchi and intra-pulmonary 
airways at 2 hours and 24 hours after final intranasal OVA challenge……………………………  146 
Figure 5.3. Effect of diclofenac on OVA induced MVL into the trachea and the bronchi and 
intra-pulmonary airways of mice………………………………………………………………………  147 
Figure 5.4. Effect of OVA induced MVL into the trachea and the bronchi and intra-pulmonary 
airways of EP2 receptor knockout mice……………………………………………………………… 148 
Figure 5.5. Effect of OVA induced MVL into the trachea and the bronchi and intra-pulmonary 
airways of EP4 receptor knockout mice……………………………………………………………… 149 
Figure 5.6. Effect of PF-04418948 and ER-819762 on OVA induced MVL into the trachea 
and the bronchi and intra-pulmonary airways of mice……………………………………………… 150 
Figure 6.1. Effect of PGE2, PGD2, PGF2α, U46619 and Iloprost on MVL into the trachea and 
the bronchi and intra-pulmonary airways of mice…………………………………………………...  159 
Figure 6.2. Effect of PGD2 in wild type, DP1 and DP2 receptor knockouts……………………….  160 
Figure 6.3. Effect of PGF2α on MVL in the trachea and the bronchi and intra-pulmonary 161 
13 
 
airways of wild type and FP receptor knockout mice……………………………………………….  
Figure 6.4. Effect of U46619 on MVL in the trachea and the bronchi and intra-pulmonary 
airways of wild type and TP receptor knockout mice……………………………………………….  162 
Figure 6.5. Effect of Iloprost on MVL in the trachea and the bronchi and intra-pulmonary 
airways of wild type and IP receptor knockout mice……………………………………………….. 163 
Figure 6.6. An example gel showing the PCR products of DNA extracted from wild type, DP1-
2, FP, IP and TP KO mice……………………………………………………………………………...  164 
Figure 6.7. Effect of PGD2, PGF2α, U46619 and Iloprost on mean arterial blood pressure in 
C57BL/6 mice…………………………………………………………………………………………...  165 
Figure 7.1. The effect of LPS and Cigarette smoke on total protein in BAL fluid of C57Bl6 
mice………………………………………………………………………………………………………  180 
Figure 7.2. Effect of the TP agonist, U46619, on Human Lung Microvascular Endothelial Cell 
(HLMVEC) permeability………………………………………………………………………………..  181 
Figure 7.3. mRNA expression of prostanoid receptors (EP1-4, DP1-2, FP, IP, TP) in HLMVEC...  182 
  
14 
 
List of Tables 
 
Table 2.1. Primer sequences used to genotype prostanoid receptor KO mice…………………. 71 
Table 4.1.  Optimised PCR conditions for genotyping prostanoid receptor KO mice…………... 116 
Table 4.2. Antagonism of ONO-AE1-329-induced relaxation by ER-819762 in rat trachea…… 126 
Table 4.3. Schild plot analysis data for ONO-AE1-329 vs. ER-819762 in rat trachea………….. 127 
Table 6.1.  Optimised PCR conditions for genotyping prostanoid receptor KO mice…………... 158 
  
15 
 
List of Abbreviations  
 
5-HT 5-Hydroxytryptamine 
AC Adenylyl Cyclase 
ACh Acetylcholine 
AHR Airway hyperresponsiveness 
AOD Assay on Demand 
APC Antigen Presenting Cell 
ASM Airway Smooth Muscle 
BAL Bronchoalveolar Lavage 
BRET Bioluminescence resonance energy transfer 
cAMP Cyclic adenosine monophosphate 
cDNA Complementary deoxyribonucleic acid 
COPD Chronic Obstructive Pulmonary Disease 
COX Cyclooxygenase 
CR Concentration response 
CRTH2 
Chemoattractant receptor-homologous molecule 
expressed on T helper Type 2 cells 
CS Cigarette Smoke 
DAG Diacylglycerol 
Der f Dermatophagoides farina 
Der p Dermatophagoides pteronyssinus 
DMSO Dimethyl Sulphoxide 
DNA Deoxyribonucleic acid 
DP D-prostanoid receptor 
EAR Early asthmatic response 
EB Evans Blue 
ECIS Electric cell-substrate impedance sensing 
EDTA Ethylenediaminetetraacetic acid 
EP E-prostanoid receptor 
16 
 
FBS Foetal bovine serum 
FcεR1 Fcε receptors 
FITC Fluorescein isothiocyanate conjugate 
Gd-DTPA Gadolinium diethylenetriamine pentaacetic acid 
GOLD Global Initiative for Chronic Obstructive Lung Disease 
GPCR G-protein coupled receptor 
HDM House dust mite 
hEGF Human endothelial growth factor 
h-FGF-B Human fibroblast growth factor basic 
HLMVEC Human lung microvascular endothelial cells 
i.p. Intra peritoneal 
i.v. Intra venous 
ICS Inhaled corticosteroids 
IFN Interferon  
IL- Interleukin 
IP Prostacyclin receptor 
IP3 Inositol trisphosphate 
IPA Intrapulmonary airways 
IVM Intra vital microscopy 
KHS Krebs-Henseleit solution 
KO Knock-out 
LABA Long acting beta-adrenoceptor agonist 
LAMA Long acting muscarinic antagonist 
LAR Late asthmatic response 
LPS Lipopolysaccharide  
MHC-II Major histocompatibility complex class II molecules 
MLC Myosin light chain 
MLCK Myosin light chain kinase 
MLCP Myosin light chain phosphatase 
mRNA messenger ribonucleic acid  
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MTT 
3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium 
Bromide 
MVL Microvascular leak 
NF-κB Nuclear factor kappa-B 
OVA Ovalbumin 
p.o. per os 
PCR Polymerase chain reaction 
PET Polyethylene terephthalate 
PGD2 Prostaglandin D2 
PGE2 Prostaglandin E2 
PGF2α Prostaglandin F2α 
PGG2 Prostaglandin G2 
PGH2 Prostaglandin H2 
PGI2 Prostacyclin 
PGJ2 Prostaglandin J2 
PKA Protein kinase A 
PKC Protein kinase C 
PKG Protein kinase G 
PLC Phospholipase C 
R3-IGF-1 Insulin-like growth factor 1 
RNA ribonucleic acid 
s.e.m. Standard error of the mean 
TCR T cell receptor 
TEER Transendothelial electrical resistance 
TNFα Tumour Necrosis Factor alpha 
TP Thromboxane A2 receptor 
TXA2 Thromboxane A2 
VE-cadherin Vascular endothelial cadherin 
VEGF Vascular endothelial growth factor 
WT Wild type 
  
18 
 
 
 
 
 
 
 
 
 
Chapter One 
 
Introduction  
 
 
 
 
 
 
 
 
 
 
  
19 
 
1. Introduction 
 
1.1. Airway Inflammatory Diseases 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are two chronic lung 
diseases which are associated with significant morbidity and mortality worldwide 
(Edwards et al, 2009).  Both are characterised by airway obstruction that is variable 
and reversible in asthma but irreversible and progressive in COPD.  Additionally, 
chronic inflammation of the respiratory tract is apparent in both diseases.  Asthma 
and COPD represent an increasing burden on health services as their incidence 
increases worldwide.  Currently they stand as the fourth leading cause of death in 
the world, and it has been predicted by the World Health Organisation that the death 
toll from smoking related diseases, such as COPD, could reach 8 million by 2030 
(Minino et al, 2007; The World Health Organisation, 2011).  Furthermore, it has been 
estimated that approximately 300 million people globally are affected by asthma and 
it has been predicted that this will continue to rise with a further 100 million people 
affected by 2025 (Masoli et al. 2004). 
Microvascular leak, the exudation of plasma and plasma proteins, is a key feature in 
airway inflammatory diseases.  Increased levels of albumin and other plasma 
proteins have been measured in the airways of asthma (Meerschaert et al, 1999; 
Svensson et al, 1995; Van Rensen et al, 2002) and COPD patients (Hill et al, 1999; 
Minikata et al, 2005; Bessa et al, 2012).  Airway microvascular leak is thought to play 
an important role in the thickening of bronchial mucosa, airway hyperresponsiveness 
and exacerbations seen in asthmatic patients (Van de Graaf et al, 1991; Khor et al, 
2009; Paredi & Barnes, 2009).  Similarly, in COPD this increase in plasma exudation 
and thickening of airway mucosa is thought to influence the obstructive processes of 
this disease (Bosken et al, 1990; Kuwano et al, 1993).  Additionally the exuded 
plasma will be abundant in pro-inflammatory mediators that possess the ability to 
induce various events, such as inflammatory cell recruitment, compromised epithelial 
integrity and cilia function, as well as the activation of sensory neural pathways. 
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1.1.1. Asthma 
 
Bronchial asthma is usually defined as a chronic inflammatory pathology 
characterised by reversible airflow obstruction resulting from bronchoconstriction, 
inflammation and airway hyperresponsiveness (AHR).  This leads to recurrent 
episodes of wheezing, dyspnoea, coughing, and chest tightness, associated with a 
decrease in lung function (James & Wenzel, 2007).   A wide range of endogenous 
and environmental stimuli have been shown to induce an asthma attack.  These 
triggers can include allergic stimuli, such as pollen, animal dander and dust mite 
faeces, or non-allergic stimuli, such as exercise and cold air (Holgate, 2008a,b; 
McKenzie & Boulet, 2008; Passalacqua & Ciprandi, 2008).  Allergic or ‘atopic’ 
asthma represents the largest overall phenotype among patients, while few are 
defined as non-atopic (or intrinsic) (Wenzel, 2006).   
 
1.1.1.1. Allergic Sensitisation and Responses 
 
The immune response in allergic asthma involves two phases; the sensitisation 
phase following allergen exposure, and then the challenge or allergic response 
phase.  During the sensitisation phase allergens are detected by antigen presenting 
cells (APCs), primarily dendritic cells in the airways, where they are internalised and 
processed onto a major histocompatibility complex class II molecules (MHC-II) which 
they express on their cell surface.  This then enables the allergen to be ‘presented’ 
to naïve CD4+ T cells and a complex to be formed between the MHC-II/allergen 
molecule and T cells that express the specific T cell receptor (TCR). Accordingly, the 
antigen must be presented to the relevant T cell that expresses the right TCR.  
However, it has been recognised that each TCR can in fact recognise a number of 
different antigenic peptides (Wooldridge et al, 2012).  This complex formation and 
additional co-stimulatory signals subsequently leads to T cell proliferation and 
differentiation; predominantly Th1 or Th2 effector cells.  In asthma, the Th2 
phenotype is a key immunological feature and factor in the pathogenesis of the 
disease where it dominates the allergic immune response and is most likely to be 
responsible for on-going chronic inflammation.  It is the Th2 cells that then release 
interleukin (IL)-4 and IL-13 which in turn stimulates B cells to produce and release 
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allergen specific IgE (Grünig et al, 1998; McKenzie et al, 1999).  These IgE 
molecules bind to high affinity Fcε receptors (FcεR1) expressed on mast cells and 
basophils thus priming them for future allergen exposure (Figure 1.1).   
 
 
Figure 1.1.  Schematic representation of the inflammatory cascade in allergic asthma. 
(Adapted from Bradding et al, 2006). 
1.1.1.1.1. EAR and LAR 
 
Subsequent allergen exposure results in an allergic response, activating sensitised 
mast cells by crosslinking surface bound IgE molecules to release several 
bronchoconstrictor mediators, including histamine, cysteinyl leukotrienes and 
prostaglandin D2 (PGD2) (Barnes 2008).  This reaction is termed the early asthmatic 
response (EAR) and is characterised by rapid bronchoconstriction, oedema and 
plasma extravasation, and mucus secretion which all contribute to airflow 
obstruction.  Approximately 4-8 hours after initial allergen challenge the late 
asthmatic response (LAR) occurs in about 50% of patients (Booij-Noord et al 1971, 
1972).  This is usually characterised by bronchoconstriction and an influx of 
inflammatory cells, such as eosinophils, mast cells, neutrophils and T cells (Hogan et 
al 1998). 
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1.1.1.1.2. Airway Hyperresponsiveness 
 
One of the defining physiological characteristics of asthma is AHR.  AHR is defined 
as an increased narrowing of the airways of asthmatic patients in response to stimuli 
which do not usually cause bronchoconstriction in healthy individuals.  Such stimuli 
include pollution, allergens, cold air and spasmogens such as methacholine and 
histamine (Spina & Page, 2002).  This response leads to excessive 
bronchoconstriction and airflow limitation, which results in shortness of breath and 
chest tightness. Several mechanisms are thought to contribute to AHR including 
hypertrophy and hyperplasia of airway smooth muscle (Ebina et al, 1993; Lambert et 
al, 1993) and airway wall oedema (Van de Graaf et al, 1991; Kimura et al, 1992; 
Chung et al, 1999).  It has also been suggested that inflammation and inflammatory 
mediators are driving AHR, which is supported by the fact that inhaled and oral 
corticosteroids are able to attenuate AHR in asthmatic patients (Djukanović et al, 
1992, 1997; Laitinen et al, 1992; Chalmers et al, 2002; Clearie et al, 2012).  
Increases in cytokines (IL-4, IL-5 and IL-13), eosinophils and IgE can also lead to 
hyperresponsiveness (Grünig et al, 1998; Walter et al, 2001; Taube et al, 2002), with 
eosinophilic inflammation correlating with asthma severity and AHR (Bousquet et al, 
1990).   
 
1.1.1.2. Treatments  
 
Current management of asthma involves the use of short and long acting β2-
adrenergic receptor agonists and inhaled corticosteroids (ICS).  β2-agonists act as 
bronchodilators for symptomatic relief as they are able to relax airway smooth 
muscle, reversing airflow obstruction.  Short acting β2-agonists, such as salbutamol, 
are commonly prescribed to those with mild intermittent asthma symptoms. 
However, for moderate to severe cases the most common, and highly effective, 
strategy is regular ICS with long-acting β2-agonists (LABAs) in combination inhalers. 
LABAs most frequently used include salmeterol and formoterol.  Briefly, β2-agonists 
exert their effects through the activation of the β2 adrenoceptor on airway smooth 
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muscle, which leads to an increase in cyclic adenosine monophosphate (cAMP) and 
protein kinase A (PKA) or PKG activity.  This induces a relaxation of the airway 
smooth muscle thus causing bronchodilation.  In addition, there is evidence to 
suggest that anti-spasmogenic effects of these compounds may be mediated via 
PKA/PKG-independent mechanisms (Torphy et al, 1982; Torphy, 1994; Spicuzza et 
al, 2001). 
ICS, such as budesonide or fluticasone, have become a mainstay of asthma 
management and are recommended as a first-line therapy for patients of all ages 
with persistent asthma (Bateman et al, 2008).  Furthermore, they are extremely 
effective at controlling varying degrees of asthma severity.  ICS are potent anti-
inflammatories that act at glucocorticoid receptors (GR) to activate various anti-
inflammatory genes as well as suppressing pro-inflammatory genes (Barnes, 2011).  
The main action is the switching off of multiple activated inflammatory genes, 
encoding for cytokines, chemokines, adhesion molecules and inflammatory 
receptors. Furthermore, there have been concerns over the safety of LABAs when 
administered alone but there has been no evidence of this risk when administered in 
combination with ICS (Jaeschke et al, 2008; Sears, 2009; Weatherall et al, 2010). 
Although combination therapy with inhaled ICS and LABAs is highly effective, 
approximately 5 to 10% of patients are not well controlled even with maximum doses 
of inhaled therapies (Heaney & Robinson, 2005; Wenzel 2005). Although this 
percentage appears small, it accounts for a huge amount of health care spending, 
highlighting an urgent need for new treatments.  
 
1.1.1.3. In vivo models of Asthma  
 
Although there are both allergic and non-allergic variants of asthma, the majority of 
in vivo models are based on the allergic form.  This section will therefore outline two 
of the most commonly used experimental models of allergic asthma; the ovalbumin 
(OVA) and house dust mite (HDM) models.  It is important to note that these in vivo 
models are not exact recreations of human disease but they allow us to investigate 
the mechanistic, pathophysiological and physiological characteristics of asthma.  In 
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addition, most laboratory animals do not spontaneously develop an allergic response 
so this must be artificially induced (Slauson & Hahn, 1980; Kurucz & Szelenyi, 2006).  
  
1.1.1.3.1. Ovalbumin Model 
 
Ovalbumin (OVA) is a protein allergen that is found in chicken egg white, which has 
been used for decades to induce an allergic response in rodents.  To produce an 
allergic response to  OVA, the model requires an initial sensitisation phase followed 
by a challenge phase.  Typically, animals are sensitised systemically (by 
intraperitoneal or subcutaneous administration) with OVA, in combination with an 
adjuvant.  The adjuvant, such as Alum or aluminium hydroxide, acts by priming the 
immune system towards a Th2 phenotype.  Sensitisation to OVA usually requires 
two systemic doses, separated by at least one week.  This phase is then followed by 
allergen exposure to the airways one to two weeks later.  The exact protocols in 
terms of timings, doses and routes of administration can vary between different 
research groups.   The OVA model has proved effective in replicating some of the 
major features of allergic asthma, including IgE production, mucus secretion, EAR 
and LAR, non-specific AHR and oedema (as reviewed in Stevenson & Belvisi, 2008).  
In addition, these responses to OVA can be modulated by glucocorticoids and β2-
agonists (Birrell et al, 2003; Eum et al, 2003; Wyss et al, 2007).  The OVA model has 
been utilised in guinea pigs, rats and mice, with the brown-Norway rat and BALB/C 
mouse being the most commonly used strains (Trifilieff et al, 2000; Hylkema et al, 
2002).  The C57/BL6 mice are also regularly used, as there are a number of 
genetically modified mice created using this strain. 
However, this model is not without any shortcomings. Firstly, the use of OVA is not a 
clinically relevant antigen as it is rarely associated with triggering asthma in humans.  
Secondly, the route of sensitisation and use of an adjuvant does not replicate what 
would occur in man, where airborne allergens are probably more relevant. Finally, 
there is evidence to suggest that tolerance occurs in chronic OVA models (Swirski et 
al, 2002; Van Hove et al, 2007), with suppression of eosinophilia, AHR and OVA-
specific IgE having been demonstrated (Sakai et al, 2001).  In contrast some groups 
have demonstrated airway remodelling (e.g. goblet cell hyperplasia and airway 
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fibrosis) following chronic OVA-exposure (Temelkovski et al, 1998; McMillan & Lloyd, 
2004; Van Hove et al, 2009). 
 
1.1.1.3.2. House Dust Mite Model 
 
The house dust mite (HDM) model of allergic asthma was developed as an 
alternative to the OVA model, using a more clinically relevant allergen.  House dust 
mite has been shown to induce a positive skin prick test in approximately 80% of 
asthmatic patients (Smith et al, 1969) and is associated with a number of other 
allergic disorders, including allergic rhinitis and atopic dermatitis (Platt-Mills, 1995).  
The two commonly used house dust mite allergens are Dermatophagoides 
pteronyssinus (Der p) and Dermatophagoides farina (Der f), which can produce 
proteins and macromolecules that induce IgE antibodies in allergic individuals 
(Chapman & Platts-Mills, 1980).  Typical protocols using HDM involves multiple 
topical instillations over several weeks, rather than separate sensitisation and 
challenge phases. Modelling allergic asthma using HDM has several advantages 
over the OVA model.  Firstly, no adjuvant or systemic sensitisation is required as 
animals can be sensitised to HDM via the respiratory mucosa.  Secondly, 
eosinophilic inflammation is sustained following chronic exposure in addition to 
structural remodelling (Johnson et al, 2004; Southam et al, 2007).  However, unlike 
the OVA model, very little is known about the HDM model and the role played by 
immune cell populations and inflammatory mediators involved. In addition, it has 
been shown that a single topical dose of HDM in the rat was able to induce asthma-
like airway inflammation, suggesting that initial inflammation in this model is innate in 
nature (De Alba et al, 2010).  
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1.1.2. Chronic Obstructive Pulmonary Disease 
 
Chronic obstructive pulmonary disease (COPD) is a term that encompasses a group 
of respiratory diseases including emphysema, chronic bronchitis and small airways 
disease (Stockley et al, 2009).  It is characterised by progressive and irreversible 
airflow obstruction caused by chronic inflammation of the small airways and lung 
parenchyma.  This aberrant inflammatory response is associated with various 
different stimuli, including cigarette smoke, pollution and viral or bacterial infections.  
COPD is a major public health problem, which the World Health Organisation (2008) 
has estimated to become the third leading cause of death worldwide in 2030.  
Unfortunately there are no effective treatments that halt the progression of this 
disease, with current therapies only alleviating symptoms and acute exacerbations.  
Classical symptoms of COPD include cough, sputum production and dyspnoea, 
eventually leading to a loss in lung function.   Additionally, there are several extra-
pulmonary comorbidities that affect COPD patients, including skeletal muscle 
dysfunction, cardiovascular disease, metabolic diseases, depression and 
osteoporosis (Gan et al, 2004; Agustí, 2005; Sin et al, 2006; Barnes & Celli, 2009; 
Barr et al, 2010).  These comorbidities probably stem from the systemic inflammation 
observed in COPD (Gan et al, 2004; Agustí, 2005; Barnes, 2010). 
As described above COPD describes a group of diseases, often divided into chronic 
bronchitis, small airways disease and emphysema.  Chronic bronchitis involves 
persistent inflammation of the epithelium, characterised by mucus hypersecretion, 
goblet cell hypertrophy and hyperplasia and epithelial barrier disruption (Hogg, 
2004). Small airways disease (or bronchiolitis) describes inflammation and 
remodelling specific to conducting airways less than 2mm in diameter, which are the 
major site of airflow obstruction (Hogg, 2004).  Finally, emphysema refers to the 
destruction of structural lung tissue, reducing the maximum expiratory airflow and 
lung elastic recoil (Mead et al, 1967).    
Cigarette smoking accounts for the majority of COPD cases in high income 
countries, while in lower-income countries other risk factors are important, such as 
indoor air pollution from biomass fuels (Salvi & Barnes, 2009).  The harmful effects 
of cigarette smoke are thought to arise from the toxic constituents that it is composed 
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of (including acrolein, benzene and formaldehyde) as well as an increase in reactive 
oxygen species (Owen, 2008; Bodnar et al, 2012).  α1-antitrypsin deficiency is one of 
the only known genetic causes of COPD and is involved in approximately 1-3% of 
cases (Stoller & Aboussouan, 2012).   Despite tobacco smoke being a primary risk 
factor (about 80-90% of COPD patients) (Stevensen et al, 2006), only about 25% of 
smokers develop the disease (Løkke et al, 2006).   This suggests that there may be 
genetic, epigenetic or environmental factors that determine susceptibility. 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has outlined a 
classification system of airflow limitation which is divided into four grades (GOLD 1, 
mild; GOLD 2, moderate; GOLD 3, severe; and GOLD 4, very severe).  These 
grades are based upon the fixed ratio, post-bronchodilator FEV1/FVC (Forced 
Expiratory Volume in 1 second and Forced Vital Capacity, respectively) less than 
0.7, as an indication of airflow limitation (Vestbo et al, 2013).  Additional COPD 
assessment is based upon symptom severity, history of exacerbations, spirometric 
abnormality and comorbidities.  A combined COPD assessment then splits patients 
into four different categories; group A, low risk less symptoms; group B, low risk, 
more symptoms; group C, high risk, less symptoms; group D, high risk, more 
symptoms.  Assessing COPD using this combined approach reflects the complexity 
of the disease and provides a more robust guide to treatment and disease 
management (Vestbo et al, 2013). 
 
1.1.2.1. Treatments 
 
One of the main risk factors associated with COPD is smoking; however smoking 
cessation strategies have not been hugely successful, especially in patients that are 
more severely affected (Scanlon et al, 2000; Willemse et al, 2005).   
In terms of pharmacological therapies, bronchodilators are commonly used to 
manage the symptoms of COPD.  Bronchodilators used include β2-agonists, anti-
cholinergics and methylxanthines, with long-acting formulations favourable as they 
are both more effective and convenient compared to short-acting (Dahl et al, 2001; 
Oostenbrink et al, 2004; Vestbo et al, 2013). These drugs may be effective at 
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relaxing the airway smooth muscle but they fail to treat or reduce the inflammation 
associated with the disease. 
The use of corticosteroids (e.g. fluticasone or budesonide) is also common among 
COPD patients.  Like asthma, COPD involves chronic inflammation of the airways. 
However, most patients with COPD respond poorly to inhaled corticosteroids (ICS) 
showing little improvement in lung function or symptom severity (Suissa & Barnes, 
2009; Barnes, 2010; Yang et al, 2012).  Nevertheless, approximately 80% of COPD 
patients are using high-dose ICS.  The overuse of glucocorticoids can have various 
long term side effects, including osteoporosis, muscle breakdown and an increased 
risk of pneumonia (Drummond et al, 2008; Barnes, 2010).  However, several large 
clinical trials have shown that combination therapy with ICS and long acting β2-
agonists (LABAs) produces better control of respiratory symptoms, lung function and 
quality of life (Calverley et al, 2003a; Calverley et al, 2003b; Szafranski et al, 2003; 
Calverley et al, 2007; Nannini et al, 2007; Bathoorn et al, 2008). Furthermore, 
combining a LABA and a long-acting muscarinic antagonist (LAMA) have additive 
effects on bronchodilation with greater clinical benefit than each given alone.  
Combinations inhalers include indacaterol-glycopyrrolate, olodaterol-tiotropium and 
vilanterol-umeclidinium (Barnes, 2013).  
 
1.1.2.2. In vivo models of COPD 
 
1.1.2.2.1. Lipopolysaccharide Model 
 
Lipopolysaccharide (LPS) is a bacterial endotoxin that is found in cigarette smoke.  It 
is a widely used model of acute lung injury, where it is characterised by prominent 
lung neutrophilia, peaking between 6 and 24 hours (Ferretti et al, 2003).  The 
neutrophil is a primary source of neutrophil elastase in COPD and thus regarded as 
one of the most important mediators driving emphysema.  In addition, the LPS model 
has been favourable as the protocol is quick and easy, involving just a single dose of 
LPS.  Furthermore, chronic administration of LPS has demonstrated airway 
remodelling, emphysema and changes in lung function (Stolk et al, 1992; Savov et 
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al, 2003; Brass et al, 2008).  However, LPS-induced inflammation, unlike human 
COPD, is sensitive to glucocorticoid treatment (Birrell et al, 2005; Håkansson et al, 
2012), bringing into question the clinical relevance of this model.  Although no longer 
used as a COPD-like model it does provide a model of acute innate immunity-driven 
inflammation and also serves as a model of bacterial exacerbation (Wright et al, 
2008). 
 
1.1.2.2.2. Cigarette Smoke Model 
 
The use of cigarette smoke (CS) to model COPD in small animals has become 
favourable over LPS and elastase models (a single stimulus) as CS smoke contains 
over 4700 chemical compounds and more than 1015 oxidants/free radicals (reviewed 
in Vlahos & Bozinovski, 2014).  In addition, CS is the primary etiological agent in 
human COPD.  Several hallmark features of human COPD have been observed in 
rodent CS models, including chronic lung inflammation, impaired lung function, 
emphysema, mucus hypersecretion, airway wall remodelling, and vascular 
remodelling.  In addition, CS-induced inflammation in rodents is insensitive to 
glucocorticoids, resembling that seen in human COPD (Marwick et al, 2004; Marwick 
et al, 2009).  However, it can be difficult to compare findings from different research 
groups as protocols for CS exposure can vary immensely.  For example, differences 
occur with delivery systems (nose-only or whole-body), types of cigarettes, smoke 
concentration, duration and frequency as well as species and strain of animal.  
Furthermore, a lot of the changes seen in rodent CS models are very mild in 
comparison to those seen in humans. Subsequently, for lung function, small airway 
remodelling and emphysematous changes to develop chronic exposures of 6 months 
or more are required (Churg et al, 2004; Barreiro et al, 2012; Yao et al, 2012), which 
is both time consuming and expensive.  With that being said, acute exposure models 
(<1 week) are effective as primary models to explore mechanisms of smoke-induced 
lung inflammation as well as testing potential treatments.    
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1.2. Prostanoids and Prostanoid Receptors 
Within the airways prostanoids have been shown to contribute to airflow regulation, 
bronchoconstriction, mucus secretion and microvascular leak, all of which are 
prominent features in asthma and COPD.  In addition, increased levels of 
prostanoids, in particular PGE2 and PGD2, have been measured in the airways of 
asthma and COPD patients (Murray et al, 1986; Montushi et al, 2003; Long et al, 
2004).  It has also been suggested that prostanoids initiate protective mechanisms in 
the airways and inhibit the release of inflammatory mediators from airway cells 
(Clarke et al, 2004; Kay et al, 2006; Pavord & Tattersfield, 1995).  There appears to 
be a fine balance between the pro-inflammatory and anti-inflammatory effects of 
prostanoids but it is clear that they have important functions in the airways.   
   
1.2.1. Synthesis 
Prostanoids are described as lipid mediators that belong to a diverse family of 
eicosanoids synthesised by cyclooxygenase (COX)-mediated metabolism of the 
unsaturated 20-carbon fatty acid arachidonic acid.  Arachidonic acid is liberated from 
the cell membrane by phospholipase A2 and oxidised by COX enzymes into PGG2.  
This then undergoes a reduction reaction by COX to form an unstable 
endoperoxidase PGH2.  PGH2 subsequently acts as a substrate for a number of 
specific synthase enzymes which produce the five bioactive prostanoids (Flower, 
1978; Goulet et al, 2004; Hata & Breyer, 2004).  These are PGE2, PGF2α, PGD2, 
Prostacyclin (PGI2) and thromboxane A2 (TXA2), as shown in Figure 1.2.  There are 
two forms of COX enzyme, simply termed COX-1 and COX-2.  In the majority of cell 
types within the body COX-1 is expressed constitutively, while COX-2 is inducible in 
response to inflammatory stimuli, such as endotoxin, pro-inflammatory cytokines, 
Interleukin 1β (IL-1β) and tumour necrosis factor α (TNF-α) and regulated by nuclear 
factor κ B (NF-κB) (Newton et al, 1997).  
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Figure 1.2. Schematic representation of the biosynthesis of prostanoids. Arachidonic 
acid is metabolised by cyclooxygenase-1 or -2 (COX-1/2) to PGH2.  The prostanoids PGE2, PGF2α, 
PGD2, TxA2 and PGI2 are formed by their individual synthase enzymes PGES, PGFS, PGDS, TxAS 
and PGIS respectively. 
 
1.2.2. Prostanoid Receptors 
In order to exert their biological effects prostanoids bind to specific cell surface 
receptors.  These receptors belong to the Rhodopsin-like family of the seven 
transmembrane domain G-Protein Coupled Receptors (GPCRs).  Currently there are 
nine known prostanoid receptors, FP, IP, TP, DP1+2, and EP1-4, named according to 
the prostanoid affinity profiles i.e. of all the prostanoids PGE2 has the most affinity for 
the 4 EP receptors (Figure 1.2) (Coleman et al, 1994). Although individual 
prostaglandins have the highest affinity for their cognate receptor, there is 
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considerable cross reactivity between a given prostanoid and other receptors within 
the family. For example, PGD2 has been shown to act via TP receptors to mediate 
different responses (Coleman & Sheldrick, 1989; Nishimura et al, 2001).  
Furthermore, the observation that PGE2 can have multiple and often opposing 
functional effects on a single tissue, is likely accounted for by the existence of 
multiple receptors (Woodward et al, 2011).  The G-proteins and downstream 
signalling pathways activated by each prostanoid receptor are discussed in more 
detail later.  The schematic in figure 1.3 outlines the main signalling pathways for 
each prostanoid receptor. 
 
 
Figure 1.3. Signalling cascade of prostanoid receptors. The EP1, FP and TP receptors 
predominantly couple to Gq, the EP2, EP4, DP1 and IP receptors to Gs and the EP3 and DP2 receptors 
to G1. Although the existence of EP3 splice variants may alter the signalling pathway.  Activation of Gq 
causes phospholipase C (PLC) activation and an increase in calcium/protein kinase C (PKC). Gs 
coupling activates adenylyl cyclase (AC) and subsequent increase in cAMP, while G i inhibits AC and 
decreases cAMP. 
 
  
EP1 FP TP EP2+4 DP1 IP EP3 DP2 
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1.2.2.1. Prostaglandin E2 and EP receptors  
Prostaglandin E2 (PGE2) is generated by PGE synthase that catalyses the 
isomerization of PGH2 to PGE2.   As previously mentioned, PGE2 has the highest 
affinity for EP receptors, EP1-4, which are encoded for by the genes Ptger1-4 
(Coleman et al, 1994).  Original discovery of multiple receptor subtypes was 
confirmed through molecular cloning from human tissue (Adam et al, 1994; Bastien 
et al, 1994; Funk et al, 1993; Regan et al, 1994) as well as mouse tissue (Sugimoto 
et al, 1992; Honda et al, 1993; Watabe et al, 1993; Katsuyama et al, 1995). 
Additionally, it was demonstrated that the EP3 receptor has multiple splice variants 
(Adam et al, 1994).   In terms of affinity, the EP3 and EP4 receptors bind PGE2 with 
the highest affinity (Kd < 1nM) while the EP1 and EP2 receptors show a slightly lower 
affinity (Kd > 10nM) (Abramovitz et al, 2000). 
With four different receptor subtypes it is unsurprising that PGE2 has the most 
diverse range of physiological effects. In the gastrointestinal tract, PGE2 protects the 
integrity of the gastric mucosa, while the use of non-steroidal anti-inflammatory drugs 
(NSAIDs) has been associated with significant adverse gastrointestinal effects (Woo 
et al, 1986; Warner et al, 1999).  In the kidney, PGE2 is crucial in preserving renal 
blood flow and glomerular filtration rate (reviewed in Breyer & Breyer, 2001).  PGE2 
also plays an important role in the cardiovascular system where it is able to maintain 
blood pressure following salt overload (Kennedy et al, 1999).  Opposing effects of 
PGE2 has also been noticed; on airway and vascular smooth muscle it can cause 
both relaxation and contraction and within the immune system it appears to have 
both pro- and anti-inflammatory actions. The signal transduction mechanisms 
mediating their effects differ between each receptor subtype, which accounts for the 
diverse role of PGE2.  More detail on individual EP receptors and their biological 
functions is discussed below. 
 
1.2.2.1.1. EP1 Receptors 
The human EP1 receptor cDNA encodes a 402-amino-acid sequence which shares 
83% and 85% homology with the rat and mouse EP1 receptors, respectively (Funk et 
al, 1993).  It is predominantly thought to couple to the Gq pathway with the activation 
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of phospholipase C (PLC) and Ca2+ mobilisation (Nicola et al, 2005; Tang et al, 
2005).  However, in mouse EP1 receptors, this increase in Ca
2+ correlated with 
negligible IP3 response, indicating a signalling pathway independent of Gq (Narumiya 
et al, 1999).  
EP1 receptors are not widely distributed in higher species and are considerably more 
common in guinea pigs and mice (Coleman et al, 1994b).  However, functional EP1 
receptors have been observed in the myometrium (Senior et al, 1991), pulmonary 
veins (Norel et al, 2004), mast cells (Wang & Lau, 2006) and keratinocytes (Konger 
et al, 2009).  The physiological functions of EP1 receptors include allodynia (Stock et 
al, 2001), cardiovascular homeostasis (Audoly et al, 1999; Stock et al, 2001), 
inflammatory pain and hyperalgesia (Minami et al, 1994; Nakayama et al, 2004) and 
stress-induced impulse behaviour (Matsuoka et al, 2005).  In the airways, EP1 
receptors mediate airway constriction in mice (Tilley et al, 2003) and guinea pigs 
(Coleman & Kennedy, 1985; Ndukwu et al, 1997) and surfactant secretion from rat 
alveolar type II cells (Morsy et al, 2001). 
Previously, 17-Phenyl PGE2 was the selective agonist used to investigate the EP1 
receptor but its selectivity was only modest (Lawrence et al, 1992).  The ligand ONO-
D1-004 produced by ONO pharmaceuticals (Japan) is more favourable due to its 
superior selectivity (Okada et al, 2000; Suzawa et al, 2000).  The most suitable 
selective antagonist is considered to be GW848687X (Giblin et al, 2007; Jones et al, 
2009). 
 
1.2.2.1.2. EP2 Receptors 
The human EP2 receptor cDNA encodes a 358-amino-acid polypeptide which has 
also been cloned in the rat, mouse and rabbit (Boie et al, 1997; Guan et al, 2002; 
Katsuyama et al, 1995; Regan et al, 1994).  EP2 receptors mediate their effects 
through Gs coupling and an increase in cAMP (Regan et al, 1994).  Additionally, it 
has been suggested that a positive feedback loop exists whereby cAMP signalling 
enhances the expression of EP2 receptors (Sagana et al, 2009).   
Earlier studies on EP2 receptor mRNA expression indicated relatively low levels and 
an uncertain distribution pattern (Regan et al, 1994; Narumiya et al, 1999; Smock et 
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al, 1999).  However, in the past decade it has become apparent that it is more widely 
distributed.  In the airways, expression has been reported throughout, including 
airway smooth muscle, epithelial cells and inflammatory cells (Coleman et al, 1994).  
According to functional studies, EP2 receptor activation invariably leads to relaxation.  
Indeed, EP2-mediated relaxation of vascular smooth muscle and vasodepressor 
responses has long been known (Armstrong et al, 1976; Audoly et al, 1999).  
Kennedy et al (1999) demonstrated that mice deficient in the EP2 receptor developed 
salt-sensitive hypertension.  In addition, EP2 receptors were thought to mediate 
PGE2-induced bronchodilation in isolated airway tissue in a variety of species 
including humans (Norel et al, 1999), mice (Tilley et al, 2003), guinea pigs (Nials et 
al, 1993) and cats (Gardiner 1986).  However, more recently it has been shown that 
in rat and human airway smooth muscle EP4 receptor activation mediates relaxation 
and bronchodilation (Buckley et al, 2011). 
Currently, ONO-AE1-259 is the preferred selective EP2 agonist and has proved 
valuable in characterising EP2 receptor systems (Cao et al, 2002; Clarke et al, 2004).  
AH6809 was previously used as a mixed EP1/EP2 receptor antagonist as there were 
no other potent or selective compounds in this class (Woodward et al, 1995).  
However, Forselles et al (2011) recently reported on the development of a selective 
EP2 antagonist, PF-04418948. Results from our group confirmed its selectivity, 
relative to other prostanoid receptors, using a range of isolated tissue based systems 
(Birrell et al, 2013).  
 
1.2.2.1.3. EP3 Receptors 
Following pharmacological investigations into the EP3 receptor it was evident that its 
activation mediated a diverse range of effects.  This has been attributed to the 
existence of multiple splice variants, with at least eight having been identified in 
human tissue (Bos et al, 2004).   The major signalling pathway for EP3 receptors is 
through Gi coupling and an inhibition of adenylyl cyclase (Narumiya et al, 1999).  
However, the presence of alternative splice variants has demonstrated a wide 
repertoire of signalling pathways.  EP3 receptor activation has been reported to show 
activation of the Gs pathway, increases in intracellular Ca
2+ and Rho kinase 
stimulation (An et al, 1994; Namba et al, 1993; Hasegawa et al, 1997; Macias-Perez 
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et al, 2008).  Currently, there is no consistent nomenclature for these alternative 
splice variants. 
Through Northern blotting, in situ hybridisation and functional studies the EP3 
receptor has demonstrated a wide distribution, including high expression levels in the 
central nervous system, cardiovascular system, reproduction system, kidney, uterus, 
adrenal gland and stomach (Yang et al, 1994; Abramovitz et al, 1995; Sugimoto & 
Narumiya, 2007; Woodward et al, 2011).  This wide distribution and existence of 
multiple receptor isoforms appears to correlate with the diverse range of effects EP3 
activation has.  The EP3 receptor mediates PGE2-induced hyperalgesia (Minami et 
al, 2001) and plays a major role in hyperpyrexia (Ushikubi et al, 1998).  Within the 
cardiovascular system EP3 receptors can mediate platelet aggregation by 
potentiation of the effects of pro-aggregatory agents (Matthews & Jones, 1993; 
Armstrong, 1996; Fabre et al, 2001; Ma et al, 2001; Gross et al, 2007; Singh et al, 
2009).  EP3 receptors also have a range of effects in the airways including sensory 
nerve activation (Maher et al, 2009), constriction of human pulmonary artery (Qian et 
al, 1994), bronchoconstriction and allergic responses in mice (Tilley et al, 2003; 
Kunikata et al, 2005) and anti-proliferative effects on human airway smooth muscle 
(Burgess et al, 2004).  Furthermore, opposing effects on oedema formation have 
been described.  In rat and mouse skin, EP3 receptor activation inhibited oedema 
formation (Ahluwalia & Perretti, 1994), while PGE2-induced mouse paw oedema was 
EP3 receptor-mediated (Claudino et al, 2006).     
Sulprostone has been used as an EP3 agonist in functional studies (Coleman & 
Sheldrick, 1989; Maher et al, 2009) but it has only modest EP3 versus EP1 selectivity 
which has limited its utility (Coleman et al, 1987).  ONO-AE-248 is a more suitable 
agonist as it has proved to be highly selective at the EP3 receptors (Okada et al, 
2000; Suzawa et al, 2000) despite having only modest potency (Jones et al, 2008).  
EP3 antagonist L-826266 demonstrated high potency and selectivity (Gallant et al, 
2002; Jones et al, 2009) but does have a slow onset of action owing to its lipophilicity 
(Jones et al, 2008). 
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1.2.2.1.4. EP4 Receptors 
The human EP4 receptor cDNA encodes a 488-amino-acid sequence (Bastien et al, 
1994) and this sequence has been cloned in the mouse, rat, rabbit and cow (An et 
al, 1994; Boie et al, 1997; Breyer et al, 1996; Honda et al, 1993).  Originally, the 
pharmacologically defined EP4 receptor was named EP2 (Honda et al, 1993; Bastien 
et al, 1994) until the authentic EP2 receptor was cloned (Regan et al, 1994b).  The 
EP4 receptor primarily couples to Gs and the subsequent increase in cAMP 
(Narumiya et al, 1999) but when compared with EP2 receptor signalling the 
functional coupling to cAMP appeared less efficient for the EP4 receptor (Fujino et al, 
2002, 2005).  In addition, several cAMP-independent signalling cascades have been 
identified following EP4 receptor activation (Fiebich et al, 2001; Pozzi et al, 2004; 
Mendez & LaPointe, 2005; Frias et al, 2007; George et al, 2007; Rao et al, 2007). 
EP4 receptors are widely distributed and expression has been detected in tissues 
including the small intestine, lung, kidney, spleen, adrenal glands and thymus 
(Honda et al, 1993; Bastien et al, 1994; Breyer et al, 1996).  Functionally, EP4 
receptor activation mediates relaxation of vascular smooth muscle of pulmonary 
arterial veins (Foudi et al, 2008) and is essential in closing the ductus arteriosus in 
newborns (Nguyen et al, 1997).  Relaxation of airway smooth muscle can also be 
mediated via EP4 receptor activation in both the rat (Lydford & McKechnie, 1994; 
Buckley et al, 2011) and human trachea (Buckley et al, 2011).  Additionally, the EP4 
receptor has demonstrated anti-inflammatory effects in various cell based assays 
(Takayama et al, 2002; Clarke et al, 2004; Okano et al, 2006; Ratcliffe et al, 2007) as 
well as Th1 cell differentiation and Th17 expansion (Yao et al, 2009). 
One of the most extensively used EP4 agonists is ONO-AE1-329 which has 
demonstrated high selectivity as a full EP4 agonist with relatively high potency 
(Okada et al, 2000; Suzawa et al, 2000; Cao et al, 2002).  AH23848 was one of the 
first EP4 receptor antagonists (Coleman et al, 1994a) but has since been overtaken 
by more selective and potent antagonists.  These more selective antagonists include 
GW627368X (Wilson et al, 2006), ONO-AE3-208 (Kabashima et al, 2002) and ER-
819762 (Chen et al, 2010). 
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1.2.2.2. Prostaglandin D2 and DP receptors 
Prostaglandin D2 (PGD2) is generated by PGD synthase (Urade et al, 1995) and is 
able to bind and activate, with similar affinity, two distinct receptors; DP1 (Boie et al, 
1995) and DP2 (CRTH2) (Nagata et al, 1999; Hirai et al, 2001). PGD2 is primarily 
produced by activated mast cells and/or T cells and is associated with inflammatory 
conditions (Roberts et al, 1980; Lewis et al, 1982).  In addition, BAL fluid analyses 
have shown increased levels of PGD2 in the airways following antigen challenge 
(Murray et al, 1986). The different functions and biological effects of each receptor 
subtype is described below.  
 
1.2.2.2.1. DP1 Receptors 
The human DP1 receptor cDNA encodes a 359 amino-acid polypeptide and is 
expressed in low levels in most tissues (Boie et al, 1995).  Receptor activation is 
predominantly coupled to Gs and stimulation of cAMP production (Gorman et al, 
1977; Halushka et al, 1989; Hirata et al, 1994; Boie et al, 1995) and DP1 expressing 
cells have also elicited increases in intracellular Ca2+ through cAMP-dependent 
mechanisms (Boie et al, 1995; Zaccolo, 2009). 
Compared to the other prostanoid receptors, DP1 is the least abundant in tissues.  
Northern blot analyses demonstrated expression in the retina and small intestine 
(Boie et al, 1995) and in mice, expression is moderate in the ileum and weak in the 
stomach, lung and uterus (Hirata et al, 1994).  In contrast, functional studies have 
demonstrated that DP1 receptor expression is limited to certain areas and/or specific 
cells, which may explain low levels of detection (Narumiya et al, 1999).  Activation of 
the DP1 receptor mediates many physiological events, including allergic responses 
and the production of chemokines and cytokines that recruit inflammatory 
lymphocytes and eosinophils (Matsuoka et al, 2000).  Further, these cells are known 
to be involved in the airway inflammation and AHR seen in asthma (Kabashima & 
Narumiya, 2003).  Functional DP1 receptors also inhibit platelet aggregation (Whittle 
et al, 1983; Seiler et al, 1990), induce sleep (Mizoguchi et al, 2001), inhibit 
angiogenesis and plasma leakage (Murata et al, 2008) and mediate smooth muscle 
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relaxation and contraction (Narumiya & Toda, 1985).  Differential effects of PGD2 on 
airway smooth muscle tone has been reported and attributed to its agonism of 
contractile TP receptors (Beasley et al, 1987; McKenniff et al, 1991; Underwood et 
al, 1994). 
A commonly used agonist for DP1 receptors is BW245C as it exhibits minimal DP2 
agonism (Monneret et al, 2001; Yoshimura-Uchiyama et al, 2004) compared to 
PGD2 (Hirai et al, 2001). Originally, the DP1 antagonist AH-6809 was most frequently 
used (Keery & Lumley, 1988), however, its low affinity and its mixed selectivity with 
EP1 and EP2 receptors has since limited its utility (Abramovitz et al, 2000). The use 
of BWA868C has become favourable and the first choice antagonist as it is a 
selective and competitive blocker of high affinity (Giles et al, 1989; Lydford et al, 
1996).  
 
1.2.2.2.2. DP2 Receptors 
PGD2 is also a primary ligand for the DP2 receptor; however, the DP2 receptor has 
no significant homology with the DP1 receptor or any other prostanoid receptor that 
was described in the original classification (Abe et al, 1999; Hirai et al, 2001; Hata et 
al, 2005).  In fact, DP2 receptors are more closely related to chemoattractant 
receptors, hence its previous name being chemoattractant receptor-homologous 
molecule expressed on T helper Type 2 cells (CRTH2) (Abe et al, 1999; Hirai et al, 
2001).  It is the arginine residue in the seventh domain, which is conserved in all 
receptors of the original classification that is missing in the DP2 receptors.  In 
addition, the widespread distribution of the receptor outside of the immune system 
made its classification as DP2 more appropriate (Jones et al, 2009).   
DP2 receptors primarily signal via a Gi-coupled pathway, resulting in decreases in 
cAMP levels (Sawyer et al, 2002; Gallant et al, 2007) and mobilisation of intracellular 
Ca2+ (Hirai et al, 2001; Gallant et al, 2007).  Its distribution appears to be 
widespread, with high levels of expression found in the human stomach, heart, 
thymus and small intestine; moderate expression in the colon, blood and spinal cord 
and lower levels in the brain, skeletal muscle and spleen (Sawyer et al, 2002).  
Subsequent functional analyses found that DP2 receptors were also present in 
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smooth muscle, the cardiovascular system and the eye (Jones et al, 2009).   The 
expression of DP2 receptors has also been reported on a number of human 
leukocytes, including eosinophils, Th2 cells and basophils (Hirai et al, 2001; Nagata 
et al, 1999). 
DP2 receptors have been implicated in immune regulation, more specifically in the 
development of allergic responses such as asthma and atopic dermatitis.  Its 
expression in CD4+ T cells is enhanced in allergic subjects and correlates with 
disease severity (Kostenis & Ulven, 2006).  In addition, activation of the DP2 receptor 
leads to increased production of cytokines such as IL-4, IL-5 and IL-13 (Honda et al, 
2003; Gallant et al, 2005; Xue et al, 2005; Kostenis & Ulven, 2006; Herlong & Scott, 
2006), chemotaxis of eosinophils (Gervais et al, 2001; Hirai et al, 2001; Monneret et 
al, 2001; Sugimoto et al, 2003; Böhm et al, 2004) and the activation of basophils 
(Hirai et al, 2001; Cossette et al, 2007). 
DP2 receptors have the highest affinity for PGD2 but have also shown affinity for the 
PGD2 metabolites DK-PGD2 and PGJ2 (Hirai et al, 2001).  Selective agonists have 
also been described, including 15R-methyl PGD2 (Monneret et al, 2003) and L-
888,607 (Gervais et al, 2005).  In addition, indomethacin has also been shown to be 
a DP2 agonist (Hirai et al, 2002).   The development of selective antagonists has 
stemmed from the use of ramatroban, which is a TP antagonist that has 
demonstrated antagonism of DP2 receptors, although with lower affinity (Mathiesen 
et al, 2005; Sugimoto et al, 2003; Mathiesen et al, 2006).  Modification of ramatroban 
led to the development of CAY-10471, which has a higher affinity for DP2 over TP 
receptors (Ulven & Kostenis, 2005).   
 
1.2.2.3. Prostaglandin F2α and the FP receptor 
Prostaglandin F2α (PGF2α) is formed through three pathways from PGE2, PGD2 or 
PGH2 by PGE 9-ketoreductase, PGD 11-ketoreductase, or PGH 9-,11-endoperoxide 
reductase, respectively (Watanabe, 2002).  PGF2α is known to activate a single 
prostanoid receptor, FP, that has two splice variants; FPA, FPB (Abramovitz et al, 
1994; Pierce et al, 1997).  The human FP receptor cDNA encodes an amino acid 
sequence of 359 residues (Abramovitz et al, 1994).  The FP receptor is primarily 
41 
 
coupled to Gq and subsequent activation of PLC (Ito et al, 1994) but has also 
demonstrated G12/13 coupling and the activation of Rho (Pierce et al, 1999).   
FP receptors are widely distributed and is expressed in tissues including the kidneys, 
uterus, placenta, spinal cord and eye (Abramovitz et al, 1994; Sugimoto et al, 1994a; 
Schlötzer-Schrehardt et al, 2002; Suzuki-Yamamoto et al, 2009).  Its most prominent 
function has been in reproduction.  Sugimoto et al (1997) observed that in mice 
lacking the FP receptor parturition was abolished.  PGF2α has also demonstrated 
pathophysiological effects in the cardiovascular system where it increases blood 
pressure and promotes atherosclerosis (Yu et al, 2009b).  Although no FP receptor 
expression has been observed in immune cells (Tilley et al, 2001; Hata & Breyer, 
2004) it has been shown to induce bronchoconstriction in vitro (Coleman & 
Sheldrick, 1989) and in asthmatic patients (Fish et al, 1984).  In addition, bleomycin-
induced pulmonary fibrosis was suppressed in FP-deficient mice while pulmonary 
inflammation was comparable with wild-type mice (Oga et al, 2009).   
PGF2α itself is most potent at FP receptors but this receptor is also able to bind both 
PGD2 and PGE2 at nanomolar concentrations (Abramovitz et al, 2000).  In addition, 
PGF2α does not have a high degree of selectivity for FP receptors as it is also able to 
bind to the EP1 and EP3 receptors with high affinity (Breyer et al, 2001).  The most 
frequently used antagonist for FP receptors is AL8810 (Griffin et al, 1999) but has 
only modest affinity for FP receptors (Sharif et al, 2006) and also blocks TP 
receptors (Hutchinson et al, 2003; Vysniauskiene et al, 2006).  Furthermore, its 
inhibitory effect on FP receptors has been shown to be through partial agonism and 
no true competitive antagonism (Woodward et al, 2007).   
 
1.2.2.4. Prostacyclin and the IP receptor 
Prostaglandin I2 (PGI2) or prostacyclin is formed by PGI synthase and binds the 
prostanoid IP receptor.  The human IP receptor cDNA encodes a sequence of 386 
amino acids and couples to the stimulatory Gs protein which mediates an increase in 
cAMP production via stimulation of adenylyl cyclase (Boie et al, 1994).  The 
activation of the cAMP-PKA pathway appears to be responsible for several 
prostacyclin-mediated events (Nasrallah et al, 2001; Ritchie et al, 2004; Kamio et al, 
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2007; Muja et al, 2007).  In addition, IP receptors have also demonstrated coupling 
to other pathways, including Gi and Gq (Hebert et al, 1998; Katsuyama et al, 1994; 
Namba et al, 1994; Schwaner et al, 1995). 
IP receptors have long been recognised for their key role in vascular homeostasis, 
mediating vasodilation and inhibiting thrombosis (Vane & Botting, 1995).  PGI2 
production from endothelial cells may confer protection and counteract the 
vasoconstriction and platelet aggregation induced by thromboxane (TxA2) during 
vascular dysfunction (Cheng et al, 2002; Tan et al, 2007).  Additionally, IP receptors 
play a central role in oedema formation, hyperalgesia and pain (Bley et al, 1998; 
Hata & Breyer, 2004).  Anti-inflammatory properties of IP receptors have also been 
observed including suppression of Th2-mediated responses (Hata & Breyer, 2004), 
inhibition of Th2 cytokines (IL-4, IL-10, IL-13) and Th1 cytokine (IFNγ) production 
(Zhou et al, 2007) and attenuation of allergic inflammatory responses (Jaffar et al, 
2002; Takahashi et al, 2002).   
The endogenous IP receptor ligand, PGI2, is highly unstable and so has little 
experimental use.  Therefore, more stable IP agonists were developed such as 
cicaprost, iloprost and beraprost to study this receptor.  However, Iloprost has shown 
potent EP1 agonism and some EP3 agonism, while cicaprost is more selective (Dong 
et al, 1986; Lawrence et al, 1992; Abramovitz et al, 2000; McCormick et al, 2010).   
Chemical screening highlighted two IP antagonists, RO-1138452 and RO-3244794 
(Bley et al, 2006). 
 
1.2.2.5. Thromboxane A2 and the TP receptor 
Thromboxane A2 (TxA2) is generated via thromboxane synthase and signals through 
the activation of the TP receptor (Nusing et al, 1990; Tanabe & Ullrich, 1995).  The 
human TP receptor was the first eicosanoid receptor cloned (Hirata et al, 1991) and 
encodes a 343 amino acid protein. Two isoforms have been described; TPα 
(placental/platelet) and TPβ (endothelial).  These two isoforms are generated 
through alternative splicing in the carboxy-terminal region after the seventh 
transmembrane domain (Raychowdhury et al, 1994).  TP receptors are known to be 
Gq-coupled, activating PLC and inositol trisphosphate (IP3)/diacylglycerol (DAG) with 
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an increase in Ca2+/PKC (Hirata et al, 1991; Dorn & Becker, 1993; Kinsella et al, 
1997; Offermanns, 2006; Nakahata, 2008).   However, the range of G protein 
coupling for TP receptors is extensive and may also couple to Gs (Hirata et al, 1996; 
Walsh et al, 1998; Mir & Le Breton, 2008) and Gi (Ushikubi et al, 1994; Song et al, 
2009). 
The TP receptor was first identified in human platelets (Ushikubi et al, 1989) and has 
been known to induce shape change and platelet aggregation (Offermanns, 2006; 
Nakahata, 2008).  In addition, TP receptor-deficient mice have prolonged bleeding 
times and cannot form stable thrombi (Thomas et al, 1998).  Furthermore, TP 
receptors are widely expressed throughout the cardiovascular system, including 
endothelial cells, vascular smooth muscle and cardiomyocytes, and are often 
associated with cardiovascular disease.  Increased production of TxA2 is thought to 
contribute to endothelial dysfunction and subsequent vasoconstriction (Gendron & 
Thorin, 2007; Francois et al, 2008; Denniss & Rush, 2009; Félétou et al, 2009; 
Graham & Rush, 2009) and TxA2 mimetic U46619 can cause arrhythmia (Wacker et 
al, 2009).  Outside of the cardiovascular system, TP receptors are prominently 
expressed in bronchial smooth muscle (Capra et al, 2003).  TP activation has shown 
potent bronchoconstriction in isolated tissue from a number of different species 
(Coleman & Sheldrick, 1989; Armour et al, 1989; McKenniff et al, 1991; Underwood 
et al, 1994) as well as in clinical and in vivo studies (Saroea et al, 1995; Lewis & 
Broadley, 1995; Cyphert et al, 2012).   
Although TxA2 can potently activate TP receptors, it is very chemically unstable and 
so is of limited use in experimental protocols.  Stable analogs were therefore 
developed and the most widely used is U46619.  SQ29548 is a highly selective and 
potent TP antagonist and its use is favourable over older, less selective antagonists 
such as AH23848 (Abramovitz et al, 2000; Jones et al, 2009).  
 
1.2.3. Prostanoids in Airway Disease 
The role that prostanoids play in airway inflammation has been subject to extensive 
investigation, in particular their role in asthma and COPD.  The role of prostanoids in 
mediating inflammatory responses in airway diseases, such as asthma and COPD, 
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is often varied, where pro- and anti-inflammatory actions of prostanoids can present 
in a single disease process (Narumiya, 2009).  Notably, non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit many processes mediated by prostanoids, 
through an inhibition of the cyclooxygenase enzymes (Vane, 1971; Flower & Vane, 
1974; Coleman et al, 1994; Narumiya et al 1999).  For example, prostanoids are able 
to mediate fever (Ushikubi et al, 1998), oedema and pain (Murata et al, 1997; Ueno 
et al, 2000), hyperalgesia (Moriyama et al, 2005; Ueno et al, 2001) and arthritic 
inflammation (Honda et al, 2006). This has led to the assumption that they act as a 
pro-inflammatory mediators in several inflammatory diseases (McIlroy et al, 2006).  
However, it is well documented that exacerbations in asthma can be associated with 
aspirin.  Additionally, this aspirin-sensitivity is associated with the inhibition of COX 
enzymes (Szczeklik & Stevenson 2003).  Their effects in the airways is summarised 
below and includes their role in mediating airway tone and airway inflammatory 
processes.   
 
1.2.3.1. Airway Tone  
Bronchodilation following inhaled PGE2 has been demonstrated in both normal 
subjects and in patients with asthma and chronic bronchitis (Gauvreau et al, 1999; 
Kawakami et al, 1973; Seth et al, 1981).  This effect has also been observed in 
isolated airway smooth muscle in mice, where several reports have suggested that it 
is mediated via the activation of the EP2 receptors (Fortner et al, 2001; Sheller et al, 
2000). Similar findings have also been shown in constricted tracheal tissue from 
guinea pigs and monkeys (Buckley et al, 2011).  However, Buckley et al (2011) 
recently demonstrated that it is actually the EP4 receptor that is key in mediating this 
effect in humans.  Experiments using selective EP ligands on human airway tissue 
found that an EP4 agonist was effective in relaxing smooth muscle, while EP1-3 were 
unable to induce this effect.  These findings were also mimicked in isolated rat 
trachea (Buckley et al, 2011).  IP receptor activation has also been shown to mediate 
bronchodilation; in canine (Tamaoki et al, 1993) and human (Norel et al, 1999) 
isolated smooth muscle IP receptor agonists induced substantial relaxation, but in 
mouse (Richter & Sirois, 2000) and rat (Lydford & McKechnie, 1994) IP activation 
only produced small relaxation responses.  
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PGD2-induced bronchoconstriction in normal and asthmatic subjects has been 
demonstrated (Hardy et al, 1984) and expression of DP1 receptors has been 
reported in airway smooth muscle (Coleman et al, 1994). Additionally, tracheal tissue 
under basal tone has shown DP-induced increases in airway tone (Beasley et al, 
1987; McKenniff et al, 1991; Underwood et al, 1994). However, DP1 activation in 
isolated human airway smooth muscle also causes relaxation (Norel et al, 1999). An 
explanation of these discrepancies may be due to PGD2 agonism at TP receptors.  
TxA2 is a potent constrictor of bronchial smooth muscle and is considered an 
important mediator in asthma and COPD.  Increased levels of TxA2 have been 
observed in the airways of asthma patients following allergen challenge (Wenzel et 
al, 1991) and its bronchoconstrictor effects in clinical and in vivo studies have also 
been reported (Saroea et al, 1995; Lewis & Broadley, 1995; Cyphert et al, 2012).  In 
addition, increased levels of TxA2 metabolites were seen in COPD patients 
compared to healthy subjects (Davi et al, 1997).  Its potent effects on platelet 
aggregation may be important in the pathogenesis of COPD as thromboembolic 
events and pulmonary hypertension are common in COPD (Zheng et al, 1991).  
Although FP receptor expression in the lung is low (Coleman et al, 1994), PGF2α can 
induce bronchoconstriction in vitro (Coleman & Sheldrick, 1989) and in asthmatic 
patients (Fish et al, 1984). 
Another important characteristic of chronic airway disease, such as asthma, is 
airway smooth muscle (ASM) proliferation which may contribute significantly to 
airway hyperresponsiveness and decline in lung function (Roscioni et al, 2011).  
Several studies have indicated a role for PGE2, via activation of EP2 and EP4 
receptors, in inhibiting this ASM proliferation through an elevation of cAMP (Clarke et 
al, 2005; Roscioni et al, 2011; Yan et al, 2011).   
 
1.2.3.2. Immune and Inflammatory Responses 
PGD2 is a prominent mediator of airway inflammation and is the major prostanoid 
produced by mast cells where it is released in large amounts following antigen 
challenge. Matsuoka et al (2000) found DP1 knock-out mice demonstrated a 
substantial reduction in asthmatic responses in the OVA model; the levels of Th2 
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cytokines and eosinophil infiltration were greatly reduced in the knock-outs.   
Activation of the DP1 receptor has also been shown to inhibit airway inflammation in 
mice by modulating regulatory T cells and dendritic cells (Hammad et al, 2007).  
Additionally, the discovery of DP2 receptor as a Th2 cell chemoattractant further 
implicated PGD2 in mediating inflammatory responses (Hirai et al, 2001). Enhanced 
expression of DP2 receptors on CD
+ T cells has been observed in atopic subjects 
(Kostenis & Ulven, 2006) and activation of DP2 causes chemotaxis and 
degranulation of eosinophils (Gervais et al, 2001; Hirai et al, 2001; Monneret et al, 
2001; Sugimoto et al, 2003; Böhm et al, 2004).  In contrast, Chevalier et al (2005) 
examined the effects of OVA-induced allergic asthma in DP2 knock-outs and saw an 
increase in eosinophil recruitment into the BAL fluid.   
Long et al (2004) reported that increased PGE2 levels in bronchoalveolar lavage 
(BAL) fluid and in the plasma of patients with asthma may correlate with the severity 
of airway obstruction.  Additionally, in murine B cells, PGE2 is able to prolong 
eosinophil survival and Sturm et al (2008) demonstrated that the chemotactic 
responsiveness of isolated human eosinophils is restrained by low concentrations of 
PGE2 in vitro.  In addition they showed that this attenuation in eosinophil locomotion 
is attenuated via EP2 receptors (Sturm et al, 2008).  Furthermore, in vitro data from 
human alveolar macrophages indicates that both EP2 and EP4 receptors mediate the 
anti-inflammatory actions of PGE2 (Ratcliffe et al, 2007).  In vivo, an agonist selective 
for the EP3 receptor was effective in suppressing allergic inflammatory reactions in 
murine airways, while  EP3 receptor deficient mice demonstrated enhanced allergic 
reactions in the ovalbumin-challenge model, suggesting that suppression of allergic 
inflammation is mediated via PGE2-EP3 signalling (Kunikata et al, 2005).  PGE2 has 
also been implicated in COPD, where Montuschi et al (2003) observed 2.2 fold 
higher exhaled PGE2 levels in COPD patients compared to healthy subjects.  There 
is also recent evidence for a possible role for COX-2, along with PGE2, on the 
infiltration of neutrophils (Profita et al, 2010).  Furthermore, cigarette smoke, a major 
risk factor, may play a significant role by increasing the expression of COX enzymes 
as well as specific EP receptors in alveolar macrophages and neutrophils (Profita et 
al, 2010).   
IP receptor mRNA has been shown to be expressed by Th2 cells but not Th1 cells 
and Jaffar et al (2002) showed elevated production of anti-inflammatory cytokine, IL-
47 
 
10, following PGI2-Th2 activation.  In vivo studies using allergen-induced asthma 
also demonstrated an inhibitory role for IP receptors (Takahashi et al, 2002).  Yuhki 
et al (2004), however, demonstrated that IP receptors mediated exudate formation in 
a carrageenan-induced mouse pleurisy model, which suggests that the PGI2 can 
elicit inflammatory responses in a context dependent manner.  Additionally, PGI2 and 
IP receptor activation causes prominent vasodilation and increased blood flow which 
is a classic sign of inflammation.   
 
1.2.3.3. Sensory Nerve Activation 
The beneficial effects of inhaled PGE2 have been hindered by its irritancy of the 
upper airway and associated cough.  This cough reflex is initiated by the activation of 
sensory afferent nerve endings in the airways, which PGE2 has been shown to 
mediate (Coleridge et al, 1976; Mohammed et al, 1993).  Furthermore, it appears 
that this effect is mediated via the EP3 receptor. Maher et al (2009) used prostanoid 
receptor-deficient mice and pharmacology to provide substantial evidence that this is 
the receptor that mediates PGE2 sensory nerve activation.  Additionally, 
depolarization of guinea pig vagus has been observed with PGF2α, PGD2, Iloprost 
and U46619 (Birrell et al, 2009; Maher et al, 2009). 
 
  
48 
 
1.3. Microvascular Leak 
 
1.3.1. Introduction 
Microvascular leakage (MVL) and plasma exudation represent classical features in 
the pathogenesis of various inflammatory diseases and is thought of as a cardinal 
sign of inflammation leading to tissue swelling (“tumor”) (Paredi & Barnes, 2009).   
In a healthy endothelium the semipermeable barrier carefully regulates the 
movement of water, solutes and proteins between the blood and tissue.  In this state, 
water and low molecular weight solutes are able to pass via the paracellular route.  
Larger macromolecules such as albumin are only able to move across via the 
transcellular route.  However, during an inflammatory response such as in sepsis 
and acute lung injury, this barrier is disrupted allowing fluid and large 
macromolecules to move across through interendothelial gaps (Figure 1.4).  Briefly, 
during an inflammatory challenge there is the release of several mediators, such as 
histamine, 5-hydroxytryptamine (5-HT), leukotrienes and cytokines, which act directly 
upon post capillary venules to cause the opening of these intercellular gaps and thus 
increasing vascular permeability.  This increase in permeability causes plasma to 
‘leak’ into extravascular sites due to hydrostatic pressure gradients (Olivenstein et al, 
1997; Reynolds et al, 2002). These hydrostatic pressure gradients form between the 
microvasculature and the lamina propria, resulting in a rapid and widespread 
distribution of plasma in the lamina propria and epithelium (Greiff et al, 2003). 
This phenomena is a very distinctive feature of acute inflammation but is also 
observed in more chronic diseases such as asthma (Laitinen et al, 1987; Li & 
Wilson, 1997, Innes et al, 2009; Khor, 2009) and COPD (Hill et al, 1999; Minikata et 
al, 2005; Bessa et al, 2012).  Microvascular leak can often present as an adverse 
side effect of disease, exacerbating a patient’s condition, or it can be the main 
underlying cause of a disease.  For example, in pathological states where there is a 
significant increase in vascular permeability, excessive leak can aggravate acute life-
threatening disorders, such as airway obstruction in asthma, acute lung injury and 
related pulmonary diseases.  Vascular leakage is also a prominent feature in sepsis 
where it causes circulatory collapse (Amerongen & Hinsburgh, 2002). 
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In the early sixties, Majno and Palade were able to study the effects of histamine and 
5-HT on vascular leakage using an electron microscope.  They showed that this 
plasma exudation was occurring only in postcapillary venules and not in capillaries of 
the systemic circulation (Majno & Palade, 1961).  The use of particulate tracers, such 
as Monastral blue and colloidal gold, has allowed the visualisation of where plasma 
leak is occurring.  Erjefalt et al (1998) administered Monastral blue to OVA-
challenged mice and identified the extravasating vessels of the trachea as 
postcapillary venules.  These venules had a mean diameter of 30 + 2.3µm (Erjefalt 
et al, 1998).  McDonald (1994) also observed a similar response in rat airways where 
Monastral blue particles were trapped in interendothelial gaps of postcapillary 
venules.   
 
Figure 1.4. Schematic representation of microvascular leakage in the airways. During 
an inflammatory insult various mediators at upon endothelial cells in postcapillary venules causing 
them to contract producing intercellular gaps.  This gap formation allows the movement of plasma 
(and plasma proteins) out into extravascular sites, such as the airway lumen. This can contribute to 
the formation and exacerbation of oedema.  
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1.3.2.      Regulation of Endothelial Permeability 
Current hypotheses regarding the mechanisms that cause an increase in 
microvascular permeability suggest a disruption in the endothelial barrier and the 
opening of interendothelial gaps allowing fluid and macromolecules to leak out.  
Specific signalling pathways may lead to an increase in the contractility of the acto-
myosin cytoskeleton, or a decrease in junction integrity by weakening intercellular 
junctions, primarily tight and adherens junctions (Schweitzer et al, 2011). 
 
1.3.2.1. Myosin Light Chain Kinase-Dependent Hyperpermeability 
It was Majno in the 1960s that first suggested that the formation of these gaps was 
due to endothelial cells actively contracting in response to inflammatory stimuli 
(Majno & Palade, 1961; Majno et al, 1961).  From microscopy studies he noticed the 
nuclei of these cells formed deep membrane indentations suggesting cell shortening 
and contraction.  The thought is that the contraction of adjacent endothelial cells will 
modulate cell shape causing a ‘rounding’ of the cell and the formation of these 
intercellular gaps (Mehta & Malik, 2006). Most in vitro studies working on isolated 
and cultured endothelial cells have indicated that a balance of competing contractile 
and adhesive forces lead to the modulation of cell shape and gap formation (Garcia 
et al, 1995).  Additionally, there is evidence revealing an association of myosin with 
actin, thus enhancing the cell contraction-cell separation theory (Drenckhahn & 
Wagner, 1986; Schnittler et al, 1990). More specifically, it has been shown that 
increasing the activity of myosin light chain kinase (MLCK) induces barrier 
dysfunction while a normal basal level of MLCK activity is required to maintain 
physiological microvascular permeability.  MLCK is a serine/threonine-specific 
protein kinase whose primary biological function is to phosphorylate the regulatory 
myosin light chain II (MLC-II) (Takashima, 2009; Shen et al, 2010). Phosphorylation 
occurs at Ser-19 and then Thr-18 which subsequently causes an ATP-dependent 
contraction of the actomyosin complex (Verin et al, 1998; Lazar & Garcia, 1999; 
Shen et al, 2010).  This MLCK-dependent contractility is associated with arteriolar 
vasoconstriction and capillary and venule permeability.  In order to control basal 
cytoskeletal tension a balance is needed between phosphorylation by MLCK and 
dephosphorylation by MLC phosphatase (MLCP).  Dephosphorylation by MLCP 
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decreases actomyosin contraction causing the actin cytoskeleton to relax and 
permeability to decrease. (Schnittler et al, 1990; Verin et al, 1995; Chrzanowska-
Wodnicka & Burridge, 1996; Cai et al, 1998).  Furthermore, inhibition of MLCP can 
increase the phosphorylation of MLC and subsequent cytoskeletal contraction 
without an increase in MLCK activity. 
 
1.3.2.2. Endothelial Cell-Cell Junctions and Hyperpermeability 
As well as an increase in endothelial cell contraction, cell-cell interactions play an 
enormous role in modulating barrier function and the development of interendothelial 
gaps.  Indeed, Moy et al (1996) demonstrated that in human umbilical vein 
endothelial cells histamine caused a decrease in monolayer resistance without 
endothelial cell contraction.  Simultaneously, they also showed that thrombin 
produced a similar effect and at the same time caused endothelial contraction (Moy 
et al, 1996).  This data suggests that neither process acting alone is sufficient to 
impair endothelial barrier integrity.  Subsequently, others have also confirmed that 
gap formation occurred with a loss of cell-cell adhesion but not always with cell 
contraction (Corada et al, 1999; Winter et al, 1999; Moy et al, 2000).  What does 
appear to be the case is that endothelial contraction can increase the magnitude of 
the gap size and the duration that the gap remains open but only in the presence of 
junctional reorganisation (Ochoa & Stevens, 2012).   
Endothelial cell-cell junctions are made up of membrane proteins that are expressed 
on the lateral surface of endothelial cells and consist of both extracellular and 
intracellular domains.  It is the interaction of the extracellular domains which forms 
the barrier between adjacent endothelial cells and the passage of large 
macromolecules across the endothelium.  The intracellular domain of these 
junctional proteins is linked to adaptor proteins that form connections with the actin 
cytoskeleton (Rigor et al, 2013).  The two main types of junctions involved in 
mediating this response include adherens and tight junctions. Adherens junctions 
play the more prominent role as they are present in the vascular endothelium of most 
organs and tissues (Mehta & Malik, 2006; Vandenbroucke et al, 2008; Komarova et 
al, 2010).  Tight junctions, however, are primarily found in the microvasculature of 
specialised tissues, for example, the blood-brain barrier or blood-retinal barrier 
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(Hawkins & Davis, 2005; Engelhardt & Sorokin, 2009; Cosine & Engelhardt, 2011).  
The principal structural element of adherens junctions between endothelial cells is 
vascular endothelial cadherin (VE-cadherin), which is able to connect neighbouring 
cells in a calcium dependent manner (Goldenberg et al, 2011). For VE-cadherin, 
intracellular connections to the actin cytoskeleton occur via catenins (α, β, γ and 
p120), while tight junctions have specialised proteins: occludin and claudins (see 
Figure 1.5) (Dudek & Garcia, 2001; Vandenbroucke et al, 2008; Prasain & Stevens, 
2009; Shen et al, 2009).  It is the disassembly of these junctional proteins during an 
inflammatory response that weakens the endothelial barrier and causes vascular 
leakage. The cadherin-catenin complex is phosphorylated and then internalised via 
endocytosis. For example, inflammatory mediators such as thrombin and VEGF are 
able to induce MVL though the phosphorylation and internalisation of VE-cadherin 
(Rabiet et al, 1996; Cohen et al, 1999; Ukropec et al, 2000; Gavard & Gutkind, 2006; 
Gavard et al, 2009). 
However, modulation of these responses involves complex signalling pathways 
which are not fully understood and various signalling cascades have been proposed.   
Furthermore, the majority of research into these pathways is carried out on cultured 
endothelial cells which do not develop the permeability characteristics of intact 
endothelium and so have therefore not been validated in vivo (Jiang et al, 2008). 
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Figure 1.5.  Schematic representation of the mechanisms involved in endothelial 
barrier disruption.  The critical features include myosin-actin interactions leading to cell contraction 
and a loss of junctional integrity.   
 
1.3.3. Intracellular Signalling Pathways Modulating Endothelial Permeability 
Most of the literature describing the signalling pathways involved in the disruption or 
enhancement of the endothelial barrier focus on research conducted in cultured 
endothelial cells and intact microvessels, including a variety of species and 
subtypes.  As described the main endothelial subtype that is important in regulating 
permeability are the microvascular endothelial cells from postcapillary venules.  
While a lot of information has been obtained from such research, it cannot be a true 
representation of what occurs in vivo.   
Endothelial barrier dysfunction occurs due to a misregulation of intracellular 
signalling that is associated with maintaining barrier integrity, or via the activation of 
signalling pathways that lead to a hyperpermeable endothelium (Yuan, 2000; Yuan, 
2002; Shen et al, 2010).  In either case, the subsequent increase in myosin light 
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chain kinase (MLCK) activity is the primary cause of barrier dysfunction.  In a 
‘healthy’ endothelium a basal level of MLCK activity is needed to maintain and 
regulate the permeability of the microvasculature.  However, when MLCK activity is 
elevated in disease an increase in microvascular leak is observed (Shen et al, 2010). 
Additionally, cell to cell interactions via adherens and tight junctions play a vital role 
in regulation barrier integrity.  How these factors induce hyperpermeability was 
described in section 1.3.2.  Outlined below is the role that key cell signalling 
pathways play in mediating microvascular permeability, and how they influence 
MLCK and cell-cell interactions.  
 
1.3.3.1. Calcium 
Increasing intracellular calcium (Ca2+) is pivotal to the control of MLCK activity and 
subsequent increases in endothelial permeability.  Ca2+/calmodulin binding to MLCK 
is known to release the MLCK autoinhibition and thus increase its activity (Ito et al, 
1991; Blue et al, 2002; Hong et al, 2011).  This pathway is thought to be responsible 
for the rapid and transient increase in permeability to vasoactive agents such as 
histamine and substance P.  Histamine has been shown to increase cytoplasmic 
Ca2+ concentration in endothelial cells (Shasby et al, 1997) as well as increasing 
endothelial permeability.  This increase in endothelial permeability has been inhibited 
by a Ca2+ chelator as well as a calmodulin inhibitor (van Niew Amerongen et al, 
1998). 
In smooth muscle the binding of Ca2+ to calmodulin activates smooth muscle 
(sm)MLCK and induces actin-myosin contraction.  However, in the endothelium this 
alone does not appear to be sufficient to cause cytoskeletal contraction, suggesting 
other signalling pathways are involved (Garcia et al, 1997). 
 
1.3.3.2. RhoA/Rho Kinase 
Rho GTPases are a family of small signalling G proteins that are involved in the 
regulation of endothelial cell contractility. This regulation is dominated by three of the 
most prominent members; RhoA, Rac and cdc42 (Steinberg et al, 2012; van Nieuw 
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Amerongen & van Hinsbergh, 2002).  Stimulation by inflammatory mediators, such 
as thrombin, destabilises the endothelial junction and increases vascular 
permeability by signalling through RhoA.  Thrombin and VEGF have both been 
shown to initiate endothelial barrier disruption through RhoA/Rho Kinase signalling 
(Lorenzo et al, 2013; Sun et al, 2006; Qiao et al, 2003; van Nieuw Amerongen et al, 
2000). RhoA controls endothelial cell contractility by stabilising the phosphorylated 
state of MLC, which is thought to occur via the activation of Rho kinase.  Rho kinase 
inactivates myosin light chain phosphatase thus increasing MLC phosphorylation 
and the subsequent cytoskeletal contraction (Amano et al, 1996; Kimura et al, 1996; 
Kawano et al, 1999, Katoh et al, 2001).  Additionally, Rho kinase activity leads to a 
reduction in VE-cadherin stability and so disassembly of junctional proteins (Essler et 
al, 1998). 
 
1.3.3.3. Cyclic AMP 
In contrast to Ca2+ and RhoA signalling, increasing concentrations of cyclic AMP 
(cAMP) have been associated with a reduction in endothelial permeability.   In 
addition, increasing endothelial cAMP does not only reduce the increase in 
permeability caused by inflammatory mediators but also reduces baseline levels 
(reviewed by Michel & Curry, 1999).  It was earlier studies that demonstrated β-
adrenergic stimuli inhibited histamine-induced leakage in animals and this effect 
appeared to be related to enhanced cAMP concentrations in the endothelial cells 
(Rippe & Grega, 1978).  Later studies have also established the effectiveness of 
elevated endothelial cAMP in reducing vascular permeability in vitro (Stelzner et al, 
1989; Langeler & van Hinsbergh, 1991; Moy et al, 1993) as well as reducing 
histamine-induced leak in vivo (Kobayashi et al, 2013).  This elevation of cAMP 
stabilises endothelial junctions, inhibits MLCK and actomyosin contraction and the 
formation of stress fibres (He & Curry, 1993; Moy et al, 1993; Moy et al, 1998; 
Siflinger-Birnboim et al, 1993; Adamson et al, 1998).  Furthermore, the effects of 
cAMP have been linked to protein kinase A (PKA) activation where studies have 
demonstrated the effectiveness of cAMP and PKA in reducing endothelial 
permeability (Garcia et al, 1995; Garcia et al, 1997; Qiao et al, 2003).  Liu et al 
(2001) pharmacologically reduced PKA activity in endothelial cells which induced 
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actin stress fibre formation and subsequent cell contraction.  It has also been 
suggested that activation of the cAMP/PKA pathway inhibited endothelial contraction 
by inhibiting the activation of the RhoA/Rho kinase pathway (Qiao et al, 2003; 
Birukova et al, 2004; Baumer et al, 2008; Baumer et al, 2009; Birukova et al, 2010).  
Qiao et al (2003) found that cAMP-elevating agents inhibited thrombin-induced RhoA 
activation in human microvascular endothelial cells and protected against endothelial 
barrier dysfunction.  Birukova et al (2004) also demonstrated PKA-mediated 
inhibition of RhoA and Rho kinase resulted in decreased MLC phosphorylation, 
actomyosin contraction and endothelial permeability.   
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1.3.4. Airway Microvascular Leak 
Within healthy airways, the bronchial microvasculature provides a multitude of 
important functions that are essential for maintaining pulmonary homeostasis.  For 
example, it is able to provide oxygen and appropriate nutrients, aids in the regulation 
of temperature and in humidifying air, as well as acting as the initial site for immune 
responses (Zanini et al, 2010).  During chronic inflammation, in airway diseases such 
as asthma and COPD, vascular remodelling can be extensive.  One of the main 
features of bronchial vascular remodelling is angiogenesis, the formation of new 
vessels within the airway wall.  What is often observed is that newly generated 
vessels tend to be hyperpermeable and increase oedema (Bousquet et al, 2000). 
Furthermore, an increase in bronchial subepithelial blood flow has also been 
observed as well as increased vascular permeability and plasma exudation.  These 
factors all contribute to the narrowing of the airway lumen seen in inflamed airways 
(Zanini et al, 2010).  
 
1.3.4.1. Asthma 
Since the sixties post-mortem observations have highlighted oedematous bronchial 
mucosa with dilated and congested blood vessels within the airways of those with 
fatal asthma (Dunnill et al, 1969).  Additionally, bronchial biopsies from mild 
asthmatics appear more vascular and endothelial gaps are prominent in the 
bronchial mucosal microvasculature than control subjects (Laitinen et al, 1987; Li & 
Wilson, 1997). More recent biopsy studies have also demonstrated an increase in 
the number of microvessels within the airways of chronic asthma patients with 
additional endothelial proliferation (Vrugt et al, 2000; Wilson & Robertson, 2002; 
Barbato et al, 2006).  Despite the importance of microvascular leak in the 
pathogenesis of asthma, it is not often measured when monitoring airway 
inflammation in asthmatic patients (Van Rensen et al, 2002).  Several studies have 
investigated microvascular permeability in asthma by measuring albumin levels in 
induced sputum and/or BAL fluid, as well as other proteins such as fibronectin and 
alpha 2-macroglobulin (Meerschaert et al, 1999; Svensson et al, 1995; Van Rensen 
et al, 2002). Albumin is one of the most abundant plasma proteins, at least 60%, and 
is found in higher concentrations in airways secretions from acute asthmatic patients 
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(List et al, 1978; Travis, 2003).  Innes et al (2009) postulated that the leakage of 
these proteins into the airway lumen can reduce mucus clearance in acute severe 
asthma and may be an underlying cause of fatal asphyxiation.  Following ex vivo 
analyses of airway mucus from patients in acute asthma exacerbations (and control 
subjects), they found that albumin within the mucus inhibits normal mucus 
degradation.  Additionally, Khor (2009) demonstrated that reduction in inhaled 
corticosteroid dosage was associated with an increase in albumin exudation and 
they hypothesise that this is an early feature of asthma deterioration.  Unlike other 
human studies, they also assessed biopsies from these patients by staining sections 
for albumin and found this was also elevated in asthmatic subjects (Khor 2009). 
Animal models of allergic asthma have also illustrated a measurable increase in 
airway microvascular permeability.  Using the ovalbumin model of allergic asthma 
several groups have demonstrated significant increases in airway microvascular leak 
following antigen challenge in guinea pigs (Erjefält et al, 1995; Liaw & Chao, 2001), 
rats (Olivenstein et al, 1997; Hele et al, 2001; Tillie-Leblond et al, 2007) and mice 
(Erjefält et al, 1998; Lee et al, 2004; Kim et al, 2012). 
Airway MVL is thought to have a critical role in thickening the bronchial mucosa and 
the resulting airway hyperresponsiveness (Van de Graaf et al, 1991; Paredi & 
Barnes, 2009).  In addition, leakage of plasma proteins is often associated with 
exacerbations of asthma due to mucosal oedema and so worsening airflow 
obstruction and reducing airway calibre (Khor et al, 2009).  Particularly, 
extravasation into the airway lumen can cause this increase in airway resistance.  
During bronchospasm the constricted airways compress the mucosa forming 
epithelial folds and so exuded plasma can then fill the interstices between these 
folds, thus amplifying bronchoconstriction (Olivenstein et al, 1997).  Furthermore, 
during chronic inflammation blood vessels in the airways are in a hypervascularised 
and destabilised state and so increasing microvascular permeability (Kanazawa et 
al, 2004).   
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1.3.4.2. COPD 
Vascular remodelling and changes in endothelial permeability are also prominent in 
COPD, where vascular intimal thickening in small pulmonary arteries has been 
attributed to chronic inflammatory processes (Peinado et al, 1998; de Boer et al, 
2007).  COPD is characterised by this chronic inflammation that occurs along the 
entire bronchial tree, with airways becoming oedematous, having excess mucus 
production and impaired epithelial ciliary function (Bailey et al, 2009).  Cigarette 
smoking is thought to lead to endothelial dysfunction as a result of exogenous 
oxidative stress and/or the endogenous production of oxygen-free radicals (Mendes 
et al, 2006).  This dysfunction precipitates attenuated vascular relaxation responses 
in the systemic circulation.  The importance of such vascular changes in the 
development of bronchitis is subject to speculation but these changes would 
certainly exacerbate inflammatory cell recruitment, leukocyte migration and the 
formation of endothelial gaps and vascular leak (Baluk et al, 1998).  Nevertheless, 
endothelial function has been shown to be impaired in smokers and ex-smokers with 
COPD (Mendes et al, 2006) and increased levels of albumin have been measured in 
the sputum of COPD patients (Hill et al, 1999; Minikata et al, 2005; Bessa et al, 
2012).  Minikata et al (2005) collected airway epithelial lining fluid from patients with 
differing severities of COPD and noticed a strong correlation with airway albumin 
levels and the forced expiratory volume in 1 second values.  This suggests that an 
increase in airway microvascular leak may contribute to the subsequent obstructive 
process of COPD.  Studies have also reported that the airways of patients with 
COPD were thicker compared to healthy control subjects (Bosken et al, 1990; 
Kuwano et al, 1993) and several groups have shown alterations in the vascularity of 
COPD airways (Hashimoto et al, 2005 ; Calabrese et al, 2006; Zanini et al, 2009).  
Calabrese et al (2006) looked at bronchial biopsies from the central airways of 
smokers and observed an increase in vascular area as well as an increase in the 
number of vessels in smokers with COPD and symptomatic smokers with normal 
lung function.  In addition, Zanini et al (2009) saw a higher vascular area but no 
change in vessel number in clinically stable COPD patients compared to controls.  
Similar characteristics have been observed in animal models of COPD.  Cigarette 
smoke (CS) is the most common etiological factor of COPD and so CS exposure in 
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vivo provides an excellent model for examining disease processes.  Several groups 
have demonstrated increases in protein extravasation in the airways of various 
species in response to CS exposure (Lundberg & Saria, 1983; Geppetti et al, 1993; 
Andrè et al, 2008; Nassini et al, 2012).  Schweitzer et al (2011) examined the effects 
of CS on vascular permeability both in vitro and in vivo.  Using primary rat and 
human lung microvascular endothelial cells they demonstrated a dose-dependent 
decrease in barrier function following CS exposure.  Furthermore, they noted 
significant increases in ceramide production following CS exposure (in vitro and in 
vivo) which itself caused a dose-dependent increase in FITC-albumin extravasation 
from the alveolar microcirculation of conscious rats (Schweitzer et al, 2011). 
 
1.3.5. Methods for Investigating Microvascular Leak 
Current methods used to investigate microvascular leak use varying degrees of 
complexity, ranging from cultured endothelial cells to conscious animal preparations. 
All models come with distinct advantages over others as well as a number of 
limitations.  The most frequently used methods to study vascular permeability will be 
outlined below, with discussion of the advantages and disadvantages of each. 
 
1.3.5.1. In vitro 
1.3.5.1.1. Cell Culture 
One of the most widely employed in vitro models of microvascular leak uses cultured 
microvascular endothelial cells.  Either human or animal microvascular endothelial 
cell monolayers are grown on semi-permeable tissue culture well inserts, which 
allows the movement of large substrates across the endothelial barrier to be 
measured.  The most commonly used substrates are albumin or dextran conjugated 
to a fluorophore such as fluorescein isothiocyanate (FITC) and come in a variety of 
polymer sizes. The principle behind this method is measuring the movement of 
FITC-albumin/dextran across the endothelial monolayer from the upper chamber of 
the well insert into the bottom chamber under various conditions.  This allows simple 
and accurate quantification of barrier integrity (Imai-Sasaki et al, 1995; Gavard & 
Gutkind, 2006; Tharakan et al, 2009; Li et al, 2010; Diebel & Liberati, 2011; 
61 
 
Tharakan et al, 2012; Yu et al, 2013). The use of cell culture also enables easier 
dissection of the complex signalling pathways activated during hyperpermeability.  
Additionally, in vitro methods using microvascular endothelial cells allows translation 
between animal and human which is not possible with most in vivo methods 
examining microvascular permeability.   
An additional in vitro assay that is often employed uses an electrical current to 
assess the integrity of the endothelial monolayer (Qiao et al, 2003; Michail & 
Abernathy, 2004; Liu et al, 2008; Bogatcheva et al, 2009; Konya et al, 2011; 
Schweitzer et al, 2011; Booth & Kim, 2012; Griep et al, 2012).  Transendothelial 
electrical resistance (TEER) assays involve an electrical current being passed 
across the cell monolayer and uses impedance as a measure of barrier integrity.  
The voltage across the monolayer then allows the TEER to be calculated.  A higher 
TEER value would indicate a stable barrier while lower TEER values would suggest 
disruption of the barrier and an increase in permeability.  TEER is often measured in 
combination with FITC-albumin flux, thus providing a more accurate representation 
of barrier function (Armstrong et al, 2012; Birukova et al, 2012).  However, more 
recently electric cell-substrate impedance sensing (ECIS) has replaced TEER 
measurements (Lo et al, 1995; Birukova et al, 2004; Solodushko et al, 2008; Lorenzo 
et al, 2013).  The difference with this assay is that the endothelial monolayer is 
grown in specialised plates which have electrodes embedded into it.  Briefly, as cells 
grow and form a monolayer, the current that is applied is impeded.  When cells are 
then stimulated with a permeability increasing mediator the changes in cell 
morphology and function alter the impedance.  A significant advantage of this 
technique over TEER is the ability to continuously measure barrier integrity and 
permeability in real time (Fordjour & Harrington, 2009; Wang et al, 2010).   
One of the major limitations of cultured endothelial cells is that they do not accurately 
reflect the permeability characteristics of intact microvascular endothelium in vivo.  
For example, they lack the shear stress that the endothelium is exposed to in vivo, 
including changes in blood flow (Dai et al, 2004; Davies, 2009).  Additionally, the 
interaction and effects of other cell types, such as smooth muscle cells is also 
eliminated in these preparations.  Structural differences have also been observed 
between cultured endothelial monolayers and in situ microvessels; inter-endothelial 
gaps in cultured monolayers are upwards of 5-10 µm while in isolated microvessels 
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these gaps are usually less than 1 µm (Baluk et al, 1997; Curry & Adamson, 2010; 
McDonald et al, 1999). Furthermore, using primary cells over immortalised cell lines 
does not necessarily eliminate certain problems; specifically, the de-differentiation 
that occurs when cultured without their specific microenvironment (Cleaver & Melton, 
2003).  
 
1.3.5.1.2. Whole Vessel Preparations 
The use of intact microvessels in specialised perfusion systems aims to eliminate 
some of the limitations outlined for cultured monolayers and acts as an intermediate 
between cell culture and whole animal studies.  They allow investigation of whole 
vessels in a more physiological environment where sheer stress and alterations in 
flow dynamics can be applied (Gunther et al, 2010).  Vessels are either dissected 
from animals or humans and are mounted in a microfluidic perfusion rig where 
intraluminal perfusion pressure and flow can be controlled (Yuan et al, 1993).  
Vascular permeability can be measured by transvascular flux of a labelled tracer, 
such as FITC-albumin, or by confocal microscopy using fluorescent microspheres to 
mark endothelial gaps (Yuan et al, 1993; Breslin et al, 2006; Sun et al, 2006; Jiang et 
al, 2008).  These methods represent a more physiologically accurate model of 
endothelial dynamics and more closely mimic an in vivo environment.  However, 
there are still a number of limitations with this method.  Firstly, they involve the 
dissection and direct interference with the vessel and secondly, they are often 
restricted to convenient vessel types.  The microcirculation may differ between 
different vascular beds. Moss et al (2010) described a similar preparation, developed 
by Biopta, whereby vascular function and vascular permeability could be measured 
simultaneously.  Vascular permeability was measured by the extravasation of Evans 
Blue dye into the wall of isolated vessels.  However, this was achieved through 
image analysis rather than direct quantification.  Additionally, they looked at small 
subcutaneous arteries and not post capillary venules.   
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1.3.5.2. In vivo 
1.3.5.2.1. Intact Microvessels 
Similar to whole mounted vessel preparations described above, the permeability of 
individual vessels can be studied in situ in unconscious animals (Michel et al, 1974; 
He et al, 2006; Jiang et al, 2008; Ereso et al, 2009).  Briefly, animals are 
anaesthetised and the vascular bed of interest is removed and placed on the pillar of 
an inverted microscope.  Here, an individual venule is cannulated and perfused with 
a physiological solution.  Measurements of vascular permeability are based upon 
hydraulic conductivity, assessing the volume flux of water across the microvessel 
wall (Clough et al, 1988).  These preparations allow quantitative measurements of 
vascular permeability under well-controlled experimental conditions. One of the main 
drawbacks of this technique is the vascular bed examined needs to be easily 
accessible.  The mesentery is most commonly used as it can be excised with ease 
while the animal remains unconscious. This would not be possible for deeper 
tissues, such as post capillary venules within the lower airways.     
 
1.3.5.2.2. Miles Assay 
One of the most widely used techniques to detect microvascular permeability in vivo 
is the Miles assay, which was first developed to assess inflammatory plasma leak in 
guinea pig skin using Evans blue (EB) dye (Miles & Miles, 1952).  The principle 
behind this method is that intravenous EB dye binds non-covalently to circulating 
albumin, the most abundant plasma protein, and then leaks out of the 
microcirculation in response to various mediators.  The target tissue is dissected out 
at a given time point and the dye extracted and quantified by spectrophotometry. 
Rapid perfusion of the circulation to remove intravascular dye prior to tissue 
dissection improves the sensitivity of this assay (Renkin & Tucker, 1998; Nedrebo et 
al, 2003; Curry et al, 2010). Additionally, this technique is easily applicable to most 
species and the extravasation can be simultaneously determined in several tissue 
types.  Subsequently, it has been used for decades to quantitatively assess vascular 
permeability in various different tissues across a variety of species (Miles & Miles, 
1952; Evans et al, 1987; Rogers et al, 1988; Baluk et al, 1999; Reynolds et al, 2002; 
Xle et al, 2003; Zhuang et al, 2011).  Studies using this assay have yielded important 
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information regarding the nature of inflammatory mediators and their impact on the 
microvasculature.  Furthermore, the use of EB dye as a marker of plasma leak has 
extended into disease models of inflammation (Rogers et al, 1988; Geppetti et al, 
1993; Olivenstein et al, 1997; Mirza et al, 1998; Hele et al, 2000; Hele et al, 2001; 
Irie et al, 2001; Lee et al, 2004; Kim et al, 2012). 
The major disadvantage of this method is that it is a terminal procedure.  This means 
that each animal is limited to a single intervention or time point so large cohorts are 
required for adequate comparisons between groups.  In addition, the data only 
provides a reference to the net accumulation and doesn’t pin point any fluctuations 
that may be occurring in vascular permeability.  The use of radiolabelled albumin and 
a double tracer method has been used in an attempt to eliminate some of these 
problems.  However, the use of radiolabelled tracers as an alternative to Evans Blue 
dye does not provide a more accurate measure and comes with the obvious safety 
hazards associated with radiation (Udaka et al, 1970; Rogers et al, 1989). 
 
1.3.5.2.3. Intravital Fluorescence Microscopy 
More recently, the use of intravital microscopy (IVM) has become popular for 
examining microvascular permeability as well as leukocyte endothelial interactions.  
This technique uses epifluorescence, confocal or two-photon microscopy to visualise 
the microvasculature in living animals (Chappell et al, 2006).  Similar to the intact 
microvessels, the tissue being studied is exteriorised for assessment but here a 
fluorescent plasma marker, such as FITC-albumin, is administered intravenously to 
visualise plasma leak in real time (Svensjo et al, 1979).  One of the main advantages 
of this technique over the Miles assay is that is allows both temporal and spatial 
characteristics of plasma exudation to be determined. This means that changes in 
leakage over a given time can be measured.  Additionally, it has contributed 
immensely to our knowledge of the localisation of endothelial gaps to the 
postcapillary venules.  However, since tissue needs to be exteriorised this 
preparation is limited to thin tissues or easily accessible organs.  For example, IVM 
is commonly used for the skin, mesentery, cremaster muscle and superficial veins of 
the brain (Boric et al, 1987; Wu & Baldwin, 1992; Raud & Lindbom, 1994; Kubes & 
Gaboury, 1996; Jin et al, 2010).  Attempting to view microvasculature of deeper 
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tissues would result in blurry images and fluorescent quenching.  Studying the 
bronchial circulation and airway microvascular leak would be extremely difficult using 
IVM.  Furthermore, this technique is time-consuming and requires delicate surgery 
making it very low throughput with only one animal being examined at a time.  
Maintenance of physiological conditions of the excised tissue is pivotal to ensure 
limited inflammation occurs following surgery (Raud & Lindbom, 1994). 
 
1.3.5.2.4. Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) has been used to visualise permeability 
changes in the brain (Jiang et al, 2005; Knotkova & Pappagallo, 2007; Nagaraja et 
al, 2008) and the lung (Tournebize et al, 2006; Tigani et al, 2007; Serkova et al, 
2008; Ble et al, 2009) in clinical settings as well as in experimental animals.  High 
molecular weight contrast agents are often used to carry out longitudinal studies of 
plasma leakage in selected tissues and organs (Fu et al, 2004; Huxley et al, 2007).  
A commonly used marker is gadolinium diethylenetriamine pentaacetic acid (Gd-
DTPA) which has a molecular weight of 550 Da (Pautler, 2004; Nagaraja et al, 
2008). An advantage of using MRI is that it enables visualisation of the whole organ 
without any invasive techniques.  This allows measurements to be carried out 
continually over days, weeks or months.  However, the images obtained are usually 
low resolution, making quantification of plasma leakage difficult.  In addition, MRI 
scanners are expensive and complex. 
 
1.3.6. Prostanoids in airway microvascular leak 
As previously discussed, prostanoids are involved in various inflammatory 
processes, including those seen in asthma and COPD.  With high concentrations of 
certain prostaglandins found at inflammatory sites, it is possible that they may in part 
mediate the microvascular leakage observed.  PGE2-induced airway MVL has not 
been widely examined, especially in vivo, but has been investigated for its effects in 
cutaneous plasma leak.  These studies have demonstrated that PGE2 induces 
significant MVL and oedema in mouse (Goulet et al, 2004) and rat (Flower & 
Kingston, 1975; Takagi et al, 1987) skin.  Additionally, the EP2 and EP4 receptors 
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have been implicated in acute skin inflammation in mice following ultraviolet B 
exposure (Kabashima et al, 2007).  In vitro studies, however, have illustrated 
opposing effects where PGE2 appears to enhance microvascular endothelial barrier 
function (Birukova et al, 2007; Konya et al, 2013b).  PGI2 and the IP receptor have 
also been implicated in plasma leak and oedema formation (Murata et al, 1997; 
Yuhki et al, 2004) but, similar to PGE2, have also demonstrated inhibitory effects on 
induced MVL (Moller & Grande, 1997; Cureton et al, 2010).  The effects of PGD2 in 
airway disease are well documented but its role in MVL has not been highly 
investigated. It has been shown to induce increases in vascular permeability in rat 
skin (Flower & Kingston, 1975; Flower et al, 1976) and long-lasting erythema in 
human skin (Flower et al, 1976).  Nishimura et al (2001) observed a dose-dependent 
increase in Evans Blue dye in guinea pig airways with PGD2 administration, but this 
response appeared to be mediated via TP receptor activation.  Others have also 
demonstrated TP-induced airway MVL in rats and in guinea pigs (Lötvall et al, 1992; 
Bertolino et al, 1995).   
 
As outlined in this introduction airway microvascular leak (MVL) represents a 
cardinal sign of inflammation and is a prominent feature in the pathogenesis of 
airway inflammatory diseases, including asthma and COPD. Understanding the 
mechanism and the role of possible mediators in producing airway MVL is an 
important step in the development of new and effective therapies.  PGE2 has been 
subject to extensive investigation as a potential therapy due to its beneficial effects in 
the airways.   PGE2 has been shown to act as a bronchodilator and an anti-
inflammatory in cell based systems, in vivo models and clinically in healthy and 
asthmatic patients.  However, inhaled PGE2 caused airway irritancy and cough.  
Recent work in our lab has identified that EP3 receptor activation mediates this 
tussive effect, while EP2 and EP4 receptors mediate bronchodilation.  The aim of this 
thesis is to further investigate the role of PGE2 and the EP receptors in airway 
inflammation, specifically their role in airway microvascular leak.   It is prudent to 
identify the receptor(s) responsible for mediating any adverse effects especially if an 
agonist could be developed as a bronchodilator and/or anti-inflammatory.    
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1.4. Thesis Plan 
1.4.1. Hypothesis 
The hypothesis that formed the basis of this project was;  
“PGE2 acts through specific EP receptor(s) to induce microvascular leak within the 
airways.”  
1.4.2. Aims 
A multidisciplinary approach was used to investigate PGE2-induced airway 
microvascular leak and to identify the receptor(s) involved. Therefore, the aims of 
this thesis are to: 
 Characterise an in vivo model to measure airway microvascular leak using a 
known mediator of MVL (5-HT) and establish the effect of exogenous PGE2 
administration in this system (Chapter 3). 
 
 Investigate the EP receptor mediating PGE2-induced MVL using genetically 
modified mice and a range of pharmacological tools.  This will involve 
characterisation of a novel EP4 receptor antagonist that has not been 
previously used in our lab (Chapter 4). 
 
 Characterise the measurement of airway MVL in an allergic model of asthma 
(OVA model) and use EP receptor-deficient mice and selective antagonists to 
investigate the role of PGE2 (Chapter 5). 
 
 Begin preliminary work exploring the role of the other prostanoids in mediating 
airway MVL (Chapter 6).   
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Chapter Two 
 
Methodology  
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2. Methodology 
 
2.1.  Breeding of Knock-Out Mice 
 
Homozygous breeding pairs of mice genetically modified to disrupt one of the 
following genes; Ptger1 (EP1), Ptger2 (EP2), Ptger3 (EP3) (Ushikubi et al. 1998), 
Ptger4 (EP4), Ptgdr (DP) (Matsuoka et al. 2000), Gpr44 (DP2), Ptgfr (FP) (Sugimoto 
et al. 1997), Ptgir (IP) (Murata et al. 1997), Tbxa2r (TP) (Kabashima et al. 2003) 
were kindly provided by Dr S Narumiya, Kyoto University, Gpr44 (DP2) (Satoh et al, 
2006) knock-out mice were kindly supplied by Dr. Hiroyuki Hirai and Professor 
Masataka Nakamura, Tokyo Medical and Dental University, and breeding colonies 
maintained at Imperial College London.  All strains had been backcrossed at least 8 
times onto the C57BL/6 background, except the Ptger4-/- (EP4) mice as they do not 
survive on this background due to patent ductus arteriosus (Segi et al. 1998) and so 
were backcrossed on a mixed background of 129/Ola X C57bl/6.  These wild type 
mice were also provided by Kyoto University while C57BL/6 wild type mice were 
bred internally.  The DP2 knockout mice were originally bred on a balb/c background 
and so were backcrossed onto a C57BL/6 strain before used in experiments. 
2.1.1. Animal Husbandry 
Male Dunkin Hartley guinea pigs and male Brown Norway rats were purchased from 
Harlan (Bichester, UK).  Mice were bred in house as described above.  All animals 
were housed in individually ventilated cages (IVC) and provided with food and water 
ad libitum in a controlled environment.  A 12 hour light-dark cycle was maintained for 
all animals.  All studies and procedures were performed in accordance with Home 
Office guidelines under the Animals (Scientific Procedures) Act of 1986.   
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2.2 Genotyping of KO Mice 
 
2.2.1 DNA Extraction and Quantification 
 
DNA was extracted from mouse tail tips using Quanta Biosciences Extracta DNA 
prep for PCR kit.  Tail tips were transferred into autoclaved 0.5 ml eppendorfs and 
75µl of extraction reagent was added.  These were then heated for 30 minutes at 
95ºC.  Once samples had cooled to room temperature, 75µl of stabilisation reagent 
was added. 
The purity and integrity of each DNA sample was then assessed by A260/A280 
spectrophotometry on the GeneQuant RNA/DNA quantifier (Amersham Pharmacia 
Biotech, U.K.).  Following quantification samples were diluted to 10 ng µl-1 and 
stored at -20 ºC. 
2.2.2 Polymerase Chain Reaction 
 
PCR reactions were run using mouse genomic DNA primers that had been 
previously optimised and validated.  Primer sequences are listed in table 2.1. The 
PCR reaction contained 1x Green GoTaq Flexi buffer, 0.2mM dNTPs, 2mM MgCl2, 
1.25µl enzyme (GoTaq polymerase), 10pmol forward and 10pmol reverse primers, 
and a volume of DNA (50ng) or Nuclease-free water for control, made up to 25µl with 
Nuclease-free water (Promega U.K. Ltd).  The reaction was used to exponentially 
amplify the sections of DNA in between the primer pair. 
Using the ABI Prism 7000 (Applied Biosystems, Warrington, Cheshire, UK) the 
samples were heated to 94ºC for 2 minutes followed by 40 cycles of denaturing, 
annealing and extension steps.  All samples were denatured at 94ºC for 30 seconds 
as this is dependent on the enzyme.  The annealing temperature is specific to the 
primer pair and temperatures are between 58-65ºC for 30-45 seconds.  The 
temperature of the extension step is also primer dependent and the length of time 
that the reaction is held for depends on the product size.  This was followed by a 
final extension step for 10 minutes at 68-75ºC.  The reaction was then stopped by 
cooling to 4ºC. 
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2.2.3 Visualisation of PCR Products 
 
The PCR products and DNA ladder (Hyperladder II or IV, Bioline Ltd, London) were 
run on a 2% agarose gel in Tris Borate EDTA (TBE) buffer containing 0.05 µl ml-1 of 
Safeview (NBS Biologicals Ltd, Huntingdon, U.K.) at 80 V for at least one hour.  The 
gel was then visualised under ultra-violet light and photographed using the Molecular 
Imager® ChemiDocTM XRS System with Image LabTM software (Bio-Rad, UK). 
Table 2.1. Primer sequences used to genotype prostanoid receptor KO mice. 
Primer Name Sequence 
EP1 
forward 5’-TGA GCC TAG CGG ATG AGG CAG C-3’ 
reverse 5’-GCG GAG AGT CCG GCT AGA GAA G-3’ 
neomycin 5’-CCT GGG TGG AGA GGC TTT TT-3’ 
EP2 
forward 5’-CTG GCC ATT ATG ACC ATC ACC TTC GCC A-3’ 
reverse 5’-CTG AGC AAC ACC CAT GTT TCT ATC CTG G-3’ 
neomycin 5’-TGA TAT TGC TGA AGA GCT TGG CGG CGA A-3’ 
EP3 
forward 5’-AAA GTG ACT AGC ACC CAG AAT TCC TGC C-3’ 
reverse 5’-GAG TCC TCC ACT TTG GTG TAC ACA GTA C-3’ 
neomycin 5’-TGC CGA ATA TCA TGG TGG AAA ATG GCC G-3’ 
EP4 
forward 5’-TCT ACT TGC TCC CAG TGG ACA TAG A-3’ 
reverse 5’-GAA CAG ACT CCT GAA CTG GGT ATG G-3’ 
neomycin 5’-TGC CGA ATA TCA TGG TGG AAA ATG G-3’ 
FP 
forward 5’-GCC CAT CCT TGG ACA CCG AGA TTA TCA A-3’ 
reverse 5’-AGA GTT GGC AAG CTG TGA CTT CGT CTT T-3’ 
neomycin 5’-TGA TAT TGC TGA AGA GCT TGG CGG CGA A-3’ 
IP 
forward 5’-GAG CAG AAA AAT TCC CAG AGG CTT-3’ 
reverse 5’-GTA TCT TTC AGT ACC TGA GGA CTG-3’ 
neomycin 5’-TGA CCG CTT CCT CGT GCT TTA C-3’ 
TP 
forward 5’-ACT TCA TGG GGT CAG AAG CA-3’ 
reverse 5’-ACA TGG CTC CTA AGC CTG AC-3’ 
72 
 
neomycin 5’-CTC GTC CTG CAG TTC ATT CA-3’ 
DP1 
forward 5’-TCG GTC TTT TAT GTG CTC GTG-3’ 
reverse 5’-GGA TCA TCT GGA TGA AAC ACC-3’ 
neomycin 5’-CCC GTG ATA TTG CTG AAG AGC-3’ 
DP2 
(CRTH2) 
wt forward 5’-CGT AGC CGT GAG CCT GCG ACT G-3’ 
wt reverse 5’-GGC GAT TGC GGA GCC CAC CAC T-3’ 
KO forward 5’-GAG CAC GTA CTC GGA TGG AA-3’ 
KO reverse 5’-TCC TCG AGG CTA CTT TTG C-3’ 
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2.3 Microvascular Leak 
 
Airway wall microvascular leak was measured using Evans Blue dye as a marker for 
serum albumin extravasation.  As discussed in the introduction, Evans Blue binds 
avidly to albumin so allows us to track the movement of this protein out of the 
circulation and into airway tissue.  An increase in the concentration of Evans Blue in 
the tissue is indicative of an inflammatory response. 
 
2.3.1 Compound Administration 
 
Animals were anaesthetised with intra-peritoneal (i.p) Urethane (2 g kg-1; 200 μl of a 
25% solution given at two sites, followed by a further 50-100 μl when supine if 
necessary). Mice breathe spontaneously under urethane and so were therefore not 
artificially ventilated.  Depth of anaesthesia was assessed using the pedal and 
corneal reflex.  Once surgical anaesthesia was reached the jugular veins were then 
exposed following a midline incision over the thorax.  The left jugular vein was most 
often used, except when a third injection was needed or it was unsuitable for 
anatomical reasons.   Intravenous administration was achieved by passing the 
injection needle through the pectoralis major as this helped to prevent bleeding on 
withdrawal. 
Animals would receive Evans Blue dye (5 mg ml-1 at 4 ml kg-1) followed by the 
specific mediator or its vehicle one minute later (4 ml kg-1). The doses and timings 
used were those shown to be effective in previous studies within the group and from 
the literature (Hele et al, 2001). 
 
2.3.2 Measurement of Plasma Extravasation 
 
Five or 30 minutes after vehicle or compound administration, the thoracic cavity was 
opened and a small incision was made in the left ventricle and also the left atria of 
the heart (Figure 2.1).  A cannula was then inserted into the left ventricle and the 
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systemic circulation perfused with sterile saline (0.9%) at a pressure of 
approximately 100mmHg.  This was continued until the perfusate ran clear (2-5 
minutes).  The purpose of this was to remove any intravascular dye. 
 
 
Figure 2.1. Schematic of (A) injection site used for intra venous administration in mice 
and (B) anatomy of the mouse heart illustrating where incisions were made for saline 
perfusion. 
The heart, lungs and oesophagus were removed en bloc and then the trachea and 
lungs separated from the heart and oesophagus.  The oesophagus and bladder were 
taken from all animals and used as non-airway tissue controls (data not shown).  The 
trachea was isolated by cutting just above the bifurcation of the bronchi and the 
larynx removed.  The parenchyma was then carefully scraped off using a scalpel to 
reveal the intra pulmonary airways (IPA).  The trachea, the bronchi and IPA, the 
oesophagus and the bladder were then all weighed and the wet tissue weight 
recorded.  Each tissue was then placed into an eppendorf with 120µl of formamide 
and incubated at 37.5˚C for at least 18 hours to facilitate the extraction of Evans Blue 
dye. 
 
  
A B 
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2.3.3 Analysis 
 
The concentration of Evans Blue extracted from each tissue was determined by light 
absorbance at 620nm using a spectrophotomer (Biotek Powerwave XS Plate 
Reader, Biotek, UK).  100µl of formamide was removed from each eppendorf and 
pipetted into a 96 well plate alongside a standard curve of Evans Blue in formamide 
(0, 0.3125, 0.625, 1.25, 2.5, 5, 10 and 20 µg ml-1).  The concentration was then 
calculated by interpolation from the standard curve and expressed as ng mg-1 of 
tissue. 
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2.4 Blood Pressure Measurements 
 
2.4.1 Cannulation of Carotid Artery 
 
Mice were anaesthetised with Urethane (2 g kg-1; 200-300 μl of a 25% solution given 
at two sites i.p).  Mice breathe spontaneously under urethane and so were therefore 
not artificially ventilated.  Depth of anaesthesia was assessed using the pedal reflex.  
Body temperature was continuously monitored with a rectal thermometer and 
maintained at 37ºC with a heated blanket and control unit (Harvard).  Mice were 
placed under a dissecting microscope.  
Once surgical anaesthesia was reached, a midline incision in the neck region was 
made, the trachea exposed and the salivary glands carefully separated. The right 
carotid artery was then isolated and three ligatures applied; one fixed tightly at the 
cranial end, one loose at the caudal end pulled taught and a third loose loop in the 
middle. A small incision was made using vannas scissors and a polyethylene 
catheter was then inserted and secured with the two caudal ligatures (Figure 2.2).  
 
 
Figure 2.2.  Diagram of right carotid artery cannulation Illustrating ligature placement 
on the vessel as well as the incision site for inserting the cannula. The ligature at the 
cranial end is fixed, occluding the vessel, while the two ligatures caudal to this are only 
loosely applied until the cannula is inserted. The arrow indicates the direction the cannula is 
inserted in. Once the cannula is in place these ligatures are pulled tightly to secure the 
cannula. 
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2.4.2 Measuring Blood Pressure 
 
Once the carotid was cannulated the systemic arterial blood pressure was measured 
using a pressure transducer. Heart rate was also obtained from the arterial pulse 
trigger using Spike 2 software (CED). Systemic arterial blood pressure and heart rate 
were continuously recorded on the Spike 2 software data acquisition system via a 
CED Micro1401 interface.  
Following this the left jugular vein was exposed to allow for intra venous 
administration. After surgery the animals were allowed to stabilize and after a control 
baseline recording of 5 minutes, vehicle or compound (all at 4 ml kg-1) were 
administered via the jugular vein. Blood pressure was monitored and recorded for 30 
minutes following which animals were culled via cervical dislocation.  
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2.5 Ovalbumin Model of Allergic Asthma 
 
A standard Ovalbumin (OVA) model of allergic asthma that has been previously 
developed and characterised ‘in house’ (Birrell et al, 2003) was used to assess 
airway microvascular leak in a disease setting.  Four different treatment groups were 
initially used.  These were vehicle sensitised/saline challenged, vehicle 
sensitised/OVA challenged, OVA sensitised/saline challenged and OVA 
sensitised/OVA challenged.  Following a small time course study it was deemed 
practical to include just two groups for all other experiments; OVA sensitised/saline 
challenged and OVA sensitised/OVA challenged. AlumTM was used as an adjuvant 
for the sensitisation of all mice and was diluted 1:1 with saline.  AlumTM is made up of 
20 mg ml-1 of aluminium hydroxide and 20 mg ml-1 of magnesium.    
Male C57BL/6 mice (20-25 g) were sensitised with OVA in AlumTM (10µg per mouse, 
100 µl i.p.) or vehicle (AlumTM diluted 1:1 with saline, 100µl i.p) on days 0 and 14 
(Figure 2.3).  Subsequently on days 24, 25 and 26 mice were given a single 
intranasal (i.n) challenge of either OVA (50 µg in 50µl) or saline. For the intranasal 
dosing, mice were placed into a PerspexTM chamber connected to an anaesthetic 
machine (Bowring Medical Engineering Ltd, Witney, UK) and exposed to 4% 
isoflurane in 0.5% oxygen.  Once mice were lightly anaesthetised 50 µl was slowly 
dropped with a pipette onto both nostrils until passively inhaled.  Mice were 
monitored closely during recovery. 
 
 
Figure 2.3.  Timeline demonstrating the protocol used for the ovalbumin model. 
79 
 
2.5.1 Assessing airway Microvascular Leak 
 
Evans Blue dye was used as a marker of airway microvascular leak induced by 
OVA.  2 and 24 hours following the final intra nasal challenge mice were 
anaesthetised (Urethane 2 g kg-1 200-300 µl i.p) and the jugular veins exposed to 
allow for a single i.v dose of Evans Blue dye (5 mg ml-1 in 4 ml kg-1).  Thirty minutes 
later, the circulation was perfused and airways dissected out as described before. In 
the first study only wet tissue weight was recorded and then in subsequent 
experiments the tissue was dried for one hour at 60°C and wet and dry weights were 
recorded. As before, the tissue was incubated in formamide and concentration of 
Evans Blue dye assessed using a spectrophotometer.  
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2.6 In vitro Organ Bath Experiments 
 
To assess the selectivity of the EP4 antagonist (ER-819762) in a functional bioassay 
system, isolated rat trachea was used.  PGE2-induced relaxation of induced tone in 
rat tracheal tissue has previously been shown to be mediated by the EP4 receptor 
(Lydford & McKechnie, 1994; Buckley et al, 2011; Benyahia et al, 2012) and so this 
was used as an assay system to assess the functionality at this receptor subtype. 
 
2.6.1. Physiological salt solutions 
 
For all experiments, tissues were cleaned, dissected and bathed in modified Krebs-
Henseleit solution (KHS).  This solution was composed of (mM); NaCl (118), KCl 
(5.9), MgSO4 (1.2), NaH2PO4 (1.2), CaCl2 (2.5), Glucose (6.6), NaHCO3 (25.5), 
dissolved in distilled water.  The KHS was maintained at 37°C and a 95% O2/5% 
CO2 gas mixture bubbled through.  Additionally, 10µM indomethacin (a non-selective 
COX inhibitor) was added to the solution to prevent the formation and release of any 
endogenous prostanoids (Patel et al. 1995; Takahashi et al. 1994). 
 
2.6.2. Isolated airway preparation 
 
Male Sprague Dawley rats (225-300g) were euthanized with an overdose of 
pentobarbitone (200 mg kg-1 i.p) and the trachea carefully dissected out and quickly 
placed in KHS.  All extraneous connective tissue was dissected clear and the 
trachea opened via a longitudinal incision along the cartilage opposite the smooth 
muscle.  The trachea was then divided into 4 equal transverse segments and 
sutured appropriately for attachment to the transducer.  Once the tracheal strips 
were set up in the organ bath they were left to equilibrate for 1 hour under a resting 
tension of 1000mg. 
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2.6.3. Isolated airway organ bath protocols 
2.6.3.1. General protocol 
 
Each prepared tracheal section was attached to force-displacement transducers 
(Model FT-03; Grass Instruments Co., Quincy, MA, USA) connected to a data 
acquisition system (MP100) operating on a Windows PC using AcqKnowledge 
software (BIOPAC systems, USA).  The tissue was left to equilibrate in 10 ml organ 
baths in KHS for one hour and washed at 30 minutes with fresh KHS.  Following this, 
a supramaximal response to 1mM acetylcholine (ACh) was obtained three times, 
with three washes and re-equilibration between each ACh administration. 
 
2.6.3.2. Induced tone protocol 
 
Once the tissues had returned and stabilised to resting tension levels, an increase in 
muscular tone was induced by administering 1µM carbachol to the organ bath.  The 
tissues were then left to equilibrate at this increased resting tension until stable, 
typically about 20 minutes.  The EP4 antagonist (ER-819762) or vehicle was then 
administered to the baths and left to incubate for 20 minutes, during which time the 
baseline tension was monitored to ensure that the antagonist was not affecting the 
tension itself.  Following this, a cumulative concentration response curve to the EP4 
agonist (ONO-AE1-329) was performed.  Finally, once a plateau was reached to the 
highest agonist concentration, 100µM of papaverine was added to produce standard 
maximal relaxation responses. 
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2.6.4. Data Analysis 
 
Data was expressed as mean + s.e.m. of n individual observations.  Concentration 
response data was analysed using PRISM 5 (GraphPad Software, CA, USA) and 
curves were fitted by non-linear regression of data using a four parameter logistic 
equation (below) from which EC50 values were then calculated: 
    Bottom   
(Top   Bottom)
    (         )          
 
 
Where: Bottom = Y value at the bottom plateau, Top = Y value at the top plateau, 
LogEC50 = X value when the response is halfway between Bottom and Top, 
HillSlope = Description of gradient of curve. 
 
Estimates of antagonist affinity were calculated using the Gaddum-Schild equation 
as described previously (Gaddum 1957): 
         (    )          
Where: CR = Concentration ratio between individual EC50 values.   
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2.7 Human Cell Based Assay of Microvascular Leak 
 
To further explore the mechanisms by which prostanoids induce microvascular leak, 
human lung microvascular endothelial cells were used.  Eliminating physiological 
parameters such as blood pressure and blood flow using a cell based system 
allowed investigation into the actions of prostanoids directly on endothelial cells.  
Endothelial barrier permeability to albumin was used as an indicator of microvascular 
leak.  Data is presented in chapter 7 as future work (section 7.2.6.). 
 
2.7.1 Cell Culture 
 
Human Lung Microvascular Endothelial cells (HLMVECs) were purchased from 
Lonza (Lonza Walkersville, Inc., Walkersville, MD, USA) and arrived at passage 5.  
These cells were isolated from small vessels within normal human lung but not 
specified as post capillary venules.  Cells were grown and used at passage 8.  They 
were cultured in Endothelial Growth Medium (EGMTM-2 MV BulletKitTM Medium, 
Lonza.) containing the following growth factors; FBS, hydrocortisone, hFGF-B, 
VEGF, R3-IGF-1, ascorbic acid, hEGF, Gentamicin and Amphotericin B. Cells were 
maintained at 37˚C in a humidified atmosphere of 5% CO2-95% air. Cells were 
passaged using a Trypsin/EDTA solution when they reached 90% confluency and 
seeded at 800,000 cells per flask. 
 
2.7.2 Measuring Endothelial Barrier Permeability 
 
Cell culture inserts with a 3.0 micron, transparent polyethylene terephthalate (PET) 
membrane (BD FalconTM) were used in all experiments.  Before seeding, complete 
medium was added to both insert and well and the membrane equilibrated for 3 
hours at 37˚C in 5% CO2-air. Cells were seeded onto culture inserts at 4 x 10
4 cells 
per insert.  Seeded inserts were incubated for 48 hours at 37˚C in 5% CO2-air.  At 
the end of incubation cultures were examined under light-microscopy and those with 
damaged monolayers were discarded. 
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Vehicle (DMSO, final concentration 0.1%, V/V) or compound was added to the upper 
chamber and incubated for one hour in a humidified atmosphere (95% air, 5% (v/v) 
CO2) at 37˚C.  After the 60 minute incubation cultures were once again examined 
and any with a damaged monolayer were discarded. To detect changes in 
monolayer permeability fluorescein isothiocyanate conjugate (FITC)-albumin (100 
μg/ml) was then added to the upper chamber of each insert in a volume of 250μl and 
750μl of assay medium was also added to each lower well to ensure similar 
hydrostatic pressure on both sides of the monolayer.  Cells were incubated with 
FITC-albumin for a further 60 minutes (Figure 2.4). 
 
Figure 2.4. Diagram illustrating method used for measuring endothelial barrier 
permeability in human lung microvascular endothelial cells (HLMVECs). 
At the end of the incubation, inserts were carefully removed and medium in each 
lower well thoroughly mixed.  100 μl samples were then collected from the lower 
chambers were analysed for FITC fluorescent intensity using a fluorometric plate 
reader (Ettan Dige Imager) at excitation 492nm and emission 520nm.  
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After assay of culture permeability, cultures were examined under phase-contrast 
microscopy for intactness of monolayers.  Data from cultures with damaged 
monolayers was excluded.  Additionally cell viability will be assessed by MTT assay. 
 
2.7.3 MTT Assay 
 
Mitochondrial enzymes produced from viable cells cleave the yellow tetrazolium salt 
MTT to blue formazan. Hence, formazan is directly proportional to the number of 
living cells present during MTT colorimetric analysis and can be used to 
quantitatively determine cell viability (Sylvester 2011). 500µL of MTT in RPMI 
(1mg/mL) was added to each well of the 24 well plates post J774 cell treatment and 
transfer. After incubating for 20 minutes, the plates were emptied and dried overnight 
before absorbance was recorded in a microplate reader at 570nm. 
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2.8 Measurement of Gene Expression 
 
2.8.1 RNA Extraction 
 
RNA was extracted from the human lung microvascular endothelial cells (3 patients) 
to detect and quantify the presence of prostanoid receptors in this cell type.  The 
cells were first isolated by centrifugation of a cell suspension at 12,000 x g for 5 
minutes and discarding the supernatant.   1 ml of Tri Reagent (Sigma-Aldrich Co., 
Poole, UK) was then added to each pellet of cells.  Tri Reagent is a mixture of 
guanidine thiocyanate and phenol in a non-phase solution which is able to effectively 
dissolve DNA, RNA and protein on lysis with the sample.  Samples were then left to 
stand at room temperature for 5 minutes to ensure the complete dissociation of 
nucleoprotein complexes.  After this, 0.2 ml of chloroform was added to each tube, 
mixed and left to stand for approximately 15 minutes.  Samples were then 
centrifuged at 15,000 x g for 15 minutes at 4ºC in a microcentrifuge.  This step 
causes the mixture to separate into three phases: a colourless upper aqueous phase 
(containing RNA), an interphase (containing DNA) and a red organic phase at the 
bottom (containing protein).  Only the RNA was required so the aqueous phase was 
removed and placed into an autoclaved 1.5ml centrifuge tube.  To this, 1/10 volume 
of isopropanol was added, mixed and left at room temperature for 5 minutes.  
Samples were then centrifuged at 12,000 x g for 10 minutes at 4ºC and the 
supernatant transferred to an autoclaved 1.5ml tube.  The remaining volume of 
isopropanol was then added (a total of 0.5ml of isopropanol is needed per 1ml of Tri 
Reagent used), mixed and left to stand at room temperature for 10 minutes.  This will 
lead to the formation of an RNA precipitate in the sample.  Samples were then 
centrifuged at 12,000 x g for 10 minutes at 4ºC and this time the supernatant was 
carefully discarded leaving an RNA pellet.  This pellet was then washed with 1ml of 
75% ethanol, vortexed and centrifuged at 12,000 x g for 5 minutes at 4ºC.  Following 
this, the ethanol was removed, being careful not to disturb the RNA pellet, and left to 
air dry for 5-10 minutes.  The RNA pellet was subsequently resuspended in 50µl of 
nuclease-free water.  The purity and integrity of the RNA was assessed via A260/A280 
spectrophotometric measurements on the GeneQuant RNA/DNA quantifier 
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(Amersham Pharmacia Biotech, U.K).  Samples were then diluted to a concentration 
of 0.05 ng ml-1. 
 
2.8.2 Reverse Transcription 
 
RNA samples (1µg) were reverse transcribed to complementary deoxyribonucleic 
acid (cDNA), using a master mix (TaqMan reverse transcription reagents, Applied 
Biosystems, Warrington, Cheshire, U.K.) containing 1X TaqMan RT buffer, 5.5mM 
MgCl2, deoxyNTPs mixture (500µM per NTP), 2.5µM random hexamers, 0.4U µl
-1 
RNase inhibitor and 1.25U µl-1 Multiscribe reverse transcriptase, in a final reaction 
volume of 50µl (10µl RNA sample).  The samples were incubated in a Perkin Elmer 
480 thermal cycler (Boston, MA, U.S.A.) at 25ºC for 10 minutes, then reverse 
transcribed at 48ºC for 30 minutes and then the enzyme was denatured at 95ºC for 2 
minutes.  Samples were stored at -80ºC until required for gene expression analysis. 
 
2.8.3 Real Time Polymerase Chain Reaction (PCR) 
 
Real time polymerase chain reaction (PCR) was carried out to detect transcriptional 
expression of target mRNA transcripts in RNA samples by using fluorescently 
labelled Taqman probes (Applied Biosystems, Warrington, Cheshire, UK) and 
analysed with the ABI Prism 7000 Sequence Detection System (Applied Biosystems, 
Warrington, Cheshire, UK).    The oligonucleotide probes are constructed so that 
they contain a reporter fluorescent dye on the 5’ end and a quencher dye on the 3’ 
end.  While intact, the close proximity of the quencher dye to the reporter dye greatly 
reduces the level of fluorescence emitted.  If the target sequence is present, the 
probe anneals downstream from one of the primer sites and is cleaved by the 5’ 
nuclease activity of Taq DNA polymerase as this primer is extended.  This cleavage 
separates the reporter dye from the quencher dye and so increases the signal of the 
reporter dye.  The TaqMan machine is able to measure the fluorescence emitted 
cycle by cycle. 
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Pre-developed Assays on Demand for the target genes of interest were purchased 
from Applied Biosystems and contained the primers and probe in one reagent.  The 
TaqMan probe has a fluorescent reporter dye, FAM, covalently linked to its 5’ end 
and a downstream quencher dye, TAMRA, linked to the 3’ end.  The probe is 
designed to anneal to a DNA sequence in between primers on the gene of interest.  
Reactions were internally controlled with 18s rRNA internal control (Applied 
Biosystems, Warrington, Cheshire, UK).  18s is designed in the same way as the 
assay probe but uses VIC as its quencher dye so that both reporter signals in the 
reaction can be measured.     
The PCR reactions were performed using 3µl of cDNA (2.5ng ul-1), 12.5µl of TaqMan 
Universal Master Mix, 1.25µl 18s internal control, 1.25µl of the assay on demands 
(AOD) and 7µl of Nuclease-free water, to make a total reaction volume of 25µl.  The 
amplification and detection was carried out using the ABI Prism 7000 Sequence 
Detection System (Applied Biosystems, Warrington, Cheshire, UK) using the 
following protocol; 1 cycle at 50ºC for 2 minutes, 1 cycle at 95ºC for 10 minutes, 40 
cycles at 95ºC for 15 seconds, and 60ºC for 1 minute. 
 
2.8.4 Analysis of Real Time PCR Results 
 
Real Time PCR results were analysed using the Sequence Detection Software 
where the relative amount of target gene transcript was normalised to the amount of 
18s internal control transcript in the same cDNA sample.  The critical threshold (ct), 
which is defined as the cycle at which the fluorescence from the TaqMan probe 
becomes detectable above background, is inversely proportional to the logarithm of 
the initial number of template molecules.  Therefore the higher the target 
concentration, the lower the number of amplification cycles needed to measure the 
rise above baseline.  The ct was set during the exponential phase of cDNA 
replication and the relative difference between 18s and AOD ct (Δct) was then 
calculated.  Data was expressed using the following equation; 2-delta ct i.e. 2-(target ct-18s 
ct), written as 2-Δct. 
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2.9 Statistical Analysis 
 
All data was analysed using GraphPad Prism 5.  Parametric data was expressed as 
mean + s.e.m and non-parametric data presented as the median with the 
interquartile range. Multiple measurements were analysed by one-way ANOVA, non-
parametric Kruskal-Wallis test and post-hoc comparisons were performed by Dunn’s 
multiple comparison test, comparing selected columns to a control.  Additionally, an 
unpaired t test and/or non-parametric Mann Whitney test, with two-tailed p values, 
were carried out to determine statistical significance between two groups. 
Differences were considered statistically significant if p<0.05.  The figures have been 
graphically presented on a range-specific axis 
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Chapter Three 
 
Characterisation of an in vivo 
preparation to measure airway MVL 
and the effect of Prostaglandin E2  
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3. Characterisation of an in vivo preparation to measure airway 
MVL and the effect of Prostaglandin E2 
 
3.1. Rationale 
Airway microvascular leakage and plasma exudation are prominent features in both 
asthma and COPD representing signs of airway inflammation (Paredi & Barnes, 
2009).  Increased levels of PGE2 have been reported in BAL fluid and plasma of 
asthma patients, and enhanced levels in the condensate of COPD patients 
(Montushi et al, 2003; Long et al, 2004).  However, its role in airway inflammation 
remains varied and inconclusive and there appears to be a fine balance between the 
pro and anti-inflammatory effects of this prostanoid in human airways.  Microvascular 
leak has been extensively studied in larger species, such as the guinea pig, using 
various different methods, as described in Chapter 2.  However the aim of this 
chapter was to establish whether the mouse was an appropriate species to use to 
investigate PGE2’s effects on airway MVL.  There are several reasons why using the 
mouse would be advantageous; it is the species of choice to model asthma and 
COPD, the availability of prostanoid receptor knock-out mice, cost and lesser 
quantities of compound are required.   
3.1.1. Chapter Hypothesis 
“Exogenous PGE2 is able to cause microvascular leak in rodent airways.” 
3.1.2. Aims 
 Characterise the Evans Blue model in the mouse using 5-HT, which is a 
known and potent inducer of airway MVL (Germonpre et al, 1997; Olivenstein 
et al, 1997; Hele et al 2001).   
 To investigate a dose dependent relationship to PGE2 and determine the ideal 
length of time over which to measure this effect.   
 Compare the response to PGE2 in a larger species (guinea pig).   
 Investigate whether the MVL measured coincided with a change in systemic 
blood pressure, as PGE2 has been implicated in the vasodilation observed in 
inflammatory processes and additionally bronchial vasodilators have 
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demonstrated increases in plasma extravasation (Narumiya et al, 1999; 
Paredi & Barnes, 2009). 
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3.2. Methods 
 
The following experiments were carried out as described in Chapter 2.  Details of 
individual experiments are described below. 
3.2.1. Characterisation of airway MVL in mice using 5-HT 
 
A dose response to 5-HT was first established to help characterise the microvascular 
leakage model in mice.  Animals received Evans Blue (EB; 5 mg kg-1 at 4 ml kg-1) 
and one minute later received 5-HT (0.1, 1 or 10 mg kg-1 at 4 ml kg-1) or vehicle (1% 
ethanol in saline). Five minutes after vehicle/5-HT administration, animals were 
culled for the measurement of EB extravasation as described in section 2.3. The 
doses and timings used were those shown to be effective in previous studies within 
the group and from the literature (Hele et al, 2001). 
To confirm that 5-HT induced MVL was through activation of 5-HT receptors the non-
selective 5-HT receptor antagonist methysergide was used.  Methysergide (10 mg 
kg-1; Hele et al., 2001) or vehicle (0.9% saline; 4 ml kg-1) was given i.v. 1 minute after 
EB.  Five minutes after this a sub maximal dose of 5-HT (1 mg kg-1) or vehicle was 
administered (1% ethanol in saline; 4 ml kg-1).  After a further 5 minutes EB 
extravasation was measured.  
 
3.2.2. Dose Response of PGE2 - induced airway MVL in Mice 
 
A dose response to PGE2 was established where male C57BL/6 mice were given 
PGE2 (0.1, 0.3, 1, 3, or 10 mg kg
-1 at 4 ml kg-1), 5-HT (10 mg kg-1 at 4 ml kg-1) as a 
positive control or vehicle (1% ethanol in saline).   5 minutes following administration 
EB extravasation was measured. 
 
 
 
 
 
94 
 
3.2.3. Time Course of PGE2 - induced airway MVL in Mice 
As only a small increase in MVL was observed in response to PGE2, the PGE2 
exposure time was increased to 30 minutes and compared to 5 minutes.  In this 
study a single dose of PGE2 (10 mg kg
-1) was used, as well as a vehicle control. As 
an enhanced increase in MVL was demonstrated at 30 minutes, the dose response 
to PGE2 was repeated. 
 
3.2.4. Effect of Diclofenac on PGE2-induced airway MVL in Mice 
A non-selective COX inhibitor, diclofenac (30 mg kg-1 in 10 ml kg-1), or vehicle (0.5% 
methylcellulose, 0.2% Tween 80 in water) was administered orally 60 minutes prior 
to PGE2 administration.  This was to block any endogenous prostanoids that may be 
influencing the baseline or PGE2-induced response. 
 
3.2.5. Effect of intranasal dosing of PGE2 on airway MVL in Mice 
 
Having assessed the effect of intravenous administration of PGE2, I wanted to 
examine whether I could reproduce the same effect via topical delivery straight to the 
airways to more closely mimic what might happen in airway disease. Here mice were 
anaesthetised and then dosed intra-nasally (i.n) with either vehicle (1% ethanol in 
saline) or PGE2 (3 mg kg
-1) in 50μl.  Once surgical anaesthesia was reached, mice 
were then given Evans Blue and culled 30 minutes later. 
 
3.2.6. PGE2-induced airway MVL in Guinea Pigs 
Guinea Pigs were chosen as a second (larger) species to assess PGE2-induced 
airway MVL as they more closely resemble humans in terms of their respiratory 
anatomy (lobing and branching) and physiology (mediator release).  In this study it 
was more suitable to look at only one dose of PGE2 for reasons pertaining to cost 
and time.  Male Dunkin Hartley Guinea Pigs (300-600g) were anaesthetised with 
urethane (2 g kg-1 i.p of a 25% solution).  Once surgical anaesthesia was reached 
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animals received EB (5 mg ml-1 at 1 ml kg-1 i.v) and then one minute later vehicle 
(1% ethanol in saline), PGE2 (3 mg kg
-1) or 5-HT (1 mg kg-1), all intravenously at 1 ml 
kg-1.  5 minutes following 5-HT or 30 minutes after PGE2 EB extravasation was 
measured. 
 
3.2.7. Effect of PGE2 on Systemic Blood Pressure in Mice 
Male C57BL/6 mice were anaesthetised as previously described and their carotid 
artery cannulated (as outlined in 2.4).  Once a baseline blood pressure recording 
was achieved (approximately 5 minutes), the jugular veins were exposed and an 
intravenous dose of PGE2 (3 mg kg
-1) or vehicle (1% ethanol in saline) administered. 
Mean arterial blood pressure (MAP) was measured over 30 minutes after which 
animals were culled.  Along with PGE2, the IP agonist Iloprost and TP agonist 
U46619 were given as positive controls (Walch et al, 1999; 2001). 
 
3.2.8. Statistical Analysis 
 
All data was analysed using GraphPad Prism 5.  Parametric data was expressed as 
mean + s.e.m and non-parametric data presented as the median with the 
interquartile range. Multiple measurements were analysed by one-way ANOVA, non-
parametric Kruskal-Wallis test and post-hoc comparisons were performed by Dunn’s 
multiple comparison test, comparing selected columns to a control.  Additionally, an 
unpaired t test and/or non-parametric Mann Whitney test, with two-tailed p values, 
were carried out to determine statistical significance between two groups. 
Differences were considered statistically significant if p<0.05.  The figures have been 
graphically presented on a range-specific axis. 
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3.3. Results 
 
3.3.1. Characterisation of airway MVL in mice using 5-HT 
 
In order to validate this model in mice, a known inducer of MVL, 5-HT, was used 
(Hele et al, 2001). An increase in Evans Blue dye concentration correlates with an 
increase in microvascular leak and is expressed in ng mg-1 of tissue.  Intravenous 
administration of 5-HT (0.1, 1 and 10 mg kg-1) caused substantial increases in Evans 
blue extravasation into the trachea and bronchi and IPA (Figure 3.1 and Figure 3.2). 
However, from the photo in figure 3.1 it appears that EB leak in the lower airways 
(IPA) is substantially less than in the bronchi.  This could possibly ‘dilute’ the final 
value of EB leak.  From this data a first effective dose of 1 mg kg-1 5-HT was chosen.  
As a dose ranging study an n number of 3 was appropriate and complied with the 
3R’s (Replacement, Reduction and Refinement).  Additionally statistical analysis with 
an n of 3 was not possible.  
                            
Figure 3.1. Photograph of mouse airway tissue illustrating the effects of intravenous 5-HT on 
microvascular leak.  
Bronchi and IPA Trachea 
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Figure 3.2. Effect of 5-HT (0.1, 1 and 10 mg kg
-1
 i.v) after 5 minutes on MVL into (A) the trachea 
or (B) the bronchi and intra-pulmonary airways (IPA) of mice. Data expressed as mean + s.e.m of 
the concentration of Evans blue dye (ng mg
-1
 of tissue). n=3. 
A non-selective 5-HT receptor antagonist, methysergide, was then used to determine 
whether 5-HT was inducing MVL via activation of 5-HT receptors.  Figure 3.3 clearly 
shows that methysergide is able to significantly inhibit MVL induced by the sub-
maximal dose of 5-HT (1 mg kg-1).  
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Figure 3.3. Effect of methysergide (10 mg kg-1 i.v; 5 minutes) on 5-HT (1 mg kg-1 i.v; 5 minutes) 
induced MVL into (A) the trachea or (B) the bronchi and intra-pulmonary airways of mice. Data 
expressed as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of tissue). n=6. Unpaired 
t test for parametric data.  * p<0.05 representing a significant increase from vehicle control and # 
p<0.05 a significant decrease from treatment control. 
 
3.3.2. Dose Response of PGE2 - induced airway MVL in Mice 
 
Intravenous administration of PGE2 for 5 minutes (0.1, 0.3, 1, 3 and 10mg kg
-1) 
caused only minor increases in MVL in the trachea and bronchi and IPA of mice 
(Figure 3.4).  Although not significant, PGE2 induced MVL in a dose dependent 
manner in the trachea.  The positive control, 5-HT produced a significant increase in 
MVL in both the trachea and bronchi and IPA further validating this model.     
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Figure 3.4. Effect of PGE2 (0.1, 0.3, 1, 3 and 10 mg kg
-1
 i.v; 5 minutes) or 5-HT (10 mg kg
-1
 i.v; 5 
minutes) on MVL into (A) trachea or (B) bronchi and intra-pulmonary airways of mice. Data 
expressed as median, with interquartile range, of the concentration of Evans blue dye (ng mg
-1
 of 
tissue). n=6. One-way ANOVA non-parametric Kruskal Wallis test. * p<0.05. 
 
3.3.3. Time Course of PGE2 - induced airway MVL in Mice 
To determine whether PGE2 could induce greater MVL after a longer period of time, 
the exposure time was increased from 5 minutes to 30 minutes.  After this length of 
time PGE2 significantly increased extravasation of Evans blue dye into the trachea 
as well as the bronchi and IPA, which is comparable to the increase seen with the 5 
minute time point (Figure 3.5).  Additionally, there was no difference in MVL in the 
vehicle treated group over time. 
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Figure 3.5.  Effect of PGE2 (10 mg kg
-1
 i.v) on MVL after 30 minutes (n=5) compared to 5 
minutes (n=6), into (A) trachea or (B) bronchi and intra-pulmonary airways of mice. Data 
expressed as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of tissue). n=5-6. 
Unpaired t test for parametric data. *p<0.05. 
 
A dose response to intravenous PGE2 (0.1, 0.3, 1, 3, 10 mg kg
-1) was repeated using 
the 30 minute time point and this induced an enhanced dose dependent increase in 
MVL in both the trachea and the bronchi and IPA (Figure 3.6).  From this a sub 
maximal dose of 3 mg kg-1 was chosen.  Again, as this was a dose ranging study an 
n number of 3-4 was appropriate and complied with the 3R’s.  Additionally statistical 
analysis with an n of 3-4 was not possible. What is also interesting to note is that in 
general, the responses to PGE2 are more pronounced and higher in the tracheal 
segment in comparison to the lower airways. However, as seen with 5-HT this could 
be due to variation between the bronchi and the IPA.   
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Figure 3.6. Effect of PGE2 (0.1 – 10 mg kg
-1
 i.v) on MVL after 30 minutes into (A) trachea or (B) 
bronchi and intra-pulmonary airways of mice. Data expressed as mean + s.e.m of the 
concentration of Evans blue dye (ng mg
-1
 of tissue). n=3-4.  
 
3.3.4. Effect of Diclofenac on PGE2-induced airway MVL in Mice 
Diclofenac, a non-selective COX inhibitor, was administered prior to PGE2 
administration to block the production and release of endogenous prostanoids to 
ensure that they were not influencing baseline or PGE2-induced airway leak.  The 
data clearly shows that diclofenac had no effect on baseline or PGE2 induced leak in 
the trachea or bronchi and IPA (Figure 3.7).  In both the vehicle and diclofenac 
treated groups, PGE2 significantly increased airway MVL. 
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Figure 3.7. Effect of diclofenac (30 mg kg
-1
 in 10 ml kg
-1
 p.o; 1 hour) on MVL in vehicle and 
PGE2 (3 mg kg
-1
 i.v; 30 minutes) treated mice. (A) Trachea and (B) Bronchi and intra-pulmonary 
airways.  Data expressed as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of tissue). 
n=4. Unpaired t test for parametric data. *p<0.05.  
  
3.3.5. Effect of intranasal dosing of PGE2 on airway MVL in Mice 
 
Having established that when given intravenously PGE2 is able to induce significant 
MVL in murine airways I wanted to see whether such a response could be replicated 
via topical administration direct to the airways.  This would mimic what may occur in 
disease when there is an increase of PGE2 in the airways.  Therefore I administered 
a single intranasal dose of PGE2 (3 mg kg
-1) and measured EB leak after 30 minutes.  
Interestingly, via this route of administration PGE2 was able to induce significant 
MVL and the extent to which was almost identical to that seen with i.v administration 
(Figure 3.8). 
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Figure 3.8.  Effect of an intranasal dose of PGE2 (3 mg kg
-1
 i.n) on MVL after 30 minutes into (A) 
trachea or (B) bronchi and intra-pulmonary airways (IPA) of mice. Data expressed as median, 
with interquartile range, of the concentration of Evans blue dye (ng mg
-1
 of tissue). n=6.  Non-
parametric Mann Whitney test. * p<0.05.significant increase from veh control. 
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3.3.6. PGE2-induced airway MVL in Guinea Pigs 
To rule out whether the effect seen with PGE2 was exclusive to the mouse, I gave 
the sub maximal dose of PGE2 to guinea pigs alongside 5-HT, acting as a positive 
control.  When PGE2 (3 mg kg
-1) was given intravenously there was a remarkable 
increase in airway microvascular leak in the trachea and in the bronchi and 
intrapulmonary airways (Figure 3.9).  This response was comparable to 5-HT. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.  Effect of PGE2 (3 mg kg
-1
 i.v) after 30 minutes or 5-HT (1 mg kg
-1
) after 5 minutes 
(respectively) into (A) upper trachea, (B) lower trachea or (C) bronchi and intra-pulmonary 
airways (IPA) of Dunkin Hartley Guinea Pigs. Data expressed as mean + s.e.m of the 
concentration of Evans blue dye (ng mg
-1
 of tissue).  n= 3   
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3.3.7. Effect of PGE2 on Systemic Blood Pressure in Mice 
Following PGE2 administration there was little change in the systemic blood 
pressure, with only a small decrease apparent (Figure 3.10).  This is different to the 
effects seen with the TP and IP agonists.  As expected the TP agonist U46619 
caused a rapid and substantial increase in blood pressure compared to the vehicle 
response, while the IP agonist Iloprost had a completely opposite effect, 
demonstrating an almost instant drop in the mean arterial pressure.  While the effect 
of U46619 seemed to be relatively transient, the decrease seen with Iloprost 
appeared to be sustained (Figure 3.10). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10.  Effect of PGE2, Iloprost and U46619 (3 mg kg
-1
 i.v) on the mean arterial blood 
pressure of C57BL/6 mice.  Following carotid artery cannulation mice were given an i.v dose of 
either PGE2, Iloprost, U46619 or vehicle and systemic blood pressure measured and recorded over a 
20 minute period. Arrow indicates time of administration. n=3-4.  
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3.4. Discussion 
 
The aim of this chapter was to characterise a method for measuring airway 
microvascular leak in vivo using Evans Blue dye and to establish the effect of 
prostaglandin E2 in both mouse and guinea pig airways.   
Airway microvascular leakage and plasma exudation are prominent features in both 
asthma and COPD representing signs of airway inflammation (Paredi & Barnes, 
2009). Many mediators (e.g. cysteinyl leukotrienes) are capable of inducing this 
effect when released in response to an inflammatory insult in the airway.  These 
inflammatory mediators act upon the endothelium of post capillary venules to open 
intercellular gaps.  This effect causes plasma to ‘leak’ out into extravascular sites 
(Reynolds et al, 2002; Greiff et al, 2003).  Measuring this event in vivo provides a 
specific index representing to what degree the airway mucosa has been affected by 
the inflammatory process of a mediator (Greiff et al, 2003).   Events such as these 
have been associated with the development and exacerbations of airway 
inflammation, thus modulation of this response represents a key pathway in 
developing new treatments.  What I wanted to investigate was whether prostaglandin 
E2 (PGE2) was involved in mediating this response.   
PGE2 is a ubiquitous eicosanoid that has been implicated in the pathogenesis of 
both asthma and COPD. It exerts its biological effects via activation of four cell-
surface GPCRs, termed EP1-4, encoded for by the genes Ptger1-4 (Coleman et al, 
1994).    Increased levels of PGE2 have been reported in BAL fluid and plasma of 
asthma patients (Brightling et al, 2000; Birring et al, 2003; Long et al, 2004; Sastre et 
al, 2008), and enhanced levels in the condensate of COPD patients (Montushi et al, 
2003; Chen et al, 2008; Antczak et al, 2012).  Additionally, increased levels of PGE2 
have been observed in the BAL fluid of allergen-sensitised mice (Herrerias et al. 
2009). However, its role in airway inflammation remains varied and inconclusive and 
there appears to be a fine balance between the pro and anti-inflammatory effects of 
this prostanoid in human airways.   
Before investigating the effect of PGE2, however, I needed to determine whether the 
mouse was a suitable species to model MVL in.  Therefore I used 5-
hydroxytryptamine (5-HT) as a tool for validating this model, as previous reports 
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have shown potent effects in rats (Hele et al, 2001).  Here, 5-HT induced a dose 
related increase in MVL in both the trachea and the bronchi and IPA of mice. 
However, from the photograph illustrating a typical EB response following 5-HT, it 
appears that the leak in the IPA is much less than what occurred in the bronchi.  This 
effect may mask a larger increase following 5-HT.  Furthermore, I determined that 5-
HT was acting via 5-HT receptors by using a non-selective 5-HT receptor antagonist 
methysergide (Hele et al, 2001). 
Once the model of MVL was successfully validated in the mouse, the effects of PGE2 
were then investigated.  In an initial study PGE2 produced only a moderate increase 
in MVL, using timings taken from the 5-HT study. This was evident in both the 
trachea and the bronchi and IPA, where only a marginal dose response relationship 
was obvious.  The effect of PGE2 on airway microvascular leak has not been shown 
previously, and so timings of administration were based upon previous methods 
within the group and the literature.  However, increasing the time post PGE2 
administration from 5 minutes to 30 minutes produced a greater increase in MVL in 
the airways of mice.  Additionally, a dose response relationship was more evident 
using this time point in both the trachea and bronchi and IPA.  Five minutes was 
based on the data from 5-HT and it is interesting that it was after 30 minutes that 
PGE2 was able to cause significant microvascular leak as PGE2 has been shown to 
have a short biological half-life, around 30 seconds (Kozak et al, 2001; Brochhausen 
et al, 2009).  To fully elucidate why this may be the case would take a considerable 
amount of time.  One explanation may be that PGE2 is causing the release of other 
mediators that are involved in inducing microvascular leak.  Aso et al (2012) 
demonstrated that in vitro activation of human pulmonary microvascular endothelial 
cells by PGE2 enhanced IL-8 production. IL-8 itself has subsequently been shown to 
promote endothelial permeability, as well as other cytokines such as TNF-α and IL-
1β ( u et al, 2013). In addition, LPS effects on the endothelium may be occurring 
secondary to the release of TNF-α, IL-1β and IL-8 (Horgan et al, 1993; Ishii et al, 
1993).  Furthermore, PGE2 has been demonstrated in several studies to stimulate 
the production and release of the pro-angiogenic mediator VEGF (Pai et al, 2001; 
Bradbury et al, 2005).  The potent permeability enhancing effects of VEGF are well 
documented both in vivo and in vitro (Esser et al, 1998; Feng et al, 1999; Paul et al, 
2001; Gavard & Gutkind 2006).  One other possible explanation may be a positive 
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feedback loop amplifying the initial signal and sustaining the inflammatory response, 
whereby activation of EP receptors by PGE2 leads to production and release of 
PGE2. Such positive feedback loops have been shown in animal models of chronic 
inflammatory diseases (Aoki et al, 2011).  However, I demonstrated that blocking the 
production of endogenous prostanoids with the COX inhibitor diclofenac did not 
impact on PGE2-induced MVL.  It is therefore unlikely that a positive feedback loop is 
occurring in this situation.   
Having demonstrated that i.v. dosing of PGE2 caused dose dependent increases in 
airway MVL, an alternative route of administration was then investigated. The data 
showed that an intranasal dose of PGE2 was just as effective at inducing airway MVL 
in the mice as with i.v. dosing which shows that the effects we are seeing are not 
specific to a certain route of administration.   
As previously mentioned, the majority of research into airway MVL has been 
achieved using larger species, including the rat and the guinea pig.  I wanted to rule 
out that what was being observed with PGE2 was not exclusive to the mouse.  In the 
guinea pig PGE2 produced a large, substantial increase in airway MVL that was 
comparable to that seen with 5-HT.  Both the mouse and the guinea pig produced 
similar profiles in the magnitude of their responses demonstrating that the effect of 
PGE2 is translated across species.   
The effect of PGE2 on airway microvascular leak has not been extensively 
investigated, especially in vivo.  A lot of research appears to be focused on 
cutaneous inflammation in relation to prostanoids, particularly PGE2 (Takagi et al, 
1987; Goulet et al 2004; Kabashima et al, 2007).  Goulet et al (2004) examined the 
effect of arachidonic acid on mouse ear tissue and established a primary role for 
PGE2 in mediating the oedema formation in this model.  Prior to this, Takagi et al 
(1987) observed, both pharmacologically and histologically, that in a rat air pouch 
model PGE2 increases vascular permeability via the degranulation of mast cells.  
Data from in vitro investigations is often contradictory, with some reporting barrier 
enhancing effects and others describing an increase in permeability following PGE2 
(Moreno 2009; Konya et al, 2013).  These opposing effects are most likely due to the 
fact that PGE2 activates four different receptor subtypes (EP1-4). Investigation into 
109 
 
the roles of each EP receptor in mediating PGE2-induced leak is described in the 
following chapter (Chapter 4). 
As described above small changes in blood flow may impact on MVL, especially in 
the mouse where the bronchial circulation is small, so it could be possible that the 
PGE2-induced MVL may be caused by vasodilation and an increase in blood flow to 
the airways.  Rogers et al (1990) suggested that the vasodilator prostaglandins 
PGE2 and PGI2 are able to potentiate MVL in the skin by increasing blood flow.  In 
contrast to the rapid and substantial drop in blood pressure (vasodilation) seen with 
the IP agonist Iloprost, PGE2 appeared to have very little effect on the systemic 
blood pressure in mice.  Although this does not represent local changes in blood 
pressure and flow (i.e. in the bronchial circulation) it does suggest that there is not a 
clear and defined association between vasodilation and increased airway 
microvascular leak in this study.  Zhang et al (2000), however, did observe that i.v. 
administration of PGE2 caused a significant decrease in mean arterial pressure 
(MAP) in wild type (C57BL/6) mice at doses lower than what was used in this 
present study.  Audoly et al (1999) reported almost identical findings, where PGE2 
caused a marked and immediate fall in blood pressure, where maximal blood 
pressure reduction occurred within the initial 20 seconds after PGE2 infusion (using 
129/SvEv mice). However, as already mentioned, deciphering which EP receptor is 
mediating this effect will further elucidate the role PGE2 is playing. 
To summarise, this chapter has demonstrated that the mouse is a suitable species to 
investigate the effects of PGE2 on airway MVL and most importantly that PGE2 is 
able to induce substantial and significant MVL in the trachea and the bronchi and 
IPA of mice and guinea pigs.  Additionally this effect appears to be distinct from any 
changes in systemic blood pressure as using the same dose produced no significant 
increase or decrease in blood pressure.  The data presented in this chapter therefore 
allows me to accept the hypothesis stated in section 3.1.1.  The next step is to 
decipher which of the four EP receptors (EP1-4) is mediating this response (Chapter 
4). 
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Chapter Four 
 
Identifying the EP Receptor Mediating 
PGE2-induced MVL in mouse airways 
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4. Identifying the EP Receptor Mediating PGE2-induced MVL in 
mouse airways 
4.1. Rationale 
 
In chapter 3 I demonstrated that the mouse was a suitable model to investigate 
airway microvascular leak using Evans Blue dye and that PGE2 induced significant 
extravasation in both the trachea and bronchi and IPA.  PGE2 acts via the activation 
of four different receptor subtypes, termed EP1-4, and has already demonstrated a 
wide range of effects in the airways.  Therefore it seemed logical to determine which 
EP receptor may be mediating this airway microvascular leak in the mouse. 
4.1.1. Chapter Hypothesis 
“PGE2 activates a specific EP receptor to mediate microvascular leak in mouse 
airways” 
4.1.2. Aims 
 Investigate the effect of PGE2 in individual EP receptor knock out mice (EP1-
4). 
 Investigate the effect of selective EP receptor agonists from ONO 
Pharmaceuticals. 
 Charactise selective EP2 (PF-04418948) and EP4 (ER-819762) receptor 
antagonists against relevant selective EP agonists. 
 Use selective EP antagonists against PGE2 to confirm KO data. 
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4.2. Methods 
 
The following experiments were carried out as described in chapter 2. Details of 
individual experiments are described below. 
 
4.2.1. The Effect of PGE2-induced MVL in EP Receptor Knock-Out Mice 
 
The same microvascular leakage protocol was used as before with a single sub 
maximal dose of PGE2 (3 mg kg
-1) or vehicle (1% ethanol in saline) used as well as 
the 30 minute time point. Tail tips were also taken to determine genetic status by 
genotyping. 
Additionally, the response to 5-HT in EP receptor knock-outs (ptger2-/- and ptger4-/-) 
and their wild types was investigated to ensure their lack of response to PGE2 was 
not due to an overall disruption in MVL. A sub maximal dose of 5-HT (1 mg kg-1) was 
used as a known-inducer of MVL. 
 
4.2.2. Effect of ONO-D1-004, ONO-AE1-259, ONO-AE-248 and ONO-AE1-329 on 
MVL 
 
To parallel the effects seen in the EP receptor deficient mice, the response to 
selective EP agonists was studied. Following EB administration, animals were given 
selective EP receptor agonists (Okada et al, 2000; Suzawa et al, 2000; Cao et al, 
2002); ONO-D1-004 (EP1), ONO-AE1-259 (EP2), ONO-AE-248 (EP3), ONO-AE1-329 
(EP4) or PGE2 (3 mg kg
-1) i.v at 4 ml kg-1 or Vehicle (1% ethanol in saline). The 30 
minute time point was used for all agonists. 
 
4.2.3. Investigating the EP2 receptor in airway MVL 
 
Having shown using EP receptor knockout mice that the EP2 receptor appears to 
have a role in mediating airway MVL I wanted to validate an EP2 receptor antagonist 
113 
 
for use in vivo to confirm this data.  First of all I carried out a dose response to ONO-
AE1-259 (EP2 agonist) to establish whether 3 mg kg
-1 was a suitable dose to use.  
The doses used were 0.1, 0.3, 1 and 3 mg kg-1 (i.v at 4 ml kg-1) and unfortunately I 
was not able to go higher due to compound availability.   
The EP2 antagonist PF-04418948 was used in subsequent studies and first dosed 
orally at 100 mg kg-1 or vehicle control (0.5% methylcellulose, 0.2% tween 80 in 
water) one hour prior to ONO-AE1-259 administration (3 mg kg-1 in 4 ml kg-1 i.v).  
The dosing was based on data shown by Forselles et al (2011), however, I decided 
to go higher as their top dose (30 mg kg-1) was unable to block a PGE2-induced 
response and the EP2 agonist they used (Butaprost) is less potent than ONO-AE1-
259. 
An alternative route of antagonist administration (intraperitoneal; i.p.) was then 
investigated.  Here mice were dosed with PF-04418948 at 3, 10, 30 or 100 mg kg-1 
(10 ml kg-1 i.p.) or vehicle (0.5% methylcellulose, 0.2% tween 80 in saline) one hour 
before ONO-AE1-259 administration (3 mg kg-1 in 4 ml kg-1 i.v.) 
It must be noted that PF-04418948 did not go into solution in the vehicles being used 
and was therefore delivered as a suspension. 
 
4.2.4. Investigating the EP4 receptor in airway MVL 
 
4.2.4.1. Rat Tracheal Organ Bath Preparation 
Before beginning in vivo work, I wanted to validate a reported EP4 antagonist, ER-
819762 (Chen et al, 2010) using a functional bioassay.  This antagonist was chosen 
as it proved effective in their in vivo model.  To do this I used rat trachea organ bath 
set up as outlined in chapter 2.6.  PGE2-induced relaxation of induced tone in rat 
tracheal tissue has previously been shown to be mediated via the activation of EP4 
receptors (Lydford and McKechnie, 1994; Buckley et al, 2011; Benyahia et al, 2012) 
and so was used as an assay system to assess functionality at this receptor subtype. 
In these experiments, carbachol (CCh; 1 mM) was used to induce a stable 
contraction of the tissues. The tissues were then incubated with vehicle or ER-
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819762 (100 nM to 10 μM) for 30 minutes before cumulative concentration–response 
curves were performed to ONO-AE1-329 (10-9 to 10-5 M).  At the end of the 
experiment, the non-specific PDE inhibitor, papaverine (100 μM), was added to 
assess the maximum capacity for relaxation of each tissue.  
 
4.2.4.2. In Vivo Characterisation 
Next a dose response to ONO-AE1-329 (EP4 agonist) was carried out in C57BL/6 
mice.  The doses used were 0.1, 0.3, 1 and 3 mg kg-1 (i.v at 4 ml kg-1) and 
unfortunately I was not able to go higher due to compound availability.   
 
The EP4 antagonist ER-819762 was used in subsequent studies and was first dosed 
orally at 100 mg kg-1 (Chen et al, 2010) or vehicle control (0.5% methylcellulose, 
0.2% tween 80 in water) one hour prior to ONO-AE1-329 administration (3 mg kg-1 in 
4 ml kg-1 i.v).  Dosing was based on data from Chen et al (2010). 
An alternative route of antagonist administration was then investigated 
(intraperitoneal; i.p.). Here mice were dosed with ER-819762 at 3, 10, 30 or 100 mg 
kg-1 (10 ml kg-1 i.p.) or vehicle (0.5% methylcellulose, 0.2% tween 80 in saline) one 
hour before ONO-AE1-329 administration (3 mg kg-1 in 4 ml kg-1 i.v.) 
Doses were initially based on those used by Chen et al (2010).  Additionally, it must 
be noted that ER-819762 did not go into solution in the vehicles being used and was 
therefore delivered as a suspension. 
 
 
4.2.5. Effect of the EP2 and EP4 receptor antagonists against PGE2-induced 
MVL in mice 
Having determined suitable doses and route of administration for the EP2 and EP4 
receptor antagonists, the next step was to try and replicate the findings from the EP 
receptor knockout mice.  Here mice were dosed with PF-04418948 (10 mg kg-1 at 10 
ml kg-1 i.p), ER-819762 (30 mg kg-1 at 10 ml kg-1 i.p) or vehicle (0.5% 
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methylcellulose, 0.2% tween 80 in saline) one hour prior to PGE2 administration (3 
mg kg-1 at 4 ml kg-1 i.v.). 
Additionally, in a separate study, mice were dosed with both PF-04418948 and ER-
819762 simultaneously one hour before PGE2. 
 
 
4.2.7. Genotyping of KO Mice 
DNA was extracted from tail tips (0.5-1cm) of wild type and prostanoid receptor 
knockout mice using Quanta Biosciences Extracta DNA prep for PCR kit.  The purity 
and integrity of the DNA samples was assessed using a PowerWave XS Microplate 
Spectrophotometer (Biotek, Bedfordshire, UK).  PCR reactions were run using 
mouse genomic DNA primers that had been previously optimised and validated. The 
PCR reaction contained 1x Green GoTaq Flexi buffer, 0.2mM dNTPs, 2mM MgCl2, 
1.25µl enzyme (GoTaq polymerase), 10pmol forward and 10pmol reverse primers, 
and a volume of DNA (50ng) or Nuclease-free water for control, made up to 25µl with 
Nuclease-free water.  Samples were then run on a Taqman machine under the 
conditions detailed in table 4.1.  EP1 and EP2 primers were run in singleplex 
reactions, so wild type and knock-out primers had to be run as separate reactions, 
while EP3 and EP4 primers were run as multiplex reactions, so wild type and knock-
out primers could be run in the same PCR reaction.  
The PCR products and DNA ladder (Hyperladder II or IV) were run on a 2% agarose 
gel in Tris Borate EDTA (TBE) buffer containing 5µl per 100ml Safeview at 80V for 
about 1 hour.  The gel was then visualised under ultra-violet light and photographed 
using the Molecular Imager® ChemiDocTM XRS System with Image LabTM software 
(Bio-Rad, UK). 
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Table 4.1.  Optimised PCR conditions for genotyping prostanoid receptor KO mice. EP1 and 
EP2 were run as singleplex (indicated by a “-“ where that primer isn’t included so no band expected) 
while EP3 and EP4 were run as multiplex reactions. 
 
4.2.8. Statistical Analysis 
All data was analysed using GraphPad Prism 5.  Parametric data was expressed as 
mean + s.e.m and non-parametric data presented as the median with the 
interquartile range.  Multiple measurements were analysed by one-way ANOVA, 
non-parametric Kruskal-Wallis test and post-hoc comparisons were performed by 
Dunn’s multiple comparison test, comparing selected columns to a control.  
Additionally, an unpaired t test and/or non-parametric Mann Whitney test, with two-
tailed p values, were carried out to determine statistical significance between two 
groups. Differences were considered statistically significant if p<0.05.  The figures 
have been graphically presented on a range-specific axis.  Analysis of the organ 
bath work is detailed in chapter 2 (section 2.6.3.3.).  
Receptor PCR Conditions 
Expected Primer Bands 
(bp) 
 Denaturing Annealing Extension Wild Type Knockout 
EP1 (w.t) 
for/rev 
94ºC / 30 s 59ºC / 30 s 68ºC / 120 s 1000 2100 
EP1 (KO) 
neo/rev 
95ºC / 30 s 60ºC / 30 s 68ºC / 90 s - 1000 
EP2 (w.t) 
for/rev 
94ºC / 30 s 58ºC / 30 s 68ºC / 60 s 650 - 
EP2 (KO) 
neo/rev 
94ºC / 30 s 65ºC / 30 s 75ºC / 60 s - 470 
EP3 
for/rev/neo 
95ºC / 30 s 65ºC / 30 s 75ºC / 60 s 350 550 
EP4 
for/rev/neo 
95ºC / 30 s 65ºC / 30 s 75ºC / 60 s 450 700 
117 
 
4.3. Results 
 
4.3.1. The Effect of PGE2-induced MVL in EP Receptor Knock-Out Mice 
 
The effect of PGE2 (3 mg kg
-1) on MVL was compared in WT and mice deficient in 
individual EP receptors (Ptger1-4-/-).   The data has demonstrated a significant 
increase in MVL in wild-type, Ptger1-/- and Ptger3-/- mice in response to PGE2. 
However, a substantial and significant reduction in PGE2-induced MVL was shown in 
Ptger2-/- and Ptger4-/- mice (Figure 4.1).  This was apparent in the trachea and 
bronchi and IPA.   
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Figure 4.1. Effect of PGE2 (3 mg kg
-1
 i.v) on MVL after 30 minutes into (A) trachea or (B) bronchi 
and intra-pulmonary airways (IPA) of wild-type (WT) and EP1-3 receptor deficient mice and (C) 
trachea or (D) bronchi and IPA of WT and EP4 receptor deficient mice. Non-parametric data 
expressed as median, with interquartile range, and parametric data expressed as mean + s.e.m. of 
the concentration of Evans blue dye (ng mg
-1
 of tissue). n=6. Non-parametric Mann Whitney test or 
unpaired t test for parametric data.  * p<0.05.significant increase from veh control. 
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To determine whether their lack of response to PGE2 was not due to an overall 
disruption in MVL, 5-HT was administered to Ptger2-/- and Ptger4-/- mice.  Here, 5-HT 
produced a significant increase in MVL in the trachea and in the bronchi and IPA, 
with no difference seen between the EP-receptor deficient mice and their wild types 
(Figure 4.2.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Effect of 5-HT (1 mg kg
-1
 i.v.; 5 minutes) on MVL into (A) trachea or (B) bronchi and 
intra-pulmonary airways (IPA) of wild-type (WT) and EP2 receptor deficient mice and (C) 
trachea or (D) bronchi and IPA of WT and EP4 receptor deficient mice. Non-parametric data 
expressed as median, with interquartile range, and parametric data expressed as mean + s.e.m. of 
the concentration of Evans blue dye (ng mg
-1
 of tissue). n=6.  Unpaired t test for parametric data or 
Non-parametric Mann Whitney test. * p<0.05.significant increase from vehicle control. 
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Figure 4.3 shows an example gel from genotyping for the Ptger3 gene in wild-type 
and Ptger3-/- mouse tail tips.  Primers for the wild-type gene produced a band at 
400bp while Ptger3-/- at 550bp. This confirms that the Ptger3 gene was present in 
WT, Ptger1-/- and Ptger2-/- as primers specific for the WT gene produce a band 
corresponding to 400bp.  In addition, the band at 550bp is specific for the primer 
sequence of the knock out Ptger3 gene, thus confirming the Ptger3-/- mice were 
deficient of the correct gene.  
 
 
 
Figure 4.3. Example gel of genotyping for the Ptger3
-/-
 mice.  Primers for the wild-type gene 
produced a band at 400bp while Ptger3
-/-
 at 550bp.  
 
  
  Water      WT      Ptger1-/-   Ptger2-/-  Ptger3-
/- 
550bp 
400bp 
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4.3.2. Effect of ONO-D1-004, ONO-AE1-259, ONO-AE-248 and ONO-AE1-329 on 
MVL 
 
Having shown an inhibition in PGE2-induced MVL in EP2 and EP4 receptor deficient 
mice, selective EP receptor agonists were investigated in order to parallel these 
results.  ONO-AE1-259 (EP2) and ONO-AE1-329 (EP4) both significantly increased 
MVL in both the trachea and bronchi and IPA of mice, while ONO-D1-004 (EP1) and 
ONO-AE-248 (EP3) had little or no effect on MVL in either trachea or bronchi and 
IPA (Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Effect of PGE2, ONO-D1-004 (EP1), ONO-AE1-259 (EP2), ONO-AE-248 (EP3) and ONO-
AE1-329 (EP4) (3 mg kg
-1
 i.v.; 30 minutes) on MVL into (A) trachea or (B) bronchi and intra-
pulmonary airways of mice. Data presented as the median, with interquartile range, of the 
concentration of Evans blue dye (ng mg
-1
 of tissue). n=6 One-way ANOVA, non-parametric Kruskall-
Wallis test with post-hoc comparisons using Dunn’s multiple comparison test. * p<0.05.significant 
increase from vehicle control. 
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4.3.3. Investigating the EP2 receptor in airway MVL 
 
The data shown from the knock-out mice and the EP receptor agonists clearly 
demonstrates a role for the EP2 and the EP4 receptors in mediating airway MVL in 
mice.  Although knock-out mice are excellent tools for investigating the role these 
receptors play in disease they aren’t without their limitations.  Therefore, I wanted to 
confirm this data using selective EP2 and EP4 antagonists.  
First of all I wanted to establish a dose response with the EP2 agonist (ONO-AE1-
259) to see if 3 mg kg-1 was the most suitable dose to use.  Due to the quantity of 
compound available this was the highest dose possible and from figure 4.5 it is 
evident that 3 mg kg-1 induced a significant increase in MVL in the trachea.  
Therefore I carried on using this dose in the antagonist studies. 
 
 
 
 
 
 
 
 
 
Figure 4.5. Effect of ONO-AE1-259 (EP2) (0.1, 0.3, 1 and 3 mg kg
-1
 i.v.; 30 minutes) on MVL into 
(A) trachea or (B) bronchi and intra-pulmonary airways of mice. Non-parametric data presented 
as median, with interquartile range, of the concentration of Evans blue dye (ng mg
-1
 of tissue). n=6. 
One-Way ANOVA non-parametric Kruskall-Wallis test with post-hoc comparisons using Dunn’s 
multiple comparison test.  * p<0.05.significant increase from vehicle control. 
 
Next I wanted to examine what would be the best route of administration for the EP2 
receptor antagonist (PF-04418948).  A single oral dose of 100 mg kg-1 had no 
significant effect on airway MVL induced by ONO-AE1-259 (Figure 4.6). 
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Figure 4.6. Effect of PF-04418948 (100 mg kg
-1
 p.o; 1 hour) on ONO-AE1-259-induced MVL (3 
mg kg
-1
 i.v.; 30 minutes) into (A) trachea or (B) bronchi and intra-pulmonary airways of mice. 
Data expressed as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of tissue). n=6. 
Unpaired t test for parametric data. * p<0.05.significant increase from vehicle control.  ns = non 
significant.  
I then wanted to investigate whether giving this same antagonist by an 
intraperitoneal injection would yield a better result and inhibit the MVL-induced by 
ONO-AE1-259.  Indeed, as demonstrated in figure 4.7, there appears to be a dose 
dependent trend in inhibiting MVL with a dose of 30 mg kg-1 showing a significant 
inhibition of EP2-induced MVL.  Therefore, I decided to continue using 30 mg kg
-1 
i.p.in future studies. 
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Figure 4.7. Effect of PF-04418948 (3, 10, 30 and 100 mg kg
-1
 i.p.; 1 hour) on ONO-AE1-259-
induced MVL (3 mg kg
-1
 i.v.; 30 minutes) into (A) trachea or (B) bronchi and intra-pulmonary 
airways of mice. Data presented as median, with interquartile range, of the concentration of Evans 
blue dye (ng mg
-1
 of tissue). n=6 One-Way ANOVA, non-parametric Kruskall-Wallis test with post-hoc 
comparisons using Dunn’s multiple comparison test. * p<0.05.significant increase from vehicle/vehicle 
control. # p<0.05 significant decrease from agonist/vehicle control. 
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4.3.4. Investigating the EP4 receptor in airway MVL 
 
Prior to utilising the EP4 antagonist (ER-819762) I wanted to characterise it in vitro 
first, so I looked at a concentration response against ONO-AE1-329-induced 
relaxation in an EP4 receptor mediated system. ONO-AE1-329 caused a 
concentration-dependent relaxation of pre-contracted rat trachea (38.8% + 3.4) that 
was inhibited by the EP4 receptor antagonist (ER-819762).  ER-819762, compared 
to its vehicle control (0.1% DMSO), produced a graded, parallel rightward shift of the 
ONO-AE1-329 concentration response curves (Figure 4.8 and Table 4.1).   
 
 
 
 
 
 
 
 
 
Figure 4.8.  Relaxation of rat isolated rat tracheal tissue. Effect of vehicle (DMSO, 0.1%) or ER-
819762 (10
-8 
M- 10
-5
 M) on ONO-AE1-329-induced relaxation of carbachol pre-contracted rat tracheal 
tissue. Data represent mean + s.e.m. n=6-13 
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Table 4.2. Antagonism of ONO-AE1-329-induced relaxation by ER-819762 in rat trachea. 
Antagonist n 
Maximum Relaxation EC50 (M) of 
papaverine 
response 
Mean CCh 
baseline 
tension (mg) (mg) % papaverine 
DMSO 13 394 + 47 38.8 + 3.4 2.3 x 10
-8
  2121 + 108 
100 nM ER-819762 7 305 + 51 36.0 + 9.2 2.7 x 10
-8
 1940 + 147 
1 μM ER-819762 7 353 + 98 32.4 + 6.2 6.5 x 10
-8
 2171 + 149 
10 μM ER-819762 6 332 + 62 34.8 + 4.7 4.0 x 10
-7
 2548 + 214 
 
Schild plot analysis indicated a linear relationship between the concentration of ER-
819762 and degree of antagonism produced, indicating surmountable competitive 
antagonism at the EP4 receptor.  Accordingly, the Schild slope factor value obtained 
was 1.01, from which a pKB value of 6.236 was derived (Figure 4.9 and Table 4.2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Schild plot analysis of the antagonism of ONO-AE1-329 with ER-819762. 
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Table 4.3. Schild plot analysis data for ONO-AE1-329 vs. ER-819762 in rat trachea.  
[ER-819762] (M) Log (CR-1) 
10-7 -0.77 
10-6 0.26 
10-5 1.21 
 
Just as I characterised the EP2 receptor antagonist, I also wanted to investigate the 
novel EP4 receptor antagonist ER-819762 in vivo using ONO-AE1-329 (EP4 agonist) 
before examining its effect against PGE2.  First, a dose response to ONO-AE1-329 
was established which is clearly demonstrated in figure 4.10 below.  As with ONO-
AE1-259, the highest dose I was able to use was 3 mg kg-1 and as shown this was 
the only dose to induce a significant increase in airway MVL. 
 
 
 
 
 
 
 
 
 
Figure 4.10. Effect of ONO-AE1-329 (EP4) (0.1, 0.3, 1 and 3 mg kg
-1
 i.v.; 30 minutes) on MVL into 
(A) trachea or (B) bronchi and intra-pulmonary airways of mice. Data presented as median, with 
interquartile range, of the concentration of Evans blue dye (ng mg
-1
 of tissue). n=6. One-Way ANOVA, 
non-parametric Kruskall-Wallis test with post-hoc comparisons using Dunn’s multiple comparison test. 
* p<0.05 significant increase from vehicle control.     
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Next I looked at a single oral dose of ER-819762 (100 mg kg-1) against ONO-AE1-
329 induced MVL.  At this dose and route of administration, the antagonist did not 
inhibit MVL induced by the EP4 agonist (Figure 4.11).   
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Effect of ER-819762 (100 mg kg
-1
 p.o.; 1 hour) on ONO-AE1-329-induced MVL (3 
mg kg
-1
 i.v.; 30 minutes) into (A) trachea or (B) bronchi and intra-pulmonary airways of mice. 
Data presented as the median, with interquartile range, of the concentration of Evans blue dye (ng 
mg
-1
 of tissue). n=6. Non-parametric Mann Whitney test.  * p<0.05.significant increase from vehicle 
control. 
 
As with the EP2 antagonist I then decided to explore whether an alternative route of 
administration would be better and so carried out a dose response via i.p dosing.  
The doses used were 3, 10, 30 and 100 mg kg-1.  Figure 4.12 shows that at 10 and 
100 mg kg-1 ER-819762 was able to significantly inhibit MVL in the trachea induced 
by ONO-AE1-329.  Although not a dose dependent relationship there was a trend 
towards reducing airway MVL induced by the EP4 agonist.  From this data I decided 
to use this compound at 10 mg kg-1 (i.p) in the following PGE2 experiments. 
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Figure 4.12. Effect of ER-819762 (3, 10, 30 and 100 mg kg
-1
 i.p.; 1 hour) on ONO-AE1-329-
induced MVL (3 mg kg
-1
 i.v.; 30 minutes) into (A) trachea or (B) bronchi and intra-pulmonary 
airways of mice. Data expressed as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of 
tissue). n=6 One-Way ANOVA with post-hoc comparisons using Dunnett’s multiple comparison test.    
*p<0.05.significant increase from vehicle control. # p<0.05 significant decrease from treatment 
control. 
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4.3.5. Effect of the EP2 and EP4 receptor antagonists against PGE2-induced 
MVL in mice 
Having shown that the EP2 antagonist (PF-04418948) and the EP4 antagonist (ER-
819762) are able to block airway MVL induced by their respective receptor agonists, 
I then wanted to replicate the data from the knockout mice.  Initially each antagonist 
was dosed separately, however as demonstrated in figure 4.13 neither antagonist 
was able to inhibit PGE2-induced airway MVL. When both antagonists were given 
simultaneously there was a significant reduction in PGE2-induced MVL in the trachea 
and in the bronchi and IPA (Figure 4.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Effect of PF-04418948 (30 mg kg
-1
 i.p.; 1 hour) and ER-819762 (10 mg kg
-1
 i.p.; 1 
hour) on PGE2-induced MVL (3 mg kg
-1
 i.v.; 30 minutes) into (A) trachea or (B) bronchi and 
intra-pulmonary airways of mice. Data expressed as mean + s.e.m of the concentration of Evans 
blue dye (ng mg
-1
 of tissue). n=3   
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Figure 4.14. Effect of simultaneous dosing of PF-04418948 (30 mg kg
-1
 i.p.; 1 hour) and ER-
819762 (10 mg kg
-1
 i.p.; 1 hour) on PGE2-induced MVL (3 mg kg
-1
 i.v.; 30 minutes) into (A) 
trachea or (B) bronchi and intra-pulmonary airways of mice. Data expressed as mean + s.e.m of 
the concentration of Evans blue dye (ng mg
-1
 of tissue). n=5-6 Unpaired t test for parametric data.  * 
p<0.05 significant increase from vehicle control. # p<0.05 significant decrease from treatment control. 
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4.4. Discussion 
 
Prostaglandin E2 (PGE2) is an endogenous lipid eicosanoid synthesised by 
cyclooxygenase (COX)-mediated metabolism of free arachidonic acid.  It is produced 
in a variety of cells, including airway smooth muscle, epithelial cells, alveolar 
macrophages and pulmonary endothelial cells (Meyrick et al, 1989; Widdicombe et 
al, 1989).  In addition, PGE2 has been shown to have immunomodulatory effects, 
effects on airway smooth muscle and nerves, allowing it to modulate airway calibre 
(Buckley et al, 2011; Cocks et al, 1999; Maher et al, 2009; Portanova et al, 1996; 
Walters et al, 1984).  It mediates its actions via 4 distinct G-protein coupled 
receptors, termed EP1-4, encoded for by the genes Ptger1-4 (Coleman et al, 1994).   
In Chapter 3 I demonstrated a clear role for PGE2 mediating airway microvascular 
leak in mice and guinea pigs.  Furthermore, using Evans Blue dye as a marker of 
plasma protein exudation proved effective.  The aim of this chapter was to 
investigate the role of each EP receptor in mediating this PGE2-induced leak.  To do 
this I used mice deficient of each individual EP receptor as well as a range of 
pharmacological tools, including agonists and antagonists targeting each receptor 
subtype.  As discussed previously the effect of PGE2 on airway microvascular leak 
has not been extensively investigated, especially in vivo.  As microvascular leak and 
plasma exudation are both prominent features in airway inflammatory diseases, such 
as asthma, elucidating the role of endogenous mediators is an important step in 
developing novel therapies. 
Having shown that PGE2 induces MVL in the mouse I wanted to determine which of 
the EP receptors were central to this response.  Differing effects of PGE2 have been 
demonstrated in vivo and these, often opposing, effects can be attributed to the 
activation of different receptor subtypes (EP1-4) with different signalling 
characteristics (Breyer et al, 2001).  Through gene targeting and the development of 
mice deficient in specific prostanoid receptors we are able to identify the receptor/s 
mediating the inflammatory actions of PGE2, a step that has been difficult with 
current selective EP agonists and antagonists (Goulet et al, 2004).  What was 
evident in both the trachea and the bronchi and IPA was that the response to PGE2 
in the EP2 and EP4 knock-out mice was completely abolished. This data suggests 
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that both the EP2 and EP4 receptors may be essential in this process.  For these 
knock-out mice to be a suitable tool for investigating airway microvascular 
permeability, it was important to determine if there were any major differences in 
their ability to produce this inflammatory response.  5-HT was administered to wild 
type, EP2 and EP4 knock-out mice and the leakage of Evans Blue measured.  A 
significant increase in airway leak was observed in EP2 and EP4 knock-out mice in 
response to 5-HT, identical to that seen in the wild-type mice.  So lacking either the 
EP2 or the EP4 receptor did not impact the effectiveness of other inflammatory 
mediators, supporting these knock-outs as suitable tools for future studies.   
As well as the knock-outs I was also able to use selective EP receptor agonists that 
were kindly provided by ONO Pharmaceuticals. These allowed direct comparisons to 
be made with the knock-out data.  The four agonists, ONO-D1-004 (EP1), ONO-AE1-
259 (EP2), ONO-AE-248 (EP3) and ONO-AE1-329 (EP4) were administered in the 
same way as PGE2.  The data clearly demonstrated that, similar to PGE2, the EP2 
and EP4 agonists significantly increased the airway plasma leakage.  This confirmed 
that activation of these EP receptors mediates microvascular leak in mouse airways, 
while activation of EP1 and EP3 produced no measurable increase. 
EP2 and EP4 receptors both couple to Gs and signal through an increase in cAMP 
(Sugimoto & Narumiya, 2007). Various intracellular signalling pathways are thought 
to lead to an increase in microvascular fluid leak.  In particular increases in 
intracellular calcium concentration have been closely linked. It has been suggested 
that an increase in calcium ions is an essential signal that is responsible for the 
phosphorylation of myosin light-chain kinase (MLCK) in endothelial cells.  This 
causes actin-myosin stress fibres to develop force and a contraction of the 
cytoskeleton leading to the formation of intercellular gaps between endothelial cells 
(Ereso et al, 2009; Goeckeler & Wysolmerski, 1995).  EP1 receptors have been 
shown to mediate their effects through this intracellular pathway; however the data 
presented clearly demonstrated a role for EP2 and EP4 receptors in mediating PGE2-
induced MVL and both these receptors couple to Gs and signal through an increase 
in cAMP (Sugimoto & Narumiya, 2007).  Furthermore, an increase in cAMP has 
been associated with restoration and strengthening of endothelial barrier function 
thus preventing an increase MVL in response to certain mediators (Mehta & Malik, 
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2006).   There is evidence to suggest that activation of Protein Kinase A (PKA) 
through this increase in cAMP inhibits the activation of MLCK and so preventing the 
contraction of endothelial cells and opening of gap junctions (Garcia et al, 1995). It is 
interesting that the EP3 receptor does not appear to mediate any PGE2-induced MVL 
as this receptor is coupled to Gi and a decrease in cAMP.  It must be emphasised, 
however, that the majority of research into the signalling pathways involved in 
vascular permeability has been studied in vitro, and so is not a true representation of 
the permeability characteristics of intact microvascular endothelium (Jiang et al, 
2008).   
In chapter 3 I was also unable to detect any major change in systemic blood 
pressure following PGE2 administration.  It would have been reasonable to assume 
that the response being observed was a result of an increase in bronchial blood flow 
as it has been suggested that vasodilator prostaglandins PGE2 and PGI2 are able to 
potentiate MVL (Rogers et al, 1990).  However, the lack of response to PGE2 may be 
explained by opposing effects of the four EP receptors.  There is considerable 
evidence indicating that EP2 and EP4 receptors are pivotal in mediating the 
vasodepressor actions in mouse and human vascular preparations (Davis et al, 
2004; Imig et al, 2002; Kennedy et al, 1999; Zhang et al, 2000).  Additionally, the 
EP1 and EP3 receptors have previously been shown to mediate contraction of 
vascular smooth muscle in wild type mice (Baxter et al, 1995; Qian et al, 1994; Stock 
et al, 2001; van Rodijnen et al, 2007; Walch et al, 2001). Measuring changes in 
blood pressure in response to individual EP agonists is a key study for future 
investigations and is outlined in more detail in Chapter 7. 
It has only been in recent years that novel EP2 and EP4 receptor antagonists that are 
potent and selective for their respective receptor have emerged.  This has enabled 
me to further examine the data that I have generated, and explore the role of these 
two receptors further.  Although knock-out mice for each prostanoid receptor subtype 
has helped to investigate the physiological and pathological roles of this receptor 
family, they are only limited to the mouse.  Having demonstrated a clear role for EP2 
and EP4 receptors in mediating airway microvascular leak, I wanted to examine 
these further using pharmacological tools.   
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Previously, the EP2 antagonist relied on by most investigators was AH6809 but this 
has been shown to act at EP1 and DP1 receptors (Jones et al, 2009; Woodward et al, 
2011).  However, Forselles et al (2011) recently described a novel and selective EP2 
receptor antagonist, PF-04418948.  This antagonist was then further characterised 
by our lab where it was clear that PF-04418948 was only selective for the EP2 
receptor (Birrell et al, 2013).  Before using PF-04418948 a dose response to ONO-
AE1-259 was carried out to establish an appropriate dose to use against the 
antagonist.  A dose-dependent increase in MVL was evident with 3 mg kg-1 showing 
a significant increase.  It would have been ideal to investigate all agonists at higher 
doses, however, this would have required large amounts of compound while 
increasing the cost in terms of reagents and number of animals used. As such, 3 mg 
kg-1 was then used to test the antagonist.  To investigate its effects on EP2-induced 
airway microvascular leak, PF-04418948 was given orally one hour prior to EP2 
agonist, ONO-AE1-259.  However, no inhibition in Evans Blue leak was seen.  
Interestingly, when delivered via the intra peritoneal (i.p) route PF-04418948 
demonstrated a dose-dependent inhibition in EP2-induced MVL, with a significant 
block at 30 mg kg-1.  However, Forselles et al (2011) showed that orally administered 
PF-04418948 attenuated EP2-induced responses in their rat model of cutaneous 
blood flow.  They also report that the oral absorption was high with an oral 
bioavailability of 78%, however, the plasma protein binding was very high (unbound 
fraction of 0.003) (Forselles et al, 2011).  Unfortunately, I was not able to measure 
plasma levels of this compound and asses its pharmacokinetic properties in mice.  
One problem that was encountered was the solubility of the compound.  It did not go 
into solution in the vehicle used (0.5% methylcellulose, 0.2% tween 80 in saline) and 
so was delivered as a suspension.   
In 2010, Chen et al described a novel EP4 receptor antagonist, ER-819762, that was 
highly selective for EP4 receptors in a number of different in vitro assays as well as 
being effective in both mouse and rat models of arthritis and chronic pain (Chen et 
al, 2010).  So this antagonist was chosen as a suitable tool to investigate the EP4 
receptor in MVL in mouse airways.  Before studying the effects of this antagonist in 
vivo, I wanted to confirm its functionality and potency in a suitable EP4 receptor 
mediated system.  PGE2-induced relaxation of induced tone in rat and human 
trachea has been shown to be mediated by the activation of the EP4 receptor 
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(Lydford and McKechnie, 1994; Buckley et al, 2011; Benyahia et al, 2012).  Here, 
ER-819762 behaved as a surmountable competitive antagonist, producing rightward 
parallel shifts of the ONO-AE1-329 (EP4 agonist) concentration response curves with 
a pKB value of 6.24.  For the in vivo work I first demonstrated that ONO-AE1-329 
induced a dose-dependent increase in Evans Blue leak in murine airways, with 3 mg 
kg-1 producing a significant rise.  Similarly, the effect of ER-819762 was initially 
examined against EP4-mediated responses.  A single oral dose of ER-819762 (100 
mg kg-1) did not show any inhibition of EP4-induced airway MVL.  However, when 
given i.p ER-819762 produced a dose-dependent inhibition of EP4-induced MVL, 
with a significant drop seen at 10 and 100 mg kg-1.   The doses used in this study 
were based on those used by Chen et al (2010) and so it is interesting that when 
given orally it was unable to block EP4-induced leak.  In their models ER-819762 
successfully suppressed clinical signs of arthritis in two different mouse models, as 
well as inhibiting chronic pain in a rat model of inflammatory pain (Chen et al, 2010).  
Unfortunately I cannot comment on the pharmacokinetic properties of the antagonist, 
but it may simply be due to differences in dosing regimen and the animal models 
used.  Animals were dosed on a daily basis and disease progression over several 
weeks was monitored and scored.  With the MVL model, only a single dose was 
given and the response measured was an acute inflammatory reaction.   
Having established that both the EP2 receptor (PF-04418948) and EP4 receptor 
antagonists (ER-819762) were able to inhibit airway MVL induced via their 
respective agonists, the next step was to examine their effects on PGE2-induced 
MVL.  In initial experiments, neither antagonist was able to inhibit PGE2-mediated 
airway MVL.  Looking back at the previous data it is clear that both the EP2 and EP4 
receptor are able to mediate leak to the same extent, so it seemed possible that 
blocking either was not enough to inhibit PGE2.  Indeed, when both antagonists were 
dosed simultaneously, at the same doses and time points, a decrease in PGE2-
induced MVL was evident, with a significant inhibition seen the trachea and in the 
bronchi and IPA.  This emphasised the possibility for a dual role for EP2 and EP4 
receptors in mediating PGE2 induced responses and it is obvious here that both 
receptors are important in airway MVL.  Little research has been published on their 
role in airway MVL so the data presented demonstrates an EP receptor activity 
profile which will aid in further understanding its role in airway inflammation.  Yuhki et 
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al (2004) presented evidence that suggested EP2 and EP3 participate in 
inflammatory exudation in their Carrageenin-induced mouse pleurisy model.  
Furthermore, EP2 and EP4 receptor signalling has been implicated in acute skin 
inflammation by enhancing blood flow in the microenvironment (Kabashima et al, 
2007).  In contrast, Goulet et al (2004) found that PGE2 promotes acute cutaneous 
inflammation by activating EP3 receptors.  In addition, data from in vitro studies has 
illustrated that PGE2 actually reduces endothelial permeability to macromolecules, 
such as dextran or albumin, and achieves this via activation of the EP4 receptor 
(Birukova et al, 2007; Konya et al, 2013b). Konya et al (2013) used human 
pulmonary endothelial cells and observed that only the EP4 agonist, ONO-AE1-329, 
mimicked the barrier enhancing effects of PGE2 (Konya et al, 2013b).   It is also 
important to note that expression of EP4 receptors has been detected in pulmonary 
endothelial cells in human, rat and mouse (Aso et al, 2012; Martin et al, 2002; Rao et 
al, 2007).  
An interesting observation from the data here was that both EP2 and EP4 agonists 
caused almost identical responses in airway MVL and in the knock-out mice 
response to PGE2 were almost completely abolished in both EP2 and EP4 receptor 
knockouts.  Moreover, the selective receptor antagonists required simultaneous 
dosing to block the stimulatory effects of PGE2.  This suggests that EP2 and EP4 may 
be functionally interdependent.  Subbaramaiah et al (2008) saw a similar effect when 
studying the activity of PGE2 in human adipocytes and breast cancer cells.  They 
observed that both receptors played a role in mediating the induction of aromatase 
and that inhibiting either receptor abrogated the effects of PGE2 (Subbaramaiah et 
al, 2008). One hypothesis is that the EP2 and EP4 receptors form heterodimers.  The 
data from the knock-outs indicates that without functional EP2 or EP4 receptors PGE2 
is unable to induce MVL.  Furthermore, when EP2 and EP4 antagonists were 
administered alone, with both functional receptors present, PGE2-induced significant 
MVL.  Only when both receptors were antagonised simultaneously was PGE2-
induced leak attenuated (see figure 4.15).   
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Figure 4.15. Schematic of possible EP2/4 heterodimer and how this interaction 
influences PGE2-induced airway microvascular leak. (A) PGE2 and EP2 and EP4 agonists 
are all able to induce a significant increase in airway MVL.  However, in EP2 and EP4 
receptor knock outs this response to PGE2 is absent.  With either functional receptor missing 
the EP2/4 heterodimer cannot form and so stimulation with PGE2 cannot elicit a response. (B) 
Pharmacological inhibition of either receptor with an antagonist does not inhibit airway MVL. 
When both EP2 and EP4 antagonists are administered simultaneously both receptors are 
blocked and PGE2-induced MVL is attenuated. 
 
There is increasing evidence that GPCRs are able to heterodimerise and that this 
interaction can affect the function of either receptor (Wilson et al, 2007; McGraw et 
al, 2006).  Wilson et al (2007) demonstrated a functionally important 
Wild Type EP2 Knock-Out EP4 Knock-Out A 
B 
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heterodimerisation of TP and IP receptors in human and mouse aortic smooth 
muscle cells. Additionally, McGraw et al (2006) used fluorescence microscopy in 
airway smooth muscle cells and bioluminescence resonance energy transfer (BRET) 
and co-immunoprecipitation in a cell line to show heterodimerisation between EP1 
receptors and β2 adrenoceptors. However, more investigation is obviously needed to 
establish whether this is occurring between the EP2 and EP4 receptors. 
Airway microvascular leak represents a prominent feature in airway inflammation 
and the data presented here highlights a key role for PGE2 and the EP2 and EP4 
receptors. These findings suggest that my hypothesis is correct and that activation of 
specific EP receptors mediates PGE2-induced microvascular leak in rodent airways. 
Only agonists selective for the EP2 and EP4 receptors were able to induce airway 
MVL and PGE2-induced MVL was absent in EP2 and EP4 receptor deficient mice. 
Furthermore, by antagonising both the EP2 and the EP4 receptors simultaneously, 
PGE2-induced MVL was attenuated.  However, as discussed not all findings were 
significant, so further investigation may be warranted. As I have stated previously, 
little research has been published on the effects of PGE2 and the EP receptors in 
mediating airway plasma exudation and so these findings are novel and make an 
exciting addition to the expanding repertoire of the effects of EP receptors in airway 
disease. 
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Chapter Five 
 
Identifying the Role of EP Receptors in 
Ovalbumin-induced MVL in Mouse 
Airways 
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5. Identifying the Role of EP Receptors in Ovalbumin-Induced MVL 
in Mouse Airways 
 
5.1 Rationale 
 
Having established in Chapters 3 and 4 that PGE2 is able to mediate airway 
microvascular leak when given exogenously, I wanted to investigate its role in a 
disease model of airway inflammation.  To do this I decided to study airway leak in 
our Ovalbumin mouse model of allergic asthma.  It has been widely reported that 
vascular permeability is common among asthmatics, where it is thought to have an 
essential role in thickening the bronchial mucosa and the resulting airway 
hyperresponsiveness.  Additionally, albumin has been found in high concentrations 
in airway secretions from acute asthmatic patients (Svensson et al. 1995, Van 
Rensen et al. 2002).  Therefore, the next step was to examine PGE2 and the EP2 
and EP4 receptors in a disease model of asthma. 
The ovalbumin (OVA) model of allergic asthma has been well characterised in our 
lab and our standard protocol was used, as described in section 2.5.  Furthermore, 
our group and others have demonstrated that OVA-induced MVL is measureable in 
in a variety of species (Hele et al, 2001; Lee et al, 2004; Kim et al, 2012).  However 
the role of EP receptors in mediating these effects has not been extensively 
investigated. 
5.1.1. Chapter Hypothesis 
“Activation of EP2 and EP4 receptors by endogenous PGE2 causes airway 
microvascular leak during allergic inflammation in mice” 
5.1.2. Aims 
 Establish a time point post OVA challenge to measure Evans Blue MVL in 
mouse airways and whether Evans Blue was still an appropriate marker in this 
model. 
 Examine the role of prostanoids in mediating OVA-induced MVL using a non-
selective COX inhibitor, diclofenac. 
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 Study the effects of OVA-induced airway MVL in EP2 and EP4 receptor 
deficient mice. 
 Confirm data from the KOs using the EP2/EP4 antagonist protocol outlined in 
the previous chapter. 
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5.2. Methods 
 
5.2.1. Characterisation of Ovalbumin-induced Microvascular Leak in Mouse 
Airways 
 
C57BL/6 mice were sensitised and challenged as described in section 2.5.  As 
previously mentioned, I first wanted to establish at which time point was it suitable to 
measure MVL.  2 hours and 24 hours after final challenge were chosen to measure 
for Evans blue extravasation.  These time points were loosely based on previous 
model development in our lab where total protein in BAL samples was found to be 
highest at these two time points.  Additionally, 4 groups were included in the 
characterisation; vehicle sensitised/saline challenged, vehicle sensitised/OVA 
challenged, OVA sensitised/saline challenged and OVA sensitised/OVA challenged. 
 
5.2.2. Effect of Diclofenac on Ovalbumin-induced MVL 
 
Following on from the characterisation it was appropriate to continue using two 
groups; OVA sensitised/saline challenged and OVA sensitised and OVA challenged.  
Additionally, the two hour time point was preferable over 24 hours and was used for 
all other studies.  Finally, the dissected tissue was dried out at 60ºC for one hour 
prior to extraction of dye in formamide.  Wet and dry tissue weight was recorded and 
the data from this study onwards are presented as the concentration of Evans blue in 
ng mg-1 of dry tissue weight. To examine whether prostanoids are responsible for the 
MVL seen in this ovalbumin model, a non-selective cyclooxygenase inhibitor, 
diclofenac, was used (Mitchell et al. 1993).  Diclofenac or vehicle (0.5% 
methylcellulose, 0.2% tween 80 in water) was dosed orally (30 mg kg-1 at 10 ml kg-1) 
one hour prior to Evans blue administration. 
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5.2.3. The role of EP receptors in Ovalbumin-induced MVL 
 
Wild type (C57Bl/6 and 129/Ola X C57Bl/6), Ptger2-/- and Ptger4-/- mice were used to 
investigate whether PGE2, acting via the EP2 and/or EP4 receptors, was inducing the 
MVL demonstrated.  These two receptors were chosen based on data presented in 
Chapter 4 which indicated that it was the EP2 and EP4 receptors that were mediating 
PGE2-induced MVL seen in mouse airways.  For reasons pertaining to cost and time 
it was not possible to investigate ovalbumin-induced MVL in all prostanoid receptor 
deficient mice.  
In Chapter 4, EP2 and EP4 receptor antagonists were characterised in vivo and it 
appears that both need to be administered simultaneously to significantly block 
PGE2-induced MVL.  Therefore, this next experiment was designed to establish 
whether the knock out data could be replicated by co-administering the two 
antagonists to block OVA-induced MVL.  One hour after final intranasal challenge 
and one hour before MVL assessment, mice were dosed with vehicle (0.5 % 
methylcellulose, 0.2% tween 80 in saline) or PF-0441898 (30 mg kg-1) and ER-
819762 (10 mg kg-1) at 10 ml kg-1 i.p.  
 
5.2.4. Statistical Analysis 
 
All data was analysed using GraphPad Prism 5.  Parametric data was expressed as 
mean + s.e.m and non-parametric data presented as the median with the 
interquartile range.  Multiple measurements were analysed by one-way ANOVA, 
non-parametric Kruskal-Wallis test and post-hoc comparisons were performed by 
Dunn’s multiple comparison test, comparing selected columns to a control.  
Additionally, an unpaired t test and/or non-parametric Mann Whitney test, with two-
tailed p values, were carried out to determine statistical significance between two 
groups. Differences were considered statistically significant if p<0.05.  The figures 
have been graphically presented on a range-specific axis. 
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5.3. Results 
 
5.3.1. Characterisation of Ovalbumin-induced Microvascular Leak in Mouse 
Airways 
 
Although the ovalbumin model of allergic asthma has been well characterised in our 
group, its effect on airway microvascular leak had not been previously established. 
Firstly, I needed to determine the appropriate time point to use to investigate this 
response using the same Evans Blue method employed in Chapters 3 and 4.  It was 
clear that 2 hours following a final intra nasal challenge of OVA in OVA-sensitised 
mice there was a measurable and significant increase in EB leak into the trachea 
and in the bronchi and IPA, whereas 24 hours after this response is absent (Figure 
5.1)   
 
 
 
 
 
 
 
 
Figure 5.1. Effect of Ovalbumin-challenge on airway MVL in C57BL/6 mice into (A) the trachea 
or (B) the bronchi and intra-pulmonary airways, 2 and 24 hours after final intra nasal OVA 
challenge. Four groups were included in this study, vehicle-sensitised/saline challenged, OVA-
sensitised/saline challenged, vehicle-sensitised/OVA challenged and OVA-sensitised/OVA 
challenged.  Data presented as the median, with the interquartile range, of the concentration of Evans 
blue dye (ng mg
-1
 of tissue). n=4. Mann Whitney t-test for non-parametric data. * p<0.05 representing 
a significant increase from OVA/Saline control.   
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One important observation in this study was that the wet weight of the airway tissue 
was considerably heavier in the OVA-sensitised/OVA-challenged group (Figure 5.2).  
As the concentration of EB in the tissue is calculated based on the weight of the 
tissue, this increase in weight underestimated the EB leak in the airways.  To 
overcome this I decided in future studies to dry out the tissue prior to incubating in 
formamide.       
 
 
 
 
 
 
 
 
Figure 5.2. Effect of Ovalbumin-challenge on wet weight of the bronchi and intra-pulmonary 
airways at (A) 2 hours or (B) 24 hours after final intranasal OVA challenge. Four groups were 
included in this study, vehicle-sensitised/saline challenged, OVA-sensitised/saline challenged, 
vehicle-sensitised/OVA challenged and OVA-sensitised/OVA challenged.  Data expressed as mean + 
s.e.m of the wet tissue weight (mg of tissue). n=4. Unpaired t test for parametric data.  * p<0.05 
representing a significant increase from OVA/Saline control 
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5.3.2. Effect of Diclofenac on Ovalbumin-induced MVL 
 
As outlined in the rationale, I wanted to investigate whether prostanoids were 
involved in mediating the MVL observed in this ovalbumin model.  So to begin with I 
used a non-selective COX inhibitor, diclofenac.  Interestingly, different effects were 
seen between the trachea and the bronchi and IPA.  In the trachea diclofenac (30 
mg kg-1) partially reduced the OVA-induced microvascular leak, whereas in the 
bronchi and IPA it had no effect (Figure 5.3).  As before, 2 hours following OVA-
challenged there was a large and statistically significant increase in microvascular 
leak in mouse airways. 
 
 
 
 
 
 
 
 
Figure 5.3. Effect of diclofenac (30 mg kg-1 p.o) on OVA induced MVL into (A) the trachea or (B) 
the bronchi and intra-pulmonary airways of mice, 2 hours following final intra nasal challenge. 
Two groups were included in this study, OVA-sensitised/saline challenged and OVA-sensitised/OVA 
challenged.  Additionally, airway tissue was dried prior to extraction of EB in formamide. Data 
expressed as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of dry tissue). n=7-8 
Unpaired t test for parametric data.  * p<0.05 representing a significant increase from vehicle control. 
ns = non significant increase 
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5.3.3. The Role of EP2 and EP4 Receptor Knock-outs in Ovalbumin-Induced 
Airway MVL 
 
Following inconclusive data using diclofenac to inhibit OVA-induced leak, I wanted to 
investigate the role of the EP receptors more specifically.  Having already 
demonstrated that the EP2 and the EP4 receptors are the key receptors in PGE2-
induced MVL, I used the EP2 and EP4 receptor knockout mice in the OVA model and 
measured the level of EB leak into the airways.   
As both receptor knock outs are bred on different backgrounds, so different wild type 
controls, they are presented on separate graphs.  Additionally, due to difficulties with 
breeding, the n numbers for the EP4 knock outs are varied.  C57BL/6 wild types 
demonstrated a measurable and significant increase in EB leak in the trachea and 
the bronchi and IPA.  However, in the EP2 receptor knock-outs there was a 
significant reduction in MVL (Figure 5.4). 
 
 
 
 
 
 
 
 
 
Figure 5.4. Effect of OVA induced MVL into (A) the trachea or (B) the bronchi and intra-
pulmonary airways of EP2 receptor knockout mice, 2 hours following final intra nasal 
challenge. Two groups were included in this study, OVA-sensitised/saline challenged and OVA-
sensitised/OVA challenged.  Additionally, airway tissue was dried prior to extraction of EB in 
formamide. Data expressed as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of dry 
tissue). n=8 Unpaired t test for parametric data.  * p<0.05 representing a significant increase from 
vehicle control and # p<0.05 a significant decrease from wild type control. 
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Similarly, the EP4 wild type controls showed a significant increase in EB leak, while 
in the knock outs this response was abolished in both the trachea and the bronchi 
and IPA (Figure 5.5). 
 
 
 
 
 
 
 
 
 
Figure 5.5. Effect of OVA induced MVL into (A) the trachea or (B) the bronchi and intra-
pulmonary airways of EP4 receptor knockout mice, 2 hours following final intra nasal 
challenge. Two groups were included in this study, OVA-sensitised/saline challenged and OVA-
sensitised/OVA challenged.  Additionally, airway tissue was dried prior to extraction of EB in 
formamide. Data expressed as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of dry 
tissue). n=4-8 Unpaired t test for parametric data.  * p<0.05 representing a significant increase from 
vehicle control and # p<0.05 a significant decrease from wild type control. 
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5.3.4. The Role of EP2 and EP4 Receptor Antagonists in Ovalbumin-Induced 
Airway MVL 
 
Having shown that mice with no functional EP2 or EP4 receptors have significantly 
less MVL in the airways after OVA-challenge, I then wanted to determine whether 
this data could be replicated using selective EP2 and EP4 receptor antagonists.  
Previously, both antagonists were characterised in vivo and it was apparent that both 
needed to be administered simultaneously to significantly block PGE2-induced MVL 
(Chapter 4) and so the same dosing regimen was used in this study.   
In both the trachea and the bronchi and IPA, OVA-induced MVL was reduced 
following PF-04418948 (30 mg kg-1) and ER-819762 (10 mg kg-1), but this did not 
reach statistical significance (Figure 5.6).  
 
 
 
 
 
 
 
 
 
Figure 5.6. Effect of PF-04418948 (30 mg kg-1 i.p) and ER-819762 (10 mg kg-1 i.p) or vehicle 
(0.5% methylcellulose, 0.2% tween 80 in saline, i.p) on OVA induced MVL into (A) the trachea 
or (B) the bronchi and intra-pulmonary airways of mice, 2 hours following final intra nasal 
challenge. Two groups were included in this study, OVA-sensitised/saline challenged and OVA-
sensitised/OVA challenged.  Additionally, airway tissue was dried prior to extraction of EB in 
formamide. Non-parametric data presented as the median, with the interquartile range, and 
parametric data expressed as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of dry 
tissue). n=6 Unpaired t test for parametric data or Mann-Whitney for non-parametric data.  * p<0.05 
representing a significant increase from saline control. ns = non significant increase 
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5.4. Discussion 
 
It has been well documented that microvascular leak and oedema are prominent 
features in allergic airway diseases such as asthma, which is associated with 
thickening of the airway wall and narrowing of the airway (Kanazawa et al, 2000, 
2002; Khor et al, 2009).  Additionally, high concentrations of plasma proteins, such 
as albumin, have been measured in airway secretions from acute asthmatic patients 
(Meerschaert et al, 1999; Tseliou et al, 2012). Similar effects have also been 
observed in animal models of allergic airway disease, including the Ovalbumin model 
of allergic asthma (Lee et al, 2004, 2006; Kim et al, 2012).   
Having already demonstrated that prostaglandin E2 was able to induce airway 
microvascular leak in mice via the EP2 and EP4 receptors, I wanted to investigate 
this response in a disease model.  I chose the Ovalbumin model of allergic asthma 
as it has been well characterised within our group.  However, I had to first validate 
the measurement of Evans blue extravasation into the airways as this marker had 
not previously been used.  Prior time course studies measured total protein in the 
bronchoalveolar lavage fluid at various time points and so from this data I chose to 
measure MVL at 2 and 24 hours following a final intra nasal challenge. 
The data demonstrated a measurable increase in airway MVL 2 hours after a final 
intra nasal challenge of OVA, while after 24 hours this response was absent.  It must 
also be emphasised that what is being measured here is a snapshot of airway leak 
that is occurring for 30 minutes following OVA challenge.  What was also apparent 
was that in the OVA-sensitised/OVA-challenged there was an increase in the bronchi 
and IPA weights which led to an underestimation in the EB concentration. So in all 
other studies the airway tissue was dried prior to EB extraction in formamide.  Other 
groups have also used Evans Blue dye to successfully measure OVA-induced MVL 
in mouse (Lee et al. 2004, 2006, Kim et al. 2012), rat (Olivenstein et al. 1997, Hele et 
al. 2001) and guinea pig airways (Mirza et al. 1998).  They all showed an increase in 
Evans Blue dye in the airways and/or lung tissue following OVA challenge providing 
a valuable measure for investigating MVL in allergic asthma.   
As mentioned before, my primary aim was to determine whether PGE2 and the EP 
receptors are involved in this response.  So firstly I used diclofenac, a non-selective 
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COX inhibitor, to block endogenous prostanoid production (Mitchell et al. 1993).  
Diclofenac was dosed orally 1 hour prior to EB administration and so one hour 
following OVA challenge.  The data demonstrated that diclofenac was able to 
significantly inhibit EB MVL in the trachea but not within the lower airways (bronchi 
and IPA) suggesting that prostanoids may have a tissue specific role in OVA-induced 
MVL.  Although this doesn’t indicate which prostanoid may be mediating this effect, it 
does indicate that they may be of importance here.  Of course, diclofenac is only 
being used as a tool as it is well known that the use of NSAIDs is contraindicated in 
asthma patients. Following on from the previous two chapters, I wanted to continue 
and look more specifically at PGE2 and the EP2 and EP4 receptors.   
In all wild type controls there was a significant increase in MVL within the trachea 
and in the bronchi and IPA following OVA challenge, but in the EP2 and the EP4 
knock-out mice this response was absent.  This data indicates a role for PGE2 in 
mediating airway MVL in this model of allergic airway inflammation via the activation 
of the EP2 and the EP4 receptors.  Of course knock outs do not represent the perfect 
model, as it is not clear at which point this gene knock out is important, i.e. is it at the 
point of sensitisation or challenge.  It may be different for each different knock out.  
Unfortunately, a significant attenuation of OVA-induced MVL was not observed when 
the EP2 antagonist (PF-04418948) and the EP4 antagonist (ER-819762) were 
administered to OVA challenged wild-type mice. 
There has been little research on the EP receptors and their effects on MVL in 
asthma models but their effects on other aspects of asthma have been investigated.  
Interestingly, Herrerias et al (2009) observed an increase in EP2 mRNA expression 
in the lungs of mice sensitised and challenged with house dust mite (HDM), as well 
as in increase in PGE2 in their BAL fluid.  Additionally, a similar finding has been 
observed in airway smooth muscle cells from asthmatic patients where a selective 
upregulation of EP2 receptors was seen (Burgess et al. 2004).  Swedin et al (2009) 
observed increased levels of PGE2 in the BAL fluid of OVA challenged mice.  
Moreover, they demonstrated significant reductions in eosinophils and IL-4 levels 
following diclofenac administration (Swedin et al, 2009).  Kunikata et al (2005) 
investigated all four EP receptor knock-outs in their OVA model and indicated a 
primary role for the EP3 receptors.  They demonstrated that mice lacking EP3 
receptors developed more pronounced allergic inflammation while a selective EP3 
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agonist suppressed airway inflammation.  Furthermore, their immunohistochemical 
studies showed that microsomal prostaglandin E synthase 1 is highly expressed in 
the airway epithelial cells of antigen-challenged mice (Kunikata et al. 2005).  
Unfortunately I was unable to look into all four EP knock-outs in this part of the 
thesis, but from the data obtained in chapter 2 there was a clear rationale for only 
looking into the EP2 and EP4 receptor knock-outs. 
In summary, this chapter has demonstrated that Evans Blue dye is a suitable marker 
for measuring airway MVL seen in the murine OVA model of allergic asthma and that 
there may be a role for prostanoids in mediating this effect.  Furthermore 
investigations using EP receptor knock-out mice has elucidated a role for EP2 and 
EP4 receptors in mediating this airway MVL. However, I cannot fully accept the 
chapter hypothesis as the data using the EP2 and EP4 antagonists proved 
inconclusive and does not indicate a definitive role for these receptors. This is a 
novel finding that will hopefully further understanding into the role that PGE2 plays in 
airway inflammation. 
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Chapter Six 
 
The Role of Additional Prostanoids in 
Mediating Airway MVL in the Mouse   
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6. The role of additional prostanoids in mediating airway MVL in the 
mouse 
 
6.1. Rationale 
 
Having extensively investigated PGE2 and the EP receptors in mediating airway MVL 
throughout this thesis, the next step was to begin studying the role that other 
prostanoids play.  Like PGE2, PGD2, PGF2α, PGI2 and TXA2 are products of 
cyclooxygenase mediated metabolism of arachidonic acid and respective synthases.  
They exert there biological effects via the activation of specific G-protein coupled 
receptors; DP1-2, FP, IP and TP, respectively (Coleman et al, 1994). Within the 
airways prostanoids have been known to powerfully contribute to airflow regulation, 
constricting bronchial smooth muscles, increasing mucous secretion, microvascular 
leakage and functioning as a chemoattractant for inflammatory cells (Barnes et al, 
1998) 
As mentioned previously we had all prostanoid receptor knock-out mice available to 
use (DP1, DP2, FP, IP and TP) as well as agonists for each receptor subtype.  This 
enabled me to begin preliminary work on prostanoid-induced airway MVL.  As both 
PGI2 and TXA2 are chemically unstable and very short acting, stable analogues of 
each were used.  Iloprost was used as an IP agonist and U46619 as a TP agonist. 
6.1.1. Chapter Hypothesis 
“Activation of additional prostanoid receptors can result in an increase in 
microvascular leak in mouse airways”. 
6.1.2. Aims 
 Investigate the effect of a single dose of each prostanoid ligand (PGD2, 
PGF2α, Iloprost, U46619). 
 Investigate whether each agonist is acting via their own receptor subtype to 
mediate this effect. 
 Examine the effect of each agonist on systemic blood pressure. 
  
156 
 
6.2. Methods 
 
The following experiments were carried out as described in Chapter 2.  Details of 
individual experiments are described below. 
 
6.2.1. Effect of PGD2, PGF2α, U46619 and Iloprost on airway MVL in mice 
 
Having established that PGE2 induces MVL in the airways of mice, the role of the 
other prostanoids was then investigated. Following EB administration, animals 
received PGD2, PGF2α, U46619 (TP receptor agonist), Iloprost (IP receptor agonist) 
or PGE2 (3 mg kg
-1) i.v. at 4 ml kg-1 or Vehicle (1% ethanol in saline). The 30 minute 
time point was used for all agonists. 
 
6.2.2. Effect of PGD2, PGF2α, U46619 and Iloprost in individual prostanoid 
receptor knock-out mice 
 
To establish whether the prostanoid receptor agonists were mediating MVL via their 
own receptor, DP1, DP2, TP, IP and FP receptor deficient mice were used.  One 
minute after Evans Blue WT animals received PGD2, PGF2α, U46619, or Iloprost or 
vehicle, DP1+2 KOs vehicle or PGD2, FP KOs vehicle or PGF2α, TP KOs vehicle or 
U46619 and IP KOs vehicle or Iloprost.  All wild types were C57BL/6 littermate 
controls. The 30 minute time point still applied here. 
 
6.2.3. Effect of PGD2, PGF2α, U46619 and Iloprost on systemic blood pressure 
Male C57BL/6 mice were anaesthetised as previously described and their carotid 
artery cannulated (as outlined in 2.4).  Once a baseline blood pressure recording 
was achieved (approximately 5 minutes), the jugular veins were exposed and an 
intravenous dose of PGD2, PGF2α, U46619, Iloprost (3 mg kg
-1) or vehicle (1% 
ethanol in saline) administered. Mean arterial blood pressure (MAP) was measured 
over 30 minutes after which animals were culled. 
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6.2.4. Genotyping of Prostanoid Receptor Knockouts 
DNA was extracted from tail tips (0.5-1cm) of wild type and prostanoid receptor 
knockout mice using Quanta Biosciences Extracta DNA prep for PCR kit.  The purity 
and integrity of the DNA samples was assessed using a PowerWave XS Microplate 
Spectrophotometer (Biotek, Bedfordshire, UK).  PCR reactions were run using 
mouse genomic DNA primers that had been previously optimised and validated. The 
PCR reaction contained 1x Green GoTaq Flexi buffer, 0.2mM dNTPs, 2mM MgCl2, 
1.25µl enzyme (GoTaq polymerase), 10pmol forward and 10pmol reverse primers, 
and a volume of DNA (50ng) or Nuclease-free water for control, made up to 25µl with 
Nuclease-free water.  Samples were then run on a Taqman machine under the 
conditions detailed in table 2.  DP1 and DP2 primers were run in singleplex reactions, 
so wild type and knock-out primers had to be run as separate reactions, while FP, IP 
and TP primers were run as multiplex reactions, so wild type and knock-out primers 
could be run in the same PCR reaction.  
The PCR products and DNA ladder (Hyperladder II or IV) were run on a 2% agarose 
gel in Tris Borate EDTA (TBE) buffer containing 5µl per 100ml Safeview at 100V for 
about 1 hour.  The gel was then visualised under ultra-violet light and photographed 
using the Molecular Imager® ChemiDocTM XRS System with Image LabTM software 
(Bio-Rad, UK). 
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Table 6.1.  Optimised PCR conditions for genotyping prostanoid receptor KO mice. DP1 and 
DP2 were run as singleplex (indicated by a “-“ where that primer isn’t included so no band expected) 
while FP, IP and TP were run as multiplex reactions. 
 
6.2.5. Statistical Analysis 
 
All data was analysed using GraphPad Prism 5.  Parametric data was expressed as 
mean + s.e.m and non-parametric data presented as the median with the 
interquartile range.  Multiple measurements were analysed by one-way ANOVA, 
non-parametric Kruskal-Wallis test and post-hoc comparisons were performed by 
Dunn’s multiple comparison test, comparing selected columns to a control.  
Additionally, an unpaired t test and/or non-parametric Mann Whitney test, with two-
tailed p values, were carried out to determine statistical significance between two 
groups. Differences were considered statistically significant if p<0.05.  The figures 
have been graphically presented on a range-specific axis. 
  
Receptor PCR Conditions 
Expected Primer Bands 
(bp) 
 Denaturing Annealing Extension Wild Type Knockout 
FP 
for/rev/neo 
95ºC / 30 s 65ºC / 30 s 75ºC / 45 s 750 500 
IP 
for/rev/neo 
94ºC / 30 s 58ºC / 30 s 68ºC / 60 s 1350 900 
TP 
for/rev/neo 
95ºC / 30 s 65ºC / 30 s 75ºC / 45 s 250 650 
DP1 (w.t) 
for/rev 
95ºC / 30 s 60ºC / 30 s 75ºC / 90 s 400 1500 
DP1 (KO) 
neo/rev 
95ºC / 30 s 62ºC / 30 s 72ºC / 45 s - 340 
DP2 (w.t) 
for/rev 
94ºC / 30 s 63ºC / 45 s 72ºC / 60 s 340 - 
DP2 (KO) 
neo/rev 
94ºC / 30 s 55ºC / 45 s 72ºC / 60 s - 1000 
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6.3. Results 
6.3.1. Effect of PGD2, PGF2α, U46619 and Iloprost on airway MVL in mice 
 
Following the positive data from PGE2-induced MVL, preliminary work looking into 
the role of other prostanoids was carried out.  PGD2 significantly increased MVL in 
both the trachea and bronchi and IPA of mice, whilst PGF2α caused a significant 
increase in the trachea.  Additionally, the TP agonist U46619 induced a significant 
increase in MVL in the bronchi and IPA. In the trachea U46619 increased MVL but 
failed to reach statistical significance.  Similarly with the IP agonist Iloprost, it 
induced a small increase in airway MVL but this did not reach statistical significance 
(Figure 6.1). 
 
Figure 6.1. Effect of PGE2, PGD2, PGF2α, U46619 and Iloprost (3 mg kg
-1
 i.v.; 30 minutes) on 
MVL into (A) trachea or (B) bronchi and intra-pulmonary airways of mice. Data presented as the 
median, with the interquartile range, of the concentration of Evans blue dye (ng mg
-1
 of tissue). n=6. 
One-way ANOVA with non-parametric Kruskal-Wallis test and post-hoc comparisons using Dunn’s 
multiple comparisons test. * p<0.05 significant increase from vehicle control. ns = non significant 
increase   
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6.3.2. Effect of PGD2, PGF2α, U46619 and Iloprost in individual prostanoid 
receptor knock-out mice 
Having demonstrated that the other prostanoids were able to induce airway MVL, 
their effect in individual receptor knock-out mice was then investigated.  
Unfortunately, I only had the opportunity to look at each prostanoid agonist with their 
respective receptor knockout.  Firstly, PGD2 demonstrated a measureable (and 
significant) increase in airway MVL in the wild type and DP2 knock outs.  This 
response, however, was absent in the trachea and bronchi and IPA of DP1 knock 
outs (Figure 6.2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Effect of PGD2 (3 mg kg
-1
 i.v.; 30 minutes) in wild type, (A+B) DP1 and (C+D) DP2 
receptor knockouts.  A and C represent the trachea and B and D the bronchi and IPA. Non-
parametric data presented as the median, with the interquartile range, and parametric data expressed 
as mean + s.e.m of the concentration of Evans blue dye (ng mg
-1
 of tissue). n=5-7. Non-parametric 
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Mann Whitney test or unpaired t test for parametric data.  * p<0.05 significant increase from vehicle 
control.  # p<0.05 significant decrease from treated wild type control. 
In this study, PGF2α induced a substantial and significant increase in MVL in the 
trachea and bronchi and IPA of wild type mice compared to vehicle treated controls.  
However, when administered to FP receptor knockouts this response was 
significantly reduced (Figure 6.3). 
 
 
 
 
 
 
 
Figure 6.3. Effect of PGF2α (3 mg kg
-1
 i.v.; 30 minutes) on MVL in the (A) trachea and (B) 
bronchi and IPA of wild type and FP receptor knockout mice. Non-parametric data presented as 
the median, with the interquartile range, and parametric data expressed as mean + s.e.m of the 
concentration of Evans blue dye (ng mg
-1
 of tissue). n=6.  Non-parametric Mann Whitney test or 
unpaired t test for parametric data. * p<0.05 significant increase from vehicle control.  # p<0.05 
significant decrease from treated wild type control. 
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In wild type mice the TP agonist U46619 significantly increased MVL in both the 
trachea and bronchi and IPA. In the TP knockout mice U46619 was unable to induce 
any Evans blue leak (Figure 6.4). 
 
 
 
 
 
 
 
Figure 6.4. Effect of U46619 (3 mg kg
-1
 i.v.; 30 minutes) on MVL in the (A) trachea and (B) 
bronchi and IPA of wild type and TP receptor knockout mice. Non-parametric data presented as 
the median, with the interquartile range, and parametric data expressed as mean + s.e.m of the 
concentration of Evans blue dye (ng mg
-1
 of tissue). n=6. Non-parametric Mann Whitney test or 
unpaired t test for parametric data.  * p<0.05 significant increase from vehicle control.  # p<0.05 
significant decrease from treated wild type control. 
 
In the previous study the IP agonist Iloprost did not demonstrate a significant 
increase in MVL in either airway tissues, however on this occasion Iloprost produced 
a significant increase in MVL in the trachea.  This response was then completely 
absent in IP receptor knockout mice (Figure 6.5). 
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Figure 6.5. Effect of Iloprost (3 mg kg
-1
 i.v.; 30 minutes) on MVL in the (A) trachea and (B) 
bronchi and IPA of wild type and IP receptor knockout mice. Non-parametric data presented as 
the median, with the interquartile range, and parametric data expressed as mean + s.e.m of the 
concentration of Evans blue dye (ng mg
-1
 of tissue). n=6. Non-parametric Mann Whitney test or 
unpaired t test for parametric data.  ns = non significant increase. * p<0.05 significant increase from 
vehicle control.  # p<0.05 significant decrease from treated wild type control.   
 
All of the mice used for these experiments were genotyped using the methods 
outlined in Chapter 2.  As an example, a gel is shown to confirm the disruption of the 
gene encoding the FP receptor in FP receptor knockout mice.  Using the FP primers, 
the PCR products were run on a gel which allowed confirmation of wild type and FP 
knockouts, as well as the presence of the wild type allele and the absence of the 
knock out allele in the DP1, DP2, IP, and TP knockouts (Figure 6.6). 
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Figure 6.6. An example gel showing the PCR products of DNA extracted from wild type, DP1-2, 
FP, IP and TP KO mice.  This representation was using the FP primers.  Product size in wild type 
was 750 bp and FP KO was 500 bp. 
 
6.3.3. Effect of PGD2, PGF2α, U46619 and Iloprost on systemic blood pressure 
 
Having shown each prostanoid had the ability to induce airway microvascular leak, 
the effect on systemic blood pressure was then determined.  All prostanoid agonists 
were given intravenously at a dose of 3 mg kg-1.  Firstly, PGD2 and PGF2α only 
caused a small rise in blood pressure compared to vehicle treated animals.  The TP 
receptor agonist, U46619, caused a substantial and rapid rise in blood pressure that 
appeared transient while the IP agonist, Iloprost, induced a large drop in blood 
pressure that was sustained over the 10 minutes. 
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Figure 6.7. Effect of PGD2, PGF2α, U46619 and Iloprost (3 mg kg
-1
 at 4 ml kg
-1
 i.v.) on mean 
arterial blood pressure in C57BL/6 mice. Data expressed as mean + s.e.m of mean arterial 
pressure.  Arrow indicates approximate time of prostanoid administration.  Blood pressure was 
recorded for 10 minutes. n=3-4  
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6.4. Discussion 
 
Prostanoids, including PGE2, PGD2, PGF2α, PGI2 and TXA2 are products of 
cyclooxygenase mediated metabolism of arachidonic acid and respective synthases.  
They are formed and released following various, sometimes noxious, stimuli and act 
within the vicinity of their production where they maintain local homeostasis.  In order 
to exert their biological functions they bind to specific cell surface receptors, all of 
which are G-protein-coupled receptors.  Currently there are nine known prostanoid 
receptors, EP1-4, DP1-2, FP, IP and TP (Coleman et al, 1994).  Bronchial asthma is a 
complex disease that is characterised by recurrent episodes of breathlessness, 
wheezing, chest tightness and airway obstruction (Bousquet et al, 2000).  Both 
inflammatory cells and structural cells play a central role and release many different 
mediators that have been implicated in allergic disease (Barnes, 2011).  Of these 
mediators, prostanoids have been known to powerfully contribute to airflow 
regulation, constricting bronchial smooth muscles, increasing mucous secretion, 
microvascular leakage and functioning as a chemoattractant for inflammatory cells 
(Coleman & Sheldrick, 1989; Hardy et al, 1984; Jones et al, 1992; Lötvall et al, 1992; 
Tokuyama et al, 1991; Barnes et al, 1998). 
In Chapters three, four and five I have extensively investigated the role of PGE2 and 
the EP2 and EP4 receptors in mediating airway microvascular leak.  I demonstrated 
that these two receptors are central to the airway microvascular leak observed 
following PGE2 administration.  Furthermore, using the OVA model of asthma I saw 
a reduction in OVA-induced MVL in the airways of EP2 and EP4 receptor knockout 
mice.  In this chapter I present some preliminary data investigating additional 
prostanoids and their role in airway microvascular leak.  PGD2, PGF2α, PGI2 and 
TXA2 have all, at some point, been implicated in airway inflammation and disease.  
This preliminary work has illustrated a possible role for all prostanoids in inducing 
plasma leakage in either the trachea or bronchi and IPA or both.   
Following intravenous administration of PGD2 a substantial and significant increase 
in airway MVL was observed, a response comparable to that seen with PGE2.  
Additionally, when PGD2 was given to DP1 and DP2 receptor knockout mice a 
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reduction in airway MVL was seen only in the DP1 knockout mice while an increase 
in MVL was still apparent in the DP2 knockouts.  This suggests that the airway 
microvascular leak induced by PGD2 is via the activation of the DP1 receptor and 
subsequent downstream signalling.  PGD2 is the major prostanoid that is produced 
by activated mast cells and is highly associated with inflammatory diseases (Roberts 
et al, 1980; Lewis et al, 1982).  Furthermore, analysis of BAL fluid has indicated that 
PGD2 is released in the airways following antigen challenge (Murray et al, 1986) and 
can lead to bronchoconstriction (Hardy et al, 1984) and eosinophil infiltration (Emery 
et al, 1989).  More recently, Nishimura et al (2001) studied the effects of PGD2 in 
guinea pigs and found that it induced a dose-dependent increase in Evans Blue dye 
extravasation at all airway levels.  However, they observed large increases in 
systemic blood pressure following PGD2 administration while in our mouse studies 
no significant change in pressure was seen.  Conversely, PGD2 has consistently 
been shown to cause vasodilation and a decrease in blood pressure (Spada et al, 
2002; Walch et al, 1999; Walch et al, 2001).  
Like the EP2 and EP4 receptors DP1 receptors couple to Gs and stimulate cAMP 
formation which is the prominent signalling pathway that leads to relaxation 
responses.  As I outlined in Chapter four, increases in intracellular cAMP 
concentrations are usually associated with an increase in barrier function and so 
inhibition of microvascular leak while decreasing cAMP is associated with an 
increase in vascular permeability (Garcia et al, 1995; Patterson et al, 1995; Chetham 
et al, 1997; Moore et al, 1998).  It is interesting that DP2 does not appear to mediate 
any PGD2-induced MVL as this receptor is coupled to Gi and a decrease in cAMP 
(Sawyer et al, 2002; Gallant et al, 2007).  Although no changes in systemic blood 
pressure were seen, local changes in pressure and blood flow to the lung and 
airways may have occurred.  It could be suggested that PGD2 is causing vasodilation 
within the airways and increasing blood flow, an effect which has been known to 
potentiate microvascular leak (Williams, 1982).  
The main implications for PGF2α have been in mammalian reproduction (Sugimoto et 
al, 1997) and it has been long known that functional expression of the FP receptor in 
the myometrium mediates contraction (Senior et al, 1992; Carrasco et al, 1996).  
However, PGF2α has been shown to cause bronchoconstriction of human airways in 
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vitro (Coleman and Sheldrick, 1989) as well as in asthmatic patients (Fish et al, 
1984).  Here I have demonstrated that PGF2α is able to induce significant airway 
microvascular leak, and from using FP receptor knock outs this effect appears to be 
via the activation of the FP receptor. Arakawa et al (1993) studied the effects of 
PGF2α in guinea pig airways, and in concordance with my data they demonstrated an 
increase in Evans Blue extravasation following PGF2α administration.   Furthermore, I 
saw no real change in systemic blood pressure following FP administration.  
However, Yu et al (2009) saw that PGF2α elevates blood pressure and that systolic 
blood pressure in FP receptor knockout mice was significantly lower than that of wild 
type mice. 
FP receptors are predominantly Gq-coupled and activate the classic pathway. So, 
following PLCβ activation, there is PI turnover and a transient Ca2+ signal in 
response to inositol trisphosphate formation (Nakao et al, 1993; Sugimoto et al, 
1994; Woodward and Lawrence, 1994).  Downstream of this pathway is the 
activation of myosin light-chain kinase (Ansari et al, 2003).  According to the dogma 
on endothelial gap formation and vascular leak, activation of this protein kinase is 
essential.  Briefly, activation of this kinase leads to an increase in myosin light-chain 
phosphorylation, an increase in actin stress fibres, leading to cell contraction and 
gap formation (Curry et al, 1983; Lu & Wolf, 1993).  With no apparent change in 
blood pressure it could be assumed that the effect of PGF2α in these experiments is 
exclusively through endothelial gap formation.   
To investigate the role of TXA2 and the TP receptor U46619, a stable TXA2 mimetic, 
was used.  TXA2 has been well documented as a potent constrictor of both vascular 
and airway smooth muscle (Svensson et al, 1977; Coleman et al, 1981).  Following 
allergen challenge the stable metabolite TXB2 has been shown to be elevated in the 
airways of sensitised guinea pigs and asthma patients (Burka et al, 1981; Lupinetti et 
al, 1987) while allergen-induced bronchoconstriction has been inhibited using a TXA2 
antagonist. In initial experiments U46619 only produced a significant increase in 
MVL in the bronchi and IPA, a response which actually exceeded that seen with any 
other prostanoid.  In subsequent experiments, increases in MVL in the trachea did 
reach significance.  Furthermore, when responses to U46619 were investigated in 
TP receptor knockout mice the MVL was significantly attenuated, again suggesting 
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that this prostanoid ligand was acting via its own receptor to induce airway MVL.  
Others have also shown an increase in Evans Blue extravasation in the airways of 
rats and guinea pigs following U46619 administration (Lötvall et al, 1992; Bertolino et 
al, 1995).  In addition, Lötvall et al (1992) also found that Evans Blue dye leak was 
higher in the intrapulmonary airways compared with the trachea. More recently, 
Nishimura et al (2001) examined the role of TP receptors in airway MVL in guinea 
pigs but looked at the interaction of PGD2 with this receptor.  Interestingly, they 
found that PGD2-induced increases in Evans Blue dye extravasation were 
completely abolished following pre-treatments with TP receptor antagonists.  They 
also used a TXA2 synthase inhibitor, OKY-046, but found no inhibition of PGD2 
responses indicating that it was the activation of the TP receptor only causing these 
effects (Nishimura et al, 2001).   
As well as investigating its effect on airway MVL, systemic blood pressure was also 
measured using the same dose.  U46619 induced a massive and immediate 
increase in systemic blood pressure in mice.  This increase in blood pressure and 
vasoconstriction induced by TP receptor activation is well documented across 
various species both in vitro (Norel et al, 2002; Svensson et al, 1977; Coleman et al, 
1981; Yoshimura et al, 1989; Félétou et al, 2009) and in vivo (Nossaman et al, 1992; 
Bertolino et al, 1993; Francois et al, 2008; Denniss & Rush, 2009; Graham & Rush, 
2009).  It has been suggested that mediators that cause plasma extravasation are 
those that usually produce vasodilation and a drop in systemic blood pressure 
(Rogers et al, 1990; Persson 1987), however having shown that U46619 causes 
MVL and an increase in systemic blood pressure this may not always be the case.  It 
could be feasible that such an increase in blood pressure may have eventually 
caused an increase in bronchial blood flow and therefore potentiating Evans Blue 
exudation.  Alternatively the effect seen may be a direct action on the endothelial 
cells themselves, which have been shown to express TP receptors (Raychowdhury 
et al, 1994; Miggin & Kinsella, 1998).  TP receptors have shown coupling to Gq, thus 
activating PLCβ, generation of IP3/DAG and mobilisation of intracellular calcium 
(Hirata et al, 1991; Kinsella et al, 1997; Offermanns, 2006; Nakahata, 2008).  
Additional studies have also implicated G12/13-Rho pathway (Huang et al, 2004; Song 
et al, 2009; Zhang et al, 2009).  As I described for PGF2α Gq coupling has been 
associated with endothelial barrier disruption and in addition Rho signalling is also an 
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important pathway regulating endothelial cell contraction.  Briefly, signalling through 
RhoA destabilises the endothelial junction via Rho Kinase which inactivates myosin 
light chain phosphatase, causing myosin contraction and the destabilisation of the 
actin cytoskeleton (Essler et al, 1998; Qiao et al, 2003; Sun et al, 2006). The data I 
have presented, along with others, outlines clear evidence for the involvement of the 
TP receptors in mediating airway microvascular leak and contributing to airway 
inflammation seen in asthma. 
Finally, I examined the role of IP receptors in mediating MVL in mouse airways.  It 
was not suitable to use PGI2 itself in these experiments as it is too chemically 
unstable with a short duration of action (Coleman et al, 1994) so the stable analogue 
Iloprost was used. PGI2 plays a central role in oedema formation, hyperalgesia and 
pain (Bley et al, 1998; Hata & Breyer, 2004; Murata et al, 1997), while also 
suppressing Th2-mediated allergic inflammatory responses (Jaffar et al, 2002).  
When first tested, Iloprost caused only modest increases in MVL, failing to reach 
significance in either the trachea or the bronchi and IPA.  In subsequent experiments 
Iloprost caused a significant increase in MVL in the trachea, which coincided with an 
attenuated response in IP receptor knockouts. So although only a small response 
was observed it does appear to occur via the activation of the IP receptor.  The IP 
receptor has been investigated in several models of inflammatory swelling where it 
appears to play a key role.  For example, Murata et al (1997) examined 
carrageenan-induced paw swelling in IP receptor knockout mice and saw a 50% 
reduction in paw oedema. Yuhki et al have also demonstrated that IP receptors 
participate in exudate formation in a carrageenin-induced mouse pleurisy model, 
suggesting a role for PGI2 in plasma extravasation (Yuhki et al, 2004).  However, 
others have demonstrated that PGI2 is able to inhibit and reduce vascular 
permeability (Moller & Grande, 1997; Cureton et al, 2010).   
As with the other prostanoid ligands, I also examined the effect of Iloprost on 
systemic blood pressure in mice.  Most studies on vascular tone have described 
relaxations induced by PGI2 analogues and Iloprost has been used clinically as a 
vasodilator to treat pulmonary hypertension and Raynaud phenomenon (Moncada et 
al, 1982; Haye-Legrand et al, 1987; Coleman et al, 1994; Walch et al, 1999; 
Benedict et al, 2007).  Indeed, when a dose of 3 mg kg-1 was administered, Iloprost 
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caused a rapid drop in systemic blood pressure that was sustained for at least 10 
minutes.  It could be suggested that this vasodilatory response may cause in 
increase in blood flow to airways and thus potentiate MVL.  However, as I have 
described the MVL induced by Iloprost in this model was unremarkable so this 
assumption may be incorrect.  As for DP1 receptors, IP signals through the Gs 
pathway, which is the classic pathway responsible for relaxant responses in smooth 
muscle beds.  Conversely, Gs mediated increases in adenylyl cyclase and cAMP 
levels are associated with barrier protective responses.  It is possible that in this 
model Iloprost is acting to maintain barrier integrity but the substantial increase in 
blood flow may be counteracting this through hydrostatic changes.   
In summary, the data presented in this chapter indicates a role for DP1, FP, IP and 
TP receptors in mediating microvascular leak in mouse airways and I am therefore 
able to accept the chapter hypothesis.  However, the significance for some of the 
prostanoids (noteably Iloprost) varied between studies and between airway tissue 
types. It must be emphasised that the data presented here is preliminary work and 
more extensive investigation is required to fully elucidate the role that each 
prostanoid is playing in mediating airway microvascular leak in vivo.  Currently, it is 
only possible to speculate what may be occurring in this model and it is difficult to 
come to any firm conclusions.  The future work that is required is outlined in detail in 
the following chapter.  Nevertheless, prostanoid-induced MVL in murine airways has 
not been highly reported and is an exciting new finding that will further our 
understanding into the role that they play in airway inflammation.   
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7. Summary and Future Studies 
 
7.1. Summary and discussion 
 
Airway microvascular leak is a cardinal sign of inflammation and is a prominent 
feature in both asthma and COPD.  Various inflammatory mediators are capable of 
inducing this effect following an inflammatory insult to the airways.  These 
inflammatory mediators act upon the endothelium of post capillary venules to open 
intercellular gap junctions.  This effect causes plasma to ‘leak’ out into extravascular 
sites (Reynolds et al, 2002; Greiff et al, 2003).  Measuring this event in vivo provides 
a specific index representing to what degree the airway mucosa has been affected 
by the inflammatory process of a mediator.   Events such as these have been 
associated with the development and exacerbations of airway inflammation, thus 
modulation of this response represents a key pathway in developing new treatments.  
What I wanted to investigate was whether prostaglandin E2 (PGE2) was involved in 
mediating this response.   
PGE2 is a ubiquitous eicosanoid that has been implicated in the pathogenesis of 
both asthma and COPD. It exerts its biological effects via activation of four cell-
surface GPCRs, termed EP1-4, encoded for by the genes Ptger1-4 (Coleman et al, 
1994).    Increased levels of PGE2 have been reported in BAL fluid and plasma of 
asthma patients, and enhanced levels in the condensate of COPD patients 
(Montushi et al, 2003; Long et al, 2004).  Additionally, increased levels of PGE2 have 
been observed in the BAL fluid of allergen-sensitised mice (Herrerias et al. 2009). 
However, its role in airway inflammation remains varied and inconclusive and there 
appears to be a fine balance between the pro and anti-inflammatory effects of this 
prostanoid in human airways.   The aim of this thesis was to determine whether 
PGE2 could induce airway microvascular leak in vivo and if so which EP receptor 
was mediating this effect. 
Before investigating the effect of PGE2, however, I needed to determine whether the 
mouse was a suitable species to model MVL in.  Therefore I used 5-
hydroxytryptamine (5-HT) as a tool for validating this model, as previous reports 
have shown potent effects in rats (Hele et al, 2001).  Here, 5-HT induced a dose 
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related increase in MVL in both the trachea and the bronchi and IPA of mice.  Once 
the model of MVL was successfully validated in the mouse, the effects of PGE2 were 
then investigated.  In an initial study PGE2 produced only a moderate increase in 
MVL, using timings taken from the 5-HT study. This was evident in both the trachea 
and the bronchi and IPA, where only a marginal dose response relationship was 
obvious.  The effect of PGE2 on airway microvascular leak has not been shown 
previously, and so timings of administration were based upon previous methods 
within the group and the literature.  However, increasing the time post PGE2 
administration from 5 minutes to 30 minutes produced a greater increase in MVL in 
the airways of mice.  Additionally, a dose response relationship was more evident 
using this time point in both the trachea and bronchi and IPA.   
As previously mentioned, the majority of research into airway MVL has been 
achieved using larger species, including the rat and the guinea pig.  I wanted to rule 
out that what was being observed with PGE2 was not exclusive to the mouse.  In the 
guinea pig PGE2 produced a large, significant increase in airway MVL that was 
comparable to that seen with 5-HT.  Both the mouse and the guinea pig produced 
similar profiles in the magnitude of their responses demonstrating that the effect of 
PGE2 is translated across species.   
As described previously small changes in blood flow may impact on MVL, so it could 
be possible that the PGE2-induced MVL may be caused by vasodilation and an 
increase in blood flow to the airways. However, in contrast to the rapid and 
substantial drop in blood pressure (vasodilation) seen with the IP agonist Iloprost, 
PGE2 appeared to have very little effect on the systemic blood pressure in mice.  
Although this does not represent local changes in blood pressure and flow (i.e. in the 
bronchial circulation) it does suggest that there is not a clear and defined association 
between vasodilation and increased airway microvascular leak in this study.   
Having shown that PGE2 induces MVL in the mouse I wanted to determine which of 
the EP receptors were central to this response.   To do this I used mice deficient of 
each individual EP receptor as well as a range of pharmacological tools, including 
agonists and antagonists targeting each receptor subtype.  What was evident in both 
the trachea and the IPA was that the response to PGE2 in the EP2 and EP4 knock-
out mice was completely abolished. This data suggests that both the EP2 and EP4 
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receptors may be essential in this process.  As well as the knock-outs I was fortunate 
enough to use selective EP receptor agonists that were kindly provided by ONO 
pharmaceuticals. These allowed direct comparisons to be made with the knock-out 
data. The data clearly demonstrated that, similar to PGE2, the EP2 and EP4 agonists 
significantly increased the airway plasma leakage.  This confirmed that activation of 
these EP receptors mediates microvascular leak in mouse airways, while activation 
of EP1 and EP3 produced no measurable increase. 
Although knock-out mice for each prostanoid receptor subtype has helped to 
investigate the physiological and pathological roles of this receptor family, they are 
only limited to the mouse.  Having demonstrated a clear role for EP2 and EP4 
receptors in mediating airway microvascular leak, I wanted to examine these further 
using pharmacological tools.  An EP2 antagonist (PF-04418948) was ineffective at 
inhibiting EP2-induced MVL when dosed orally, but when delivered via the i.p route it 
produced a dose-dependent decrease in MVL.  Similarly, an EP4 antagonist (ER-
819762) was unable to block EP4-mediated MVL following oral administration, while 
after i.p administration it attenuated the response to the EP4 agonist.  The next step 
was to investigate their effects against PGE2-induced MVL.  In initial experiments 
neither antagonist was effective at inhibiting PGE2-induced airway MVL.  However, 
when both antagonists were dosed simultaneously, a prominent inhibition in PGE2 
leak was seen.  This data further suggests a dual role for the EP2 and EP4 receptors 
in mediating PGE2 induced responses. 
The next aim was to establish whether PGE2 and the EP receptors were important in 
mediating airway MVL in a disease model of asthma. Firstly, I established that Evans 
Blue was a suitable marker to measure MVL in the Ovalbumin model of allergic 
asthma. The data showed a significant increase in airway MVL two hours after a final 
intranasal challenge of OVA.  As mentioned before, my primary aim was to 
determine whether PGE2 and the EP receptors are involved in this response.  So 
firstly I used diclofenac, a non-selective COX inhibitor, to block endogenous 
prostanoid production (Mitchell et al. 1993).  Diclofenac was able to partially inhibit 
EB MVL in the trachea but not within the lower airways (bronchi and IPA) suggesting 
that prostanoids may have a tissue specific role in OVA-induced MVL.  Following on 
from this, EP2 and EP4 receptor knock-out mice were used.  In all wild type controls 
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there was a significant increase in airway MVL following OVA challenge, but in the 
EP2 and the EP4 knock-out mice this response was absent.  This effect was obvious 
in both the trachea and in the bronchi and IPA, unlike that seen following diclofenac 
administration.  Finally, this data was mimicked when the EP2 antagonist (PF-
04418948) and the EP4 antagonist (ER-819762) were administered to OVA 
challenged wild-type mice.  Simultaneous dosing of the antagonists attenuated the 
OVA-induced airway MVL. This data indicates a role for PGE2 in mediating airway 
MVL in this model of allergic airway inflammation via the activation of the EP2 and 
the EP4 receptors.   
Finally, having extensively investigated PGE2 and the EP receptors in mediating 
airway MVL, the next step was to begin preliminary work studying the role that other 
prostanoids play.  PGD2, PGF2α, Iloprost (IP) and U46619 (TP) all induced airway 
MVL in mice and it appeared that they did so via the activation of their own receptor 
subtype.  For PGD2, it was evident that it was the activation of the DP1 and not the 
DP2 receptor that mediated airway MVL.  Additionally, their effect on systemic blood 
pressure was also measured.  The TP agonist, U46619, produced a substantial 
increase in blood pressure while the IP agonist, Iloprost, showed an opposing effect, 
causing a sharp drop in mean arterial blood pressure.  PGD2 and PGF2α, however, 
did not cause any remarkable change in blood pressure at the dose tested.  It must 
be emphasised that this data is preliminary work and more extensive investigation, 
outlined in section 7.2 below, is required to fully elucidate the role that each 
prostanoid is playing in mediating airway microvascular leak in vivo. 
 
7.1.1. Limitations of the thesis 
 
The experiments that have been used throughout this thesis have provided data 
indicating that PGE2 activates both the EP2 and EP4 receptors to mediate 
microvascular leak in murine airways.  However, there are several limitations 
associated with some of the experimental techniques used.  Evans Blue dye has 
been used for decades as a marker of albumin leak in a variety of species (Miles & 
Miles, 1952; Rogers et al, 1988; Baluk et al, 1999; Reynolds et al, 2002; Xle et al, 
2003; Zhuang et al, 2011).  It has been extremely useful in helping to understand the 
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mechanisms and mediators that are involved in microvascular leak in vivo as it is a 
relatively straightforward and reliable method.   One of the main problems that is 
associated with this technique is that it is a terminal procedure, so each animal is 
limited to a single intervention.  This means that fairly large cohorts are required, 
especially for studies that examine the effects over time.  Furthermore, the data 
obtained only provides a reference to the net accumulation of dye in the tissues and 
so it is difficult to measure any fluctuations that may be occurring in vascular 
permeability.  As I have outlined in previous chapters, microvascular leak has been 
shown to be influenced by other physiological factors, namely changes in blood 
pressure and blood flow to the microvasculature.   Additionally, it could be possible 
that the perfusion of the circulation is not enough to remove all of the intravascular 
dye.  However in comparison to some of the alternatives it is safer, cheaper and 
easier to carry out while still providing an accurate measure of microvascular 
permeability (reviewed by Kenne and Lindbom, 2011).   For example, with intravital 
microscopy there are often major difficulties in quantifying the plasma leakage from 
the images obtained and is very difficult for deep tissues such as the lung. 
Furthermore, the use of radiolabelled tracers as an alternative to Evans Blue dye 
does not provide a more accurate measure and comes with the obvious safety 
hazards associated with radiation (Rogers et al, 1989). 
As I mentioned above changes in blood pressure have been shown to potentiate 
microvascular leak which is why I measured mean arterial blood pressure in mice 
following administration of prostanoids.  However, this was done independently of 
the MVL studies so direct correlations cannot be made.  More importantly, the blood 
pressure was measured via the cannulation of the carotid artery, which measured 
systemic pressure changes that does not indicate any changes occurring within the 
airway circulation.   
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7.2. Future Studies 
 
7.2.1. Effect of EP agonists on systemic blood pressure 
 
Unfortunately, due to time and compound availability, the effect of the selective EP 
agonists on systemic blood pressure was never tested.  When PGE2 was given very 
little effect was seen but this may be down to the opposing effects of the EP 
receptors.  As I described in previous chapters, EP2 and EP4 receptors have been 
shown to mediate relaxation of vascular smooth muscle and a fall in blood pressure 
(Davis et al, 2004; Imig et al, 2002; Kennedy et al, 1999; Zhang et al, 2000), while 
the EP1 and EP3 receptors are associated with vasoconstriction (Baxter et al, 1995; 
Qian et al, 1994; Stock et al, 2001; van Rodijen et al, 2007; Walch et al, 2001).  Data 
from this would fit nicely with what I have shown so far and may aid in understanding 
how PGE2-EP2/4 signalling causes airway MVL. 
 
7.2.2. The role of PGE2 and the EP receptors in the guinea pig 
 
Having demonstrated that PGE2 was able to induce substantial MVL in the guinea 
pig at 3 mg kg-1 it seems appropriate to continue this work and look at a dose 
response to establish a more suitable and perhaps lower dose to use.  Additionally 
the EP2 and EP4 receptor agonists and antagonists would be used to explore 
whether these were responsible for PGE2 induced MVL in guinea pig airways like in 
mice.  As demonstrated in chapter 4 I would dose the guinea pigs i.p with the 
antagonists at various doses. 
Furthermore I would investigate the effects of PGE2 and the EP receptor agonists on 
systemic blood pressure in guinea pigs.  Having shown that in the mouse that little 
effect was seen on blood pressure, which may have in turn had an effect on the level 
of airway microvascular leak it seems appropriate to decipher whether there are any 
differences between species. 
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7.2.3. Investigating the prostanoid receptors mediating airway microvascular 
leak 
 
Preliminary data illustrated in chapter 6 showed that all the other prostanoids (PGD2, 
PGF2α, Iloprost and U46619) are able to induce airway MVL in mice.  I also 
demonstrated that when each agonist was given to the respective receptor knock out 
it appeared their responses were mediated via their own receptor.  However it has 
been reported that PGD2 can induce its effects via the activation of the TP receptor 
(Nishimura et al, 2001).  Therefore, I would give each agonist to each knock out 
mouse, i.e., PGD2 would be administered to the FP, IP and TP receptor knock outs.  
Additionally, to follow up the data from the DP2 knock outs I would use specific DP2 
agonists or antagonists. 
 
7.2.4. Modelling OVA-induced airway MVL in prostanoid receptor knock-out 
mice 
 
I have previously shown that diclofenac (a non-selective COX inhibitor) is capable of 
inhibiting OVA-induced MVL which suggests that prostanoids may be mediating this 
effect.  However this alone does not pin point a specific prostanoid or prostanoid 
receptor.  I did then show that the EP2 and EP4 receptors may play a key role in this 
response and in chapter 6 I observed that PGD2, PGF2α, Iloprost and U46619 are all 
able to induce airway MVL in mice.  Therefore the next step would be to investigate 
the other prostanoid receptor knock outs (DP1+2, FP, IP and TP) in this OVA-induced 
MVL model.   
 
7.2.5 Modelling airway MVL in other airway disease models 
 
Microvascular leak is a prominent feature in both acute and chronic airway diseases 
and increased levels of plasma proteins has been measured in the sputum of COPD 
patients (Hill et al, 1999; Minikata et al, 2005; Bessa et al, 2012).  Studies would 
include acute Lipopolysaccharide (LPS)-exposure, which provides a model of acute 
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innate immunity-derived inflammation and is a contaminant of tobacco smoke that 
has been implicated in the development of COPD.  Additionally, both in vitro and in 
vivo LPS models have yielded significant protein extravasation (Hele et al, 2000; Irie 
et al, 2001; Bogatcheva et al, 2009; Schlegal et al, 2012; Jian et al, 2013; Sun et al, 
2013).  Acute cigarette smoke exposure acts as a model of airway inflammation 
using the same causative agent for the vast majority of COPD cases (Rabe et al, 
2007) and has shown considerable MVL in a number of different models (Lundberg 
& Saria, 1983; Geppetti et al, 1993; Andrè et al, 2008; Sharma et al, 2008; 
Schweitzer et al, 2011).  Additionally, data generated in our lab (unpublished, 
personal commincation by Birrell et al) using both of these models have 
demonstrated significant increases in protein levels in the BAL fluid (see figure 7.1). 
 
 
 
 
 
 
 
 
Figure 7.1. The effect of (A) LPS and (B) Cigarette smoke on total protein in BAL fluid 
of C57Bl6 mice.  (A) Mice were exposed to aerosolised saline or LPS (1 mg ml-1 for 30 minutes) 
and BAL fluid samples were taken 2, 6, 24, 48, 72 and 96 hours after challenge and analysed using a 
Bradford Assay to quantify protein levels. (B) Mice were exposed (for 50 minutes) twice a day (four 
hours apart) to cigarette smoke or air for 3, 7, 10, 14, 17, 21, 24 and 28 days.  24 hours after last 
exposure BAL fluid samples were taken and analysed using a Bradford Assay to quantify protein 
levels. n=5. * p<0.05; Unpaired t-test for parametric data or Mann-Whitney t-test for non-parametric 
data. 
Having demonstrated measurable increases in airway MVL in our OVA it would be 
interesting to replicate this in other airway disease models. Furthermore, the role that 
EP receptors place in mediating these effects has not been extensively investigated.   
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7.2.6. Modelling MVL in Human Lung Microvascular Endothelial Cells 
All the data that I have presented on airway MVL has been observed in vivo in 
rodents.  It would therefore be important to investigate the role of PGE2 in a human 
cell based system.  The method for measuring endothelial cell permeability to 
albumin was outlined in chapter 2. Preliminary work using Human Lung 
Microvascular Endothelial Cells (HLMVECs) highlighted a possible role for the TP 
receptor in mediating endothelial monolayer permeability (Figure 7.2) and gene 
expression studies have demonstrated that HLMVECs express EP1, EP4, FP, IP, TP 
and DP2 receptors (Figure 7.3). 
 
 
 
 
 
 
 
Figure 7.2. Effect of the TP agonist, U46619, on Human Lung Microvascular 
Endothelial Cell (HLMVEC) permeability.  The movement of FITC-albumin was used as a 
measure of permeability across the endothelial cell monolayer. N=1, n=6. The MTT Assay indicated 
that none of prostanoid agonists had an effect on cell viability. 
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Figure 7.3. mRNA expression of prostanoid receptors (EP1-4, DP1-2, FP, IP, TP) in 
HLMVEC. n=2.  
This work with the human lung microvascular endothelial cells is preliminary and only 
performed in one patient.  Therefore it would be important to repeat this set of 
experiments with more patients if and when they become available.  Additionally I 
would also investigate the various prostanoid receptor antagonists in this system.   
As I outlined in chapter 6, this may not be the best way of modelling MVL in vitro, 
certainly not by itself.  However, in terms of equipment, costs and expertise this was 
all that was available for this thesis.  If I could repeat this I would run this alongside a 
system that used electrical resistance or impedance (TEER or ECIS) as a measure 
of barrier integrity as these provide a more accurate representation of the stability of 
the endothelial barrier. 
 
7.2.7. Modelling MVL in Mouse Lung Microvascular Endothelial Cells 
 
The preliminary work described above was done using human endothelial cells.  
However, the majority of the work presented in this thesis was from mice, therefore 
to make the data more translatable I would repeat the cell work in mouse lung 
microvascular endothelial cells (MLMVEC).  The extraction of these cells has been 
described by several groups (Licht et al, 2006; Rao et al, 2007; Farley et al, 2008; 
Schniedermann et al, 2010) and would be a great addition to the data that I have 
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obtained through my in vivo studies. In addition, Rao et al (2007) also examined EP 
receptor mRNA expression on primary mouse microvascular endothelial cells and 
detected expression of EP1, EP2 and EP4. Finally, I would examine the effects of 
prostanoids in microvascular endothelial cells from the knock-out mice. 
 
7.3. Concluding Remarks 
 
In summary, the data presented in this thesis provides evidence that PGE2 is able to 
increase airway microvascular leak via the activation of EP2 and EP4 receptors and 
so I am therefore able to accept the hypothesis for this thesis.  In addition, both 
receptors also appear to play a key role in OVA-induced airway MVL. However, this 
data is only illustrated using EP receptor knock-out mice and so warrants further 
investigation.  The exact mechanism behind PGE2-induced MVL is not clear and it is 
possible that haemodynamic changes may be responsible.  Furthermore, preliminary 
data indicates a role for the other prostanoids in mediating plasma extravasation. 
The future work outlined in section 7.2 will hopefully provide further insight into 
prostanoid-induced airway MVL.     
  
184 
 
Reference List 
 
Abe, H., Takeshita, T., Nagata, K., Arita, T., Endo,  ., Fujita, T., … Sugamura, K. (1999). Molecular 
cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative 
member of the leukocyte chemoattractant receptor family. Gene, 227(1), 71–7.  
Abramovitz, M., Adam, M., Boie,  ., Carrière, M., Denis, D., Godbout, C., … Metters, K. M. (2000). 
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of 
prostaglandins and related analogs. Biochimica et Biophysica Acta, 1483(2), 285–93.  
Abramovitz, M., Adam, M., Boie, Y., Grygorczyk, R., Rushmore, T. H., Nguyen, T., Funk, C. D.,  
Bastien, L., Sawyer, N., Rochette, C., Slipetz, D. M. & Metters, K. M. (1995). Human prostanoid 
receptors: cloning and characterisation. Advances in Prostaglandin, Thromboxane and 
Leukotriene Research, 23, 499-504. 
Adam, M., Boie,  ., Rushmore, T. H., Müller, G., Bastien, L., McKee, K. T., … Abramovitz, M. (1994). 
Cloning and expression of three isoforms of the human EP3 prostanoid receptor. FEBS Letters, 
338(2), 170–4.  
Adamson, R. H., Liu, B., Fry, G. N., Rubin, L. L., & Curry, F. E. (1998). Microvascular permeability and 
number of tight junctions are modulated by cAMP. The American Journal of Physiology, 274(6 
Pt 2), H1885–94.  
Agustí, A. G. N. (2005). Systemic effects of chronic obstructive pulmonary disease. Proceedings of 
the American Thoracic Society, 2(4), 367–70; discussion 371–2.  
Ahluwalia, A., & Perretti, M. (1994). Effect of Prostanoids Evidence for a Role of EP3-Receptors ’ in 
Mouse and Rat Skin : The Journal of Pharmacology and Experimental Therapeutics, 268(3), 
1526–1531. 
Amano, M., Ito, M., Fukata, Y., Chihara, K., Nakano, T., Matsuura, Y., & Kaibuchi, K. (1996). 
Phosphorylation and Activation of Myosin by Rho-associated. The Journal of Biological 
Chemistry, 271, 20246–20249. 
Amerongen, G. P. V. N., Draijer, R., Vermeer, M. a., & van Hinsbergh, V. W. M. (1998). Transient and 
Prolonged Increase in Endothelial Permeability Induced by Histamine and Thrombin : Role of 
Protein Kinases, Calcium, and RhoA. Circulation Research, 83(11), 1115–1123.  
Amerongen, G. P. V. N., Vermeer, M. a., & van Hinsbergh, V. W. M. (2000). Role of RhoA and Rho 
Kinase in Lysophosphatidic Acid-Induced Endothelial Barrier Dysfunction. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 20(12), e127–e133.  
Armstrong, M. J., Boura, A. L. A., Hamberg, M., & Samuelsson, B. (1976). A Comparison of the 
Vasodepressor Effects of the Cyclic Endoperoxides PGG2 and PGH2 with those of PGD2 and 
PGE2 in Hypertensive and Normotensive rats. European Journal of Pharmacology, 39, 251–258. 
An, S., Yang, J., So, S. W., Zeng, L., & Goetzl, E. J. (1994). Isoforms of the EP3 subtype of human 
prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry, 
33(48), 14496–502.  
Ansari, H. R., Davis, A. M., Kaddour-Djebbar, I., & Abdel-Latif, A. a. (2003). Effects of prostaglandin 
F2alpha and latanoprost on phosphoinositide turnover, myosin light chain phosphorylation and 
contraction in cat iris sphincter. Journal of Ocular Pharmacology and Therapeutics : The Official 
Journal of the Association for Ocular Pharmacology and Therapeutics, 19(3), 217–31.  
185 
 
Antczak, A., Ciebiada, M., Pietras, T., Piotrowski, W. J., Kurmanowska, Z., & Górski, P. (2012). 
Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive 
pulmonary disease. Archives of Medical Science : AMS, 8(2), 277–85.  
Aoki, T., Nishimura, M., Matsuoka, T.,  amamoto, K., Furuyashiki, T., Kataoka, H., … Narumiya, S. 
(2011). PGE(2) -EP(2) signalling in endothelium is activated by haemodynamic stress and 
induces cerebral aneurysm through an amplifying loop via NF-κB. British Journal of 
Pharmacology, 163(6), 1237–49.  
Arakawa, H., Lötvall, J., Kawikova, I., Löfdahl, C. G., & Skoogh, B. E. (1993). Leukotriene D4- and 
prostaglandin F2 alpha-induced airflow obstruction and airway plasma exudation in guinea-pig: 
role of thromboxane and its receptor. British Journal of Pharmacology, 110(1), 127–32.  
Armour, C. L., Johnson, P. R., Alfredson, M. L., & Black, J. L. (1989). Characterization of contractile 
prostanoid receptors on human airway smooth muscle. European Journal of Pharmacology, 
165(2-3), 215–22.  
Armstrong, R. a. (1996). Platelet prostanoid receptors. Pharmacology & Therapeutics, 72(3), 171–
191.  
Aso, H., Ito, S., Mori, A., Morioka, M., Suganuma, N., Kondo, M., … Hasegawa,  . (2012). 
Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary 
microvascular endothelial cells. American Journal of Physiology. Lung Cellular and Molecular 
Physiology, 302(2), L266–73.  
Audoly, L. P., Tilley, S. L., Goulet, J., Key, M., Nguyen, M., Stock, J. L., … Coffman, T. M. (1999). 
Identification of specific EP receptors responsible for the hemodynamic effects of PGE2. The 
American Journal of Physiology, 277(3 Pt 2), H924–30. Retrieved from  
Bailey, S. R., Boustany, S., Burgess, J. K., Hirst, S. J., Sharma, H. S., Simcock, D. E., … Weckmann, 
M. (2009). Airway vascular reactivity and vascularisation in human chronic airway disease. 
Pulmonary Pharmacology & Therapeutics, 22(5), 417–25.  
Baluk, P., Bolton, P., Hirata, a, Thurston, G., & McDonald, D. M. (1998). Endothelial gaps and 
adherent leukocytes in allergen-induced early- and late-phase plasma leakage in rat airways. 
The American Journal of Pathology, 152(6), 1463–76. Retrieved from  
Baluk, P., Hirata, a, Thurston, G., Fujiwara, T., Neal, C. R., Michel, C. C., & McDonald, D. M. (1997). 
Endothelial gaps: time course of formation and closure in inflamed venules of rats. The 
American Journal of Physiology, 272(1 Pt 1), L155–70.  
Baluk, P., Thurston, G., Murphy, T. J., Bunnett, N. W., & McDonald, D. M. (1999). Neurogenic plasma 
leakage in mouse airways. British Journal of Pharmacology, 126(2), 522–8.  
Barbato, A., Turato, G., Baraldo, S., Bazzan, E., Calabrese, F., Panizzolo, C., … Saetta, M. (2006). 
Epithelial damage and angiogenesis in the airways of children with asthma. American Journal of 
Respiratory and Critical Care Medicine, 174(9), 975–81.  
Barnes, P. J. (1993). Effect of nedocromil sodium on microvascular leakage. The Journal of Allergy 
and Clinical Immunology, 92(1 Pt 2), 197–9.  
Barnes, P. J. (2000). Pro / Con Editorials Inhaled Corticosteroids Are Beneficial in Chronic Inhaled 
Corticosteroids Are Not Beneficial in Chronic. American Journal of Respiratory and Critical Care 
Medicine, 161, 341–344. 
Barnes, P. J. (2006). New therapies for asthma. Trends in Molecular Medicine, 12(11), 515–20.  
186 
 
Barnes, P. J. (2008). Immunology of asthma and chronic obstructive pulmonary disease. Nature 
Reviews. Immunology, 8(3), 183–92.  
Barnes, P. J. (2010a). Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS 
Medicine, 7(3), e1000220.  
Barnes, P. J. (2010b). Inhaled corticosteroids in COPD: a controversy. Respiration; International 
Review of Thoracic Diseases, 80(2), 89–95.  
Barnes, P. J. (2011). Glucocorticosteroids: current and future directions. British Journal of 
Pharmacology, 163(1), 29–43.  
Barnes, P. J. (2012). Severe asthma: advances in current management and future therapy. The 
Journal of Allergy and Clinical Immunology, 129(1), 48–59.  
Barnes, P. J. (2013). New anti-inflammatory targets for chronic obstructive pulmonary disease. Nature 
Reviews Drug Discovery, 12(7), 543–559.  
Barnes, P. J., & Celli, B. R. (2009). Systemic manifestations and comorbidities of COPD. The 
European Respiratory Journal, 33(5), 1165–85.  
Barnes, P. J., Chung, K. F., & Page, C. P. (1998). Inflammatory mediators of asthma: an update. 
Pharmacological Reviews, 50(4), 515–96. Retrieved from  
Barr, R. G., Bluemke, D. a, Ahmed, F. S., Carr, J. J., Enright, P. L., Hoffman, E. a, … Watson, K. E. 
(2010). Percent emphysema, airflow obstruction, and impaired left ventricular filling. The New 
England Journal of Medicine, 362(3), 217–27.  
Barreiro, E., del Puerto-Nevado, L., Puig-Vilanova, E., Pérez-Rial, S., Sánchez, F., Martínez-Galán, 
L., … Peces-Barba, G. (2012). Cigarette smoke-induced oxidative stress in skeletal muscles of 
mice. Respiratory Physiology & Neurobiology, 182(1), 9–17.  
Bastien, L., Sawyer, N., Grygorczyks, R., Metters, K. M., & Adam, M. (1994). Cloning , Functional 
Expression , and Characterization of the Human Prostaglandin E2 Receptor EP2 Subtype. The 
Journal of Biological Chemistry, 269(16), 11873–11877. 
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., … Zar, H. J. 
(2008). Global strategy for asthma management and prevention: GINA executive summary. The 
European Respiratory Journal, 31(1), 143–78.  
Bathoorn, E., Liesker, J. J. W., Postma, D. S., Boorsma, M., Bondesson, E., Koëter, G. H., … 
Kerstjens, H. a M. (2008). Anti-inflammatory effects of combined budesonide/formoterol in 
COPD exacerbations. Copd, 5(5), 282–90.  
Baumer, Y., Drenckhahn, D., & Waschke, J. (2008). cAMP induced Rac 1-mediated cytoskeletal 
reorganization in microvascular endothelium. Histochemistry and Cell Biology, 129(6), 765–78.  
Baumer, Y., Spindler, V., Werthmann, R. C., Bünemann, M., & Waschke, J. (2009). Role of Rac 1 and 
cAMP in endothelial barrier stabilization and thrombin-induced barrier breakdown. Journal of 
Cellular Physiology, 220(3), 716–26.  
Baxter, G. S., Clayton, J. K., Coleman, R. a, Marshall, K., Sangha, R., & Senior, J. (1995). 
Characterization of the prostanoid receptors mediating constriction and relaxation of human 
isolated uterine artery. British Journal of Pharmacology, 116(1), 1692–6.  
Beasley, C. R. W., Robinson, C., Featherstone, R. L., Varley, J. G., Hardy, C. C., Church, M. K., & 
Holgate, S. T. (1987). 9α,11β-Prostaglandin F2, a Novel Metabolite of Prostaglandin D2, Is a 
187 
 
Potent Contractile Agonist of Human and Guinea Pig Airways. Journal of Clinical Investigation, 
79, 978–983. 
Belvisi, M. G., Patel, H. J., Takahashi, T., Barnes, P. J., & Giembycz, M. a. (1996). Paradoxical 
facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea 
by isoprenaline. British Journal of Pharmacology, 117(7), 1413–20.  
Benedict, N., Seybert, A., & Mathier, M. a. (2007). Evidence-based pharmacologic management of 
pulmonary arterial hypertension. Clinical Therapeutics, 29(10), 2134–53.  
Benyahia, C., Gomez, I., Kanyinda, L., Boukais, K., Danel, C., Leséche, G., … Norel, X. (2012). 
PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy? 
Pulmonary Pharmacology & Therapeutics, 25(1), 115–8. doi:10.1016/j.pupt.2011.12.012 
Bertolino, F., Valentin, J. P., Maffre, M., Bessac, a M., & John, G. W. (1995). TxA2 receptor activation 
elicits organ-specific increases in microvascular permeability in the rat. The American Journal of 
Physiology, 268(2 Pt 2), R366–74.  
Bertolino, F., Valentin, J. P., Maffre, M., Jover, B., Bessac, a M., & John, G. W. (1994). Prevention of 
thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 
1 receptor antagonist. The Journal of Pharmacology and Experimental Therapeutics, 268(2), 
747–52.  
Birrell, M. a, Battram, C. H., Woodman, P., McCluskie, K., & Belvisi, M. G. (2003). Dissociation by 
steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways. 
Respiratory Research, 4, 3.  
Birrell, M. a, Maher, S. a, Buckley, J., Dale, N., Bonvini, S., Raemdonck, K., … Belvisi, M. G. (2013). 
Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay 
systems: atypical affinity at the guinea pig EP2 receptor. British Journal of Pharmacology, 
168(1), 129–38.  
Birrell, M. A., Mccluskie, K., Wong, S., Donnelly, L. E., Barnes, P. J., & Belvisi, M. G. (2005). 
Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and 
inflammatory mediators through an NF-κB-independent mechanism. The FASEB Journal, 22(2), 
1–22. 
Birring, S. S., Parker, D., Brightling, C. E., Bradding, P., Wardlaw, A. J., & Pavord, I. D. (2004). 
Induced sputum inflammatory mediator concentrations in chronic cough. American Journal of 
Respiratory and Critical Care Medicine, 169(1), 15–9.  
Birukova, A. a, Burdette, D., Moldobaeva, N., Xing, J., Fu, P., & Birukov, K. G. (2010). Rac GTPase is 
a hub for protein kinase A and Epac signaling in endothelial barrier protection by cAMP. 
Microvascular Research, 79(2), 128–38.  
Birukova, A. a, Liu, F., Garcia, J. G. N., & Verin, A. D. (2004). Protein kinase A attenuates endothelial 
cell barrier dysfunction induced by microtubule disassembly. American Journal of Physiology. 
Lung Cellular and Molecular Physiology, 287(1), L86–93.  
Birukova, A. a, Zagranichnaya, T., Fu, P., Alekseeva, E., Chen, W., Jacobson, J. R., & Birukov, K. G. 
(2007). Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- 
and Epac1/Rap1-dependent Rac activation. Experimental Cell Research, 313(11), 2504–20.  
Blé, F.-X., Cannet, C., Zurbruegg, S., Gérard, C., Frossard, N., Beckmann, N., & Trifilieff, a. (2009). 
Activation of the lung S1P(1) receptor reduces allergen-induced plasma leakage in mice. British 
Journal of Pharmacology, 158(5), 1295–301.  
188 
 
Bley, K. R., Bhattacharya, A., Daniels, D. V, Gever, J., Jahangir, A., O’ ang, C., … Jett, M.-F. (2006). 
RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP 
(prostacyclin) receptor antagonists. British Journal of Pharmacology, 147(3), 335–45.  
Bley, K. R., Hunter, J. C., Eglen, R. M., & Smith, J. a. (1998). The role of IP prostanoid receptors in 
inflammatory pain. Trends in Pharmacological Sciences, 19(4), 141–7.  
Blue, E. K., Goeckeler, Z. M., Jin,  ., Hou, L., Dixon, S. a, Herring, B. P., … Gallagher, P. J. (2002). 
220- and 130-kDa MLCKs have distinct tissue distributions and intracellular localization patterns. 
American Journal of Physiology. Cell Physiology, 282(3), C451–60.  
Bodnar, J. a, Morgan, W. T., Murphy, P. a, & Ogden, M. W. (2012). Mainstream smoke chemistry 
analysis of samples from the 2009 US cigarette market. Regulatory Toxicology and 
Pharmacology : RTP, 64(1), 35–42.  
Boer, W. I., Alagappan, V. K. T., & Sharma, H. S. (2007). Molecular mechanisms in chronic 
obstructive pulmonary disease. Cell Biochemistry and Biophysics, 47(1), 131–147.  
Böhm, E., Sturm, G. J., Weiglhofer, I., Sandig, H., Shichijo, M., McNamee, A., … Heinemann, A. 
(2004). 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of 
chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human 
eosinophils and basophils. The Journal of Biological Chemistry, 279(9), 7663–70.  
Boie, Y., Rushmore, T. H., Darmon-Goodwin, A., Grygorczyk, R., Slipetz, D. M., Metters, K. M., & 
Abramovitz, M. (1994). Cloning and Expression of a cDNA for the Human Prostanoid IP 
receptor. The Journal of Biological Chemistry, 269(16), 12173–12178. 
Boie, Y., Sawyer, N., Slipetz, D. M., Metters, K. M., & Abramovitz, M. (1995). Molecular Cloning and 
Characterization of the Human Prostanoid DP Receptor. The Journal of Biological Chemistry, 
270(32), 18910–18916. 
Boie, Y., Stocco, R., Sawyer, N., Slipetz, D. M., Ungrin, M. D., Neuschäfer-Rube, F., … Abramovitz, 
M. (1997). Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid 
receptor subtypes. European Journal of Pharmacology, 340(2-3), 227–41.  
Booij-Noord, H., Orie, N. G., & De Vries, K. (1971). Immediate and late bronchial obstructive reactions 
to inhalation of house dust and protective effects of disodium cromoglycate and prednisolone. 
The Journal of Allergy and Clinical Immunology, 48(6), 344–54.  
Booij-Noord, H., De Vries, K., Sluiter, H. J. & Orie, N. G. (1972). Late bronchial obstructive reaction to 
experimental inhalation of house dust extract. Clinical Allergy, 2, 43-61. 
Booth, R., & Kim, H. (2012). Characterization of a microfluidic in vitro model of the blood-brain barrier 
(μBBB). Lab on a Chip, 12(10), 1784–92. 
Borić, M. P., Roblero, J. S., & Durán, W. N. (1987). Quantitation of bradykinin-induced microvascular 
leakage of FITC-dextran in rat cremaster muscle. Microvascular Research, 33(3), 397–412.  
Bos, C. L., Richel, D. J., Ritsema, T., Peppelenbosch, M. P., & Versteeg, H. H. (2004). Prostanoids 
and prostanoid receptors in signal transduction. The International Journal of Biochemistry & Cell 
Biology, 36(7), 1187–205.  
Bousquet, J., Chanez, P., Lacoste, J.  ., Barneon, G., Ghavanian, N., Enander, I., … Michel, F.-B. 
(1990). Eosinophilic Inflammation in Asthma. The New England Journal of Medicine, 323(15), 
1033–1039. 
189 
 
Bousquet, J., Jeffery, P. K., Busse, W. W., Johnson, M., & Vignola, A. M. (2000). Asthma. From 
Bronchoconstriction to Airways Inflammation and Remodeling. American Journal of Respiratory 
and Critical Care Medicine, 161, 1720–1745. 
Bradbury, D., Clarke, D., Seedhouse, C., Corbett, L., Stocks, J., & Knox, A. (2005). Vascular 
endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is 
mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. The 
Journal of Biological Chemistry, 280(34), 29993–30000.  
Bradding, P., Walls, A. F., & Holgate, S. T. (2006). The role of the mast cell in the pathophysiology of 
asthma. The Journal of Allergy and Clinical Immunology, 117(6), 1277–84.  
Brass, D. M., Hollingsworth, J. W., Cinque, M., Li, Z., Potts, E., Toloza, E., … Schwartz, D. a. (2008). 
Chronic LPS inhalation causes emphysema-like changes in mouse lung that are associated with 
apoptosis. American Journal of Respiratory Cell and Molecular Biology, 39(5), 584–90.  
Breyer, M. D., & Breyer, R. M. (2001). G Protein-Coupled Prostanoid Receptors and the Kidney. 
Annual Review of Physiology, 63, 579–605. 
Breyer, R. M., Bagdassarian, C. K., Scott, A., & Breyer, M. D. (2001). Prostanoid Receptors: Subtypes 
and Signaling. Annual Review of Pharmacology and Toxicology, 41, 661–690. 
Breyer, R. M., Davis, L. S., Nian, C., Redha, R., Stillman, B., Jacobson, H. R., & Breyer, M. D. (1996). 
Cloning and expression of the rabbit prostaglandin EP4 receptor. The American Journal of 
Physiology, 270(3 Pt 2), F485–93.  
Brightling, C. E., Ward, R., Woltmann, G., Bradding, P., Sheller, J. R., Dworski, R., & Pavord, I. D. 
(2000). Induced Sputum Inflammatory Mediator Concentrations in Eosinophilic Bronchitis and 
Asthma. American Journal of Respiratory and Critical Care Medicine, 162, 878–882. 
Brochhausen, C., Zehbe, R., Watzer, B., Halstenberg, S., Gabler, F., Schubert, H., & Kirkpatrick, C. J. 
(2009). Immobilization and controlled release of prostaglandin E2 from poly-L-lactide-co-
glycolide microspheres. Journal of Biomedical Materials Research. Part A, 91(2), 454–62.  
Buckley, J., Birrell, M. a, Maher, S. a, Nials, A. T., Clarke, D. L., & Belvisi, M. G. (2011). EP4 receptor 
as a new target for bronchodilator therapy. Thorax, 66(12), 1029–35.  
Burgess, J. K., Ge, Q., Boustany, S., Black, J. L., & Johnson, P. R. a. (2004). Increased sensitivity of 
asthmatic airway smooth muscle cells to prostaglandin E2 might be mediated by increased 
numbers of E-prostanoid receptors. The Journal of Allergy and Clinical Immunology, 113(5), 
876–81.  
Burka, J. F., Ali, M., Mcdonald, J. W. D., & Paterson, N. A. M. (1981). Immunological and Non-
Immunological Synthesis and Release of Prostaglandins and Thromboxanes from Isolated 
Guinea Pig Trachea. Prostaglandins, 22(5), 683–691. 
Cai, S., Pestic-Dragovich, L., O’Donnell, M. E., Wang, N., Ingber, D., Elson, E., & De Lanerolle, P. 
(1998). Regulation of cytoskeletal mechanics and cell growth by myosin light chain 
phosphorylation. The American Journal of Physiology, 275(5 Pt 1), C1349–56. Retrieved from  
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., … Vestbo, 
J. (2007). Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary 
Disease. The New England Journal of Medicine, 356(8), 775–789. 
Calverley, P. M., Boonsawat, W., Cseke, Z., Zhong, N., Peterson, S., & Olsson, H. (2003). 
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease. 
European Respiratory Journal, 22(6), 912–919.  
190 
 
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., … Maden, C. (2003). 
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: 
a randomised controlled trial. Lancet, 361(9356), 449–56.  
Cao, J., Shayibuzhati, M., Tajima, T., Kitazawa, T., & Taneike, T. (2002). In vitro pharmacological 
characterization of the prostanoid receptor population in the non-pregnant porcine myometrium. 
European Journal of Pharmacology, 442(1-2), 115–23.  
Capra, V. (2003). Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant 
role in proliferation. European Journal of Pharmacology, 474(2-3), 149–159.  
Carrasco, M. P., Phaneuf, S., Asboth, G. & Bernal A. L. (1996). Fluprostenol activates phospholipase 
C and Ca2+ mobilization in human myometrial cells. Journal of Clinical Endocrinology & 
Metabolism, 81, 2104-2110. 
Chalmers, G. W., Macleod, K. J., Little, S. a, Thomson, L. J., McSharry, C. P., & Thomson, N. C. 
(2002). Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. 
Thorax, 57(3), 226–30.  
Chapman, M. D., & Platts-mills, T. A. E. (1980). Purification and Characterization of the Major 
Allergen from Dermatophagoides Pteronyssinus-Antigen P1. The Journal of Immunology, 
125(2), 587–592. 
Chappell, D., Beiras-Fernandez, A., Hammer, C., & Thein, E. (2006). In vivo visualization of the effect 
of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a 
primate model. Transplantation, 81(4), 552–8.  
Chen, Q., Muramoto, K., Masaaki, N., Ding,  .,  ang, H., Mackey, M., … Lamphier, M. (2010). A 
novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 
expansion and is orally active in arthritis models. British Journal of Pharmacology, 160(2), 292–
310.  
Chen, Y., Chen, P., Hanaoka, M., Droma, Y., & Kubo, K. (2008). Enhanced levels of prostaglandin E2 
and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. 
Respirology (Carlton, Vic.), 13(7), 1014–21.  
Cheng,  ., Austin, S. C., Rocca, B., Koller, B. H., Coffman, T. M., Grosser, T., … FitzGerald, G. a. 
(2002). Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (New 
York, N.Y.), 296(5567), 539–41.  
Chetham, P. M., Alexandra, H., Brough, G. H., Bridges, J. P., Joseph, W., Stevens, T., … Brough, H. 
(1997). Ca2+-inhibitable adenylyl cyclase and pulmonary microvascular permeability. American 
Journal of Physiology. Lung Cellular and Molecular Physiology, 273, L22–L30. 
Chevalier, E., Stock, J., Fisher, T., Dupont, M., Fric, M., Fargeau, H., … Li, B. (2005). Cutting Edge: 
Chemoattractant Receptor-Homologous Molecule Expressed on TH2 Cells Plays a Restricting 
Role on IL-5 Production and Eosinophil Recruitment. The Journal of Immunology, 175(4), 2056–
2060.  
Chrzanowska-Wodnicka, M., & Burridge, K. (1996). Rho-stimulated contractility drives the formation of 
stress fibers and focal adhesions. The Journal of Cell Biology, 133(6), 1403–15.  
Chung, K. F., Godard, P., Adelroth, E., Ayres, J., Barnes, N., Barnes, P., … Sterk, P. (1999). Difficult / 
therapy-resistant asthma. The need for an integrated approach to define clinical phenotypes, 
evaluate risk factors, understand pathophysiology and find novel therapies. European 
Respiratory Journal, 13, 1198–1208. 
191 
 
Churg, A., Wang, R. D., Tai, H., Wang, X., Xie, C., & Wright, J. L. (2004). Tumor necrosis factor-alpha 
drives 70% of cigarette smoke-induced emphysema in the mouse. American Journal of 
Respiratory and Critical Care Medicine, 170(5), 492–8.  
Clarke, D. L., Belvisi, M. G., Catley, M. C., Yacoub, M. H., Newton, R., & Giembycz, M. a. (2004). 
Identification in human airways smooth muscle cells of the prostanoid receptor and signalling 
pathway through which PGE2 inhibits the release of GM-CSF. British Journal of Pharmacology, 
141(7), 1141–50.  
Clarke, D. L., Belvisi, M. G., Hardaker, E., Newton, R., & Giembycz, M. A. (2005). E-Ring 8-
Isoprostanes Are Agonists at EP 2 - and EP 4 - Prostanoid Receptors on Human Airway Smooth 
Muscle Cells and Regulate the Release of Colony-Stimulating Factors by Activating cAMP-
Dependent Protein Kinase. Molecular Pharmacology, 67(2), 383–393.  
Claudino, R. F., Kassuya, C. A. L., Ferreira, J., & Calixto, B. (2006). Pharmacological and Molecular 
Characterization of the Mechanisms Involved in Prostaglandin E 2 -Induced Mouse Paw Edema. 
The Journal of Pharmacology and Experimental Therapeutics, 318(2), 611–618.  
Clearie, K. L., McKinlay, L., Williamson, P. a, & Lipworth, B. J. (2012). Fluticasone/Salmeterol 
combination confers benefits in people with asthma who smoke. Chest, 141(2), 330–8.  
Cleaver, O., & Melton, D. a. (2003). Endothelial signaling during development. Nature Medicine, 9(6), 
661–8.  
Clough, B. Y. G., & Michel, C. C. (1988). Quantitative comparisons of Hydraulic Permeability and 
Endothelial Intercellular Cleft Dimensions in Single Frog Capillaries. Journal of Physiology, 405, 
563–576. 
Cocks, T. M., Fong, B., Chow, J. M., Anderson, G. P., Frauman, A. G., Goldie, R. G., … Moffatt, J. D. 
(1999). A protective role for protease-activated receptors in the airways. Letters to Nature, 398, 
156–160. 
Cohen, a W., Carbajal, J. M., & Schaeffer, R. C. (1999). VEGF stimulates tyrosine phosphorylation of 
beta-catenin and small-pore endothelial barrier dysfunction. The American Journal of 
Physiology, 277(5 Pt 2), H2038–49. Retrieved from  
Coisne, C., & Engelhardt, B. (2011). Tight junctions in brain barriers during central nervous system 
inflammation. Antioxidants & Redox Signaling, 15(5), 1285–303.  
Coleman, R. A., Kennedy, I., Sheldrick, E. L. (1987). New evidence with selective agonists and 
antagonists for the subclassification of PGE2-sensitive (EP) receptors. Advances in 
prostaglandin, thromboxane, and leukotriene research, 17A, 467-70. 
Coleman, R. a, Grix, S. P., Head, S. a, Louttit, J. B., Mallett, a, & Sheldrick, R. L. (1994). A novel 
inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins, 47(2), 151–68.  
Coleman, R. a, Humphrey, P. P., Kennedy, I., Levy, G. P., & Lumley, P. (1981). Comparison of the 
actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and 
thromboxane A2 on some isolated smooth muscle preparations. British Journal of 
Pharmacology, 73(3), 773–8.  
Coleman, R. a, & Sheldrick, R. L. (1989). Prostanoid-induced contraction of human bronchial smooth 
muscle is mediated by TP-receptors. British Journal of Pharmacology, 96(3), 688–92.  
Coleman, R. A., & Kennedy, I. (1985). Characterisation of the Prostanoid Receptors Mediating 
Contraction fo Guinea-Pig Isolated Trachea. Prostaglandins, 29(3), 363–375. 
192 
 
Coleridge, H. M., Coleridge, J. C. G., Ginzel, K. H., Baker, D. G., Banzett, R. B., & Morrison, M. A. 
(1976). Stimulation of “irritant” receptors and afferent C-fibred in the lungs by prostaglandins. 
Nature, 264, 451–453. 
Connor, T. I. M. O., Neville, C., Burns, K. D., He, R. L., Laneuville, O., Peterson, L. N., … Peter-, L. N. 
(1998). Prostanoid signaling, localiazation, and expression of IP receptors in rat thick ascending 
limb cells. American Journal of Physiology. Renal Physiology, 275, 904–914. 
Corada, M., Mariotti, M., Thurston, G., Smith, K., Kunkel, R., Brockhaus, M., … Dejana, E. (1999). 
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. 
Proceedings of the National Academy of Sciences of the United States of America, 96(17), 
9815–20.  
Cossette, C., Walsh, S. E., Kim, S., Lee, G., Lawson, J. A., Bellone, S., … Powell, W. S. (2007). 
Agonist and Antagonist Effects of 15 R -Prostaglandin (PG) D2 and 11-Methylene-PGD2 on 
Human Eosinophils and Basophils. The Journal of Pharmacology and Experimental 
Therapeutics, 320(1), 173–179.  
Cureton, E. L., Chong, T. J., Kwan, R. O., Dozier, K. C., Sadjadi, J., Curran, B., & Victorino, G. P. 
(2010). Endothelin 1 and prostacyclin attenuate increases in hydraulic permeability caused by 
platelet-activating factor in rats. Shock, 33(6), 620–5.  
Curry, F. E. (2002). Microvascular Injury: Mechanisms and Modulation. International Journal of 
Angiology, 6, 1–6. 
Curry, F.-R. E., & Adamson, R. H. (2010). Vascular permeability modulation at the cell, microvessel, 
or whole organ level: towards closing gaps in our knowledge. Cardiovascular Research, 87(2), 
218–29.  
Curry, F., Huxley, V. & Sarelius, I. (1983). Cardiovascular Physiology. Techniques in the Life 
Sciences. New York, Elsevier, 1-34. 
Curry, F.-R. E., Rygh, C. B., Karlsen, T., Wiig, H., Adamson, R. H., Clark, J. F., … Reed, R. K. (2010). 
Atrial natriuretic peptide modulation of albumin clearance and contrast agent permeability in 
mouse skeletal muscle and skin: role in regulation of plasma volume. The Journal of Physiology, 
588(Pt 2), 325–39.  
Cyphert, J. M., Allen, I. C., Church, R. J., Latour, A. M., Snouwaert, J. N., Coffman, T. M., & Koller, B. 
H. (2012). Allergic inflammation induces a persistent mechanistic switch in thromboxane-
mediated airway constriction in the mouse. American Journal of Physiology. Lung Cellular and 
Molecular Physiology, 302(1), L140–51.  
Dahl, R., Greefhorst, L. A. P. M., Nowak, D., Nonikov, V., Byrne, A. M., Thomson, M. H., … Cioppa, 
G. Della. (2001). Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic 
Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 
164, 778–784. 
Dai, G., Kaazempur-Mofrad, M. R., Natarajan, S., Zhang,  ., Vaughn, S., Blackman, B. R., … 
Gimbrone, M. a. (2004). Distinct endothelial phenotypes evoked by arterial waveforms derived 
from atherosclerosis-susceptible and -resistant regions of human vasculature. Proceedings of 
the National Academy of Sciences of the United States of America, 101(41), 14871–6.  
Davì, G., Basili, S., Vieri, M., Cipollone, F., Santarone, S., Alessandri, C., … Enhanced, G. (1997). 
Enhanced Thromboxane Biosynthesis in Patients with Chronic Obstructive Pulmonary Disease. 
American Journal of Respiratory and Critical Care Medicine, 156, 1794–1799. 
193 
 
Davies, P. F. (2009). Hemodynamic Shear Stress and the endothelium in cardiovascular 
pathophysiology. Nature Clinical Practice Cardiovascular Medicine, 6(1), 16–26.  
Davis, R. J., Murdoch, C. E., Ali, M., Purbrick, S., Ravid, R., Baxter, G. S., … Coleman, R. a. (2004). 
EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. British 
Journal of Pharmacology, 141(4), 580–5.  
De Alba, J., Raemdonck, K., Dekkak, a, Collins, M., Wong, S., Nials, a T., … Birrell, M. a. (2010). 
House dust mite induces direct airway inflammation in vivo: implications for future disease 
therapy? The European Respiratory Journal, 35(6), 1377–87.  
Denniss, S. G., & Rush, J. W. E. (2009). Impaired hemodynamics and endothelial vasomotor function 
via endoperoxide-mediated vasoconstriction in the carotid artery of spontaneously hypertensive 
rats. American Journal of Physiology. Heart and Circulatory Physiology, 296, 1038–1047. 
Di Lorenzo, A., Lin, M. I., Murata, T., Landskroner-Eiger, S., Schleicher, M., Kothiya, M., … Sessa, W. 
C. (2013). eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin 
and Rho GTPases. Journal of Cell Science, 126, 5541–52.  
Djukanović, R., Homeyard, S., Gratziou, C., Madden, J., Walls, a, Montefort, S., … Howarth, P. 
(1997). The effect of treatment with oral corticosteroids on asthma symptoms and airway 
inflammation. American Journal of Respiratory and Critical Care Medicine, 155(3), 826–32.  
Djukanović, R., Wilson, J. W., Britten, K. M., Wilson, S. J., Walls, A. F., Roche, W. R., Howarth, P. H. 
& Holgate, S. T. (1992). Effect of an inhaled corticosteroid on airway inflammation and 
symptoms in asthma.  The American review of respiratory disease, 145, 669-674. 
Dong, Y. J., Jones, R. L., & Wilson, N. H. (1986). Prostaglandin E receptor subtypes in smooth 
muscle: agonist activities of stable prostacyclin analogues. British Journal of Pharmacology, 
87(1), 97–107.  
Dorn, G. W., & Becker, M. W. (1993). Thromboxane A2 Stimulated Signal Transduction in Vascular 
Smooth Muscle. The Journal of Pharmacology and Experimental Therapeutics, 265(1), 447–
456. 
Drenckhahn, D., & Wagner, J. (1986). Stress fibers in the splenic sinus endothelium in situ: molecular 
structure, relationship to the extracellular matrix, and contractility. The Journal of Cell Biology, 
102(5), 1738–47.  
Drummond, M. B., Dasenbrook, E. C., Pitz, M. W., Murphy, D. J., & Fan, E. (2008). Inhaled 
Corticosteroids in Patients with Stable Chronic Obstructive Pulmonary Disease. A Systematic 
Review and Meta Analysis. JAMA, 300(20), 2407–2416. 
Dudek, S. M., & Garcia, J. G. N. (2001). Cytoskeletal regulation of pulmonary vascular permeability. 
Journal of Applied Physiology, 91, 1487–1500. 
Dunnill, M. S., Massarella, G. R., & Anderson, J. a. (1969). A comparison of the quantitative anatomy 
of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in 
emphysema. Thorax, 24(2), 176–9.  
Ebina, M., Takahashi, T., Chiba, T., & Motomiya, M. (1993). Cellular Hypertrophy and Hyperplasia of 
Airway Smooth Muscles Underlying Bronchial Asthma. A 3-D Morphometric Study. American 
Reviews of Respiratory Disease, 148, 720–726. 
Edwards, M. R., Bartlett, N. W., Clarke, D., Birrell, M., Belvisi, M., & Johnston, S. L. (2009). Targeting 
the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacology & 
Therapeutics, 121(1), 1–13.  
194 
 
Emery, D. L., Djokic, T. D., Graf, P. D., & Nadel, J. A. (1989). Prostaglandin D2 causes accumulation 
of eosinophils in the lumen of the dog trachea. Journal of Applied Physiology, 67(3), 959–962. 
Engelhardt, B., & Sorokin, L. (2009). The blood-brain and the blood-cerebrospinal fluid barriers: 
function and dysfunction. Seminars in Immunopathology, 31(4), 497–511.  
Ereso, A. Q., Cureton, E. L., Cripps, M. W., Sadjadi, J., Dua, M. M., Curran, B., & Victorino, G. P. 
(2009). Lipoxin a(4) attenuates microvascular fluid leak during inflammation. The Journal of 
Surgical Research, 156(2), 183–8.  
Erjefält, J. S., Andersson, P., Gustafsson, B., Korsgren, M., Sonmark, B., & Persson, C. G. (1998). 
Allergen challenge-induced extravasation of plasma in mouse airways. Clinical and 
Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 28(8), 
1013–20.  
Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T., & Risau, W. (1998). Vascular 
endothelial growth factor induces endothelial fenestrations in vitro. The Journal of Cell Biology, 
140(4), 947–59.  
Essler, M. (1998). Thrombin Inactivates Myosin Light Chain Phosphatase via Rho and Its Target Rho 
Kinase in Human Endothelial Cells. Journal of Biological Chemistry, 273(34), 21867–21874.  
Eum, S.-Y., Maghni, K., Hamid, Q., Eidelman, D. H., Campbell, H., Isogai, S., & Martin, J. G. (2003). 
Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by 
dexamethasone: Role of eosinophils, IL-5, eotaxin, and IL-13. Journal of Allergy and Clinical 
Immunology, 111(5), 1049–1061.  
Fabre, J. E., Nguyen, M., Athirakul, K., Coggins, K., McNeish, J. D., Austin, S., … Koller, B. H. (2001). 
Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet 
aggregation. The Journal of Clinical Investigation, 107(5), 603–10.  
Félétou, M., Verbeuren, T. J., & Vanhoutte, P. M. (2009). Endothelium-dependent contractions in 
SHR: a tale of prostanoid TP and IP receptors. British Journal of Pharmacology, 156(4), 563–74.  
Feng, D., Nagy, J. a, Hipp, J., Dvorak, H. F., & Dvorak, a M. (1996). Vesiculo-vacuolar organelles and 
the regulation of venule permeability to macromolecules by vascular permeability factor, 
histamine, and serotonin. The Journal of Experimental Medicine, 183(5), 1981–6.  
Ferretti, S., Bonneau, O., Dubois, G. R., Jones, C. E., & Trifilieff, a. (2003). IL-17, Produced by 
Lymphocytes and Neutrophils, Is Necessary for Lipopolysaccharide-Induced Airway 
Neutrophilia: IL-15 as a Possible Trigger. The Journal of Immunology, 170(4), 2106–2112.  
Fiebich, B. L., Schleicher, S., Spleiss, O., Czygan, M., & Hüll, M. (2001). Mechanisms of 
prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like 
receptors, p38 mitogen-activated protein kinase and protein kinase C. Journal of 
Neurochemistry, 79(5), 950–8.  
Fish, J. E., Jameson, L. S., Albright, A., Norman, P. S. (1984). Modulation of the bronchomotor effects 
of chemical mediators by prostaglandin F2 alpha in asthmatic subjects. American Review of 
Respiratory Disease, 130 (4), 571-574. 
Flower, R. J. (1973). Aspirin-like drugs and prostaglandins. American Heart Journal, 86(6), 844–846. 
Flower, R. J. (1978). Biosynthesis of prostaglandins. CIBA Foundation Symposium, 65, 123-142. 
Flower, R. J., Harvey, E. A., & Kingston, W. P. (1976). Inflammatory Effects of Prostaglandin D2 in 
Rat and Human Skin. British Journal of Pharmacology, 56, 229–233. 
195 
 
Flower, R. J., & Kingston, W. P. (1975). Prostglandin D1 inhibits the increase in vascular permeability 
in rat skin produced by prostaglandin E1, E2, and D2. Proceedings of the British 
Pharmacological Society. 
Flower, R. J., & Vane, J. R. (1974). Inhibition of prostaglandin biosynthesis. Biochemical 
Pharmacology, 23, 1439–1450. 
Fordjour, A. K., & Harrington, E. O. (2009). PKCdelta influences p190 phosphorylation and activity: 
events independent of PKCdelta-mediated regulation of endothelial cell stress fiber and focal 
adhesion formation and barrier function. Biochimica et Biophysica Acta, 1790(10), 1179–90.  
Fortner, C. N., Breyer, R. M., & Paul, R. J. (2001). EP2 receptors mediate airway relaxation to 
substance P, ATP, and PGE2. American Journal of Physiology. Lung Cellular and Molecular 
Physiology, 281(2), L469–74.  
Forselles, K. J., Root, J., Clarke, T., Davey, D., Aughton, K., Dack, K., & Pullen, N. (2011). In vitro and 
in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP₂ 
receptor antagonist. British Journal of Pharmacology, 164(7), 1847–56.  
Foudi, N., Kotelevets, L., Louedec, L., Leséche, G., Henin, D., Chastre, E., & Norel, X. (2008). 
Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor 
subtype. British Journal of Pharmacology, 154(8), 1631–9.  
Francois, H., Makhanova, N., Ruiz, P., Ellison, J., Mao, L., Rockman, H. A., & Coffman, T. M. (2008). 
A role for the thromboxane receptor in L -NAME hypertension. American Journal of Physiology. 
Renal Physiology, 295, 1096–1102.  
Frias, M. a, Rebsamen, M. C., Gerber-Wicht, C., & Lang, U. (2007). Prostaglandin E2 activates Stat3 
in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy. Cardiovascular 
Research, 73(1), 57–65.  
Fu, B. M., & Shen, S. (2004). Acute VEGF effect on solute permeability of mammalian microvessels in 
vivo. Microvascular Research, 68(1), 51–62.  
Fujino, H., Salvi, S., & Regan, J. W. (2005). Differential Regulation of Phosphorylation of the cAMP 
Response Element-Binding Protein after Activation of EP 2 and EP 4 Prostanoid Receptors by 
Prostaglandin E 2. Molecular Pharmacology, 68(1), 251–259.  
Fujino, H., West, K. a, & Regan, J. W. (2002). Phosphorylation of glycogen synthase kinase-3 and 
stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by 
prostaglandin E2. The Journal of Biological Chemistry, 277(4), 2614–9.  
Funk, C. D., Furci, L., FitzGerald, G. a, Grygorczyk, R., Rochette, C., Bayne, M. a, … Metters, K. M. 
(1993). Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. 
The Journal of Biological Chemistry, 268(35), 26767–72.  
Gallant, M. a, Samadfam, R., Hackett, J. a, Antoniou, J., Parent, J.-L., & de Brum-Fernandes, A. J. 
(2005). Production of prostaglandin D(2) by human osteoblasts and modulation of 
osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. Journal of Bone 
and Mineral Research : The Official Journal of the American Society for Bone and Mineral 
Research, 20(4), 672–81.  
Gallant, M. a, Slipetz, D., Hamelin, E., Rochdi, M. D., Talbot, S., de Brum-Fernandes, A. J., & Parent, 
J.-L. (2007). Differential regulation of the signaling and trafficking of the two prostaglandin D2 
receptors, prostanoid DP receptor and CRTH2. European Journal of Pharmacology, 557(2-3), 
115–23.  
196 
 
Gallant, M., Carrière, M. C., Chateauneuf, a, Denis, D., Gareau, Y., Godbout, C., … Labelle, M. 
(2002). Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) 
prostanoid receptor. Bioorganic & Medicinal Chemistry Letters, 12(18), 2583–6.  
Gan, W. Q. (2004). Association between chronic obstructive pulmonary disease and systemic 
inflammation: a systematic review and a meta-analysis. Thorax, 59(7), 574–580.  
Garcia, J. G., Davis, H. W. & Patterson, C. E. (1995). Regulation of endothelial cell gap formation and 
barrier dysfunction: role of myosin light chain phosphorylation. Journal of Cellular Physiology, 
163, 510-522. 
Garcia, J. G. N., Lazar, V., Gilbert-mcclain, L. I., Gallagher, P. J., & Verin, A. D. (1997). Myosin Light 
Chain Kinase in Endothelium: Molecular Cloning and Regulation. American Journal of 
Respiratory Cell and Molecular Biology, 16, 489–494. 
Gardiner, P. J. (1986). Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly 
selective agonist, TR4979. British Journal of Pharmacology, 87(1), 45–56.  
Gauvreau, G. M., Watson, R. M., & O’Byrne, P. M. (1999). Protective effects of inhaled PGE2 on 
allergen-induced airway responses and airway inflammation. American Journal of Respiratory 
and Critical Care Medicine, 159(1), 31–6.  
Gavard, J., & Gutkind, J. S. (2006). VEGF controls endothelial-cell permeability by promoting the 
beta-arrestin-dependent endocytosis of VE-cadherin. Nature Cell Biology, 8(11), 1223–34.  
Gendron, M.-E., & Thorin, E. (2007). A change in the redox environment and thromboxane A 2 
production precede endothelial dysfunction in mice. American Journal of Physiology. Heart and 
Circulatory Physiology, 293, 2508–2515.  
George, R. J., Sturmoski, M. a, Anant, S., & Houchen, C. W. (2007). EP4 mediates PGE2 dependent 
cell survival through the PI3 kinase/AKT pathway. Prostaglandins & Other Lipid Mediators, 83(1-
2), 112–20.  
Germonpré, P. R., Joos, G. F., Mekeirele, K., & Pauwels, R. a. (1997). Role of the 5-HT receptor in 
neurogenic inflammation in Fisher 344 rat airways. European Journal of Pharmacology, 324(2-
3), 249–55.  
Gervais, F. G., Cruz, R. P., Chateauneuf, a, Gale, S., Sawyer, N., Nantel, F., … O’neill, G. P. (2001). 
Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the 
PGD2 receptors CRTH2 and DP. The Journal of Allergy and Clinical Immunology, 108(6), 982–
8.  
Gervais, F. G., Morello, J., Beaulieu, C., Sawyer, N., Denis, D., Greig, G., … Neill, G. P. O. (2005). 
Identification of a Potent and Selective Synthetic Agonist at the CRTH2 Receptor. Molecular 
Pharmacology, 67(6), 1834–1839.  
Giblin, G. M. P., Bit, R. a, Brown, S. H., Chaignot, H. M., Chowdhury, A., Chessell, I. P., … Wilson, R. 
(2007). The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-
cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin 
EP1 receptor antagonist for the treatment of inflammatory pain. Bioorganic & Medicinal 
Chemistry Letters, 17(2), 385–9.  
Giles, H., Leff, P., Bolofo, M. L., Kelly, M. G., & Robertson, a D. (1989). The classification of 
prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and 
potent competitive antagonist. British Journal of Pharmacology, 96(2), 291–300.  
197 
 
Goeckeler, Z. M., & Wysolmerski, R. B. (1995). Myosin light chain kinase-regulated endothelial cell 
contraction: the relationship between isometric tension, actin polymerization, and myosin 
phosphorylation. The Journal of Cell Biology, 130(3), 613–27.  
Goldenberg, N. M., Steinberg, B. E., Slutsky, A. S., & Lee, W. L. (2011). Broken barriers: a new take 
on sepsis pathogenesis. Science Translational Medicine, 3(88), 88ps25.  
Gorman, R. R., Bunting, S., & Miller, O. V. (1977). Modulation of Human Platelet Adenylate Cyclase 
by Prostacyclin. Prostaglandins, 13(3), 377–388. 
Goulet, J. L., Pace, A. J., Key, M. L., Byrum, R. S., Nguyen, M., Tilley, S. L., … Koller, B. H. (2004). E-
prostanoid-3 receptors mediate the proinflammatory actions of prostaglandin E2 in acute 
cutaneous inflammation. Journal of Immunology (Baltimore, Md. : 1950), 173(2), 1321–6.  
Graham, D. A., & Rush, J. W. E. (2009). Cyclooxygenase and thromboxane / prostaglandin receptor 
contribute to aortic endothelium-dependent dysfunction in aging female spontaneously 
hypertensive rats. Journal of Applied Physiology, 107, 1059–1067.  
Greiff, L., Andersson, M., Erjefält, J. S., Persson, C. G. a, & Wollmer, P. (2003). Airway microvascular 
extravasation and luminal entry of plasma. Clinical Physiology and Functional Imaging, 23(6), 
301–6.  
Griep, L. M., Wolbers, F., de Wagenaar, B., ter Braak, P. M., Weksler, B. B., Romero, I. a, … van den 
Berg, a. (2013). BBB on chip: microfluidic platform to mechanically and biochemically modulate 
blood-brain barrier function. Biomedical Microdevices, 15(1), 145–50.  
Griffin, B. W., Klimko, P., Crider, J. Y., & Sharif, N. a. (1999). AL-8810: a novel prostaglandin F2 alpha 
analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. The Journal 
of Pharmacology and Experimental Therapeutics, 290(3), 1278–84.  
Gross, S., Tilly, P., Hentsch, D., Vonesch, J.-L., & Fabre, J.-E. (2007). Vascular wall-produced 
prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 
receptors. The Journal of Experimental Medicine, 204(2), 311–20.  
Grünig, G. (1998). Requirement for IL-13 Independently of IL-4 in Experimental Asthma. Science, 
282(5397), 2261–2263.  
Guan,  ., Stillman, B. a, Zhang,  ., Schneider, A., Saito, O., Davis, L. S., … Breyer, M. D. (2002). 
Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacology, 2, 14.  
Günther, A.,  asotharan, S., Vagaon, A., Lochovsky, C., Pinto, S.,  ang, J., … Bolz, S.-S. (2010). A 
microfluidic platform for probing small artery structure and function. Lab on a Chip, 10(18),  
Håkansson, H. F., Smailagic, A., Brunmark, C., Miller-Larsson, A., & Lal, H. (2012). Altered lung 
function relates to inflammation in an acute LPS mouse model. Pulmonary Pharmacology & 
Therapeutics, 25(5), 399–406.  
Halushka, P. V, Mais, D. E., Mayeux, P. R., & Morinelli, T. a. (1989). Thromboxane, prostaglandin and 
leukotriene receptors. Annual Review of Pharmacology and Toxicology, 29, 213–39.  
Hammad, H., Kool, M., Soullié, T., Narumiya, S., Trottein, F., Hoogsteden, H. C., & Lambrecht, B. N. 
(2007). Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung 
dendritic cell function and induction of regulatory T cells. The Journal of Experimental Medicine, 
204(2), 357–67.  
Haque, R., Hakim, A., Moodley, T., Torrego, A., Essilfie-Quaye, S., Jazrawi, E., … Usmani, O. S. 
(2013). Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation 
198 
 
and efficacy in sputum macrophages in COPD. The Journal of Allergy and Clinical Immunology, 
132(5), 1166–73.  
Hardy, C. C., Robinson, C., Tattersfield, A. E. & Holgate, S. T. (1984). The Bronchoconstrictor Effect 
of Inhaled Prostaglandin-D2 in Normal and Asthmatic Men. New England Journal of Medicine, 
311 (4), 209-213. 
Hasegawa, H., Negishi, M., Katoh, H., & Ichikawa, a. (1997). Two isoforms of prostaglandin EP3 
receptor exhibiting constitutive activity and agonist-dependent activity in Rho-mediated stress 
fiber formation. Biochemical and Biophysical Research Communications, 234(3), 631–6.  
Hata, A. N., & Breyer, R. M. (2004). Pharmacology and signaling of prostaglandin receptors: multiple 
roles in inflammation and immune modulation. Pharmacology & Therapeutics, 103(2), 147–66.  
Hata, A. N., Lybrand, T. P., & Breyer, R. M. (2005). Identification of determinants of ligand binding 
affinity and selectivity in the prostaglandin D2 receptor CRTH2. The Journal of Biological 
Chemistry, 280(37), 32442–51.  
Hawkins, B. T., & Davis, T. P. (2005). The Blood-Brain Barrier / Neurovascular Unit in Health and 
Disease. Pharmaco, 57(2), 173–185.  
Haye-Legrand, I., Bourdillat, B., Labat, C., Cerrina, J., Norel, X., Benveniste, J., & Brink, C. (1987). 
Relaxation of Isolated Human Pulmonary Muscle Preparations with Prostacyclin (PGI2) and Its 
Analogs. Prostaglandins, 33(6), 845–854. 
He, P., & Curry, F. E. (1993). Differential actions of cAMP on endothelial [Ca2+]i and permeability in 
microvessels exposed to ATP. The American Journal of Physiology, 265(3 Pt 2), H1019–23.  
Heaney, L. G., & Robinson, D. S. (2005). Severe asthma treatment: need for characterising patients. 
Lancet, 365(9463), 974–6.  
Hele, D. J., Birrell, M. a, Webber, S. E., Foster, M. L., & Belvisi, M. G. (2001). Mediator involvement in 
antigen-induced bronchospasm and microvascular leakage in the airways of ovalbumin 
sensitized Brown Norway rats. British Journal of Pharmacology, 132(2), 481–8.  
Herlong, J. L., & Scott, T. R. (2006). Positioning prostanoids of the D and J series in the 
immunopathogenic scheme. Immunology Letters, 102(2), 121–31.  
Herrerias, A., Torres, R., Serra, M., Marco, A., Pujols, L., Picado, C., & de Mora, F. (2009). Activity of 
the cyclooxygenase 2-prostaglandin-E prostanoid receptor pathway in mice exposed to house 
dust mite aeroallergens, and impact of exogenous prostaglandin E2. Journal of Inflammation 
(London, England), 6, 30.  
Hill, a T., Bayley, D., & Stockley, R. a. (1999). The interrelationship of sputum inflammatory markers in 
patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine, 
160(3), 893–8.  
Hirai, H., Tanaka, K., Takano, S., Ichimasa, M., Nakamura, M., & Nagata, K. (2002). Cutting Edge: 
Agonistic Effect of Indomethacin on a Prostaglandin D2 Receptor, CRTH2. The Journal of 
Immunology, 168(3), 981–985.  
Hirai, H., Tanaka, K.,  oshie, O., Ogawa, K., Kenmotsu, K., Takamori,  ., … Nagata, K. (2001). 
Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and 
basophils via seven-transmembrane receptor CRTH2. The Journal of Experimental Medicine, 
193(2), 255–61.  
199 
 
Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S., & Narumiya, S. (1991). 
Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349, 617–620. 
Hirata, M., Kakizuka, a, Aizawa, M., Ushikubi, F., & Narumiya, S. (1994). Molecular characterization of 
a mouse prostaglandin D receptor and functional expression of the cloned gene. Proceedings of 
the National Academy of Sciences of the United States of America, 91(23), 11192–6.  
Hirata, T., Ushikubi, F., Kakizuka, A., Okuma, M., & Narumiya, S. (1996). Two Thromboxane A2 
Receptor Isoforms in Human Platelets. Journal of Clinical Investigation, 97(4), 949–956. 
Hogan, S. P., Koskinen, A., Matthaei, K. I., Young, I. G. & Foster, P. S. (1998). Interleukin-5-
producing CD4+ T cells play a pivotal role in aeroallergen-induced eosinophilia, bronchial 
hyperreactivity, and lung damage in mice.  American Journal of Respiratory and Critical Care 
Medicine, 157, 210-218. 
Hogg, J. C. (2004). Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. 
Lancet, 364(9435), 709–21.  
Holgate, S. T. (2008a). Pathogenesis of asthma. Clinical and Experimental Allergy : Journal of the 
British Society for Allergy and Clinical Immunology, 38(6), 872–97.  
Holgate, S. T. (2008b). The airway epithelium is central to the pathogenesis of asthma. Allergology 
International : Official Journal of the Japanese Society of Allergology, 57(1), 1–10.  
Honda, a, Sugimoto, Y., Namba, T., Watabe, a, Irie, a, Negishi, M., … Ichikawa, a. (1993). Cloning 
and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. The Journal of 
Biological Chemistry, 268(11), 7759–62. Retrieved from  
Honda, K., Arima, M., Cheng, G., Taki, S., Hirata, H., Eda, F., … Fukuda, T. (2003). Prostaglandin D2 
reinforces Th2 type inflammatory responses of airways to low-dose antigen through bronchial 
expression of macrophage-derived chemokine. The Journal of Experimental Medicine, 198(4), 
533–43.  
Honda, T., Segi-Nishida, E., Miyachi, Y., & Narumiya, S. (2006). Prostacyclin-IP signaling and 
prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced 
arthritis. The Journal of Experimental Medicine, 203(2), 325–35.  
Hong, F., Haldeman, B. D., Jackson, D., Carter, M., Baker, J. E., & Cremo, C. R. (2011). Biochemistry 
of smooth muscle myosin light chain kinase. Archives of Biochemistry and Biophysics, 510(2), 
135–46.  
Horgan, M. J., Palace, G. P., Everitt, J. E., & Malik, a B. (1993). TNF-alpha release in endotoxemia 
contributes to neutrophil-dependent pulmonary edema. The American Journal of Physiology, 
264(4 Pt 2), H1161–5.  
Huang, J. (2004). Cell signalling through thromboxane A2 receptors. Cellular Signalling, 16(5), 521–
533.  
Hutchinson, J., Marshall, K. M. & Senior, J. (2003). Preliminary studies using a putative FP-receptor 
antagonist, AL-8810, on isolated mouse uterus.  Proceedings of the British Pharmacological 
Society. Available at: http://www.pa2online.org/Vol1Issue3abst038P.html. 
Huxley, V. H., Wang, J. J., & Sarelius, I. H. (2007). Adaptation of coronary microvascular exchange in 
arterioles and venules to exercise training and a role for sex in determining permeability 
responses. American Journal of Physiology. Heart and Circulatory Physiology, 293, 1196–1205.  
200 
 
Hylkema, M. N., Hoekstra, M. O., Luinge, M., & Timens, W. (2002). The strength of the OVA-induced 
airway inflammation in rats is strain dependent. Clinical and Experimental Immunology, 129(3), 
390–6.  
Ichinose, M., Sugiura, H.,  amagata, S., Koarai, a., Tomaki, M., Ogawa, H., … Hattori, T. (2003). 
Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways. 
European Respiratory Journal, 22(3), 457–461.  
Ichinose, M., Sugiura, H., Yamagata, S., Koarai, A., & Shirato, K. (2000). Increase in Reactive 
Nitrogen Species Production in Chronic Obstructive Pulmonary Disease Airways. American 
Journal of Respiratory and Critical Care Medicine, 162, 701–706. 
Imig, J. D., Breyer, M. D., & Breyer, R. M. (2002). Contribution of prostaglandin EP(2) receptors to 
renal microvascular reactivity in mice. American Journal of Physiology. Renal Physiology, 
283(3), F415–22.  
Innes, A. L., Carrington, S. D., Thornton, D. J., Kirkham, S., Rousseau, K., Dougherty, R. H., … Fahy, 
J. V. (2009). Ex vivo sputum analysis reveals impairment of protease-dependent mucus 
degradation by plasma proteins in acute asthma. American Journal of Respiratory and Critical 
Care Medicine, 180(3), 203–10.  
Ishii, Y., Wang, Y., Haziot, a., del Vecchio, P. J., Goyert, S. M., & Malik, a. B. (1993). 
Lipopolysaccharide binding protein and CD14 interaction induces tumor necrosis factor-alpha 
generation and neutrophil sequestration in lungs after intratracheal endotoxin. Circulation 
Research, 73(1), 15–23.  
Ito, M., Guerriero, V. Jr. & Hartshorne, D. J. (1991). Structure-function relationships in smooth muscle 
light chain kinase. Advances in Experimental Medicine and Biology, 304, 3-10. 
Ito, S., Sakamoto, K., Mochizuki-Oda, N., Ezashi, T., Miwa, K., Okuda-Ashitaka, E., Shevchenko, V. 
I., Kiso, Y. & Hayaishi, O. (1994). Prostaglandin F2α receptor is coupled to Gq in cDNA-
transfected Chinese hamster ovary cells. Biochemical and biophysical research 
communications, 200, 756-762. 
Jaeschke, R., O’Byrne, P. M., Mejza, F., Nair, P., Lesniak, W., Brozek, J., … Guyatt, G. (2008). The 
safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: 
systematic review and metaanalysis. American Journal of Respiratory and Critical Care 
Medicine, 178(10), 1009–16.  
Jaffar, Z., Wan, K.-S., & Roberts, K. (2002). A key role for prostaglandin I2 in limiting lung mucosal 
Th2, but not Th1, responses to inhaled allergen. Journal of Immunology (Baltimore, Md. : 1950), 
169(10), 5997–6004.  
James, a L., Paré, P. D., & Hogg, J. C. (1989). The mechanics of airway narrowing in asthma. The 
American Review of Respiratory Disease, 139(1), 242–6.  
James, a L., & Wenzel, S. (2007). Clinical relevance of airway remodelling in airway diseases. The 
European Respiratory Journal, 30(1), 134–55.  
Jiang, Q., Ewing, J. R., Ding, G. L., Zhang, L., Zhang, Z. G., Li, L., … Chopp, M. (2005). Quantitative 
evaluation of BBB permeability after embolic stroke in rat using MRI. Journal of Cerebral Blood 
Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and 
Metabolism, 25(5), 583–92.  
Jiang, Y., Wen, K., Zhou, X., Schwegler-Berry, D., Castranova, V., & He, P. (2008). Three-
dimensional localization and quantification of PAF-induced gap formation in intact venular 
microvessels. American Journal of Physiology. Heart and Circulatory Physiology, 295(2), H898–
906.  
201 
 
Jin, A.  ., Tuor, U. I., Rushforth, D., Kaur, J., Muller, R. N., Petterson, J. L., … Barber, P. a. (2010). 
Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic 
stroke: a future therapeutic target for treatment of stroke. BMC Neuroscience, 11, 12.  
Johnson, J. R., Wiley, R. E., Fattouh, R., Swirski, F. K., Gajewska, B. U., Coyle, A. J., … Jordana, M. 
(2004). Continuous exposure to house dust mite elicits chronic airway inflammation and 
structural remodeling. American Journal of Respiratory and Critical Care Medicine, 169(3), 378–
85.  
Jones, G. L., Saroea, H. G., Watson, R. M., & O’Byrne, P. M. (1992). Effect of an inhaled 
thromboxane mimetic (U46619) on airway function in human subjects. The American Review of 
Respiratory Disease, 145(6), 1270–4.  
Jones, R. L., Giembycz, M. a, & Woodward, D. F. (2009a). Prostanoid receptor antagonists: 
development strategies and therapeutic applications. British Journal of Pharmacology, 158(1), 
104–45.  
Jones, R. L., Giembycz, M. A., & Woodward, D. F. (2009b). Prostanoid receptor antagonists : 
development strategies and therapeutic applications. British Journal of Pharmacology, 158, 
104–145.  
Jones, R., Woodward, D., & Wang, J. (2008). Investigation of the slow kinetics of the prostanoid EP3 
receptor antaonists L-798106 and L-826266 on guinea pig aorta. Fundamental & Clinical 
Pharmacology, 22 (Suppl), 69–79. 
Kabashima, K., Murata, T., Tanaka, H., Matsuoka, T., Sakata, D.,  oshida, N., … Narumiya, S. 
(2003b). Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates 
acquired immunity. Nature Immunology, 4(7), 694–701 
Kabashima, K., Nagamachi, M., Honda, T., Nishigori, C., Miyachi, Y., Tokura, Y., & Narumiya, S. 
(2007). Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 
receptors. Laboratory Investigation; a Journal of Technical Methods and Pathology, 87(1), 49–
55.  
Kabashima, K., & Narumiya, S. (2003a). The DP receptor, allergic inflammation and asthma. 
Prostaglandins, Leukotrienes and Essential Fatty Acids, 69(2-3), 187–194 
Kabashima, K., Saji, T., Murata, T., Nagamachi, M., Matsuoka, T., Segi, E., … Narumiya, S. (2002). 
The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in 
the gut. Journal of Clinical Investigation, 109, 883–893.  
Kamio, K., Liu, X., Sugiura, H., Togo, S., Kobayashi, T., Kawasaki, S., … Rennard, S. I. (2007). 
Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA 
pathway. American Journal of Respiratory Cell and Molecular Biology, 37(1), 113–20.  
Kanazawa, H., Asai, K., Hirata, K., & Yoshikawa, J. (2002). Vascular involvement in exercise-induced 
airway narrowing in patients with bronchial asthma. Chest, 122(1), 166–70.  
Kanazawa, H., Hirata, K., & Yoshikawa, J. (2000). Role of endogenous nitric oxide in exercise-
induced airway narrowing in patients with bronchial asthma. The Journal of Allergy and Clinical 
Immunology, 106(6), 1081–7.  
Kanazawa, H., Nomura, S., & Yoshikawa, J. (2004). Role of microvascular permeability on 
physiologic differences in asthma and eosinophilic bronchitis. American Journal of Respiratory 
and Critical Care Medicine, 169(10), 1125–30.  
202 
 
Katoh, K., Kano, Y., Amano, M., Onishi, H., Kaibuchi, K., & Fujiwara, K. (2001). Rho-kinase--mediated 
contraction of isolated stress fibers. The Journal of Cell Biology, 153(3), 569–84.  
Katsuyama, M., Nishigaki, N., Sugimoto, Y., Morimoto, K., Negishi, M., Narumiya, S., & Ichikawa, a. 
(1995). The mouse prostaglandin E receptor EP2 subtype: cloning, expression, and northern 
blot analysis. FEBS Letters, 372(2-3), 151–6.  
Katsuyama, M., Sugimoto, Y., Namba, T., Irie, a, Negishi, M., Narumiya, S., & Ichikawa, a. (1994). 
Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Letters, 344(1), 
74–8.  
Kawakami, Y., Uchiyama, K., Irie, T., & Murao, M. (1973). Evaluation of aerosols of prostaglandins E1 
and E2 as bronchodilators. European Journal of Clinical Pharmacology, 6(2), 127–32.  
Kawano,  ., Fukata,  ., Oshiro, N., Amano, M., Nakamura, T., Ito, M., … Kaibuchi, K. (1999). 
Phosphorylation of Mysoin-binding Subunit (MBS) of Myosin Phosphatase by Rho-Kinase In 
Vivo. The Journal of Cell Biology, 147(5), 1023–1037. 
Kay, L. J., Yeo, W. W., & Peachell, P. T. (2006). Prostaglandin E2 activates EP2 receptors to inhibit 
human lung mast cell degranulation. British Journal of Pharmacology, 147(7), 707–13.  
Keery, R. J., & Lumley, P. (1988). AH6809, a prostaglandin DP-receptor blocking drug on human 
platelets. British Journal of Pharmacology, 94(3), 745–54.  
Kellend, K. (2011, May 31). Smoking could kill 8 million a year by 2030:WHO. Reuters. 
http://uk.reuters.com/article/2011/05/31/health-us-smoking-deaths-idUKTRE74U29O20110531 
Kendall, S., & Michel, C. C. (1995). The measurement of permeability in single rat venules using the 
red cell microperfusion technique. Experimental Physiology, 80(3), 359–72.  
Kenne, E., & Lindbom, L. (2011). Imaging inflammatory plasma leakage in vivo. Thrombosis and 
Haemostasis, 105(5), 783–9.  
Kennedy, C. R., Zhang,  ., Brandon, S., Guan,  ., Coffee, K., Funk, C. D., … Breyer, R. M. (1999). 
Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. 
Nature Medicine, 5(2), 217–20.  
Khor, Y. H., Teoh, a K. Y., Lam, S. M., Mo, D. C. Q., Weston, S., Reid, D. W., & Walters, E. H. (2009). 
Increased vascular permeability precedes cellular inflammation as asthma control deteriorates. 
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical 
Immunology, 39(11), 1659–67.  
Kim, S. R., Lee, K. S., Lee, K. B., & Lee, Y. C. (2012). Recombinant IGFBP-3 inhibits allergic lung 
inflammation, VEGF production, and vascular leak in a mouse model of asthma. Allergy, 67(7), 
869–77.  
Kimura, K., Inoue, H., Ichinose, M., Miura, M., Katsumata, U., Takahashi, T., & Takishima, T. (1992). 
Bradykinin Causes Airway Hyperresponsiveness and Enhances Maximal Airway Narrowing. 
American Reviews of Respiratory Disease, 146, 1301–1305. 
Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata,  ., Nakafuku, M., … Kaibuchi, K. (1996). 
Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 
(New York, N.Y.), 273(5272), 245–8.  
Kinsella, B. T., O’Mahony, D. J., & Fitzgerald, G. a. (1997). The human thromboxane A2 receptor 
alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is 
203 
 
activated by the isoprostane 8-epi prostaglandin F2 alpha. The Journal of Pharmacology and 
Experimental Therapeutics, 281(2), 957–64.  
Knotkova, H., & Pappagallo, M. (2007). Imaging intracranial plasma extravasation in a migraine 
patient: a case report. Pain Medicine (Malden, Mass.), 8(4), 383–7.  
Komarova, Y., & Malik, A. B. (2010). Regulation of endothelial permeability via paracellular and 
transcellular transport pathways. Annual review of physiology,72, 463–93.  
Konger, R. L., Billings, S. D., Prall, N. C., Katona, T. M., Dasilva, S. C., Kennedy, C. R. J., … Lacelle, 
P. T. (2009). The EP1 subtype of prostaglandin E2 receptor: role in keratinocyte differentiation 
and expression in non-melanoma skin cancer. Prostaglandins, Leukotrienes, and Essential Fatty 
Acids, 81(4), 279–90.  
Konya, V., Marsche, G., Schuligoi, R., & Heinemann, A. (2013a). E-type prostanoid receptor 4 (EP4) 
in disease and therapy. Pharmacology & Therapeutics, 138(3), 485–502.  
Konya, V., Üllen, A., Kampitsch, N., Theiler, A., Philipose, S., Parzmair, G. P., … Heinemann, A. 
(2013b). Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit 
neutrophil trafficking. The Journal of Allergy and Clinical Immunology, 131(2), 532–40.e1–2.  
Kostenis, E., & Ulven, T. (2006). Emerging roles of DP and CRTH2 in allergic inflammation. Trends in 
Molecular Medicine, 12(4), 148–58.  
Kozak, K. R., Crews, B. C., Ray, J. L., Tai, H. H., Morrow, J. D., & Marnett, L. J. (2001). Metabolism of 
prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. The Journal 
of Biological Chemistry, 276(40), 36993–8.  
Kubes, P., & Gaboury, J. P. (1996). Rapid mast cell activation causes leukocyte-dependent and -
independent permeability alterations. The American Journal of Physiology, 271(6 Pt 2), H2438–
46.  
Kunikata, T.,  amane, H., Segi, E., Matsuoka, T., Sugimoto,  ., Tanaka, S., … Narumiya, S. (2005). 
Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nature 
Immunology, 6(5), 524–31.  
Kurucz, I. & Szelenyi, I. (2006). Current animal models of bronchial asthma. Current Pharmaceutical 
Design, 12, 3175-3194. 
Laitinen, L. A., Laitinen, A., & Haahtela, T. (1992). A comparative study of the effects of an inhaled 
corticosteroid , budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly 
diagnosed asthma: A randomized, double-blind, parallel-group controlled trial. Journal of Allergy 
and Clinical Immunology, 90, 32–42. 
Laitinen, L. A., Laitinen, A. & Widdicombe, J. (1987). Effects of inflammatory and other mediators on 
airway vascular beds. American Review of Respiratory Disease, 135, S67-S70. 
Lambert, R. K., Wiggs, B. R., Kuwano, K., Hogg, J. C., & Paré, P. D. (1993). Functional significance 
of increased airway smooth muscle in asthma and COPD. Journal of Applied Physiology 
(Bethesda, Md. : 1985), 74(6), 2771–81.  
Langeler, E. G., & van Hinsbergh, V. W. (1991). Norepinephrine and iloprost improve barrier function 
of human endothelial cell monolayers: role of cAMP. The American Journal of Physiology, 260(5 
Pt 1), C1052–9.  
204 
 
Lawrence, R. a, Jones, R. L., & Wilson, N. H. (1992). Characterization of receptors involved in the 
direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. British Journal of 
Pharmacology, 105(2), 271–8.  
Lee, H., Kim, S., Chung, M., Kim, J. H., & Jeon, N. L. (2014). A bioengineered array of 3D 
microvessels for vascular permeability assay. Microvascular Research, 91, 90–8.  
Lee, K. S., Kim, S. R., Park, H. S., Jin, G. Y., & Lee, Y. C. (2004). Cysteinyl leukotriene receptor 
antagonist regulates vascular permeability by reducing vascular endothelial growth factor 
expression. The Journal of Allergy and Clinical Immunology, 114(5), 1093–9.  
Lee, K. S., Kim, S. R., Park, S. J., Park, H. S., Min, K. H., Jin, S. M., … Lee,  . C. (2006). Peroxisome 
proliferator activated receptor-gamma modulates reactive oxygen species generation and 
activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway 
disease of mice. The Journal of Allergy and Clinical Immunology, 118(1), 120–7.  
Lee, K. S., Park, S. J., Kim, S. R., Min, K. H., Jin, S. M., Puri, K. D., & Lee, Y. C. (2006). 
Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a murine model of 
asthma. The Journal of Allergy and Clinical Immunology, 118(2), 403–9.  
Lewis, C. a, & Broadley, K. J. (1995). Airway hyper- or hyporeactivity to inhaled spasmogens 24 h 
after ovalbumin challenge of sensitized guinea-pigs. British Journal of Pharmacology, 116(5), 
2351–8.  
Lewis, R. a, Soter, N. a, Diamond, P. T., Austen, K. F., Oates, J. a, & Roberts, L. J. (1982). 
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. Journal 
of Immunology (Baltimore, Md. : 1950), 129(4), 1627–31.  
Li, X., & Wilson, J. W. (1997). Increased vascularity of the bronchial mucosa in mild asthma. American 
Journal of Respiratory and Critical Care Medicine, 156(1), 229–33.  
Licht, A. H., Pein, O. T., Florin, L., Hartenstein, B., Reuter, H., Arnold, B., … Schorpp-Kistner, M. 
(2006). JunB is required for endothelial cell morphogenesis by regulating core-binding factor 
beta. The Journal of Cell Biology, 175(6), 981–91.  
Lima, C., Souza, V. M. O., Soares, a L., Macedo, M. S., Tavares-de-Lima, W., & Vargaftig, B. B. 
(2007). Interference of methysergide, a specific 5-hydroxytryptamine receptor antagonist, with 
airway chronic allergic inflammation and remodelling in a murine model of asthma. Clinical and 
Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 37(5), 
723–34.  
List, S. J., Findlay, B. P., Forstner, G. G., & Forstner, J. F. (1978). Enhancement of the viscosity of 
mucin by serum albumin. The Biochemical Journal, 175(2), 565–71.  
Liu, F., Verin, a D., Borbiev, T., & Garcia, J. G. (2001). Role of cAMP-dependent protein kinase A 
activity in endothelial cell cytoskeleton rearrangement. American Journal of Physiology. Lung 
Cellular and Molecular Physiology, 280(6), L1309–17.  
Lo, C. M., Keese, C. R., & Giaever, I. (1995). Impedance analysis of MDCK cells measured by electric 
cell-substrate impedance sensing. Biophysical Journal, 69(6), 2800–7.  
Løkke, a, Lange, P., Scharling, H., Fabricius, P., & Vestbo, J. (2006). Developing COPD: a 25 year 
follow up study of the general population. Thorax, 61(11), 935–9.  
Long, J. a, Fogel-Petrovic, M., Knight, D. a, Thompson, P. J., & Upham, J. W. (2004). Higher 
prostaglandin e2 production by dendritic cells from subjects with asthma compared with normal 
subjects. American Journal of Respiratory and Critical Care Medicine, 170(5), 485–91.  
205 
 
Lötvall, J., Elwood, W., Tokuyama, K., Sakamoto, T., Barnes, P. J., & Chung, K. F. (1992). A 
thromboxane mimetic, U-46619, produces plasma exudation in airways of the guinea pig. 
Journal of Applied Physiology, 72(6), 2415–9.  
Lu, Z. & Wolf, M. B. (1993). Platelet activating factor-induced microvascular permeability increases in 
the cat hindlimb. Circulatory Shock, 41, 8-18. 
Lupinetti, M. D., Sheller, J. R., Catella, F. & Fitzgerald, G. A. (1989). Thromboxane biosynthesis in 
allergen-induced bronchospasm, evidence for platelet activation.  American Review of 
Respiratory Disease, 140 (4), 932-935. 
Lydford, S. J., & McKechnie, K. (1994). Characterization of the prostaglandin E2 sensitive (EP)-
receptor in the rat isolated trachea. British Journal of Pharmacology, 112(1), 133–6.  
Lydford, S. J., McKechnie, K. C., & Dougall, I. G. (1996). Pharmacological studies on prostanoid 
receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. 
British Journal of Pharmacology, 117(1), 13–20.  
Ma, H., Hara, a., Xiao, C.  ., Okada,  ., Takahata, O., Nakaya, K., … Ushikubi, F. (2001). Increased 
Bleeding Tendency and Decreased Susceptibility to Thromboembolism in Mice Lacking the 
Prostaglandin E Receptor Subtype EP3. Circulation, 104(10), 1176–1180.  
Macias-Perez, I. M., Zent, R., Carmosino, M., Breyer, M. D., Breyer, R. M., & Pozzi, A. (2008). Mouse 
EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis 
in vivo. The Journal of Biological Chemistry, 283(18), 12538–45.  
Maher, S. a, Birrell, M. a, & Belvisi, M. G. (2009). Prostaglandin E2 mediates cough via the EP3 
receptor: implications for future disease therapy. American Journal of Respiratory and Critical 
Care Medicine, 180(10), 923–8.  
Majno, G., Gilmore, V., & Leventhal, M. (1967). On the Mechanism of Vascular Leakage Caused by 
Histamine-Type Mediators: A Microscopic Study In Vivo. Circulation Research, 21(6), 833–848.  
Majno, G., & Palade, G. E. (1961). Studies on inflammation. 1. The effect of histamine and serotonin 
on vascular permeability: an electron microscopic study. The Journal of Biophysical and 
Biochemical Cytology, 11(2), 571–605.  
Majno, G., Palade, G. E., & Schoefl, G. I. (1961). Studies on inflammation. II. The site of action of 
histamine and serotonin along the vascular tree: a topographic study. The Journal of Biophysical 
and Biochemical Cytology, 11, 607–26.  
Majno, G., Shea, S. M., & Leventhal, M. (1969). Endothelial Contraction Induced by Histamine-Type 
Mediators. An Electron Microscopic Study. The Journal of Cell Biology, 42(1), 647–672. 
Martin, J. G., Suzuki, M., Maghni, K., Pantano, R., Ramos-barbón, D., Ihaku, D., … Powell, W. S. 
(2002). The Immunomodulatory Actions of Prostaglandin E2 on Allergic Airway Responses in 
the Rat. Journal of Immunology, 169, 3963–3969. 
Marwick, J. a, Caramori, G., Stevenson, C. S., Casolari, P., Jazrawi, E., Barnes, P. J., … Papi, A. 
(2009). Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway 
inflammation in mice. American Journal of Respiratory and Critical Care Medicine, 179(7), 542–
8.  
Marwick, J. a, Kirkham, P. a, Stevenson, C. S., Danahay, H., Giddings, J., Butler, K., … Rahman, I. 
(2004). Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat 
lungs. American Journal of Respiratory Cell and Molecular Biology, 31(6), 633–42.  
206 
 
Masoli, M., Fabian, D., Holt, S., & Beasley, R. (2004). The global burden of asthma : executive 
summary of the GINA Dissemination Committee Report. Allergy, 59, 469–478. 
Mathiesen, J. M., Christopoulos, A., Ulven, T., Royer, J. F., Campillo, M., Heinemann, A., … Kostenis, 
E. (2006). On the Mechanism of Interaction of Potent Surmountable and Insurmountable 
Antagonists with the Prostaglandin D2 Receptor CRTH2. Molecular Pharmacology, 69, 1441–
1453. 
Mathiesen, J. M., Ulven, T., Martini, L., Gerlach, L. O., Heinemann, A., & Kostenis, E. (2005). 
Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling 
Pathway of the Prostaglandin D2 Receptor CRTH2. Molecular Pharmacology, 68(2), 393–402.  
Matsuoka, T. (2000). Prostaglandin D2 as a Mediator of Allergic Asthma. Science, 287(5460), 2013–
2017.  
Matsuoka,  ., Furuyashiki, T.,  amada, K., Nagai, T., Bito, H., Tanaka,  ., … Narumiya, S. (2005). 
Prostaglandin E receptor EP1 controls impulsive behavior under stress. Proceedings of the 
National Academy of Sciences of the United States of America, 102(44), 16066–71.  
Matthews, J. S., & Jones, R. L. (1993). Potentiation of aggregation and inhibition of adenylate cyclase 
in human platelets by prostaglandin E analogues. British Journal of Pharmacology, 108(2), 363–
9.  
McCormick, C., Jones, R. L., Kennedy, S., & Wadsworth, R. M. (2010). Activation of prostanoid EP 
receptors by prostacyclin analogues in rabbit iliac artery: implications for anti-restenotic 
potential. European Journal of Pharmacology, 641(2-3), 160–7.  
Mcdonald, D. M. (1994). Endothelial gaps and permeability of venules in rat tracheas exposed to 
inflammatory stimuli. American Journal of Physiology. Lung Cellular and Molecular Physiology, 
266, 61–83. 
Mcdonald, D. M., Thurston, G., & Baluk, P. (1999). Endothelial Gaps as Sites for Plasma Leakage in 
Inflammation. Microcirculation, 6, 7–22. 
Mcgraw, D. W., Mihlbachler, K. A., Schwarb, M. R., Rahman, F. F., Small, K. M., Almoosa, K. F., & 
Liggett, S. B. (2006). Airway smooth muscle prostaglandin-EP1 receptors directly modulate β2 – 
adrenergic receptors within a unique heterodimeric complex. The Journal of Clinical 
Investigation, 116, 1400–1409.  
McIlroy, A., Caron, G., Blanchard, S., Frémaux, I., Duluc, D., Delneste,  ., … Jeannin, P. (2006). 
Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 
and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human 
dendritic cells. Immunology, 117(4), 507–16.  
McKenniff, M. G., Norman, P., Cuthbert, N. J., & Gardiner, P. J. (1991). BAY u3405, a potent and 
selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro. British Journal 
of Pharmacology, 104(3), 585–90.  
Mckenzie, B. G. J., Fallon, P. G., Emson, C. L., Grencis, R. K., & Mckenzie, A. N. J. (1999). 
Simultaneous Disruption of Interleukin (IL)-4 and IL-13 Defines Individual Roles in T Helper Cell 
Type 2-mediated Responses. Journal of Experimental Medicine, 189(10), 1565–1572. 
Mckenzie, D. C., & Boulet, L. (2008). Asthma, outdoor air quality and the Olympic Games. Canadian 
Medical Association Journal, 179(6), 543–548. 
207 
 
McMillan, S. J., & Lloyd, C. M. (2004). Prolonged allergen challenge in mice leads to persistent airway 
remodelling. Clinical and Experimental Allergy : Journal of the British Society for Allergy and 
Clinical Immunology, 34(3), 497–507.  
Mead, J., Turner, J. M., Macklem, P. T., & Little, J. B. (1967). Significance of the relationship between 
lung recoil and maximum expiratory flow. Journal of Applied Physiology, 22(1), 95–108. 
Meerschaert, J., Kelly, E. a, Mosher, D. F., Busse, W. W., & Jarjour, N. N. (1999). Segmental antigen 
challenge increases fibronectin in bronchoalveolar lavage fluid. American Journal of Respiratory 
and Critical Care Medicine, 159(2), 619–25.  
Mehta, D., & Malik, A. B. (2006). Signaling Mechanisms Regulating Endothelial Permeability. Phy, 86, 
279–367.. 
Mendes, E. S., Campos, M. a, & Wanner, A. (2006). Airway blood flow reactivity in healthy smokers 
and in ex-smokers with or without COPD. Chest, 129(4), 893–8.  
Mendez, M., & Lapointe, M. C. (2005). PGE 2 -induced hypertrophy of cardiac myocytes involves EP 
4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. American Journal 
of Physiology. Heart and Circulatory Physiology, 288, 2111–2117. 
Meyrick, B., Hoover, R., Jones, M. R., Berry, L. C. & Brigham, K. L. (1989). In Vitro Effects of 
Endotoxin on Bovine and Sheep Lung Microvascular and Pulmonary-Artery Endothelial Cells. 
Journal of Cellular Physiology, 138, 165-175. 
Michel, C. C., & Curry, F. E. (1999). Microvascular permeability. Physiological Reviews, 79(3), 703–
61.  
Michel, C. C., Mason, J. C., Curry, F. E., Tooke, J. E., & Hunter, P. J. (1974). A development of the 
Landis technique for measuring the filtration coefficient of individual capillaries in the frog 
mesentery. Quarterly Journal of Experimental Physiology and Cognate Medical Sciences, 59(4), 
283–309.  
Miggin, S. M., & Kinsella, B. T. (1998). Expression and tissue distribution of the mRNAs encoding the 
human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochimica et Biophysica Acta, 
1425(3), 543–59.  
Miles, A. A., & Miles, E. M. (1952). Vascular Reactions to Histamine, Histamine-Liberator and 
Leukotaxine in the Skin of Guinea Pigs. Journal of Physiology, 118, 228–257. 
Minakata, Y., Nakanishi, M., Hirano, T., Matsunaga, K., Yamagata, T., & Ichinose, M. (2005). 
Microvascular hyperpermeability in COPD airways. Thorax, 60(10), 882.  
Minami, T., Nakano, H., Kobayashi, T., Sugimoto, Y., Ushikubi, F., Ichikawa, a, … Ito, S. (2001). 
Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain 
responses by use of EP1 and EP3 receptor knockout mice. British Journal of Pharmacology, 
133(3), 438–44.  
Minami, T., Nishihara, I., Uda, R., Ito, S., Hyodo, M., & Hayaishi, O. (1994). Characterization of EP-
receptor subtypes involved in allodynia and hyperalgesia induced by intrathecal administration of 
prostaglandin E2 to mice. British Journal of Pharmacology, 112(3), 735–40.  
Miniño, A. M., Heron, M. P., Murphy, S. L., & Kochanek, K. D. (2007). Deaths: final data for 2004. 
National Vital Statistics Reports : From the Centers for Disease Control and Prevention, National 
Center for Health Statistics, National Vital Statistics System, 55(19), 1–119.  
208 
 
Mir, F., & Le Breton, G. C. (2008). A novel nuclear signaling pathway for thromboxane A2 receptors in 
oligodendrocytes: evidence for signaling compartmentalization during differentiation. Molecular 
and Cellular Biology, 28(20), 6329–41.  
Mirza, Z. N., Tokuyama, K., Arakawa, H., Kato, M., Mochizuki, H., & Morikawa, a. (1998). Inhaled 
procaterol inhibits histamine-induced airflow obstruction and microvascular leakage in guinea-
pig airways with allergic inflammation. Clinical and Experimental Allergy : Journal of the British 
Society for Allergy and Clinical Immunology, 28(5), 644–52.  
Mitchell, J. a, Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993). Selectivity of 
nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. 
Proceedings of the National Academy of Sciences of the United States of America, 90(24), 
11693–7.  
Mizoguchi, a, Eguchi, N., Kimura, K., Kiyohara,  ., Qu, W. M., Huang, Z. L., … Hayaishi, O. (2001). 
Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal 
forebrain and their involvement in the regulation of non-rapid eye movement sleep. Proceedings 
of the National Academy of Sciences of the United States of America, 98(20), 11674–9.  
Mohammed, S. P., Higenbottam, T. W., & Adcock, J. J. (1993). Effects of Aerosol-Applied Capsaicin, 
Histamine and Prostaglandin E2 on Airway Sensory Receptors of Anaesthetized Cats. Journal 
of Physiology, 469, 51–66. 
Moller, A. D., & Grande, P.-O. (1997). Low-dose prostacyclin has potent capillary permeability-
reducing effect in cat skeletal muscle in vivo. American Journal of Physiology. Heart and 
Circulatory Physiology, 273, 200–207. 
Moncada, S. (1982). Biological Importance of Prostacyclin. British Journal of Pharmacology, 76, 3–31. 
Monneret, G. (2001). Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts 
via a novel DP receptor. Blood, 98(6), 1942–1948.  
Monneret, G., Cossette, C., Gravel, S., Rokach, J., & Powell, W. S. (2003). 15R-Methyl-Prostaglandin 
D2 Is a Potent and Selective CRTH2/DP 2 Receptor Agonist in Human Eosinophils. The Journal 
of Pharmacology and Experimental Therapeutics, 304(1), 349–355.  
Montuschi, P. (2003). Exhaled leukotrienes and prostaglandins in COPD. Thorax, 58(7), 585–588.  
Moore, M. L., & Peebles, R. S. (2006). Update on the role of prostaglandins in allergic lung 
inflammation: separating friends from foes, harder than you might think. The Journal of Allergy 
and Clinical Immunology, 117(5), 1036–9.  
Moore, T. M., Chetham, P. M., Kelly, J. J., Stevens, T., & Timothy, M. (1998). Signal transduction and 
regulation of lung endothelial cell permeability. Interaction between calcium and cAMP. 
American Journal of Physiology. Lung Cellular and Molecular Physiology, 275, 203–222. 
Moreno, J. J. (2009). Differential Effects of Arachidonic and Eicosapentaenoic Acid- Derived 
Eicosanoids on Polymorphonuclear Transmigration Across Endothelial Cell Cultures. The 
Journal of Pharmacology and Experimental Therapeutics, 331(3), 1111–1117.  
Moriyama, T., Higashi, T., Togashi, K., Iida, T., Segi, E., Sugimoto,  ., … Tominaga, M. (2005). 
Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of 
prostaglandins. Molecular Pain, 1, 3.  
Morsy, M. a, Isohama, Y., & Miyata, T. (2001). Prostaglandin E(2) increases surfactant secretion via 
the EP(1) receptor in rat alveolar type II cells. European Journal of Pharmacology, 426(1-2), 21–
4.  
209 
 
Moy, a B., Bodmer, J. E., Blackwell, K., Shasby, S., & Shasby, D. M. (1998). cAMP protects 
endothelial barrier function independent of inhibiting MLC20-dependent tension development. 
The American Journal of Physiology, 274(6 Pt 1), L1024–9.  
Moy, a B., Shasby, S. S., Scott, B. D., & Shasby, D. M. (1993). The effect of histamine and cyclic 
adenosine monophosphate on myosin light chain phosphorylation in human umbilical vein 
endothelial cells. The Journal of Clinical Investigation, 92(3), 1198–206.  
Moy, a B., Van Engelenhoven, J., Bodmer, J., Kamath, J., Keese, C., Giaever, I., … Shasby, D. M. 
(1996). Histamine and thrombin modulate endothelial focal adhesion through centripetal and 
centrifugal forces. The Journal of Clinical Investigation, 97(4), 1020–7.  
Moy, a B., Winter, M., Kamath, a, Blackwell, K., Reyes, G., Giaever, I., … Shasby, D. M. (2000). 
Histamine alters endothelial barrier function at cell-cell and cell-matrix sites. American Journal of 
Physiology. Lung Cellular and Molecular Physiology, 278(5), L888–98.  
Muja, N., Nelson, J. K., & Devries, G. H. (2007). Schwann Cells Express IP Prostanoid Receptors 
Coupled to an Elevation in Intracellular Cyclic AMP. Journal of Neuroscience Research, 85, 
1159–1169.  
Murata, T., Lin, M. I., Aritake, K., Matsumoto, S., Narumiya, S., Ozaki, H., … Sessa, W. C. (2008). 
Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and 
angiogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of 
America, 105(50), 20009–14.  
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto,  ., … Narumiya, S. 
(1997). Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. 
Nature, 388, 678–682. 
Murray, C. J., & Lopez, a D. (1997). Alternative projections of mortality and disability by cause 1990-
2020: Global Burden of Disease Study. Lancet, 349(9064), 1498–504.  
Murray, J. J., Tonnel, A. B., Brash, A. R., Roberts, L. J., Gosset, P., Workman, R., Capron, A. & 
Oates, J. A. (1986). Release of Prostaglandin-D2 into Human Airways During Acute Antigen 
Challenge. New England Journal of Medicine, 315, 800-804. 
Nagaraja, T. N., Karki, K., Ewing, J. R., Croxen, R. L., & Knight, R. a. (2008). Identification of 
variations in blood-brain barrier opening after cerebral ischemia by dual contrast-enhanced 
magnetic resonance imaging and T 1sat measurements. Stroke; a Journal of Cerebral 
Circulation, 39(2), 427–32.  
Nagata, K., Hirai, H., Tanaka, K., Ogawa, K., Aso, T., Sugamura, K., … Takano, S. (1999). CRTH2, 
an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds 
to mast cell-derived factor(s). FEBS Letters, 459(2), 195–9.  
Nagata, K., Tanaka, K., Ogawa, K., Kemmotsu, K., Imai, T.,  oshie, O., … Takano, S. (1999). 
Selective expression of a novel surface molecule by human Th2 cells in vivo. Journal of 
Immunology, 162(3), 1278–86.  
Nakahata, N. (2008). Thromboxane A2: physiology/pathophysiology, cellular signal transduction and 
pharmacology. Pharmacology & Therapeutics, 118(1), 18–35.  
Nakao, A., Watanabe, T., Taniguchi, S., Nakamura, M., Honda, Z. I., Shimizu, T. & Kurokawa, K. 
(1993). Characterization of Prostaglandin-F2-alpha Receptor of Mouse 3T3 Fibroblasts and its 
Functional Expression in Xenopus-laevis Oocytes. Journal of Cellular Physiology, 155, 257-264. 
210 
 
Nakayama, Y., Omote, K., Kawamata, T., & Namiki, A. (2004). Role of prostaglandin receptor subtype 
EP1 in prostaglandin E2-induced nociceptive transmission in the rat spinal dorsal horn. Brain 
Research, 1010(1-2), 62–8.  
Namba, T., Oida, H., Sugimoto, Y., Kakizuka, A., Negishi, M., Ichikawa, A., & Narumiya, S. (1994). 
cDNA Cloning of a Mouse Prostacyclin Receptor. The Journal of Biological Chemistry, 269(13), 
9986–9992. 
Namba, T., Sugimoto,  ., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., … Narumiya, S. (1993). 
Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-
protein specificity. Nature, 365, 166–170. 
Nannini, L. J., Poole, P., Milan, S. J., & Kesterton, A. (2013). Combined corticosteroid and long-acting 
beta2-agonist in one inhaler versus inhaled corticosteroid alone for chronic obstructive 
pulmonary disease. The Cochrane Collaboration, (8), 1–136. 
Narumiya, S. (2009). Prostanoids and inflammation: a new concept arising from receptor knockout 
mice. Journal of Molecular Medicine (Berlin, Germany), 87(10), 1015–22.  
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999). Prostanoid receptors: structures, properties, and 
functions. Physiological Reviews, 79(4), 1193–226.  
Narumiya, S., & Toda, N. (1985). Different responsiveness of prostaglandin D2-sensitive systems to 
prostaglandin D2 and its analogues. British Journal of Pharmacology, 85(2), 367–75.  
Nasrallah, R., Zimpelmann, J., Singh, S., & Hébert, R. L. (2001). Molecular and biochemical 
characterization of prostacyclin receptors in rat kidney. American Journal of Physiology. Renal 
Physiology, 280(2), F266–77.  
Nassini, R., Pedretti, P., Moretto, N., Fusi, C., Carnini, C., Facchinetti, F., … Materazzi, S. (2012). 
Transient receptor potential ankyrin 1 channel localized to non-neuronal airway cells promotes 
non-neurogenic inflammation. PloS One, 7(8), e42454.  
Ndukwu, I. M., White, S. R., Leff, a R., & Mitchell, R. W. (1997). EP1 receptor blockade attenuates 
both spontaneous tone and PGE2-elicited contraction in guinea pig trachealis. The American 
Journal of Physiology, 273(3 Pt 1), L626–33.  
Nedrebø, T., Reed, R. K., & Berg, A. (2003). Effect of alpha-trinositol on interstitial fluid pressure, 
edema generation, and albumin extravasation after ischemia-reperfusion injury in rat hind limb. 
Shock (Augusta, Ga.), 20(2), 149–53.  
Negishi, M., Sugimoto, Y., & Ichikawa, A. (1995). Molecular mechanisms of diverse actions of 
prostanoid receptors. Biochimica et Biophysica Acta, 1259, 109–120. 
Nelson, H. S., Weiss, S. T., Bleecker, E. R., Yancey, S. W., & Dorinsky, P. M. (2006). The Salmeterol 
Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual 
pharmacotherapy plus salmeterol. Chest, 129(1), 15–26.  
Newton, R., Kuitert, L. M., Bergmann, M., Adcock, I. M., & Barnes, P. J. (1997). Evidence for 
involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. 
Biochemical and Biophysical Research Communications, 237(1), 28–32.  
Nguyen, M., Camenisch, T., Snouwaert, J. N., Hicks, E., Coffman, T. M., Anderson, P. A. W., … 
Koller, B. H. (1997). The prostaglandin receptor EP4 triggers remodelling of the cardiovascular 
system at birth. Nature, 390(6), 78–81. 
211 
 
Nials, A. T., Vardey, C. J., Denyer, L. H., Thomas, M., Sparrow, S. J., Shepherd, G. D. & Coleman, R. 
A. (1993). AH 13205, a selective prostanoid EP2-receptor agonist. Cardiovascular Drug 
Reviews, 11, 165-179. 
Nicola, C., Timoshenko, A. V, Dixon, S. J., Lala, P. K., & Chakraborty, C. (2005). EP1 receptor-
mediated migration of the first trimester human extravillous trophoblast: the role of intracellular 
calcium and calpain. The Journal of Clinical Endocrinology and Metabolism, 90(8), 4736–46.  
Nishimura, H., Tokuyama, K., Inoue, Y., Arakawa, H., Kato, M., Mochizuki, H., & Morikawa, a. (2001). 
Acute effects of prostaglandin D2 to induce airflow obstruction and airway microvascular 
leakage in guinea pigs: role of thromboxane A2 receptors. Prostaglandins & Other Lipid 
Mediators, 66(1), 1–15.  
Norel, X. (2007). Prostanoid receptors in the human vascular wall. TheScientificWorldJournal, 7, 
1359–74.  
Norel, X., Montpreville, V. De, & Brink, C. (2004). Vasoconstriction induced by activation of EP1 and 
EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. 
Prostaglandins & Other Lipid Mediators, 74(1-4), 101–112.  
Norel, X., Walch, L. & Brink, C. (2002). U46619 induced contractions: Role of prostanoids and nitric 
oxide in human pulmonary vessels. British Journal of Pharmacology, 135, Proceedings 
Supplement, 282P. 
Norel, X., Walch, L., Labat, C., Gascard, J. P., Dulmet, E., & Brink, C. (1999). Prostanoid receptors 
involved in the relaxation of human bronchial preparations. British Journal of Pharmacology, 
126(4), 867–72.  
Nossaman, B. D., McMahon, T. J., Ragheb, M. S., Ibrahim, I. N., Babycos, C. R., Hood, J. S., & 
Kadowitz, P. J. (1992). Blockade of thromboxane/endoperoxide receptor-mediated responses in 
the pulmonary vascular bed of the cat by sulotroban. European Journal of Pharmacology, 
213(1), 1–7.  
Nusing, R., Lesch, R., Ullrich, V. (1990). Immunohistochemical localization of thromboxane synthase 
in human tissues. Eicosanoids, 3, 53-58. 
Ochoa, C. D., & Stevens, T. (2012). Studies on the cell biology of interendothelial cell gaps. American 
Journal of Physiology. Lung Cellular and Molecular Physiology, 302(3), L275–86.  
Offermanns, S. (2006). Activation of Platelet Function Through G Protein-Coupled Receptors. 
Circulation Research, 99(12), 1293–1304.  
Oga, T., Matsuoka, T.,  ao, C., Nonomura, K., Kitaoka, S., Sakata, D., … Narumiya, S. (2009). 
Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis 
independently of transforming growth factor-beta. Nature Medicine, 15(12), 1426–30.  
Okada,  ., Hara, a, Ma, H., Xiao, C.  ., Takahata, O., Kohgo,  ., … Ushikubi, F. (2000). 
Characterization of prostanoid receptors mediating contraction of the gastric fundus and ileum: 
studies using mice deficient in prostanoid receptors. British Journal of Pharmacology, 131(4), 
745–55.  
Okano, M., Sugata,  ., Fujiwara, T., Matsumoto, R., Nishibori, M., Shimizu, K., … Nishizaki, K. 
(2006). E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell 
responses by prostaglandin E2. Immunology, 118(3), 343–52.  
212 
 
Olivenstein, R., Du, T., Xu, L. J., & Martin, J. G. (1997). Microvascular leakage in the airway wall and 
lumen during allergen induced early and late responses in rats. Pulmonary Pharmacology & 
Therapeutics, 10(4), 223–30.  
Oostenbrink, J. B., Rutten-van Molken, M. P. M. H., Al, M. J., Van Noord, J. a., & Vincken, W. (2004). 
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive 
pulmonary disease. European Respiratory Journal, 23(2), 241–249.  
Owen, C. a. (2008). Roles for proteinases in the pathogenesis of chronic obstructive pulmonary 
disease. International Journal of Chronic Obstructive Pulmonary Disease, 3(2), 253–68.  
Pai, R., Szabo, I. L., Soreghan, B. a, Atay, S., Kawanaka, H., & Tarnawski, a S. (2001). PGE(2) 
stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. 
Biochemical and Biophysical Research Communications, 286(5), 923–8.  
Paredi, P., & Barnes, P. J. (2009). The airway vasculature: recent advances and clinical implications. 
Thorax, 64(5), 444–50.  
Passalacqua, G., & Ciprandi, G. (2008). Allergy and the lung. Clinical and Experimental Immunology, 
153 Suppl , 12–6.  
Patel, H. J., Barnes, P. J., Takahashi, T., Tadjkarimi, S., Yacoub, M. H., & Belvisi, M. G. (1995). 
Evidence for prejunctional muscarinic autoreceptors in human and guinea pig trachea. American 
Journal of Respiratory and Critical Care Medicine, 152(3), 872–8.  
Patterson, C. E., Stasek, J. E., Schaphorst, K. L., Davis, H. W., & Garcia, J. G. N. (1995). 
Mechanisms of pertussis toxin-induced barrier dysfunction in bovine pulmonary artery 
endothelial cell monolayers. American Journal of Physiology. Lung Cellular and Molecular 
Physiology, 268, 926–934. 
Paul, R., Zhang, Z. G., Eliceiri, B. P., Jiang, Q., Boccia, a D., Zhang, R. L., … Cheresh, D. a. (2001). 
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. 
Nature Medicine, 7(2), 222–7.  
Pautler, R. G. (2004). Mouse MRI: concepts and applications in physiology. Physiology (Bethesda, 
Md.), 19, 168–75.  
Pavord, I. D., & Tattersfield, A. E. (1994). Bronchoprotective role for endogenous prostaglandin E2. 
The Lancet, 344, 436–438. 
Peinado, V. I., Barbera, J. a, Ramirez, J., Gomez, F. P., Roca, J., Jover, L., … Rodriguez-Roisin, R. 
(1998). Endothelial dysfunction in pulmonary arteries of patients with mild COPD. The American 
Journal of Physiology, 274(6), L908–13.  
Persson, C. G. A. (1987). Leakage of Macromolecules From the Tracheobronchial Microcirculation. 
American Review of Respiratory Disease, 135 (6), S71-S75. 
Pierce, K. L., Bailey, T. J., Hoyer, P. B., Gil, D. W., Woodward, D. F., & Regan, J. W. (1997). Cloning 
of a Carboxyl-terminal Isoform of the Prostanoid FP Receptor. Journal of Biological Chemistry, 
272, 883–887. 
Pierce, K. L., Fujino, H., Srinivasan, D., & Regan, J. W. (1999). Activation of FP prostanoid receptor 
isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. The 
Journal of Biological Chemistry, 274(50), 35944–9.  
Platt-Mills, T. a, Sporik, R. B., Chapman, M. D., & Heymann, P. W. (1995). The role of indoor 
allergens in asthma. Allergy, 50(22 Suppl), 5–12.  
213 
 
Portanova, J. P., Zhang, Y., Anderson, G. D., Hauser, S. D., Masferrer, J. L., Seibert, K., … Isakson, 
P. C. (1996). Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and 
interleukin 6 production in vivo. The Journal of Experimental Medicine, 184(3), 883–91.  
Pozzi, A., Yan, X., Macias-Perez, I., Wei, S., Hata, A. N., Breyer, R. M., … Capdevila, J. H. (2004). 
Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK 
activation. The Journal of Biological Chemistry, 279(28), 29797–804.  
Prasain, N., & Stevens, T. (2009). The actin cytoskeleton in endothelial cell phenotypes. 
Microvascular Research, 77(1), 53–63.  
Profita, M., Sala, A., Bonanno, A., Riccobono, L., Ferraro, M., La Grutta, S., … Gjomarkaj, M. (2010). 
Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and 
cyclooxygenase products. American Journal of Physiology. Lung Cellular and Molecular 
Physiology, 298(2), L261–9.  
Profita, M., Sala, A., Bonanno, A., Riccobono, L., Siena, L., Melis, M. R., … Vignola, A. M. (2003). 
Increased prostaglandin E2 concentrations and cyclooxygenase-2 expression in asthmatic 
subjects with sputum eosinophilia. Journal of Allergy and Clinical Immunology, 112, 709–716.  
Qian, Y. M., Jones, R. L., Chan, K. M., Stock, a I., & Ho, J. K. (1994). Potent contractile actions of 
prostanoid EP3-receptor agonists on human isolated pulmonary artery. British Journal of 
Pharmacology, 113(2), 369–74.  
Qiao, J., Huang, F., & Lum, H. (2003). PKA inhibits RhoA activation: a protection mechanism against 
endothelial barrier dysfunction. American Journal of Physiology. Lung Cellular and Molecular 
Physiology, 284(6), L972–80.  
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. a, Calverley, P., … Zielinski, J. (2007). 
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary 
disease: GOLD executive summary. American Journal of Respiratory and Critical Care 
Medicine, 176(6), 532–55.  
Rabiet, M. J., Plantier, J. L., Rival, Y. Genoux, Y. Lampugnani, M. G. & Dejana E. (1996). Thrombin-
induced increase in endothelial permeability is associated with changes in cell-to-cell junction 
organization.  Arteriosclerosis, Thrombosis and Vascular Biology, 16, 488-496. 
Rao, R., Redha, R., Macias-Perez, I., Su,  ., Hao, C., Zent, R., … Pozzi, A. (2007). Prostaglandin E2-
EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. 
The Journal of Biological Chemistry, 282(23), 16959–68.  
Ratcliffe, M. J., Walding, a, Shelton, P. a, Flaherty, a, & Dougall, I. G. (2007). Activation of E-
prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar 
macrophages. The European Respiratory Journal, 29(5), 986–94.  
Raud, J. & Lindbom, L. (1994). Studies by intravital microscopy of basic inflammatory reactions and 
acute allergic inflammation. In: The Handbook of Immunopharmacology. Academic Press, 
London, 1994, 127-170. 
Raychowdhury, M. K., Yukawa, M., Collins, L. J., Mcgrail, S. H., Kent, K. C., & Ware, J. A. (1994). 
Alternative Splicing Produces a Divergent Cytoplasmic Tail in the Human Endothelial 
Thromboxane A2 Receptor. The Journal of Biological Chemistry, 269(30), 19256–19261. 
Regan, J. W., Bailey, T. J., Pepperl, D. J., Pierce, K. L., Bogardus, A. M., Donello, J. E., … Gil, D. W. 
(1994). Cloning of a Novel Human Prostaglandin Receptor with Characteristics of the 
Pharmacologically Defined EP2 Subtype. Molecular Pharmacology, 46, 213–220. 
214 
 
Renkin, E. M., & Tucker, V. L. (1998). Measurement of Microvascular Transport Parameters of 
Macromolecules in Tissues and Organs of Intact Animals. Microcirculation, 5, 139–152. 
Reynolds, A. M., Holmes, M. D., & Scicchitano, R. (2002). Interleukin-1beta and tumour necrosis 
factor-a increase microvascular leakage in the guinea pig trachea. Respirology, 7, 23–28. 
Richter, M., & Sirois, P. (2000). Effects of eicosanoids, neuromediators and bioactive peptides on 
murine airways. European Journal of Pharmacology, 389(2-3), 225–34.  
Rippe, B. & Grega, G. J. (1978) Effects of isoprenaline and cooling on histamine induced changes of 
capillary permeability in the rat hindquarter vascular bed. Acta Physiologica Scandinavica, 103, 
252-262 
Ritchie, R. H., Rosenkranz, a C., Huynh, L. P., Stephenson, T., Kaye, D. M., & Dusting, G. J. (2004). 
Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent 
signaling. American Journal of Physiology. Heart and Circulatory Physiology, 287(3), H1179–85. 
Roberts, L. J. II., Sweetman, B. J., Lewis, R. A., Austen, K. F. & Oates, J. A. (1980). Increased 
Production of Prostaglandin D-2 in Patients with Systemic Mastocytosis. New England Journal 
of Medicine, 303, 1400-1404. 
Rodijnen, W. F. Van, Korstjens, I. J., Legerstee, N., Wee, P. M., & Tangelder, G. (2007). Direct 
vasoconstrictor effect of prostaglandin E 2 on renal interlobular arteries : role of the EP3 
receptor. American Journal of Physiology. Renal Physiology, 292, 1094–1101.. 
Rogers, D. F., Belvisi, M. G., Aursudkij, B., Evans, T. W., & Barnes, P. J. (1988). Effects and 
interactions of sensory neuropeptides on airway microvascular leakage in guinea-pigs. British 
Journal of Pharmacology, 95, 1109–1116. 
Rogers, D. F., Boschetto, P., & Barnes, P. J. (1989). Plasma exudation. Correlation between Evans 
blue dye and radiolabeled albumin in guinea pig airways in vivo. Journal of Pharmacological 
Methods, 21(4), 309–15.  
Rogers, D. F., Dijk, S., & Barnes, P. J. (1990). Bradykinin-induced plasma exudation in guinea-pig 
airways: involvement of platelet activating factor. British Journal of Pharmacology, 101(3), 739–
45.  
Rolin, S., Masereel, B., & Dogné, J.-M. (2006). Prostanoids as pharmacological targets in COPD and 
asthma. European Journal of Pharmacology, 533(1-3), 89–100.  
Roscioni, S. S., Dekkers, B. G. J., Prins, A. G., Menzen, M. H., Meurs, H., Schmidt, M., & Maarsingh, 
H. (2011). cAMP inhibits modulation of airway smooth muscle phenotype via the exchange 
protein activated by cAMP (Epac) and protein kinase A. British Journal of Pharmacology, 162(1), 
193–209.  
Royce, S. G., Cheng, V., Samuel, C. S., & Tang, M. L. K. (2012). The regulation of fibrosis in airway 
remodeling in asthma. Molecular and Cellular Endocrinology, 351(2), 167–75.  
Sagana, R. L.,  an, M., Cornett, A. M., Tsui, J. L., Stephenson, D. a, Huang, S. K., … White, E. S. 
(2009). Phosphatase and tensin homologue on chromosome 10 (PTEN) directs prostaglandin 
E2-mediated fibroblast responses via regulation of E prostanoid 2 receptor expression. The 
Journal of Biological Chemistry, 284(47), 32264–71.  
Sakai, K., Yokoyama, A., Kohno, N., Hamada, H., & Hiwada, K. (2001). Prolonged Antigen Exposure 
Ameliorates Airway Inflammation But Not Remodeling in a Mouse Model of Bronchial Asthma. 
International Archives of Allergy and Immunology, 126, 126–134. 
215 
 
Salvi, S. S., & Barnes, P. J. (2009). Chronic obstructive pulmonary disease in non-smokers. Lancet, 
374(9691), 733–43.  
Saroea, H. G., Inman, M. D., & O’Byrne, P. M. (1995). U46619-induced bronchoconstriction in 
asthmatic subjects is mediated by acetylcholine release. American Journal of Respiratory and 
Critical Care Medicine, 151(2 Pt 1), 321–4.  
Sastre, B., & del Pozo, V. (2012). Role of PGE2 in asthma and nonasthmatic eosinophilic bronchitis. 
Mediators of Inflammation, 2012, 645383.  
Sastre, B., Fernández-Nieto, M., Mollá, R., López, E., Lahoz, C., Sastre, J., … Quirce, S. (2008). 
Increased prostaglandin E2 levels in the airway of patients with eosinophilic bronchitis. Allergy, 
63(1), 58–66.  
Satoh, T., Moroi, R., Aritake, K., Urade,  ., Kanai,  ., Sumi, K., … Nakamura, M. (2006). 
Prostaglandin D2 Plays an Essential Role in Chronic Allergic Inflammation of the Skin via 
CRTH2 Receptor. The Journal of Immunology, 177(4), 2621–2629.  
Savov, J. D., Brass, D. M., Berman, K. G., McElvania, E., & Schwartz, D. a. (2003). Fibrinolysis in 
LPS-induced chronic airway disease. American Journal of Physiology. Lung Cellular and 
Molecular Physiology, 285(4), L940–8.  
Sawyer, N., Cauchon, E., Chateauneuf, A., Cruz, R. P. G., Nicholson, D. W., Metters, K. M., … 
Gervais, F. G. (2002). Molecular pharmacology of the human prostaglandin D2 receptor, 
CRTH2. British Journal of Pharmacology, 137(8), 1163–72.  
Scanlon, P. D., Connett, J. E., Waller, L. A., Altose, M. D., Bailey, W. C., Buist, A. S., & Tashkin, D. P. 
(2000). Smoking Cessation and Lung Function in Mild-to- Moderate Chronic Obstructive 
Pulmonary Disease. The Lung Health Study. American Journal of Respiratory and Critical Care 
Medicine, 161, 381–390. 
Schlötzer-Schrehardt, U., Zenkel, M., & Nüsing, R. M. (2002). Expression and localization of FP and 
EP prostanoid receptor subtypes in human ocular tissues. Investigative Ophthalmology & Visual 
Science, 43(5), 1475–87.  
Schniedermann, J., Rennecke, M., Buttler, K., Richter, G., Städtler, A.-M., Norgall, S., … Weich, H. a. 
(2010). Mouse lung contains endothelial progenitors with high capacity to form blood and 
lymphatic vessels. BMC Cell Biology, 11, 50.  
Schnittler, H., Wilke, A., Gress, T., Suttorp, N., & Drenckhahn, D. (1990a). Role of Actin and Myosin in 
the Control of Paracellular Permeability in Pig, Rat and Human Vascular Endothelium. Journal of 
Physiology, 431, 379–401. 
Schnittler, H., Wilke, A., Gress, T., Suttorp, N., & Drenckhahn, D. (1990b). Role of Actin and Myson in 
the Control of Paracellular Permeability in Pig, Rat and Human Vascular Endothelium. The 
Journal of Physiology, 431, 379–401. 
Schwaner, I., Offermanns, S., Spicher, K., Seifert, R., & Schultz, G. (1995). Differential activation of Gi 
and Gs proteins by E- and I-type prostaglandins in membranes from the human 
erythroleukaemia cell line, HEL. Biochimica et Biophysica Acta, 1265, 8–14. 
Schweitzer, K. S., Hatoum, H., Brown, M. B., Gupta, M., Justice, M. J., Beteck, B., … Petrache, I. 
(2011). Mechanisms of lung endothelial barrier disruption induced by cigarette smoke: role of 
oxidative stress and ceramides. American Journal of Physiology. Lung Cellular and Molecular 
Physiology, 301(6), L836–46.  
216 
 
Sears, M. R. (2009). Safety of long-acting beta-agonists: are new data really required? Chest, 136(2), 
604–7.  
Segi, E., Sugimoto,  .,  amasaki, a, Aze,  ., Oida, H., Nishimura, T., … Ichikawa, a. (1998). Patent 
ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochemical 
and Biophysical Research Communications, 246(1), 7–12.  
Seiler, S., Brassard, C. L., & Federici, M. E. (1990). SQ-27986 inhibition of platelet aggregation is 
mediated through activation of platelet prostaglandin D2 receptors. Prostaglandins, 40(2), 119–
130. 
Senior, J., Marshall, K., Sangha, R., Baxter, G. S., & Clayton, J. K. (1991). In vitro characterization of 
prostanoid EP-receptors in the non-pregnant human myometrium. British Journal of 
Pharmacology, 102(3), 747–53.  
Senoir, J., Sangha, R., Baxter, G. S., Marshall, K., & Clayton, K. (1992). In vitro characterisation of 
prostanoid FP-, DP-, IP- and TP-receptors on non-pregnant human myometrium. British Journal 
of Pharmacology, 107, 215–221. 
Serkova, N. J., Van Rheen, Z., Tobias, M., Pitzer, J. E., Wilkinson, J. E., & Stringer, K. A. (2008). 
Utility of magnetic resonance imaging and nuclear magnetic resonance-based metabolomics for 
quantification of inflammatory lung injury. American Journal of Physiology. Lung Cellular and 
Molecular Physiology, 295, 152–161. 
Seth, R. V, Clarke, V. S., Lewis, R. a, & Tattersfield, a E. (1981). Effect of propranolol on the airway 
response to prostaglandin E2 in normal man. British Journal of Clinical Pharmacology, 12(5), 
731–5.  
Sharif, N. a, McLaughlin, M. a, Kelly, C. R., Xu, S., Crider, J. Y., Williams, G. W., & Parker, J. L. 
(2006). Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin 
analog. Journal of Ocular Pharmacology and Therapeutics : The Official Journal of the 
Association for Ocular Pharmacology and Therapeutics, 22(5), 291–309.  
Shasby, D. M., Shasby, S. S., Sullivan, J. M., & Peach, M. J. (1982). Role of endothelial cell 
cytoskeleton in control of endothelial permeability. Circulation Research, 51(5), 657–661.  
Shasby, D. M., Stevens, T., Ries, D., Moy, A. B., Kamath, J. M., Kamath, A. M., & Shasby, S. S. 
(1997). Thrombin inhibits myosin light chain dephosphorylation in endothelial cells. American 
Journal of Physiology. Lung Cellular and Molecular Physiology, 272, 311–319. 
Sheller, J. R., Mitchell, D., Meyrick, B., Oates, J., & Breyer, R. (2000). EP2 receptor mediates 
bronchodilation by PGE2 in mice. Journal of Applied Physiology, 88, 2214–2218. 
Shen, Q., Rigor, R. R., Pivetti, C. D., Wu, M. H., & Yuan, S. Y. (2010). Myosin light chain kinase in 
microvascular endothelial barrier function. Cardiovascular Research, 87(2), 272–80.  
Shen, Q., Wu, M. H., & Yuan, S. Y. (2009). Endothelial contractile cytoskeleton and microvascular 
permeability. Journal of Cell Health and Cytoskeleton, 1, 43–50. 
Siflinger-Birnboim, A., Bode, D. C., & Malik, A. B. (1993). Adenosine 3’,5'-cyclic monophosphate 
attenuates neutrophil-mediated increase in endothelial permeability. American Journal of 
Physiology. Heart and Circulatory Physiology, 264, 370–375. 
Sin, D. D., Anthonisen, N. R., Soriano, J. B., & Agusti, a G. (2006). Mortality in COPD: Role of 
comorbidities. The European Respiratory Journal, 28(6), 1245–57.  
217 
 
Singh, D., Brooks, J., Hagan, G., Cahn, a, & O’Connor, B. J. (2008). Superiority of “triple” therapy with 
salmeterol/fluticasone propionate and tiotropium bromide versus individual components in 
moderate to severe COPD. Thorax, 63(7), 592–8.  
Singh, J., Zeller, W., Zhou, N., Hategen, G., Mishra, R., Polozov, A., … Gurney, M. E. (2009). 
Antagonists of the EP3 Receptor for Prostaglandin E2 Are Novel Antiplatelet Agents That Do 
Not Prolong Bleeding. ACS Chemical Biology, 4(2), 115–126. 
Slauson, D. O., & Hahn, F. F. (1980). Criteria for Development of Animal Models of Diseases of the 
Respiratory System. American Journal of Pathology, 101(3S), 103–122. 
Smith, J. M., Disney, M. E., Williams, J. D., & Goels, Z. a. (1969). Clinical significance of skin 
reactions to mite extracts in children with asthma. British Medical Journal, 2(5659), 723–6.  
Smock, S. L., Pan, L. C., Castleberry, T. a, Lu, B., Mather, R. J., & Owen, T. a. (1999). Cloning, 
structural characterization, and chromosomal localization of the gene encoding the human 
prostaglandin E(2) receptor EP2 subtype. Gene, 237(2), 393–402.  
Song, P., Zhang, M., Wang, S., Xu, J., Choi, H. C., & Zou, M.-H. (2009). Thromboxane A2 receptor 
activates a Rho-associated kinase/LKB1/PTEN pathway to attenuate endothelium insulin 
signaling. The Journal of Biological Chemistry, 284(25), 17120–8.  
Southam, D. S., Ellis, R., Wattie, J., & Inman, M. D. (2007). Components of airway 
hyperresponsiveness and their associations with inflammation and remodeling in mice. The 
Journal of Allergy and Clinical Immunology, 119(4), 848–54.  
Spada, C. S., Nieves, A. L., & Woodward, D. F. (2002). Vascular Activities of Prostaglandins and 
Selective Prostanoid Receptor Agonists in Human Retinal Microvessels. Experimental Eye 
Research, 75(2), 155–163.  
Spicuzza, L., Belvisi, M. G., Birrell, M. a, Barnes, P. J., Hele, D. J., & Giembycz, M. a. (2001). 
Evidence that the anti-spasmogenic effect of the beta-adrenoceptor agonist, isoprenaline, on 
guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase. British Journal of 
Pharmacology, 133(8), 1201–12.  
Spina, D., & Page, C. P. (2002). Pharmacology of airway irritability. Current Opinion in Pharmacology, 
2(3), 264–72.  
Spindler, V., Schlegel, N., & Waschke, J. (2010). Role of GTPases in control of microvascular 
permeability. Cardiovascular Research, 87(2), 243–53.  
Steinberg, B. E., Goldenberg, N. M., & Lee, W. L. (2012). Do viral infections mimic bacterial sepsis? 
The role of microvascular permeability: A review of mechanisms and methods. Antiviral 
Research, 93(1), 2–15.  
Stelzner, T. J., Weil, J. V. & O’Brien, R. F. (1989). Role of cyclic adenosine monophosphate in the 
induction of endothelial barrier properties. Journal of Cellular Physiology, 139, 157-166. 
Stevenson, C. S., & Belvisi, M. G. (2008). Preclinical animal models of asthma and chronic 
obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2(5), 631–43.  
Stevenson, C. S., & Birrell, M. a. (2011). Moving towards a new generation of animal models for 
asthma and COPD with improved clinical relevance. Pharmacology & Therapeutics, 130(2), 93–
105.  
218 
 
Stevenson, C. S., Koch, L. G., & Britton, S. L. (2006). Aerobic capacity, oxidant stress, and chronic 
obstructive pulmonary disease--a new take on an old hypothesis. Pharmacology & Therapeutics, 
110(1), 71–82.  
Stock, J. L., Shinjo, K., Burkhardt, J., Roach, M., Taniguchi, K., Ishikawa, T., … Audoly, L. P. (2001). 
The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. The 
Journal of Clinical Investigation, 107(3), 325–31.  
Stockley, R. a, Mannino, D., & Barnes, P. J. (2009). Burden and pathogenesis of chronic obstructive 
pulmonary disease. Proceedings of the American Thoracic Society, 6(6), 524–6.  
Stolk, J., Rudolphus, a, Davies, P., Osinga, D., Dijkman, J. H., Agarwal, L., … Kramps, J. a. (1992). 
Induction of emphysema and bronchial mucus cell hyperplasia by intratracheal instillation of 
lipopolysaccharide in the hamster. The Journal of Pathology, 167(3), 349–56.  
Stoller, J. K., & Aboussouan, L. S. (2012). A review of α1-antitrypsin deficiency. American Journal of 
Respiratory and Critical Care Medicine, 185(3), 246–59.  
Sturm, E. M., Schratl, P., Schuligoi, R., Konya, V., Sturm, G. J., Lippe, I. T., … Heinemann, A. (2008). 
Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. Journal of 
Immunology (Baltimore, Md. : 1950), 181(10), 7273–83.  
Subbaramaiah, K., Hudis, C., Chang, S.-H., Hla, T., & Dannenberg, A. J. (2008). EP2 and EP4 
receptors regulate aromatase expression in human adipocytes and breast cancer cells. 
Evidence of a BRCA1 and p300 exchange. The Journal of Biological Chemistry, 283(6), 3433–
44.  
Sugimoto, H., Shichijo, M., Iino, T., Manabe,  ., Watanabe, A., Shimazaki, M., … Bacon, K. B. (2003). 
An Orally Bioavailable Small Molecule Antagonist of CRTH2 , Ramatroban ( BAY u3405 ), 
Inhibits Prostaglandin D 2 -Induced Eosinophil Migration in Vitro. The Journal of Pharmacology 
and Experimental Therapeutics, 305(1), 347–352.  
Sugimoto,  ., Hasumoto, K., Namba, T., Irie, a, Katsuyama, M., Negishi, M., … Ichikawa, a. (1994). 
Cloning and expression of a cDNA for mouse prostaglandin F receptor. The Journal of Biological 
Chemistry, 269(2), 1356–60.  
Sugimoto,  ., Hasumoto, K., Namba, T., Irie, A., Katsuyama, M., Negishi, M., … Ichikawa, A. (1994). 
Cloning and Expression of a cDNA for Mouse Prostaglandin F Receptor. The Journal of 
Biological Chemistry, 269(2), 1356–1360. 
Sugimoto, Y., & Narumiya, S. (2007). Prostaglandin E receptors. The Journal of Biological Chemistry, 
282(16), 11613–7.  
Sugimoto,  .,  amasaki, A., Segi, E., Tsuboi, K., Aze,  ., Nishimura, T., … Narumiya, S. (1997). 
Failure of Parturition in Mice Lacking the Prostaglandin F Receptor. Science, 277, 681–683.  
Suissa, S., & Barnes, P. J. (2009). Inhaled corticosteroids in COPD: the case against. European 
Respiratory Journal, 34, 13–16.  
Sun, H., Breslin, J. W., Zhu, J., Yuan, S. Y., & Wu, M. H. (2006). Rho and ROCK Signaling in VEGF-
Induced Microvascular Endothelial Hyperpermeability. Microcirculation, 13, 237–247.  
Suzawa, T., Miyaura, C., Inada, M., Maruyama, T., Sugimoto,  ., Ushikubi, F., … Suda, T. (200AD). 
The Role of Prostaglandin E Receptor Subtypes (EP1, EP2, EP3, and EP4) in Bone Resorption : 
An Analysis Using Specific Agonists for the Respective EPs. Endocinology, 141(4), 1554–1559. 
219 
 
Suzuki-Yamamoto, T., Toida, K., Sugimoto, Y., & Ishimura, K. (2009). Colocalization of prostaglandin 
F2a receptor FP and prostaglandin F synthase-I in the spinal cord. Journal of Lipid Research, 
50, 1996–2003.  
Svensjo, E., Arfors, K.-E., Raymond, R. M., & Grega, G. J. (1979). Morphological and physiological 
correlation of bradykinin-induced macromolecular efflux of. American Journal of Physiology. 
Heart and Circulatory Physiology, 5(4), 600–606. 
Svensson, C., Grinneberg, R., Andersson, M., Alkner, U., Andersson, O., Billing, B., … Persson, C. G. 
A. (1995). Allergen challenge-induced entry of alpha2-macroglobulin and tryptase into human 
nasal and bronchial airways. Journal of Allergy and Clinical Immunology, 96, 239–246. 
Svensson, J., Strandberg, K., Tuvemo, T., & Hamberg, M. (1977). THROMHOXANE A2 : EFFECTS 
ON AIRWAY AND VASCULAR SMOOTH MUSCLE. Prostaglandins, 14(3), 425–436. 
Swirski, F. K., Sajic, D., Robbins, C. S., Gajewska, B. U., Jordana, M., & Stämpfli, M. R. (2002). 
Chronic Exposure to Innocuous Antigen in Sensitized Mice Leads to Suppressed Airway 
Eosinophilia That Is Reversed by Granulocyte Macrophage Colony-Stimulating Factor. The 
Journal of Immunology, 169, 3499–3506.  
Sylvester, P. W. (2011). Optimization of the Tetrazolium Dye (MTT) Colorimetric Assay for Cellular 
Growth and Viability. Methods in Molecular Biology, 716, 157–168.  
Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., … Olsson, H. 
(2003). Efficacy and safety of budesonide/formoterol in the management of chronic obstructive 
pulmonary disease. European Respiratory Journal, 21, 74–81.  
Szczeklik, A., & Stevenson, D. D. (2003). Aspirin-induced asthma : Advances in pathogenesis, 
diagnosis, and management. Journal of Allergy and Clinical Immunology, 111, 913–921.  
Takagi, T., Forrest, M. J., & Brooks, P. M. (1987). A Pharmacological and Histological Examination of 
the Microcirculation of the Rat Subcutaneous Air-Pouch: Microcirculation of the Rat Air-Pouch. 
Pathology, 19, 294–298. 
Takahashi,  ., Tokuoka, S., Masuda, T., Hirano,  ., Nagao, M., Tanaka, H., … Nagai, H. (2002). 
Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. British Journal of 
Pharmacology, 137, 315–322.  
Takayama, K., Garcia-Cardena, G., Sukhova, G. K., Comander, J., Gimbrone Jr, M. A., & Libby, P. 
(2002). Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through 
the EP4 Receptor. The Journal of Biological Chemistry, 277(46), 44147–44154.  
Tamaoki, J., Chiyotani, A., Takeyama, K., Yamauchi, F., Tagaya, E., & Konno, K. (1993). Relaxation 
and Inhibition of Contractile Response to Electrical Field Stimulation by Beraprost Sodium in 
Canine Airway Smooth Muscle. Prostaglandins, 45, 363–373. 
Tan, X., Essengue, S., Talreja, J., Reese, J., Stechschulte, D. J., & Dileepan, K. N. (2007). Histamine 
Directly and Synergistically with Lipopolysaccharide Stimulates Cyclooxygenase-2 Expression 
and Prostaglandin I2 and E2 Production in Human Coronary Artery Endothelial Cells. The 
Journal of Immunology, 179(11), 7899–7906.  
Tanabe, T., & Ullrich, V. (1995). Prostacyclin and thromboxane synthases. Journal of Lipid Mediators 
and Cell Signalling, 12(2-3), 243–55.  
Tanaka, H., Kanako, S., & Abe, S. (2005). Prostaglandin E2 receptor selective agonists E-prostanoid 
2 and E-prostanoid 4 may have therapeutic effects on ovalbumin-induced bronchoconstriction. 
Chest, 128(5), 3717–23.  
220 
 
Tang, C.-H., Yang, R.-S., & Fu, W.-M. (2005). Prostaglandin E2 stimulates fibronectin expression 
through EP1 receptor, phospholipase C, protein kinase Calpha, and c-Src pathway in primary 
cultured rat osteoblasts. The Journal of Biological Chemistry, 280(24), 22907–16.  
Taube, C., Duez, C., Cui, Z.-H., Takeda, K., Rha, Y.-H., Park, J.-W., … Gelfand, E. W. (2002). The 
Role of IL-13 in Established Allergic Airway Disease. The Journal of Immunology, 169(11), 
6482–6489.  
Temelkovski, J., Hogan, S. P., Shepherd, D. P., Foster, P. S., & Kumar, R. K. (1998). An improved 
murine model of asthma: selective airway inflammation, epithelial lesions and increased 
methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax, 
53(10), 849–56.  
Thomas, D. W., Mannon, R. B., Mannon, P. J., Latour, a, Oliver, J. a, Hoffman, M., … Coffman, T. M. 
(1998). Coagulation defects and altered hemodynamic responses in mice lacking receptors for 
thromboxane A2. The Journal of Clinical Investigation, 102(11), 1994–2001.  
Tigani, B., Cannet, C., Karmouty-quintana, H., Ble, F.-X., Zurbruegg, S., Schaeublin, E., … 
Beckmann, N. (2007). Lung inflammation and vascular remodeling after repeated allergen 
challenge detected noninvasively by MRI. American Journal of Physiology. Lung Cellular and 
Molecular Physiology, 292, 644–653.  
Tilley, S. L., Coffman, T. M., & Koller, B. H. (2001). Mixed messages : modulation of inflammation and 
immune responses by prostaglandins and thromboxanes. Journal of Clinical Investigation, 108, 
15–23.  
Tilley, S. L., Hartney, J. M., Erikson, C. J., Jania, C., Nguyen, M., Stock, J., … Panet-, R. A. (2003). 
Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. American 
Journal of Physiology. Lung Cellular and Molecular Physiology, 284(4), L599–606.  
Tokuyama, K., Lötvall, J. O., Morikawa, a, Barnes, P. J., & Chung, K. F. (1991). Role of thromboxane 
A2 in airway microvascular leakage induced by inhaled platelet-activating factor. Journal of 
Applied Physiology (Bethesda, Md. : 1985), 71(5), 1729–34.  
Torphy, T. J. (1994). Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to 
the dogma. Trends in Pharmacological Sciences, 15(10), 370–4.  
Torphy, T. J., Freese, W. B., Rinard, G. a, Brunton, L. L., & Mayer, S. E. (1982). Cyclic nucleotide-
dependent protein kinases in airway smooth muscle. The Journal of Biological Chemistry, 
257(19), 11609–16.  
Tournebize, R., Doan, B.-T., Dillies, M.-A., Maurin, S., Beloeil, J.-C., & Sansonetti, P. J. (2006). 
Magnetic resonance imaging of Klebsiella pneumoniae-induced pneumonia in mice. Cellular 
Microbiology, 8(1), 33–43.  
Travis, J. (2003). Scientists seek to identify all the proteins in plasma. Science News Online, 163, 
171. 
Trifilieff, A., El-hashim, A., & Bertrand, C. (2000). Time course of inflammatory and remodeling events 
in a murine model of asthma: effect of steroid treatment. American Journal of Physiology. Lung 
Cellular and Molecular Physiology, 279(6), L1120–8.  
Tseliou, E., Bakakos, P., Kostikas, K., Hillas, G., Mantzouranis, K., Emmanouil, P., … Loukides, S. 
(2012). Increased levels of angiopoietins 1 and 2 in sputum supernatant in severe refractory 
asthma. Allergy, 67(3), 396–402.  
221 
 
Udaka, K., Takeuchi, Y. & Movat, H. Z. (1970). Simple Method for Quantitation of Enhanced Vascular 
Permeability. Proceedings of the Society for Experimental Biology and Medicine, 133, 1384-
1387. 
Ueno, a, Matsumoto, H., Naraba, H., Ikeda,  ., Ushikubi, F., Matsuoka, T., … Oh-ishi, S. (2001). 
Major roles of prostanoid receptors IP and EP(3) in endotoxin-induced enhancement of pain 
perception. Biochemical Pharmacology, 62(2), 157–60.  
Ueno, A., Naraba, H., Ikeda, Y., Ushikubi, F., Murata, T., Narumiya, S., & Oh-ishi, S. (2000). Intrinsic 
prostacyclic contributes to exudation induced by bradykini or carregeenin: A study on the paw 
edema induced in IP-receptor-defcient mice. Life Sciences, 66(12), 155–160. 
Ukropec, J. A., Hollinger, M. K., Salva, S. M., & Woolkalis, M. J. (2000). SHP2 Association with VE-
Cadherin Complexes in Human Endothelial Cells Is Regulated by Thrombin. Journal of 
Biological Chemistry, 275(8), 5983–5986.  
Ulven, T., & Kostenis, E. (2005). Minor structural modifications convert the dual TP/CRTH2 antagonist 
ramatroban into a highly selective and potent CRTH2 antagonist. Journal of Medicinal 
Chemistry, 48(4), 897–900.  
Underwood, D. C., Muccitelli, R. M., Luttmann, M. a, Hay, D. W., Torphy, T. J., & Wasserman, M. a. 
(1994). Differential antagonism of airway contractile responses to prostaglandin (PG)D2 and 9 
alpha, 11 beta-PGF2 by atropine, SK&F 88046 and SQ 29,548 in the guinea pig. The Journal of 
Pharmacology and Experimental Therapeutics, 268(1), 304–10.  
Urade, Y., Watanabe, K., & Hayaishi, O. (1995). Prostaglandin D, E, and F synthases. Journal of Lipid 
Mediators and Cell Signalling, 12(2-3), 257–73.  
Ushikubi, F., Nakajima, M., Hirata, M., Okuma, M., Fujiwara, M., & Narumiya, S. (1989). Purification of 
the thromboxane A2/prostaglandin H2 receptor from human blood platelets. The Journal of 
Biological Chemistry, 264(28), 16496–501.  
Ushikubi, F., Nakamura, K., & Narumiya, S. (1994). Functional Reconstitution of Platelet 
Thromboxane A2 Receptors with Gq and G12 in Phospholipid Vesicles. Molecular 
Pharmacology, 46, 808–816. 
Ushikubi, F., Segi, E., Sugimoto,  ., Murata, T., Matsuoka, T., Kobayashi, T., … Narumiya, S. (1998). 
Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature, 
395(6699), 281–4.  
Van de Graaf, E. A., Out, T. A., Roos, C. M., & Jansen, H. M. (1991). Respiratory Membrane 
Permeability and Bronchial Hyperreactivity in Patients with Stable Athma. American Reviews of 
Respiratory Disease, 143, 362–368. 
Van Hinsbergh, V. W. M., & van Nieuw Amerongen, G. P. (2002). Intracellular signalling involved in 
modulating human endothelial barrier function. Journal of Anatomy, 200(6), 549–60.  
Van Hove, C. L., Maes, T., Cataldo, D. D., Guéders, M. M., Palmans, E., Joos, G. F., & Tournoy, K. 
G. (2009). Comparison of acute inflammatory and chronic structural asthma-like responses 
between C57BL/6 and BALB/c mice. International Archives of Allergy and Immunology, 149(3), 
195–207.  
Van Hove, C. L., Maes, T., Joos, G. F., & Tournoy, K. G. (2007). Prolonged inhaled allergen exposure 
can induce persistent tolerance. American Journal of Respiratory Cell and Molecular Biology, 
36(5), 573–84.  
222 
 
Van Nieuw Amerongen, G. P., & van Hinsbergh, V. W. M. (2002). Targets for pharmacological 
intervention of endothelial hyperpermeability and barrier function. Vascular Pharmacology, 39(4-
5), 257–272.  
Van Rensen, E. L. J., Hiemstra, P. S., Rabe, K. F., & Sterk, P. J. (2002). Assessment of 
microvascular leakage via sputum induction: the role of substance P and neurokinin A in 
patients with asthma. American Journal of Respiratory and Critical Care Medicine, 165(9), 
1275–9.  
Vandenbroucke, E., Mehta, D., Minshall, R., & Malik, A. B. (2008). Regulation of endothelial junctional 
permeability. Annals of the New York Academy of Sciences, 1123, 134–45.  
Vane, J. R., & Botting, R. M. (1995). Pharmacodynamic Profile of Prostacyclin. American Journal 
Cardiology, 75, 3–10. 
Verin, A. D., Patterson, C. E., Day, M. A., & Garcia, J. G. N. (1995). Regulation of endothelial cell gap 
formation and barrier function by myosin-associated phosphatase activities. American Journal of 
Physiology. Lung Cellular and Molecular Physiology, 269, 99–108. 
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., … Rodriguez-Roisin, 
R. (2013). Global strategy for the diagnosis, management, and prevention of chronic obstructive 
pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical 
Care Medicine, 187(4), 347–65.  
Vrugt, B., Wilson, S., Bron, a, Holgate, S. T., Djukanovic, R., & Aalbers, R. (2000). Bronchial 
angiogenesis in severe glucocorticoid-dependent asthma. The European Respiratory Journal, 
15(6), 1014–21.  
Vysniauskiene, I., Allemann, R., Flammer, J., & Haefliger, I. O. (2006). Vasoactive responses of 
U46619, PGF2alpha, latanoprost, and travoprost in isolated porcine ciliary arteries. Investigative 
Ophthalmology & Visual Science, 47(1), 295–8.  
Wacker, M. J., Kosloski, L. M., Gilbert, W. J. R., Touchberry, C. D., Moore, D. S., Kelly, J. K., … Orr, 
J. A. (2009). Inhibition of Thromboxane A 2 -Induced Arrhythmias and Intracellular Calcium 
Changes in Cardiac Myocytes by Blockade of the Inositol Trisphosphate Pathway. The Journal 
of Pharmacology and Experimental Therapeutics, 331(3), 917–924.  
Walch, L., de Montpreville, V., Brink, C., & Norel, X. (2001). Prostanoid EP(1)- and TP-receptors 
involved in the contraction of human pulmonary veins. British Journal of Pharmacology, 134(8), 
1671–8.  
Walch, L., Labat, C., Gascard, J. P., de Montpreville, V., Brink, C., & Norel, X. (1999). Prostanoid 
receptors involved in the relaxation of human pulmonary vessels. British Journal of 
Pharmacology, 126(4), 859–66.  
Walsh, M. T., Foley, J. F., & Kinsella, B. T. (1998). Characterization of the role of N-linked 
glycosylation on the cell signaling and expression of the human thromboxane A2 receptor alpha 
and beta isoforms. The Journal of Pharmacology and Experimental Therapeutics, 286(2), 1026–
36.  
Walter, D. M., Mcintire, J. J., Berry, G., Mckenzie, N. J., Donaldson, D. D., Rosemarie, H., … 
Dekruyff, R. H. (2001). Critical Role for IL-13 in the Development of Allergen-Induced Airway 
Hyperreactivity. The Journal of Immunology, 167(8), 4668–4675.  
Walters, E. H., O’Byrne, P. M., Fabbri, L. M., Graf, P. D., Holtzman, M. J., & Nadel, J. a. (1984). 
Control of neurotransmission by prostaglandins in canine trachealis smooth muscle. Journal of 
Applied Physiology: Respiratory, Environmental and Exercise Physiology, 57(1), 129–34.  
223 
 
Wang, X. S., & Lau, H. Y. a. (2006). Prostaglandin E potentiates the immunologically stimulated 
histamine release from human peripheral blood-derived mast cells through EP1/EP3 receptors. 
Allergy, 61(4), 503–6.  
Wang, Z., Ginnan, R., Iskandar, F., Trebak, M., Peter, A., Singer, H. A., … Vincent, P. A. (2010). 
Calcium/Calmodulin-dependent protein kinase II delta 6 (CaMKIIdelta6) and RhoA involvement 
in thrombin-induced endothelial barrier dysfunction. The Journal of Biological Chemistry, 
285(28), 21303–12.  
Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, a, Mitchell, J. a, & Vane, J. R. (1999). Nonsteroid 
drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with 
human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of 
Sciences of the United States of America, 96(13), 7563–8.  
Watabe, A., Sugimoto,  ., Honda, A., Irie, A., Namba, T., Negishi, M., … Ichikawa, A. (1993). Cloning 
and Expression of cDNA for a Mouse EP1 Subtype of Prostaglandin E Receptor. The Journal of 
Biological Chemistry, 268(27), 20175–20178. 
Watanabe, K. (2002). Prostaglandin F synthase. Prostaglandins & Other Lipid Mediators, 68-69, 401–
407.  
Weatherall, M., Wijesinghe, M., Perrin, K., Harwood, M., & Beasley, R. (2010). Meta-analysis of the 
risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. 
Thorax, 65(1), 39–43.  
Wenzel, S. (2005). Severe asthma in adults. American Journal of Respiratory and Critical Care 
Medicine, 172(2), 149–60.  
Wenzel, S. E. (2006). Asthma : defining of the persistent adult phenotypes. Lancet, 368, 804–813. 
Wenzel, S. E., Westcott, J. Y., & Larsen, G. L. (1991). Bronchoalveolar lavage fluid mediator levels 5 
minutes after allergen challenge in atopic subjects with asthma: Relationship to the development 
of late asthmatic responses. Journal of Allergy and Clinical Immunology, 87, 540–548. 
Whittle, B. J. R., Moncada, S., Mullane, K., & Vane, J. R. (1983). Platelet and Cardiovascular Activity 
of the Hydantoin BW245C, A Potent Prostaglandin Analogue. Prostaglandins, 25(2), 205–223. 
Widdicombe, J. H., Ueki, I. F., Emery, D., Margolskee, D., Yergey, J., & Nadel, J. a. (1989). Release 
of cyclooxygenase products from primary cultures of tracheal epithelia of dog and human. The 
American Journal of Physiology, 257(6 Pt 1), L361–5.  
Willemse, B. W. M., ten Hacken, N. H. T., Rutgers, B., Lesman-Leegte, I. G. a T., Postma, D. S., & 
Timens, W. (2005). Effect of 1-year smoking cessation on airway inflammation in COPD and 
asymptomatic smokers. The European Respiratory Journal, 26(5), 835–45.  
Williams, T. J. (1982). Vasoactive intestinal polypeptide is more potent than prostaglandin E2 as a 
vasodilator and oedema potentiator in rabbit skin. British Journal of Pharmacology, 77(3), 505–
9.  
Wilson, J. W., & Robertson, C. F. (2002). Angiogenesis in paediatric airway disease. Paediatric 
Respiratory Reviews, 3, 219–229.  
Wilson, R. J., Giblin, G. M. P., Roomans, S., Rhodes, S. a, Cartwright, K.-A., Shield, V. J., … Giles, H. 
(2006). GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-
yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor 
antagonist. British Journal of Pharmacology, 148(3), 326–39.  
224 
 
Winter, M. C., Kamath, A. M., Ries, D. R., Shasby, S. S., Chen, Y., Shasby, D. M., & Michael, C. 
(1999). Histamine alters cadherin-mediated sites of endothelial adhesion. The American Journal 
of Physiology, 277(5 Pt 1), L988–95.  
Woo, S. K., Roszkowski, P., Waterbury, L. D., & Garay, G. L. (1986). Gastric Mucosal Binding Studies 
with Enprostil: A Potent Anti-Ulcer Prostaglandin. Prostaglandins, 32(2), 243–257. 
Woodward, D. F., Jones, R. L., & Narumiya, S. (2011). International Union of Basic and Clinical 
Pharmacology . LXXXIII : Classification of Prostanoid Receptors, Updating 15 Years of 
Progress. Pharmacological Reviews, 63(3), 471–538.  
Woodward, D. F., Krauss, a H., Wang, J. W., Protzman, C. E., Nieves, a L., Liang,  ., … Struble, C. 
(2007). Identification of an antagonist that selectively blocks the activity of prostamides 
(prostaglandin-ethanolamides) in the feline iris. British Journal of Pharmacology, 150(3), 342–
52.  
Woodward, D. F., & Lawrence, R. a. (1994). Identification of a single (FP) receptor associated with 
prostanoid-induced Ca2+ signals in Swiss 3T3 cells. Biochemical Pharmacology, 47(9), 1567–
74.  
Woodward, D. F., Pepperl, D. J., Burkey, T. H., & Regan, J. W. (1995). 6-Isopropoxy-9-oxoxanthene-
2carboxylic Acid (AH 6809) A Human EP2 Receptor Antagonist. Biochemical Pharmacology, 
50(10), 1731–1733. 
Wooldridge, L., Ekeruche-makinde, J., Berg, H. A. Van Den, Skowera, A., John, J., Tan, M. P., … 
Miles, J. J. (2012). A single autoimmune T cell receptor recognizes more than a million different 
peptides. The Journal of Biological Chemistry, 287(2), 1168–77.  
World Health Organisation (2008). World Health Statistics. [Online] Available from: 
http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf 
Wright, J. L., Cosio, M., & Churg, A. (2008). Animal models of chronic obstructive pulmonary disease. 
American Journal of Physiology. Lung Cellular and Molecular Physiology, 295, 1–15.  
Wu, N. Z., & Baldwin, a L. (1992). Transient venular permeability increase and endothelial gap 
formation induced by histamine. The American Journal of Physiology, 262(4 Pt 2), H1238–47.  
Wyss, D., Bonneau, O., & Trifilieff, a. (2007). Synergistic effect of formoterol and mometasone in a 
mouse model of allergic lung inflammation. British Journal of Pharmacology, 152(1), 83–90.  
Xie, G., Wang,  ., Sharma, M., Gabriel, a, Mitchell, J., Xing,  ., … Palmer, P. P. (2003). 5-
Hydroxytryptamine-induced plasma extravasation in the rat knee joint is mediated by multiple 
prostaglandins. Inflammation Research : Official Journal of the European Histamine Research 
Society ... [et Al.], 52(1), 32–8.  
Xue, L., Gyles, S. L., Wettey, F. R., Gazi, L., Townsend, E., Hunter, M. G., … Gyles, L. (2005). 
Prostaglandin D2 Causes Preferential Induction of Proinflammatory Th2 Cytokine Production 
through an Action on Chemoattractant Receptor-Like Molecule Expressed on Th2 Cells. The 
Journal of Immunology, 175(10), 6531–6536.  
 an, H., Deshpande, D. a, Misior, A. M., Miles, M. C., Saxena, H., Riemer, E. C., … Penn, R. B. 
(2011). Anti-mitogenic effects of β-agonists and PGE2 on airway smooth muscle are PKA 
dependent. FASEB Journal : Official Publication of the Federation of American Societies for 
Experimental Biology, 25(1), 389–97.  
Yang, I. A., Fong, K., Eha, S., Black, P., & Lasserson, T. (2009). Inhaled corticosteroids for stable 
chronic obstructive pulmonary disease. The Cochrane Library, (2), 1–151. 
225 
 
Yang, J. H., Xia, M. H., Goetzl, E. J. & An, S. Z. (1994). Cloning and expression of EP3-subtype of 
human receptors for prostaglandin E2.  Biochemical and Biophysical Research 
Communications, 198, 999-1006. 
 ao, C., Sakata, D., Esaki,  ., Li,  ., Matsuoka, T., Kuroiwa, K., … Narumiya, S. (2009). 
Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation 
and Th17 cell expansion. Nature Medicine, 15(6), 633–40.  
 ao, H., Chung, S., Hwang, J., Rajendrasozhan, S., Sundar, I. K., Dean, D. A., … Rahman, I. (2012). 
SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in 
mice. The Journal of Clinical Investigation, 122(6), 2032–2045.  
Yoshimura, K., Tod, M. L., Pier, K. G., & Rubin, L. J. (1989). Role of venoconstriction in thromboxane-
induced pulmonary hypertension and edema in lambs. Journal of Applied Physiology, 66(2), 
929–935. 
Yoshimura-Uchiyama, C., Iikura, M.,  amaguchi, M., Nagase, H., Ishii, a, Matsushima, K., … Hirai, K. 
(2004). Differential modulation of human basophil functions through prostaglandin D2 receptors 
DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2. Clinical 
and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 
34(8), 1283–90.  
 u, H., Huang, X., Ma,  ., Gao, M., Wang, O., Gao, T., … Liu, X. (2013). Interleukin-8 regulates 
endothelial permeability by down-regulation of tight junction but not dependent on integrins 
induced focal adhesions. International Journal of Biological Sciences, 9(9), 966–79.  
 u,  ., Lucitt, M. B., Stubbe, J., Cheng,  ., Friis, U. G., Hansen, P. B., … FitzGerald, G. a. (2009). 
Prostaglandin F2alpha elevates blood pressure and promotes atherosclerosis. Proceedings of 
the National Academy of Sciences of the United States of America, 106(19), 7985–90.  
Yuan, S. Y. (2000). Signal transduction pathways in enhanced microvascular permeability. 
Microcirculation, 7(6), 395–403.  
Yuan, S. Y. (2002). Protein kinase signaling in the modulation of microvascular permeability. Vascular 
Pharmacology, 39(4-5), 213–223.  
Yuan, Y., Huang, Q., & Wu, H. M. (1997). Myosin light chain phosphorylation: modulation of basal and 
agonist-stimulated venular permeability. The American Journal of Physiology, 272(3 Pt 2), 
H1437–43.  
Yuhki, K., Ueno, A., Naraba, H., Kojima, F., Ushikubi, F., Narumiya, S., & Oh-ishi, S. (2004). 
Prostaglandin Receptors EP2 , EP3 , and IP Mediate Exudate Formation in Carrageenin-
Induced Mouse Pleurisy. The Journal of Pharmacology and Experimental Therapeutics, 311(3), 
1218–1224.  
Zaccolo, M. (2009). cAMP signal transduction in the heart: understanding spatial control for the 
development of novel therapeutic strategies. British Journal of Pharmacology, 158(1), 50–60.  
Zanini, A., Chetta, A., Imperatori, A. S., Spanevello, A., & Olivieri, D. (2010). The role of the bronchial 
microvasculature in the airway remodelling in asthma and COPD. Respiratory Research, 11, 
132.  
Zhang, L., Brass, L. F., & Manning, D. R. (2009). The Gq and G12 Families of Heterotrimeric G 
Proteins Report Functional Selectivity. Molecular Pharmacology, 75(1), 235–241.  
226 
 
Zhang, Y., Guan, Y., Schneider, A., Brandon, S., Breyer, R. M., & Breyer, M. D. (2000). 
Characterization of Murine Vasopressor and Vasodepressor Prostaglandin E2 Receptors. 
Hypertension, 35, 1129–1134. 
Zheng, L., Duan, S. F., Zhang, Z. X. (1991). Changes of thromboxane A2 (TXA2) and prostacyclin 
(PGI2) in COPD patients with pulmonary hypertension. Zhonghua Nei Ke Za Zhi, 30, 91-93. 
Zhou, W., Blackwell, T. S., Goleniewska, K., O’Neal, J. F., Fitzgerald, G. a, Lucitt, M., … Peebles, R. 
S. (2007). Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T 
cells. Journal of Leukocyte Biology, 81(3), 809–17.  
Zhuang, J., Xu, J., Zhang, C., & Xu, F. (2011). IL-1β acutely increases pulmonary SP and 
permeability without associated changes in airway resistance and ventilation in anesthetized 
rats. Respiratory Physiology & Neurobiology, 175(1), 12–9.  
  
227 
 
Appendix 
Chemicals and Reagents 
The following table lists all the chemical reagents and compounds that were used in 
this thesis.  The vehicles have also been described where necessary. 
Drug / Reagent Source Vehicle 
5-Hydroxytryptamine Sigma-Aldrich 1% ethanol in saline 
Albumin from Chicken Egg 
White (OVA) 
Sigma-Aldrich 
Saline (challenging); Alum:saline 
(sensitising) 
Agarose Sigma-Aldrich 2% in 1xTBE 
Boric Acid Sigma-Aldrich - 
CaCl2 VWR - 
Chloroform Sigma-Aldrich - 
Extracta DNA PCR kit Quanta Biosciences - 
EDTA Promega - 
EGMTM-2 MV Bulletkit Lonza - 
ER-819762 Eisai 
0.5% methylcellulose, 0.2% tween 
80 in water (p.o.) or saline (i.p.) 
Ethanol VWR - 
Evans Blue Sigma-Aldrich Saline 
FITC-Albumin Sigma-Aldrich Cell Media 
Formamide Sigma-Aldrich - 
Glucose VWR - 
Hyperladder II and IV Bioline Ltd - 
Iloprost Cayman Europe 
0.1% DMSO in Media (in vitro); 
1% Ethanol in Saline (in vivo) 
Isopropanol Sigma-Aldrich - 
KCl VWR - 
KH2PO4 VWR - 
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Methylcellulose Sigma-Aldrich - 
MgSO4 VWR - 
NaCl VWR - 
NaH2PO4 VWR - 
NaH2PO4.2H2O VWR - 
NaHCO3 VWR - 
Nuclease-free water Promega - 
PAF Sigma-Aldrich 0.1% DMSO in Media 
PGD2 Cayman Europe 
0.1% DMSO in Media (in vitro); 
1% Ethanol in Saline (in vivo) 
PGE2 Cayman Europe 
0.1% DMSO in Media (in vitro); 
1% Ethanol in Saline (in vivo) 
PGF2α Cayman Europe 
0.1% DMSO in Media (in vitro); 
1% Ethanol in Saline (in vivo) 
PF-04418948 Pfizer 
0.5% methylcellulose, 0.2% tween 
80 in water (p.o.) or saline (i.p.) 
Safeview NBS Biologicals - 
Saline (0.9% sterile) Fresenius Kabi - 
Sodium pentobarbitone Merial Animal Health - 
TRI Reagent Sigma-Aldrich - 
Trizma Base Sigma-Aldrich - 
Tween 20 Sigma-Aldrich - 
Tween 80 Sigma-Aldrich - 
U46619 Cayman Europe 
0.1% DMSO in Media (in vitro); 
1% Ethanol in Saline (in vivo) 
Urethane Sigma-Aldrich Saline 
 
 
 
 
